Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Developed by the HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission—A Working Group of the Office of AIDS Research Advisory Council (OARAC)

How to Cite the Perinatal Guidelines:


It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the AIDSinfo website (http://aidsinfo.nih.gov).

What’s New in the Guidelines

The Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women and Interventions to Reduce Perinatal HIV Transmission in the United States guidelines are published in an electronic format that can be updated as relevant changes in prevention and treatment recommendations occur. The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission is committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information.

Major revisions within the last 12 months are as follows:

June 7, 2016
1. Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy and Table 7: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy were revised to incorporate new data and publications, where available, Food and Drug Administration drug label changes, and new fixed dose combination formulations. Updates were made to the following drug sections: Atazanavir, Dolutegravir, Emtricitabine, Fosamprenavir, Indinavir, Lamivudine, Nelfinavir, Nevirapine, Rilpivirine, Ritonavir, Saquinavir, Stavudine, Tenofovir, and Tipranavir. There were no major changes related to management of these drugs during pregnancy.

April 29, 2016
1. Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy and Table 7: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy were revised.
   a. The Abacavir, Etravirine and Didanosine sections were updated to include new data and publications, including Food and Drug Administration label updates.
   b. The Amprenavir, Delavirdine, and Zalcitabine sections were removed from the guidelines as they are no longer available in the United States. Additional information on these drugs can be found in the Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women and Interventions to Reduce Perinatal HIV Transmission in the United States archives.
Table of Contents

What’s New in the Guidelines
Guidelines Panel Members
Financial Disclosure
Introduction

Preconception Counseling and Care for HIV-Infected Women of Childbearing Age

Antepartum Care

Intrapartum Care

Table 4: Clinical Trials of Pre-exposure Prophylaxis
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health

Postpartum Care........................................................................................................E-1

- Postpartum Follow-Up of HIV-Infected Women....................................................E-1
- Infant Antiretroviral Prophylaxis............................................................................E-6
  - Table 8. Recommended Neonatal Dosing for Prevention of Perinatal Transmission of HIV ....E-6
- Initial Postnatal Management of the HIV-Exposed Neonate .................................E-12
- Long-Term Follow-Up of Antiretroviral Drug-Exposed Infants.........................E-19

Appendix A: Review of Clinical Trials of Antiretroviral Interventions to Prevent Perinatal HIV Transmission.................................................................................F-1

- Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission.................................................................F-3

Appendix B: Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy ....G-1

- Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy ..................G-1
- NRTIs .......................................................................................................................G-22
  - Abacavir ...............................................................................................................G-22
  - Didanosine .........................................................................................................G-25
  - Emtricitabine .....................................................................................................G-28
  - Lamivudine ......................................................................................................G-31
  - Stavudine ..........................................................................................................G-34
  - Tenofovir ..........................................................................................................G-37
  - Zidovudine .......................................................................................................G-42
- NNRTIs ..................................................................................................................G-47
  - Efavirenz ..........................................................................................................G-47
  - Etravirine .........................................................................................................G-54
  - Nevirapine .......................................................................................................G-57
  - Rilpivirine .......................................................................................................G-62
- PIs ..........................................................................................................................G-64
  - Atazanavir ........................................................................................................G-64
  - Darunavir .........................................................................................................G-70
  - Fosamprenavir ..................................................................................................G-73
  - Indinavir ..........................................................................................................G-76
  - Lopinavir .........................................................................................................G-79
  - Nelfinavir .........................................................................................................G-84
  - Saquinavir .......................................................................................................G-87
  - Tipranavir .......................................................................................................G-90
- Entry Inhibitors ....................................................................................................G-92
  - Enfuvirtide ......................................................................................................G-92
  - Maraviroc .......................................................................................................G-95
• Integrase Inhibitors .................................................................G-97
  ▪ Dolutegravir .................................................................G-97
  ▪ Elvitegravir .................................................................G-99
  ▪ Raltegravir .................................................................G-101
• Pharmacoenhancers ..........................................................G-105
  ▪ Cobicistat .................................................................G-105
  ▪ Ritonavir .................................................................G-107
• Antiretroviral Pregnancy Registry ........................................G-110

Appendix C: Acronyms ..........................................................H-1

<table>
<thead>
<tr>
<th>Members of the Panel</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erikac Aaron, MSN, ANP, CRNP</td>
<td>Drexel University College of Medicine, Philadelphia, PA</td>
</tr>
<tr>
<td>Elaine J. Abrams, MD</td>
<td>Columbia University, New York, NY</td>
</tr>
<tr>
<td>Jean Anderson, MD</td>
<td>Johns Hopkins University School of Medicine, Baltimore, MD</td>
</tr>
<tr>
<td>Liz Barr, MA, MS</td>
<td>Madison, WI</td>
</tr>
<tr>
<td>Brookie M. Best, PharmD, MAS</td>
<td>University of California, San Diego, La Jolla, CA and Rady Children’s Hospital-San Diego, CA</td>
</tr>
<tr>
<td>Andrea Ciaranello, MD, MPH</td>
<td>Massachusetts General Hospital, Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>Rana Chakraborty, MD, MS, PhD</td>
<td>Emory University School of Medicine, Atlanta, GA</td>
</tr>
<tr>
<td>Susan E. Cohn, MD, MPH</td>
<td>Northwestern University Feinberg School of Medicine, Chicago, IL</td>
</tr>
<tr>
<td>Susan Cu-Uvin, MD</td>
<td>Alpert School of Medicine, Brown University, Providence, RI</td>
</tr>
<tr>
<td>Stephanie Deyo</td>
<td>Seattle, WA</td>
</tr>
<tr>
<td>Judith Feinberg, MD</td>
<td>University of Cincinnati College of Medicine, Cincinnati, OH</td>
</tr>
<tr>
<td>Patricia M. Flynn, MD</td>
<td>St. Jude Children’s Research Hospital, Memphis, TN</td>
</tr>
<tr>
<td>Gweneth B. Lazenby, MD, MSCR</td>
<td>Medical University of South Carolina, Charleston, SC</td>
</tr>
<tr>
<td>Judy Levison, MD, MPH</td>
<td>Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>Robert T. Maupin Jr., MD</td>
<td>Louisiana State University Health Sciences Center, New Orleans, LA</td>
</tr>
<tr>
<td>Howard Minkoff, MD</td>
<td>Maimonides Medical Center, State University of New York Brooklyn, Brooklyn, NY</td>
</tr>
<tr>
<td>Mark Mirochnick, MD</td>
<td>Boston Medical Center, Boston University School of Medicine, Boston, MA</td>
</tr>
<tr>
<td>Lynne M. Mofenson, MD</td>
<td>Elizabeth Glaser Pediatric AIDS Foundation, Washington DC</td>
</tr>
<tr>
<td>Fatima Y. Prioleau, MA</td>
<td>Brooklyn, NY</td>
</tr>
<tr>
<td>Stephen A. Spector, MD</td>
<td>University of California, San Diego, La Jolla, CA and Rady Children’s Hospital-San Diego, CA</td>
</tr>
<tr>
<td>Kathleen E. Squires, MD</td>
<td>Thomas Jefferson University, Philadelphia, PA</td>
</tr>
<tr>
<td>Meg Sullivan, MD</td>
<td>Boston Medical Center, Boston, MA</td>
</tr>
<tr>
<td>Ruth Tuomala, MD</td>
<td>Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>Geoffrey A. Weinberg, MD</td>
<td>University of Rochester School of Medicine and Dentistry, Rochester, NY</td>
</tr>
</tbody>
</table>

* American Academy of Pediatrics Committee on Pediatric AIDS liaison

* American Congress of Obstetricians and Gynecologists liaison
### Panel Executive Secretary

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>George K. Siberry, MD, MPH</td>
<td>National Institutes of Health, Rockville, MD</td>
</tr>
</tbody>
</table>

### Ex Officio Member

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deborah Cohan, MD</td>
<td>National Perinatal HIV Hotline, San Francisco, CA</td>
</tr>
</tbody>
</table>

### Members from the United States Government

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nahida Chakhtoura, MD, MsGH</td>
<td>National Institutes of Health, Rockville, MD</td>
</tr>
<tr>
<td>Brian Feit, MPA</td>
<td>Health Resources and Services Administration, Rockville, MD</td>
</tr>
<tr>
<td>Devasena Gnanashanmugam, MD</td>
<td>National Institutes of Health, Bethesda, MD</td>
</tr>
<tr>
<td>Denise Jamieson, MD, MPH</td>
<td>Centers for Disease Control and Prevention, Atlanta, GA</td>
</tr>
<tr>
<td>Steve Nesheim, MD</td>
<td>Centers for Disease Control and Prevention, Atlanta, GA</td>
</tr>
<tr>
<td>Polly E. Ross, MD</td>
<td>Health Resources and Services Administration, Rockville, MD</td>
</tr>
<tr>
<td>Alan Shapiro, MD, PhD</td>
<td>Food and Drug Administration, Rockville, MD</td>
</tr>
<tr>
<td>D. Heather Watts, MD</td>
<td>Office of the Global AIDS Coordinator and Health Diplomacy, Washington, DC</td>
</tr>
</tbody>
</table>

### Non-Voting Observers from the François-Xavier Bagnoud Center

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deborah Storm, MSN, PhD</td>
<td>François-Xavier Bagnoud Center, School of Nursing, Rutgers, The State University of New Jersey, Newark, NJ</td>
</tr>
</tbody>
</table>

### Special Thanks

We would like to acknowledge and recognize the contributions of Carolyn Burr, RN, EdD, who is retiring from the Panel on Treatment of HIV-Infected Pregnant Woman and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. As a nurse practitioner, educator, and former Deputy Director of the François-Xavier Bagnoud Center at the School of Nursing, Rutgers, The State University of New Jersey, Dr. Burr was one of the early champions for comprehensive pediatric HIV care and perinatal HIV prevention in the United States and has provided key leadership and support for both the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection and the Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States since their inception.
## Financial Disclosure List for Members of the Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission

**Financial Disclosure List for Members of the Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission** *(Last updated August 6, 2015; last reviewed August 6, 2015)*

<table>
<thead>
<tr>
<th>Name</th>
<th>Panel Status</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron, Erika</td>
<td>M</td>
<td>Gilead</td>
<td>Research Support</td>
</tr>
<tr>
<td>Abrams, Elaine J.</td>
<td>M</td>
<td>ViiV</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Anderson, Jean</td>
<td>M</td>
<td>Gilead</td>
<td>PrEP Advisory Board</td>
</tr>
<tr>
<td>Barr, Liz</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Best, Brookie</td>
<td>M</td>
<td>PPD</td>
<td>DSMB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vertex Pharmaceuticals</td>
<td>DSMB</td>
</tr>
<tr>
<td>Ciaranello, Andrea</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Chakhtoura, Nahida</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Chakraborty, Rana</td>
<td>M</td>
<td>Gilead</td>
<td>Research Support</td>
</tr>
<tr>
<td>Cohan, Deborah</td>
<td>ExOM</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Cohn, Susan E.</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Cu-Uvin, Susan</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Deyo, Stephanie</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Feinberg, Judith</td>
<td>M</td>
<td>Bristol-Myers Squibb</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GlaxoSmithKline/ViiV</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Janssen</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tobira</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gilead</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PrEP Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PrEP Speakers’ Bureau</td>
</tr>
<tr>
<td>Feit, Brian</td>
<td>HHS</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Flynn, Patricia M.</td>
<td>M</td>
<td>Johnson and Johnson (formerly Tibotec)</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck</td>
<td>DSMB Member</td>
</tr>
<tr>
<td>Gnanashanmugam, Devasena</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Jamieson, Denise</td>
<td>HHS</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Lazenby, Gweneth</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Levison, Judy</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Maupin, Robert</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Minkoff, Howard</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Financial Disclosure List for Members of the Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission *(Last updated August 6, 2015; last reviewed August 6, 2015)*

<table>
<thead>
<tr>
<th>Name</th>
<th>Panel Status</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mirochnick, Mark</td>
<td>M</td>
<td>ViV</td>
<td>DSMB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck</td>
<td>DSMB</td>
</tr>
<tr>
<td>Mofenson, Lynne</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Nesheim, Steve</td>
<td>HHS</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Prioleau, Fatima Y.</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Ross, Polly E.</td>
<td>HHS</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Shapiro, Alan</td>
<td>HHS</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Siberry, George</td>
<td>HHS, ES</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Spector, Stephen A.</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Squires, Kathleen E.</td>
<td>M</td>
<td>Gilead Sciences</td>
<td>Advisory Board Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Janssen</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Merck</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tobira</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vertex</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ViV</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Storm, Deborah</td>
<td>NVO</td>
<td>Merck</td>
<td>Stockholder</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lilly</td>
<td>Stockholder</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roche</td>
<td>Stockholder</td>
</tr>
<tr>
<td>Sullivan, Meg</td>
<td>M</td>
<td>Gilead</td>
<td>Advisory Board Research Support</td>
</tr>
<tr>
<td>Tuomala, Ruth</td>
<td>M</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Watts, D. Heather</td>
<td>HHS</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Weinberg, Geoffrey A.</td>
<td>M</td>
<td>Merck</td>
<td>Research Support</td>
</tr>
</tbody>
</table>

**Key to Acronyms:** DSMB = Data Safety Monitoring Board; ES = Executive Secretary; ExOM = Ex Officio Member; HHS = Member from Department of Health and Human Services; M = Member; N/A = Not applicable; NVO = Nonvoting Observer
Introduction (Last updated August 6, 2015; last reviewed August 6, 2015)

Recommendations regarding HIV screening and treatment of pregnant women and prophylaxis for perinatal transmission of HIV have evolved considerably in the United States since the mid-1990s, reflecting changes in the epidemic and the science of prevention and treatment. With the implementation of recommendations for universal prenatal HIV counseling and testing, antiretroviral (ARV) prophylaxis, scheduled cesarean delivery, and avoidance of breastfeeding, the rate of perinatal transmission of HIV has dramatically diminished to 2% or less in the United States and Europe. In response to this success, the Centers for Disease Control and Prevention has developed a goal of eliminating perinatal HIV transmission in the United States, defined as reducing perinatal transmission to an incidence <1 infection per 100,000 live births and to a rate of <1% among HIV-exposed infants.

The annual number of pregnancies among HIV-infected women in the United States appears to be increasing, as routine use of antiretroviral therapy (ART) results in HIV-infected women living longer, healthier lives. A focus on appropriate overall medical care for HIV-infected women is the best way to prevent HIV infection of infants, including comprehensive reproductive health, family planning and preconception care services, optimization of HIV treatment, and maintenance of care for HIV-infected women between pregnancies. A critical component of prevention of perinatal HIV transmission is ensuring the use of ART to maximally suppress viral replication as early as possible during pregnancy, as discussed in these guidelines.

These guidelines update the March 28, 2014 Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. The Department of Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission (the Panel), a working group of the Office of AIDS Research Advisory Council (OARAC), develops these guidelines. The guidelines provide health care providers with information for discussion with HIV-infected pregnant women to enable the patient/provider team to make informed decisions regarding the use of ARV drugs during pregnancy and use of scheduled cesarean delivery to reduce perinatal transmission of HIV. The recommendations in the guidelines are accompanied by discussion of various circumstances that commonly occur in clinical practice and the factors that influence treatment considerations. The Panel recognizes that strategies to prevent perinatal transmission and concepts related to management of HIV in pregnant women are rapidly evolving and will consider new evidence and adjust recommendations accordingly. The updated guidelines are available from the AIDSinfo website (http://aidsinfo.nih.gov).

The current guidelines have been structured to reflect the management of an individual mother-child pair and are organized into a brief discussion of preconception care followed by principles for management of a woman and her infant during the antepartum, intrapartum, and postpartum periods. Although perinatal transmission of HIV occurs worldwide, these recommendations have been developed for use in the United States. Alternative strategies may be appropriate in other countries.
## Guidelines Development Process

### Table 1. Outline of the Guidelines Development Process

<table>
<thead>
<tr>
<th>Topic</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Goal of the Guidelines</strong></td>
<td>Provide guidance to HIV care practitioners on the optimal use of ARV agents in pregnant women for treatment of HIV infection and for prevention of perinatal transmission of HIV and management of HIV-exposed infants in the United States.</td>
</tr>
<tr>
<td><strong>Panel Members</strong></td>
<td>The Panel is composed of approximately 30 voting members who have expertise in management of pregnant HIV-infected women (such as training in obstetrics/gynecology, infectious diseases, or women's health) and interventions for prevention of perinatal transmission (such as specialized training in pediatric HIV infection) as well as community representatives with knowledge of HIV infection in pregnant women and interventions for prevention of perinatal transmission. The U.S. government agencies are selected by Panel members after an open announcement to call for nominations. Each member serves on the Panel for a 3-year period, with an option for re-appointment. The Panel may also include liaison members from the Perinatal HIV Hotline, the American Academy of Pediatrics’ Committee on Pediatric AIDS, and the American College of Obstetricians and Gynecologists. A list of all Panel members can be found on Page IV of the guidelines.</td>
</tr>
<tr>
<td><strong>Financial Disclosures</strong></td>
<td>All members of the Panel submit a written financial disclosure annually reporting any association with manufacturers of ARV antiretroviral drugs or diagnostics used for management of HIV infections. A list of the latest disclosures is available on the AIDSinfo website (<a href="http://aidsinfo.nih.gov">http://aidsinfo.nih.gov</a>).</td>
</tr>
<tr>
<td><strong>Users of the Guidelines</strong></td>
<td>Providers of care to HIV-infected pregnant women and to HIV-exposed infants</td>
</tr>
<tr>
<td><strong>Developer</strong></td>
<td>Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission—a working group of OARAC</td>
</tr>
<tr>
<td><strong>Funding Source</strong></td>
<td>Office of AIDS Research, NIH</td>
</tr>
<tr>
<td><strong>Evidence for Recommendations</strong></td>
<td>The recommendations in these guidelines are generally based on studies published in peer-reviewed journals. On some occasions, particularly when new information may affect patient safety, unpublished data presented at major conferences or prepared by the FDA and/or manufacturers as warnings to the public may be used as evidence to revise the guidelines.</td>
</tr>
<tr>
<td><strong>Recommendation Grading</strong></td>
<td>See Table 2.</td>
</tr>
<tr>
<td><strong>Method of Synthesizing Data</strong></td>
<td>Each section of the guidelines is assigned to a small group of Panel members with expertise in the area of interest. A structured literature search is conducted by a representative from the Francois-Xavier Bagnoud Center (through funding from HRSA) and provided to the Panel working group. The members review and synthesize the available data and propose recommendations to the entire Panel. The Panel discusses all proposals during monthly teleconferences. Proposals are modified based on Panel discussion and then distributed, with ballots, to all Panel members for concurrence and additional comments. If there are substantive comments or votes against approval, the recommended changes and areas of disagreement are brought back to the full Panel (via email or teleconference) for additional review, discussion and further modification to reach a final version acceptable to all Panel members. The recommendations in these final versions represent endorsement from a consensus of members and are included in the guidelines as official Panel recommendations.</td>
</tr>
<tr>
<td><strong>Other Guidelines</strong></td>
<td>These guidelines focus on HIV-infected pregnant women and their infants. Other guidelines (all available on the AIDSinfo website <a href="http://www.aidsinfo.nih.gov">http://www.aidsinfo.nih.gov</a>) outline the use of ARV agents in non-pregnant HIV-infected adults and adolescents; use of ARV agents in HIV-infected infants and children; treatment and prevention of opportunistic infections in HIV-infected adults and adolescents, including pregnant women; treatment and prevention of opportunistic infections in HIV-infected and HIV-exposed children; and treatment of people who experience occupational or non-occupational exposure to HIV.). Preconception management for non-pregnant women of reproductive age is briefly discussed in this document. However, for more detailed discussion on issues of treatment of non-pregnant adults, the Working Group defers to the designated expertise offered by Panels that have developed those guidelines.</td>
</tr>
</tbody>
</table>
Guidelines Development Process

Table 1. Outline of the Guidelines Development Process, cont’d

<table>
<thead>
<tr>
<th>Topic</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Update Plan</td>
<td>The Panel meets monthly by teleconference to review data that may warrant modification of the guidelines. Updates may be prompted by new drug approvals (or new indications, new dosing formulations, or changes in dosing frequency), significant new safety or efficacy data, or other information that may have a significant impact on the clinical care of patients. In the event of significant new data that may affect patient safety, the Panel may issue a warning announcement and accompanying recommendations on the AIDSinfo website until the guidelines can be updated with appropriate changes. Updated guidelines are available on the AIDSinfo website.</td>
</tr>
<tr>
<td>Public Comments</td>
<td>A 2-week public comment period follows release of the updated guidelines on the AIDSinfo website. The Panel reviews comments received to determine whether additional revisions to the guidelines are indicated. The public may also submit comments to the Panel at any time at <a href="mailto:contactus@aidsinfo.nih.gov">contactus@aidsinfo.nih.gov</a>.</td>
</tr>
</tbody>
</table>

Key to Acronyms: ARV = antiretroviral; FDA = Food and Drug Administration; HRSA = Health Resources and Services Administration; NIH = National Institutes of Health; OARAC = Office of AIDS Research Advisory Council

Basis for Recommendations

Recommendations in these guidelines are based on scientific evidence and expert opinion. Each recommended statement is rated with a letter of A, B, or C that represents the strength of the recommendation and with a numeral I, II, or III, according to the quality of evidence.

Table 2. Rating Scheme for Recommendations

<table>
<thead>
<tr>
<th>Strength of Recommendation</th>
<th>Quality of Evidence for Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A: Strong recommendation for the statement</td>
<td>I: One or more randomized trials with clinical outcomes and/or validated laboratory endpoints</td>
</tr>
<tr>
<td>B: Moderate recommendation for the statement</td>
<td>II: One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes</td>
</tr>
<tr>
<td>C: Optional recommendation for the statement</td>
<td>III: Expert opinion</td>
</tr>
</tbody>
</table>

References


Preconception Counseling and Care for HIV-Infected Women of Childbearing Age  
(Last updated August 6, 2015; last reviewed August 6, 2015)

Panel’s Recommendations

| • Discuss childbearing intentions with all women of childbearing age on an ongoing basis throughout the course of their care (AII). |
| • Provide information about effective and appropriate contraceptive methods to reduce the likelihood of unintended pregnancy (AI). |
| • During preconception counseling, include information on safer sexual practices and elimination of alcohol, illicit drugs, and smoking (AI). |
| • All HIV-infected women contemplating pregnancy should be receiving combination antiretroviral therapy (cART) and have a plasma viral load below the limit of detection prior to conception (AI). |
| • When selecting or evaluating cART for HIV-infected women of childbearing age, consider a regimen’s effectiveness, a woman’s hepatitis B status, teratogenic potential of the drugs in the cART regimen, and possible adverse outcomes for the mother and fetus (AI). |
| • HIV infection does not preclude the use of any contraceptive method (AI). However, drug-drug interactions between hormonal contraceptives and cART should be taken into account. |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Overview

The Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists, and other national organizations recommend offering all women of childbearing age comprehensive family planning and the opportunity to receive preconception counseling and care as a component of routine primary medical care. The purpose of preconception care is to improve the health of each woman before conception by identifying risk factors for adverse maternal or fetal outcomes, providing education and counseling targeted to patients’ individual needs, and treating or stabilizing medical conditions to optimize maternal and fetal outcomes. Preconception care is not something that occurs in a single clinical visit but, rather, a process of ongoing care and interventions integrated into primary care to address the needs of women during the different stages of reproductive life. Because more than half of all pregnancies in the United States are unintended it is important that comprehensive family planning and preconception care be integrated into routine health visits. Providers should initiate and document a nonjudgmental conversation with all women of reproductive age concerning their reproductive desires because women may be reluctant to bring this up themselves. HIV care providers who routinely care for women of reproductive age play an important role in promoting preconception health and informed reproductive decisions.

The fundamental principles of preconception counseling and care are outlined in the CDC Preconception Care Work Group’s Recommendations to Improve Preconception Health and Health Care. In addition to the general components of preconception counseling and care that are appropriate for all women of reproductive age, HIV-infected women have specific needs that should be addressed. Because many HIV-infected women are aware of their HIV status before becoming pregnant, issues that impact pregnancy can be addressed before conception during their routine medical care for HIV disease. In addition to the principles outlined by the CDC Preconception Care Work Group, the following components of preconception counseling and care are specifically recommended for HIV-infected women. Health care providers should:

• Discuss reproductive options, actively assess women’s pregnancy intentions on an ongoing basis throughout the course of care, and, when appropriate, make referrals to experts in HIV and women’s health, including experts in reproductive endocrinology and infertility when necessary.
• Counsel on safe sexual practices (including condoms) that prevent HIV transmission to sexual partners, protect women from acquiring sexually transmitted diseases, and reduce the potential to acquire more virulent or resistant strains of HIV.

• Counsel on eliminating alcohol, illicit drug use, and cigarette smoking.

• Counsel women contemplating pregnancy to take a daily multivitamin that contains 400 mcg of folic acid to help prevent certain birth defects.

• Educate and counsel women about risk factors for perinatal transmission of HIV, strategies to reduce those risks, potential effects of HIV or of antiretroviral (ARV) drugs given during pregnancy on pregnancy course and outcomes, and the recommendation that HIV-infected women in the United States not breastfeed because of the risk of transmission of HIV to their infants and the availability of safe and sustainable infant feeding alternatives.

• When prescribing combination antiretroviral therapy (cART) to women of childbearing age, consider the regimen’s effectiveness, an individual’s hepatitis B status, the potential for teratogenicity, and possible adverse outcomes for mother and fetus.\(^{20-22}\)

• Use the preconception period in women who are contemplating pregnancy to adjust cART to exclude efavirenz or other drugs with teratogenic potential.

• Make a primary treatment goal for women who are on cART and who are planning a pregnancy to attain a sustained suppression of plasma viral load below the limit of detection prior to conception to decrease the risk of perinatal transmission and of HIV transmission to an uninfected partner.

• Evaluate and manage therapy-associated side effects such as hyperglycemia, anemia, and hepatotoxicity that may adversely impact maternal-fetal health outcomes.

• Evaluate the need for prophylaxis or treatment of opportunistic infections, considering the safety, tolerability, and potential toxicity of specific agents when used in pregnancy (see Pediatric OI Guidelines and Adult OI Guidelines).


• Encourage sexual partners to receive counseling and HIV testing and, if infected, to seek HIV care.

• Offer all women who do not desire pregnancy effective and appropriate contraceptive methods to reduce the likelihood of unintended pregnancy. HIV-infected women can use all available contraceptive methods, including hormonal contraception (e.g., pill, patch, ring, injection, implant) and intrauterine devices (IUDs).\(^{23}\) Providers should be aware of potential interactions between ARV drugs and hormonal contraceptives that could lower contraceptive efficacy (see Table 3 below).

• Offer emergency contraception as appropriate, including emergency contraceptive pills and the copper IUD. Concerns about drug interactions between ARVs and emergency contraceptive pills containing estrogen and a progestin, or containing levonorgestrel only, may be similar to concerns when those formulations are used for regular contraception.\(^{24}\) There are no data on potential interactions between ARVs and ulipristal acetate, a progesterone receptor modulator; however, ulipristal acetate is predominantly metabolized by CYP3A4, so interactions can be expected.

A World Health Organization expert group reviewed all available evidence regarding hormonal contraception and HIV transmission to an uninfected partner and recommended that women living with HIV can continue to use all existing hormonal contraceptive methods without restriction.\(^{25}\) However, drug-drug interactions between hormonal contraceptives and cART should be taken into account (see Table 3).

Data on drug interactions between ARV agents and hormonal contraceptives primarily come from drug labels Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States B-2

and limited studies,\textsuperscript{24,26-38} and the clinical implications have not been well studied. The magnitude of changes in contraceptive drug levels that may reduce contraceptive efficacy or increase contraceptive-associated adverse effects is unknown. In a study of 570 HIV-infected women in Swaziland using Jadelle implants, none of the women on nevirapine or ritonavir-boosted lopinavir-based regimens (n = 208 and 13, respectively) became pregnant, whereas 15 women on efavirenz (n = 121; 12.4\%) became pregnant.\textsuperscript{37} Hormonal contraceptives can be used with cART in women without other contraindications. Additional or alternative methods of contraception may be recommended when drug interactions are known. For women using ritonavir-boosted protease inhibitors who are on combination hormonal contraceptives (e.g., pills, patches, rings) or progestin-only pills, use of an alternative or additional method of contraception is recommended. Implants generally can be used, but providers may also consider use of an alternative method or recommend the additional use of a reliable barrier method. Depot medroxyprogesterone acetate (DMPA) can be used without restriction because of its relatively higher dose and limited studies that have shown no significant interaction between DMPA and ARVs.\textsuperscript{27,29}

Because no high-quality, definitive studies exist on pregnancy rates among women on different hormonal contraceptives and ARVs, the dosing recommendations in Table 3 are based on consensus expert opinion. Whenever possible, the recommendations are based on available data regarding pharmacokinetic (PK) interactions between ARVs and combined hormonal methods, DMPA and etonogestrel implants. The lowest decreases in PK for which an alternative method was recommended was 14\% in norethindrone (with ritonavir-boosted darunavir) and 19\% in ethinyl estradiol (ritonavir-boosted atazanavir). For women using atazanavir without ritonavir boosting (ethinyl estradiol increase 48\%, norethindrone increase 110\%), the Panel recommends use of oral contraceptives containing ≤30 μg ethinyl estradiol. The Panel did not recommend any change in ethinyl estradiol dose for etravirine (ethinyl estradiol increase 22\%), rilpivirine (ethinyl estradiol increase 14\%), or indinavir (ethinyl estradiol increase 25\%, norethindrone increase 26\%).

All recommendations in the following table are based on consensus expert opinion.

### Table 3. Drug Interactions Between Antiretroviral Agents and Hormonal Contraceptives (CIII)
(page 1 of 3)

<table>
<thead>
<tr>
<th>ARV Drug</th>
<th>Effect on Contraceptive Drug Levels</th>
<th>Dosing Recommendation/ Clinical Comment for Combined Hormonal Methods and Progestin-Only Pills</th>
<th>Dosing Recommendation/ Clinical Comment for DMPA\textsuperscript{a}</th>
<th>Dosing Recommendation/ Clinical Comment for Etonogestrel Implants</th>
</tr>
</thead>
<tbody>
<tr>
<td>NNRTIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EFV</td>
<td>Oral Ethinyl Estradiol/Norgestimate:</td>
<td>Use alternative or additional contraceptive method.</td>
<td>No additional contraceptive protection is needed.</td>
<td>Use alternative or additional contraceptive method.</td>
</tr>
<tr>
<td></td>
<td>• No effect on ethinyl estradiol concentrations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• ↓ active metabolites of norgestimate (levonorgestrel AUC ↓ 83%; norelgestromin AUC ↓ 64%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Implant:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• ↓ etonogestrel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Levonorgestrel (Emergency contraception) AUC ↓ 58%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3. Drug Interactions Between Antiretroviral Agents and Hormonal Contraceptives (CIII) (page 2 of 3)

<table>
<thead>
<tr>
<th>ARV Drug</th>
<th>Effect on Contraceptive Drug Levels</th>
<th>Dosing Recommendation/ Clinical Comment for Combined Hormonal Methods and Progestin-Only Pills</th>
<th>Dosing Recommendation/ Clinical Comment for DMPA&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Dosing Recommendation/ Clinical Comment for Etonogestrel Implants</th>
</tr>
</thead>
<tbody>
<tr>
<td>NNRTIs, continued</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETR</td>
<td>Ethinyl estradiol AUC ↑ 22%</td>
<td>No additional contraceptive protection is needed.</td>
<td>No additional contraceptive protection is needed.</td>
<td>No additional contraceptive protection is needed.</td>
</tr>
<tr>
<td></td>
<td>Norethindrone: No significant effect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NVP</td>
<td>Ethinyl estradiol AUC ↓ 20%</td>
<td>Can consider an alternative method or a reliable method of barrier contraception in addition to this method.</td>
<td>No additional contraceptive protection is needed.</td>
<td>Can consider an alternative method or a reliable method of barrier contraception in addition to this method.</td>
</tr>
<tr>
<td></td>
<td>Norethindrone AUC ↓ 19% DMPA: No significant change</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPV</td>
<td>Ethinyl estradiol AUC ↑ 14%</td>
<td>No additional contraceptive protection is needed.</td>
<td>No additional contraceptive protection is needed.</td>
<td>No additional contraceptive protection is needed.</td>
</tr>
<tr>
<td></td>
<td>Norethindrone: No significant effect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTV-Boosted PIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATV/r</td>
<td>Ethinyl estradiol AUC ↓ 19%</td>
<td>Use alternative or additional contraceptive method.</td>
<td>No additional contraceptive protection is needed.</td>
<td>Can consider an alternative method or a reliable method of barrier contraception in addition to this method.</td>
</tr>
<tr>
<td></td>
<td>Norgestimate AUC ↑ 85%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRV/r</td>
<td>Ethinyl estradiol AUC ↓ 44%</td>
<td>Use alternative or additional contraceptive method.</td>
<td>No additional contraceptive protection is needed.</td>
<td>Can consider an alternative method or a reliable method of barrier contraception in addition to this method.</td>
</tr>
<tr>
<td></td>
<td>Norethindrone AUC ↓ 14%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FPV/r</td>
<td>Ethinyl estradiol AUC ↓ 37%</td>
<td>Use alternative or additional contraceptive method.</td>
<td>No additional contraceptive protection is needed.</td>
<td>Can consider an alternative method or a reliable method of barrier contraception in addition to this method.</td>
</tr>
<tr>
<td></td>
<td>Norethindrone AUC ↓ 34%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LPV/r</td>
<td>Ethinyl estradiol AUC ↓ 42%</td>
<td>Use alternative or additional contraceptive method.</td>
<td>No additional contraceptive protection is needed.</td>
<td>Can consider an alternative method or a reliable method of barrier contraception in addition to this method.</td>
</tr>
<tr>
<td></td>
<td>Norethindrone AUC ↓ 17%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SQV/r</td>
<td>Ethinyl estradiol ↓</td>
<td>Use alternative or additional contraceptive method.</td>
<td>No additional contraceptive protection is needed.</td>
<td>Can consider an alternative method or a reliable method of barrier contraception in addition to this method.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPV/r</td>
<td>Ethinyl estradiol AUC ↓ 48%</td>
<td>Use alternative or additional contraceptive method.</td>
<td>No additional contraceptive protection is needed.</td>
<td>Can consider an alternative method or a reliable method of barrier contraception in addition to this method.</td>
</tr>
<tr>
<td></td>
<td>Norethindrone: No significant change</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3. Drug Interactions Between Antiretroviral Agents and Hormonal Contraceptives (CIII)  
(page 3 of 3)

<table>
<thead>
<tr>
<th>ARV Drug</th>
<th>Effect on Contraceptive Drug Levels</th>
<th>Dosing Recommendation/ Clinical Comment for Combined Hormonal Methods and Progestin-Only Pills</th>
<th>Dosing Recommendation/ Clinical Comment for DMPA</th>
<th>Dosing Recommendation/ Clinical Comment for Etonogestrel Implants</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIs without RTV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATV</td>
<td>Ethinyl estradiol AUC ↑ 48% Norethindrone AUC ↑ 110%</td>
<td>No additional contraceptive protection is needed. Oral contraceptive should contain ≤30 mcg of ethinyl estradiol or use alternative method. Oral contraceptives containing &lt;25 mcg ethinyl estradiol or progestins other than norethindrone or norgestimate have not been studied.</td>
<td>No additional contraceptive protection is needed.</td>
<td>No additional contraceptive protection is needed.</td>
</tr>
</tbody>
</table>
| FPV      | Amprenavir:  
• ↑ Ethinyl estradiol  
• ↑ Norethindrone  
Fosamprenavir with Ethinyl Estradiol/Norethindrone:  
• ↓ Amprenavir (AUC 22%, C_{min} 20%) | Use alternative contraceptive method. Use of fosamprenavir alone with ethinyl estradiol/norethindrone may lead to loss of virologic response. | No additional contraceptive protection is needed. | Use alternative or additional contraceptive method. |
| IDV      | Ethinyl estradiol AUC ↑ 25% Norethindrone AUC ↑ 26% | No additional contraceptive protection is needed. | No additional contraceptive protection is needed. | No additional contraceptive protection is needed. |
| NFV      | Ethinyl estradiol AUC ↓ 47% Norethindrone AUC ↓ 18% | Use alternative or additional contraceptive method. | No additional contraceptive protection is needed. | Use alternative or additional contraceptive method. |

| CCR5 Antagonist |
| MVC      | No significant effect on ethinyl estradiol or levonorgestrel | No additional contraceptive protection is needed. | No additional contraceptive protection is needed. | No additional contraceptive protection is needed. |

| Integrase Inhibitor |
| RAL       | No significant effect | No additional contraceptive protection is needed. | No additional contraceptive protection is needed. | No additional contraceptive protection is needed. |

| EVG/ COBI |
| Norgestimate AUC ↑ 226% Ethinyl estradiol AUC ↓ 75% | No additional contraceptive protection is needed. | No additional contraceptive protection is needed. | No additional contraceptive protection is needed. |

— Because the hormonal levels achieved with DMPA are substantially higher than are required for contraception, any small reduction in hormonal level due to ARVs is unlikely to reduce contraceptive effectiveness.

Key to Acronyms: ARV = antiretroviral; ATV = atazanavir; ATV/r = ritonavir-boosted atazanavir; AUC = area under the curve; C_{min} = minimum plasma concentration; COBI = cobicistat; DMPA = depot medroxyprogesterone acetate; DRV/r = ritonavir-boosted darunavir; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; FPV = fosamprenavir; FPV/r = ritonavir-boosted fosamprenavir; IDV = indinavir; LPV/r = ritonavir-boosted lopinavir; MVC = maraviroc; NFV = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SQV/r = ritonavir-boosted saquinavir; TPV/r = ritonavir-boosted tipranavir


Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

B-5

References


Reproductive Options for HIV-Concordant and Serodiscordant Couples

For Couples Who Want to Conceive

For Concordant (Both Partners are HIV-Infected) and Discordant Couples:
- Expert consultation is recommended so that approaches can be tailored to couples’ specific needs (AIII).
- Partners should be screened and treated for genital tract infections before attempting to conceive (AII).
- The HIV-infected partner(s) should attain maximum viral suppression before attempting conception (AIII).

For Discordant Couples:
- The HIV-infected partner should be receiving combination antiretroviral therapy and demonstrate sustained suppression of plasma viral load below the limits of detection (AI).
  - Periconception administration of antiretroviral pre-exposure prophylaxis for HIV-uninfected partners may offer an additional tool to reduce the risk of sexual transmission (CIII). The utility of pre-exposure prophylaxis for the uninfected partner when the infected partner is receiving combination antiretroviral therapy with maximal viral suppression has not been studied.

Discordant Couples with HIV-Infected Women:
- The safest conception option is artificial insemination, including the option of self-insemination with a partner’s sperm during the peri-ovulatory period (AIII).

Discordant Couples with HIV-Infected Men:
- The use of donor sperm from an HIV-uninfected man with artificial insemination is the safest option (AIII).
- When the use of donor sperm is unacceptable, the use of sperm preparation techniques coupled with either intrauterine insemination or in vitro fertilization should be considered (AI).
- Semen analysis is recommended for HIV-infected men before conception is attempted to prevent unnecessary exposure to infectious genital fluid when the likelihood of conception is low because of semen abnormalities (AII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

For couples in which one or both partners are HIV-infected, optimal health should be attained before attempting conception; infected partners should be receiving combination antiretroviral therapy (cART) and demonstrate sustained suppression of plasma viral load below the limits of detection.

For concordant or serodiscordant couples who want to conceive, expert consultation is recommended so that approaches can be tailored to specific needs, which may vary from couple to couple.

Before attempting to conceive, both partners should be screened for genital tract infections. Treatment of such infections is important because genital tract inflammation is associated with genital tract shedding of HIV.1-5

Serodiscordant Couples

Before conception is attempted, the HIV-infected partner should be receiving cART and demonstrate sustained suppression of plasma viral load below the limits of detection. Observational studies have demonstrated a decreased rate of transmission of HIV in heterosexual serodiscordant couples among whom the index partners were on cART compared with those not on therapy.6-8 HPTN 052 was a randomized clinical trial designed to evaluate whether immediate versus delayed initiation of cART by HIV-infected individuals with CD4 T lymphocyte (CD4) cell counts of 350 to 550 cells/mm³ could prevent sexual transmission of HIV among serodiscordant couples. Most of the participants were from Africa (54%), with 30% from Asia and 16% from North and South America. This study showed that earlier initiation of cART led to a 96% reduction in transmission of HIV to the uninfected partner. Of 28 cases of HIV infection...
documented to be genetically linked to the infected partner, 27 occurred in the 877 couples in which the HIV-infected partner delayed initiation of cART until the CD4 cell count fell below 250 cells/mm$^3$, whereas only one case of HIV infection occurred in the 886 couples with an HIV-infected partner who began immediate cART; 17 of the 27 transmissions in the delayed-therapy group occurred in individuals with CD4 cell counts $>350$ cells/mm$^3$. The majority of transmissions (82%) were observed in participants from Africa. Thus this randomized trial clearly demonstrated that provision of treatment to infected individuals can reduce the risk of transmission to their uninfected sexual partners.\textsuperscript{9}

**Use of cART reduces but may not completely eliminate the risk of HIV sexual transmission in couples who have decided to conceive through unprotected intercourse.\textsuperscript{10}** It is important to recognize that no single method (including treatment of the infected partner) is fully protective against transmission of HIV. Effective cART that decreases plasma viral load to undetectable levels is also associated with decreased concentration of virus in genital secretions. In a prospective study of 2,521 African HIV-infected serodiscordant couples, higher genital HIV RNA concentrations were associated with greater risk of heterosexual HIV-1 transmission and this effect was independent of plasma HIV concentrations.\textsuperscript{11} Each log$_{10}$ increase in genital HIV-1 RNA levels increased the risk of female-to-male or male-to-female HIV transmission by 1.7-fold.\textsuperscript{11} Discordance between plasma and genital viral loads has been reported, and individuals with an undetectable plasma viral load may have detectable genital tract virus.\textsuperscript{12-14} In addition, antiretroviral (ARV) drugs vary in their ability to penetrate the genital tract.\textsuperscript{15}

Starting cART before conception in HIV-infected women may also reduce the risk of perinatal transmission. Data suggest that early and sustained control of HIV viral replication may be associated with decreasing residual risk of perinatal transmission,\textsuperscript{16,17} but not complete elimination of the risk of perinatal transmission.\textsuperscript{17} In addition, reports are mixed on the possible effects of cART on prematurity and low birthweight, with some but not all data suggesting that such outcomes may be more frequent in women on ARV drugs at conception.\textsuperscript{18-20}

The implications of initiating therapy before conception solely for prevention of sexual and/or perinatal transmission should be discussed with the couple. These issues include the potential risks versus benefits of stopping or continuing the regimen after conception in the man or postpartum in the woman, and the need for strict adherence to achieve a plasma viral load below the limits of detection. Consultation with an expert in HIV care is strongly recommended.

For HIV-discordant couples in which the woman is the HIV-infected partner, the safest form of conception is artificial insemination, including the option to self-inseminate with the partner’s sperm during the periovulatory period. Condom use should be advised at all times.

For HIV-discordant couples in which the man is the HIV-infected partner, the use of donor sperm from an HIV-uninfected man with artificial insemination is the safest option. When the use of donor sperm is unacceptable, the use of sperm preparation techniques coupled with either intrauterine insemination or in vitro fertilization with intracytoplasmic sperm injection has been reported to be effective in avoiding seroconversion in uninfected women and offspring in several studies.\textsuperscript{21-23} Sperm preparation should utilize optimal methods that can detect the presence of HIV. Couples should also consider the cost and other possible complications of in vitro fertilization. More data are needed to demonstrate the complete efficacy of these techniques, and couples should be cautioned that there may be a small risk of transmission of HIV to the uninfected partner and to their offspring.\textsuperscript{22} Semen analysis is recommended for HIV-infected men before conception is attempted because HIV, and possibly cART, may be associated with a higher prevalence of semen abnormalities such as low sperm count, low motility, higher rate of abnormal forms, and low semen volume. If such abnormalities are present, the uninfected female partner may be exposed unnecessarily and for prolonged periods to her partner’s infectious genital fluids when the likelihood of conceiving naturally is low or nonexistent.\textsuperscript{24-27}

Discordant couples who do not have access to these reproduction services (i.e., artificial insemination, sperm preparation, in vitro fertilization) and who still want to try to conceive after comprehensive counseling
should be advised that timed, periovulatory unprotected intercourse after the infected partner has achieved plasma viral load below the limits of detection (with use of condoms at all other times) may reduce but not completely eliminate the risk of sexual transmission.\textsuperscript{22} HIV-uninfected women who become pregnant should be regularly counseled regarding consistent condom use to decrease their risk of sexual transmission of HIV and the possible risk of perinatal transmission (see Monitoring of HIV Uninfected Pregnant Women with a Partner Known to be HIV Infected).

Periconception pre-exposure prophylaxis (PrEP) may offer an additional option to minimize risk of transmission of HIV within discordant couples. PrEP is use of ARV medications by an HIV-uninfected individual to maintain blood and genital drug levels sufficient to prevent acquisition of HIV. Many studies have demonstrated that PrEP reduces the risk of HIV acquisition in both men and women, with minimal risk of incident ARV resistance. Other trials failed to demonstrate PrEP efficacy, likely related to suboptimal levels of adherence.\textsuperscript{9,28-33} Table 4 summarizes clinical trials of PrEP.\textsuperscript{34}

### Table 4. Clinical Trials of Pre-Exposure Prophylaxis

<table>
<thead>
<tr>
<th>Trial</th>
<th>Study Population</th>
<th>Location</th>
<th>Intervention</th>
<th>Outcome</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF2</td>
<td>1,219 sexually active adults; 55% male, 45% female; 94 % unmarried; approximately 90% aged 21–29</td>
<td>Botswana</td>
<td>Daily oral TDF/FTC</td>
<td>63% protection</td>
<td>&gt;30% did not complete study; cannot draw definitive conclusions for women and men separately.</td>
</tr>
<tr>
<td>PIP</td>
<td>4,758 heterosexual serodiscordant couples; 38% HIV-negative female, 68% HIV-negative male partner; 98% married; median age 33</td>
<td>Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, Zambia</td>
<td>Daily oral TDF or TDF/FTC</td>
<td>67% protection with TDF alone; 75% protection with TDF/FTC</td>
<td>Discordant couples may be a distinct, unique population.</td>
</tr>
<tr>
<td>FEM-PrEP</td>
<td>1,951 heterosexual women aged 18–35 at high risk of infection</td>
<td>Kenya, South Africa, Tanzania</td>
<td>Daily oral TDF/FTC</td>
<td>Trial discontinued for futility in April 2011.</td>
<td>Adherence assessment with monthly clinical samples to measure drug concentration is pending.</td>
</tr>
<tr>
<td>VOICE MTN-003</td>
<td>5,029 heterosexual women aged 18–45 in high-prevalence areas</td>
<td>Uganda, South Africa, Zimbabwe</td>
<td>Daily oral TDF or daily oral TDF/FTC or daily topical TFV gel</td>
<td>No study drug significantly reduced the risk of HIV acquisition. HIV incidence was 5.7 per 100 person years; effectiveness was -48.8% for TDF, -4.2% for TDF/FTC, and 14.7% for TDF gel.</td>
<td>Adherence to study drugs was low; TFV was detected in 30% of the oral TDF arm, 29% in the oral TDF/FTC arm, and 25% in the TDF gel arm.</td>
</tr>
<tr>
<td>HPTN 052</td>
<td>1,763 heterosexual serodiscordant couples; 50% HIV-negative female, 50% HIV-negative male partner; 94% married; 61% aged 26–40 years</td>
<td>Botswana, Kenya, Malawi, South Africa, Zimbabwe, Brazil, India, Thailand</td>
<td>Immediate or delayed cART in HIV-infected partner</td>
<td>96% protection on immediate cART</td>
<td>Suppression of viraemia on therapy assured by routine monitoring.</td>
</tr>
</tbody>
</table>

**Key to Acronyms:** cART = combination antiretroviral therapy; TDF = tenofovir disoproxil fumarate; TFV = tenofovir; FTC = emtricitabine

**Source:** Adapted from: Kashuba et al., Pre-exposure prophylaxis for HIV prevention: how to predict success. Table Antiretroviral-based HIV prevention studies. \textit{Lancet} 2012;379(9835): 2409-2411.
PPrEP may offer an additional strategy for safer conception. Couples should be advised to use condoms at all times except during periovulatory intercourse. Several studies evaluating the efficacy of PrEP in heterosexual discordant couples planning pregnancy are ongoing but complete data are not yet available. One study evaluated timed intercourse with PrEP in 46 heterosexual HIV-discordant couples with an HIV-uninfected female partner. The male HIV-infected partners were receiving cART and had undetectable plasma HIV RNA levels. One dose of oral tenofovir disoproxil fumarate (tenofovir) was taken by the women at luteinizing hormone peak and a second oral dose was taken 24 hours later. None of the women became HIV infected and pregnancy rates were high, reaching a plateau of 75% after 12 attempts.\(^{35}\)

Only daily dosing of combination tenofovir and emtricitabine is currently Food and Drug Administration-approved for use as PrEP. Adherence is critical. The use of continued PrEP is recommended for anyone who is at ongoing risk of HIV acquisition.

Pregnancy and breastfeeding are not contraindications to PrEP.\(^{36-40}\) Currently, there is no reported increase in congenital anomalies among children born to women exposed to tenofovir (2.3%) or to emtricitabine (2.4%) during the first trimester.\(^{41}\) Data from studies of infants born to HIV infected mothers and exposed to tenofovir through breast milk suggest limited drug exposure.\(^{42-44}\) Condom use should be encouraged in pregnancy because several studies have reported increased incidence of HIV acquisition during pregnancy, which may also lead to increased perinatal transmission.

The utility of daily oral PrEP when the HIV-infected partner is receiving cART has not been studied. If clinicians elect to use PrEP for HIV-uninfected women or men in serodiscordant couples, the couples should be educated about the potential risks and benefits and all available alternatives for safer conception. The Centers for Disease Control and Prevention (CDC) recommends that an HIV-uninfected partner planning pregnancy with an HIV-infected partner start daily oral tenofovir plus emtricitabine beginning 1 month before conception is attempted and continued for 1 month after conception is attempted.\(^{45}\) Recommended laboratory testing should include HIV diagnostic testing at baseline then every 3 months, renal function testing at baseline and then every 6 months, and pregnancy testing at baseline and every 3 months. Testing for hepatitis B virus (HBV) infection, should be performed when initiating PrEP. HBV-uninfected individuals should be vaccinated if they have not received HBV vaccination or they lack immunity to HBV. Individuals receiving PrEP should be educated about symptoms associated with acute HIV infection and advised to contact their providers immediately for further evaluation, should symptoms occur. HIV-uninfected partners should undergo frequent HIV testing to detect HIV infection quickly. If HIV infection is documented, the PrEP ARV agents should be discontinued to minimize selection of drug-resistant virus, measures should be instituted to prevent perinatal transmission if pregnancy has occurred and attempts at conception stopped if pregnancy has not occurred, and the patient should be referred to an HIV specialist immediately. Individuals with chronic HBV should be monitored for possible hepatitis flares when PrEP is stopped.\(^{46}\) Clinicians are strongly encouraged to register HIV-uninfected women who become pregnant while receiving PrEP with the Antiretroviral Pregnancy Registry.

**Concordant Couples**

Both partners should be on cART with maximum viral suppression before attempting conception. Periovulatory unprotected intercourse (with use of condoms at all other times) is a reasonable option. The risk of HIV superinfection or infection with a resistant virus is negligible when both partners are on cART and have fully suppressed plasma viral loads.\(^{47}\)

The National Perinatal HIV Hotline (1-888-448-8765) is a resource for a list of institutions offering reproductive services for HIV concordant/serodiscordant couples.

The CDC has issued guidelines for the use of PrEP in sexually active heterosexual adults.\(^{48}\)
Monitoring of HIV-Uninfected Pregnant Women with Partners Known to Be HIV-Infected

HIV-uninfected women who present during pregnancy and indicate that their partners are HIV-infected, like all pregnant women, should be notified that HIV screening is recommended and they will receive an HIV test as part of the routine panel of prenatal tests unless they decline. These women also should receive a second HIV test during the third trimester, preferably before 36 weeks’ gestation, as is recommended for high-risk women. Furthermore, pregnant women who present in labor without results of third-trimester testing should be screened on the labor and delivery unit with an expedited serum HIV test, preferably a fourth-generation antigen/antibody expedited HIV test. If at any time during pregnancy a clinician suspects that a pregnant woman may be in the “window” period of seroconversion (i.e., she has signs or symptoms consistent with acute HIV infection), then a plasma HIV RNA test should be used in conjunction with an HIV antigen/antibody fourth-generation test. If the plasma HIV RNA is negative, it should be repeated in 2 weeks. HIV-uninfected pregnant women with HIV-infected partners should always use condoms during sexual intercourse to prevent acquisition of HIV. Women should be counseled regarding the symptoms of acute retroviral syndrome (i.e., fever, pharyngitis, rash, myalgia, arthralgia, diarrhea, and headache) and the importance of seeking medical care and testing if they experience such symptoms.

Pregnancy and breastfeeding are not contraindications to PrEP, and PrEP should be considered in HIV-seronegative pregnant women who are at ongoing risk of HIV acquisition. However, the use of daily oral PrEP during pregnancy and lactation has not been well studied (see section on Serodiscordant Couples).

Women who test HIV seropositive on either conventional or rapid HIV tests should receive appropriate evaluation and interventions to reduce perinatal transmission of HIV, including immediate initiation of appropriate cART and consideration of elective cesarean delivery according to established guidelines (see Transmission and Mode of Delivery). In cases where confirmatory test results are not readily available, such as with rapid testing during labor, it is still appropriate to initiate interventions to reduce perinatal transmission (see Infant Antiretroviral Prophylaxis).

Women with HIV-infected partners who test HIV seronegative should continue to be regularly counseled regarding consistent condom use to decrease their risk of sexual transmission of HIV. Women with primary HIV infection during pregnancy or lactation are at high risk of transmitting HIV to their infants.48,49

References


and Interventions to Reduce Perinatal HIV Transmission in the United States

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States


33. Marrazo J, Ramjee G, al e. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003), abstract 26LB. Presented at: Conference on Retroviruses and Opportunistic Infections. 2013. Atlanta, GA.


Antepartum Care  (Last updated August 6, 2015; last reviewed August 6, 2015)

General Principles Regarding Use of Antiretroviral Drugs During Pregnancy

<table>
<thead>
<tr>
<th>Panel’s Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Initial evaluation of HIV-infected pregnant women should include assessment of HIV disease status and recommendations regarding initiation of combination antiretroviral therapy (cART) or the need for any modification if currently receiving cART (AIII). The National Perinatal HIV Hotline (888-448-8765) provides free clinical consultation on all aspects of perinatal HIV care.</td>
</tr>
<tr>
<td>• All pregnant HIV-infected women should receive cART to prevent perinatal transmission regardless of plasma HIV RNA copy number or CD4 T lymphocyte count (AI). The goal of cART is to maintain a viral load below the limit of detection throughout pregnancy.</td>
</tr>
<tr>
<td>• Combined antepartum, intrapartum, and infant antiretroviral prophylaxis is recommended because antiretroviral drugs reduce perinatal transmission by several mechanisms, including lowering maternal antepartum viral load and providing infant pre- and post-exposure prophylaxis (AI).</td>
</tr>
<tr>
<td>• The known benefits and potential risks of all medication use, including antiretroviral use, during pregnancy should be discussed with all HIV-infected women (AIII).</td>
</tr>
<tr>
<td>• The importance of adherence to antiretroviral regimens should be emphasized in patient counseling (AII).</td>
</tr>
<tr>
<td>• Antiretroviral drug-resistance studies should be performed before starting or modifying ARV drug regimens in women whose HIV RNA levels are above the threshold for resistance testing (i.e., &gt;500 to 1,000 copies/mL) (see Antiretroviral Drug Resistance and Resistance Testing in Pregnancy) (AIII). In pregnant women not already receiving cART, consideration should be given to initiating cART before results of drug-resistance testing are available because earlier viral suppression has been associated with lower risk of transmission. If cART is initiated before results are available, the regimen should be modified, if necessary, based on resistance assay results (BIII).</td>
</tr>
<tr>
<td>• Coordination of services among prenatal care providers, primary care and HIV specialty care providers, and when appropriate, mental health and drug abuse treatment services, and public assistance programs, is essential to ensure that infected women adhere to their antiretroviral drug regimens (AIII).</td>
</tr>
</tbody>
</table>

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

In addition to the standard antenatal assessments for all pregnant women, the initial evaluation of those who are HIV infected should include assessment of HIV disease status and recommendations for HIV-related medical care. This initial assessment should include the following:

• Review of prior HIV-related illnesses and past CD4 T lymphocyte (CD4) cell counts and plasma HIV RNA levels;
• Current CD4 cell count;
• Current plasma HIV RNA level;
• Assessment of the need for prophylaxis against opportunistic infections such as *Pneumocystis jirovecii* pneumonia and *Mycobacterium avium* complex (see Adult and Adolescent Opportunistic Infections Guidelines);
• Screening for hepatitis A virus (HAV), hepatitis C virus and tuberculosis in addition to standard screening for hepatitis B virus (HBV) infection;
• Assessment of the need for immunizations per guidelines from the American College of Obstetricians and Gynecologists, the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America with particular attention to HAV, HBV, influenza, pneumococcus, and Tdap immunizations;¹,²
• Complete blood cell count and renal and liver function testing;
• HLA-B*5701 testing if abacavir use is anticipated (see Table 7);
• History of prior and current antiretroviral (ARV) drug use, including prior ARV use for prevention of perinatal transmission or treatment of HIV and history of adherence problems;
• Results of prior and current HIV ARV drug-resistance studies;
• History of adverse effects or toxicities from prior ARV regimens; and
• Assessment of supportive care needs such as mental health services, substance abuse treatment, and smoking cessation.

The National Perinatal HIV Hotline

The National Perinatal HIV Hotline (888-448-8765) is a federally funded service providing free clinical consultation to providers caring for HIV-infected women and their infants.

Mechanism of Action of Antiretrovirals in Prevention of Perinatal Transmission

ARV drugs for prevention of perinatal transmission of HIV are recommended for all pregnant women, regardless of CD4 cell counts and HIV RNA levels. ARV drugs can reduce perinatal transmission through a number of mechanisms. Antenatal drug administration decreases maternal viral load in blood and genital secretions. Although the risk of perinatal transmission in women with undetectable plasma HIV RNA levels appears to be extremely low, it has been reported even among women on combination antiretroviral therapy (cART). 3-5 Low-level cervicovaginal HIV RNA and DNA shedding has been detected even in women treated with cART who have undetectable plasma viral load. 6-8 Penetration of ARV drugs into the female genital tract has been shown to vary between drugs. 9-11 Another mechanism of protection is infant pre-exposure prophylaxis achieved by administering ARV drugs that cross the placenta and produce adequate systemic drug levels in the fetus. Infant post-exposure prophylaxis is achieved by administering drugs after birth, providing protection from cell-free or cell-associated virus that may have entered the fetal/infant systemic circulation during labor and delivery. The importance of the pre- and post-exposure components of prophylaxis in reducing perinatal transmission is demonstrated by the reduced efficacy of interventions that involve administration of ARVs only during labor and/or to the newborns. 12-18 Therefore, combined antepartum ARV prophylaxis, intrapartum continuation of current regimen with intravenous zidovudine added if the plasma viral load is >1,000 copies/mL, and infant ARV prophylaxis are recommended to prevent perinatal transmission of HIV.

General Principles of Drug Selection

In general, guidelines for the use of cART for the benefit of maternal health during pregnancy are the same as for women who are not pregnant, with some modifications based on concerns about specific drugs and limited experience during pregnancy with newer drugs.

The known benefits and known and unknown risks of ARV drug use during pregnancy should be considered and discussed with women (see Table 7 and Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy). Potential risks of these drugs should be placed into perspective by reviewing the substantial benefits of ARV drugs for maternal health and in reducing the risk of transmission of HIV to infants. Counseling of pregnant women about ARV use should be directive but non-coercive, and providers should help them make informed decisions regarding use of ARV drugs.

Discussions with women about initiation of cART drug regimens should include information about:

• Maternal risk of disease progression and the benefits and risks of initiation of therapy for maternal health;
• Benefit of cART for preventing perinatal transmission of HIV; 4
• Benefits of therapy for reducing sexual transmission to discordant partners when viral suppression is maintained; 19
• The need for strict adherence to the prescribed drug regimen to avoid resistance;
• Potential adverse effects of ARV drugs for mothers, fetuses, and infants, including potential interactions with other medications the women may already be receiving;
• The limited long-term outcome data for women with higher CD4 cell counts who choose to stop cART after delivery rather than continuing therapy; and
• The limited long-term outcome data for infants after in utero drug exposure.

Transplacental passage of ARVs is an important mechanism of infant pre-exposure prophylaxis. Thus, when selecting an ARV regimen for a pregnant woman, at least one nucleoside/nucleotide reverse transcriptase inhibitor agent with high placental transfer should be included as a component of the cART regimen (see Table 7).\textsuperscript{20-23}

In women with plasma HIV RNA levels above the threshold for resistance testing (i.e., >500 to 1,000 copies/mL), ARV drug-resistance studies should be performed before starting cART. As with non-pregnant, HIV-infected adults, cART may be initiated before genotype results are available under certain circumstances. Starting cART pending genotype results is particularly relevant after the first trimester because taking cART for 24 weeks or more has been associated with reduced transmission rates compared to a shorter duration of cART. If cART is initiated before results are available the regimen should be modified, if necessary, based on resistance assay\textsuperscript{24} (see \textit{Antiretroviral Drug Resistance and Resistance Testing in Pregnancy}). Counseling should emphasize the importance of adherence to the ARV drug regimen to minimize the development of resistance.

Support services, mental health services, smoking cessation, and drug abuse treatment may be required, depending on a woman’s individual circumstances. Coordination of services among prenatal care providers, primary care and HIV specialty care providers, mental health and drug abuse treatment services, and public assistance programs is essential to ensure that infected women adhere to their ARV drug regimens.

All HIV-infected pregnant women should be started on cART during pregnancy to minimize the risk of transmission. Providers should work with women to develop long-range plans regarding continuity of medical care. Considerations regarding postpartum continuation of cART for maternal therapeutic indications are the same as for non-pregnant individuals.

Medical care of HIV-infected pregnant women requires coordination and communication between HIV specialists and obstetric providers. General counseling should include current knowledge about risk factors for perinatal transmission. Risk of perinatal transmission of HIV has been associated with potentially modifiable factors, including cigarette smoking, illicit drug use, genital tract infections, and unprotected sexual intercourse with multiple partners during pregnancy.\textsuperscript{25-29} Besides improving maternal health, cessation of cigarette smoking and drug use, treatment of genital tract infections, and use of condoms with sexual intercourse during pregnancy may reduce risk of perinatal transmission. In addition, the CDC and American Academy of Pediatrics recommend that HIV-infected women in the United States (including those receiving cART) refrain from breastfeeding to avoid postnatal transmission of HIV to their infants through breast milk,\textsuperscript{30,31} and avoid pre-mastication of food for their infants, a potential risk factor for transmission.\textsuperscript{32}

References


Downloaded from \url{http://aidsinfo.nih.gov/guidelines} on 6/11/2016


**Teratogenicity**  (Last updated August 6, 2015; last reviewed August 6, 2015)

### Panel’s Recommendations

- All cases of antiretroviral (ARV) drug exposure during pregnancy should be reported to the Antiretroviral Pregnancy Registry (see [http://www.APRegistry.com](http://www.APRegistry.com)) (AIII).
- Non-pregnant women of childbearing potential should undergo pregnancy testing before initiation of efavirenz and receive counseling about the potential risk to the fetus and desirability of avoiding pregnancy while on efavirenz-containing regimens (AIII).
- Alternate ARV regimens that do not include efavirenz should be considered in women who are planning to become pregnant or are sexually active and not using effective contraception, assuming these alternative regimens are not thought to compromise a woman’s health (BIII).
- Efavirenz can be continued in women receiving an efavirenz-based regimen who present for antenatal care in the first trimester, because the risk of neural tube defects is restricted to the first 5 to 6 weeks of pregnancy. Pregnancy is rarely recognized before 5 to 6 weeks, and unnecessary changes in ARV drugs during pregnancy may be associated with loss of viral control and increased risk of perinatal transmission. In such situations, fetal ultrasound is recommended at 18 to 20 weeks to assess anatomy (see [HIV-Infected Pregnant Women Who are Currently Receiving Antiretroviral Treatment](http://www.APRegistry.com)) (CIII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

### First-Trimester Exposure and Birth Defects

The potential harm to the fetus from maternal ingestion of a specific drug depends not only on the drug itself but also on the dose ingested; the gestational age of the fetus at exposure; the duration of exposure; the interaction with other agents to which the fetus is exposed; and, to an unknown extent, the genetic makeup of mother and fetus.

Information regarding the safety of drugs in pregnancy is derived from animal toxicity data, anecdotal experience, registry data, and clinical trials. Drug choice should be individualized and must be based on discussion with the woman and available data from preclinical and clinical testing of the individual drugs. Preclinical data include results of *in vitro* and animal *in vivo* screening tests for carcinogenicity, clastogenicity/mutagenicity, and reproductive and teratogenic effects. However, the predictive value of such tests for adverse effects in humans is unknown. For example, of approximately 1,200 known animal teratogens, only about 30 are known to be teratogenic in humans. Limited data exist regarding placental passage, pharmacokinetics and safety in pregnancy, and long-term safety in exposed infants of Food and Drug Administration (FDA)-approved antiretroviral (ARV) drugs (see [Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy](http://www.APRegistry.com)).

In general, reports of birth defects in fetuses/infants of women enrolled in observational studies who receive ARV regimens during pregnancy are reassuring and find no difference in rates of birth defects for first-trimester compared with later exposures. In the primary analysis by the Antiretroviral Pregnancy Registry of prospective cases of ARV exposure during pregnancy provided by health care providers, prevalence of birth defects was 2.8 per 100 live births among women with a first-trimester exposure to any ARV (203 of 7,135 exposures; 95% confidence interval [CI], 2.5–3.3). The prevalence of defects is not significantly different from that in women with an initial exposure during the second and/or third trimester (2.8 per 100 live births) (prevalence ratio 1.01; 95% CI, 0.84, 1.21). In a recent study from France that included 13,124 live births that occurred between 1994 and 2010, 5,388 (42%) had first-trimester exposure to ARV drugs. The authors reported a significant adjusted association between first-trimester zidovudine exposure and congenital heart defects (adjusted odds ratio [AOR] 2.2; 95% CI, 1.3–3.7). Because all infants in this study underwent echocardiography, the clinical significance of the cardiac findings is uncertain. The authors also reported significant associations between first-trimester didanosine (AOR 1.44, 1.08–1.92) and indinavir exposure: 13.8% vs. 9.1% (AOR 1.57; 95% CI, 1.14, 2.17).
(AOR 1.66, 1.09–2.53) exposure and head and neck defects. However, for both these drugs, the absolute numbers of defects in the exposed groups were low, leading to large confidence intervals and reinforcing caution in drawing any conclusions. In the primary analysis, no association was seen between first-trimester efavirenz exposure and birth defects. In an analysis from the Pediatric HIV/AIDS Cohort Study (PHACS) that included 2,580 live births, first-trimester ARV exposure overall was not associated with an increased risk of birth defects. In adjusted analyses, the only individual ARV drug for which first-trimester exposure was associated with birth defects was atazanavir (discussed below). In a comparison between 417 HIV- and ARV-exposed, uninfected infants and unexposed controls tested at ages 2 to 7 years, no clinically significant differences were found in echocardiographic parameters of left ventricular function and structure.

Most studies evaluating a possible association between ARV exposure and birth defects do not evaluate maternal folate use or levels. Folate antagonists (e.g., trimethoprim-sulfamethoxazole), which have been associated with an increased risk of birth defects with first-trimester use in some, but not all, studies, may be prescribed to women with advanced HIV disease. Therefore, it may be important to consider the role of folate antagonists as well as folic acid supplementation when evaluating any potential association between ARV drugs and birth defects. Maternal tobacco and alcohol use may also serve as confounders. However, concerns have been raised about the risk of several ARV agents.

### Specific Drugs

**Efavirenz**

Efavirenz use during pregnancy has received increased scrutiny because of the results of a small study in non-human primates. Significant malformations were observed in 3 of 20 infant cynomolgus monkeys receiving efavirenz from gestational days 20 to 150 at a dose resulting in plasma concentrations comparable to systemic human exposure at therapeutic dosage. The malformations included anencephaly and unilateral anophthalmia in one, microphthalmia in another, and cleft palate in the third. Among pregnancies prospectively reported to the Antiretroviral Pregnancy Registry through January 2014 that had exposure to efavirenz-based regimens, a 2.3% incidence of overall birth defects was seen with first-trimester exposure, a proportion not significantly different from that observed among U.S. births in the general population. Defects reported prospectively included one report of myelomeningocele and a separate report of anophthalmia. The case of anophthalmia included severe oblique facial clefts and amniotic banding that is known to be associated with anophthalmia. In addition, six cases of central nervous system defects, including myelomeningocele, have been retrospectively reported in infants born to mothers receiving efavirenz during the first trimester. However, retrospective reports can be biased toward reporting of more unusual and severe cases and are less likely to be representative of the general population experience.

A meta-analysis including data from 23 studies reporting on 2,026 first-trimester exposures found no increased risk of overall birth defects in infants born to women on efavirenz during the first trimester compared with those on other ARV drugs during the first trimester (relative risk 0.78; 95% CI, 0.56–1.08). One neural tube defect was observed, giving an incidence of 0.05% (95% CI, <0.01 to 0.28). However, the number of reported first-trimester efavirenz exposures still remains insufficient to rule out a 2- to 3-fold increase in low-incidence birth defects (incidence of neural tube defects in the general U.S. population is 0.02% to 0.2%).

In contrast to the meta-analysis, the Pediatric AIDS Clinical Trials Group (PACTG) protocols 219 and 219C studies reported a higher defect rate in infants with first-trimester exposure to efavirenz compared with those without first-trimester efavirenz exposure (AOR 4.31; 95% CI, 1.56–11.86). However, only 32 infants had efavirenz exposure. PACTG protocol P1025 is a companion study of PACTG 219 with considerable overlap in cases enrolled. Although P1025 reports a significant increased risk of congenital anomalies in infants born between 2002 and 2007 with first-trimester exposure to efavirenz, there is overlap in the defect cases between the 2 studies and only 41 infants with efavirenz exposure are included in this analysis. In the French study discussed above, first-trimester efavirenz use was not associated with an increase in defects in the primary analysis using the European Surveillance of Congenital Abnormalities birth defect classification system.
secondary analysis using the Metropolitan Atlanta Congenital Defects Program (MACDP) birth defect classification used by the Antiretroviral Pregnancy Registry, an association was found between first-trimester efavirenz exposure and neurologic defects. However, none of the four defects were neural tube defects, and none of the defects had common embryology. First-trimester efavirenz exposure was not associated with an increased risk of defects in the PHACS analysis. Thus, additional data are needed on first-trimester efavirenz exposures to be able to more conclusively determine whether risk of neural tube defects or other malformations is elevated.

Although a causal relationship has not been established between these events and the use of efavirenz, in light of similar findings in primates the FDA labeling advises that women avoid becoming pregnant while taking efavirenz and that efavirenz not be administered in the first trimester of pregnancy, as fetal harm may occur. Treatment with efavirenz should be avoided during the first 8 weeks of pregnancy (the primary period of fetal organogenesis) whenever possible. Women of childbearing potential should undergo pregnancy testing before initiation of efavirenz and should be counseled about the potential risk to the fetus and desirability of avoiding pregnancy while on efavirenz-containing regimens. Alternate combination antiretroviral therapy (cART) regimens that do not include efavirenz should be considered in women who are planning to become pregnant or who are sexually active and not using effective contraception if such alternative regimens are acceptable to the patient and will not compromise her health. However, the Panel now recommends that efavirenz can be continued in women who present for care in the first trimester and are receiving efavirenz-based cART that is effective in suppressing viral replication. This is because the neural tube closes at 36 to 39 days after the last menstrual period; hence, the risk of neural tube defects is restricted to the first 5 to 6 weeks of pregnancy (and pregnancy is rarely recognized before 5–6 weeks), and unnecessary changes in ARV drugs during pregnancy may be associated with a loss of virologic control and, thus, increased risk of transmission to the infant. In such situations, fetal ultrasound is recommended at 18 to 20 weeks to assess anatomy. For more details, see HIV-Infected Pregnant Women Who are Currently Receiving Antiretroviral Treatment.

**Tenofovir Disoproxil Fumarate**

Tenofovir has not demonstrated teratogenicity in rodents or monkeys. In infant monkeys with in utero exposure to tenofovir at maternal doses resulting in levels approximately 25 times those used in humans, low birth weights and reductions in fetal bone porosity were seen. Chronic administration of tenofovir to immature animals of multiple species has resulted in reversible bone abnormalities; these effects were dose-, exposure-, age-, and species-specific. Data from the Antiretroviral Pregnancy Registry show a birth defect incidence of 2.3% in 1,982 women with first-trimester tenofovir exposure, similar to that in the general population.

**Other Drugs**

As mentioned above, in the PHACS analysis atazanavir exposure (n = 222) in the first trimester was associated with an increased risk of birth defects, with an AOR of 1.93 (P = 0.004), primarily skin and musculoskeletal defects. In contrast, no increase in defect rate was detected in the Antiretroviral Pregnancy Registry among 922 births after first-trimester exposure to atazanavir. The Antiretroviral Pregnancy Registry includes additional analyses of drugs for which adequate numbers of first-trimester exposures have been reported to warrant separate analyses. For abacavir, atazanavir, darunavir, didanosine, efavirenz, indinavir, and stavudine, sufficient numbers of first-trimester exposures have been monitored to detect at least a 2-fold increase in risk of overall birth defects, and no such increases have been detected to date. For emtricitabine, lamivudine, lopinavir, nelfinavir, nevirapine, ritonavir, tenofovir, and zidovudine, sufficient numbers of first-trimester exposures have been monitored to detect at least a 1.5-fold increase in risk of overall birth defects and a 2-fold increase in risk of birth defects in the more common classes, cardiovascular and genitourinary systems. No such increases have been detected to date. A modest (but statistically significant) increase in overall birth defect rates for didanosine and nelfinavir is observed when compared with the U.S. population-based MACDP surveillance data. The lower bounds of the CIs for didanosine and nelfinavir (3.0% and 2.9%, respectively) are slightly above the higher bound (2.76%) for the
MACDP rate. No specific pattern of defects has been detected with either didanosine or nelfinavir, and the clinical relevance of this statistical finding is unclear. The Antiretroviral Pregnancy Registry will continue to monitor didanosine and nelfinavir for any signal or pattern of birth defects.

See Supplement: Safety and Toxicity of Individual Antiretroviral Drugs in Pregnancy for detailed information on individual drugs.

Antiretroviral Pregnancy Registry Reporting

Health care providers who are caring for HIV-infected pregnant women and their newborns are strongly advised to report instances of prenatal exposure to ARV drugs (either alone or in combination) to the Antiretroviral Pregnancy Registry as early in pregnancy as possible. This registry is an epidemiologic project to collect observational, nonexperimental data regarding ARV exposure during pregnancy for the purpose of assessing the potential teratogenicity of these drugs. Registry data will be used to supplement animal toxicology studies and assist clinicians in weighing the potential risks and benefits of treatment for individual patients. The Antiretroviral Pregnancy Registry is a collaborative project of pharmaceutical manufacturers with an advisory committee of obstetric and pediatric practitioners. The registry does not use patient names, and registry staff obtain birth outcome follow-up information from the reporting physician.

Referrals should be directed to:

Antiretroviral Pregnancy Registry
Research Park
1011 Ashes Drive
Wilmington, NC 28405
Telephone: 1–800–258–4263
Fax: 1–800–800–1052
http://www.APRegistry.com

References


Earlier Studies (Prior to 2005)

Early data are conflicting as to whether receipt of combination antiretroviral therapy (cART) during pregnancy is associated with adverse pregnancy outcomes, specifically, preterm birth (<37 weeks’ gestation). Previous studies were observational and included relatively small numbers of women who had received protease inhibitor (PI)-based cART. Inclusion of data necessary to control for maternal HIV disease stage as well as risk factors for adverse pregnancy outcomes varied, and no studies were able to assess the indication for cART.

An initial report from the European Collaborative Study and the Swiss Mother and Child HIV Cohort Study on HIV-infected women delivering between 1986 and 2000 demonstrated a roughly 2-fold increase in the odds of preterm birth for infants exposed to cART with or without PIs compared with no antiretroviral (ARV) drugs. Women initiating cART before pregnancy were twice as likely to deliver preterm as those who initiated ARVs during the third trimester (≥28 weeks’ gestation). Exposure to nucleoside reverse transcriptase inhibitor (NRTI) single-drug prophylaxis (primarily zidovudine) was not associated with preterm birth.1

In an updated report from the European Collaborative Study, which included women who delivered from 1986 to 2004, initiation of cART before and during pregnancy was associated with preterm birth, compared to mono- or dual-NRTI ARV regimens. Use of cART before pregnancy was associated with a 2.1-fold increased risk of preterm birth at <37 weeks and a 4.4-fold increased risk of preterm birth at <34 weeks. Initiation of cART during pregnancy was associated with a 1.9-fold increased risk of preterm delivery at <37 weeks and a 2.5-fold risk of preterm birth at <34 weeks.2

In contrast, an analysis of seven prospective clinical studies of women delivering from 1990 to 1998 did not demonstrate an association between ARV regimens and adverse pregnancy outcomes. This analysis accounted for maternal CD4 T lymphocyte (CD4) cell count, HIV disease stage, and history of adverse pregnancy outcomes. Compared to no ARVs or monotherapy, cART with or without PIs was not associated with increased rates of preterm birth, low birth weight, or stillbirth.3 A subsequent analysis of the Women and Infants Transmission Study extended to women delivering through 2002 (some of whom were included in the aforementioned meta-analysis) did not find significant associations between use of ARV drugs by class or by category and adverse pregnancy outcomes.4

Recent Studies (2005–Current)

Results of studies published since 2005 are conflicting with regard to an association between preterm birth and cART use. Multiple observational studies with similar limitations published through 2008 have detected small but significant increases in preterm birth with PI- and non-PI-based cART (odds ratio [OR] 1.2–1.8 in the largest studies).5-8 A meta-analysis of 14 European and American clinical studies demonstrated that use of cART during pregnancy did not increase the overall risk of preterm birth. A subgroup analysis demonstrated a modest increased risk of preterm birth with PI-based cART use compared to non-PI based cART (OR 1.35; 95% confidence interval [CI], 1.08–1.7).9

Panel’s Recommendations

- Clinicians should be aware of a possible small increased risk of preterm birth in pregnant women receiving protease-inhibitor (PI)-based combination antiretroviral therapy. However, given the clear benefits of such regimens for both a woman’s health and the prevention of perinatal transmission, PIs should not be withheld for fear of altering pregnancy outcome (AII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion
Subsequent studies that have controlled for maternal characteristics, including HIV disease severity, have not demonstrated an association between PI-based ARV regimens and adverse pregnancy outcomes, including preterm birth and low birth weight.\textsuperscript{10-12} Other reports have found increased rates of preterm birth when cART is compared with dual-ARV regimens\textsuperscript{13} and when non-nucleoside reverse transcriptase inhibitor-based cART regimens were compared with other forms of cART.\textsuperscript{14}

Conflicting findings regarding preterm birth and cART use may be influenced by variability in the data available for analysis. For example, some studies have reported increased rates of preterm birth when cART is initiated before or in early pregnancy compared to later in pregnancy. Variables other than prevention of perinatal transmission, such as HIV disease severity, may affect the timing of cART initiation during pregnancy. These variables may be associated with preterm birth independent of cART use.\textsuperscript{14,15} More recent reports have attempted to assess variables associated with cART initiation. In order to control for medical or obstetrical factors associated with iatrogenic preterm birth, two studies have assessed spontaneous preterm birth alone. One study included women initiating ARV drugs during pregnancy. Neither study reported an association between ARV use and preterm birth.\textsuperscript{16,17}

A U.S. study of women delivering from 2007 to 2010 found an increased risk of spontaneous and overall preterm birth with exposure to PI-based cART in the first trimester (<14 weeks’ gestation) compared to exposure after the first trimester to PI- or non-PI-based cART (OR 1.59; 95% CI, 1.0–2.30 and OR 1.55; 95% CI, 1.16–2.17, respectively). Exposure to non-PI-based regimens in the first trimester was not associated with increased risk of preterm birth.\textsuperscript{18} In an analysis of women enrolled in the ANRS French Perinatal Cohort from 1990 to 2009, preterm birth rates increased over time. Preterm birth was associated with cART compared to either mono- or dual-ARV regimens (adjusted odds ratio [AOR] 1.69; 95% CI, 1.38–2.07). Preterm delivery rates were highest in those initiating ARV drugs before pregnancy (AOR 1.31; 95% CI, 1.11–1.55).\textsuperscript{19} A restricted analysis within this cohort comparing boosted versus non-boosted PI-based cART regimens reported an association with iatrogenic preterm delivery and boosted PI regimens (AOR 2.03; 95% CI, 2.06–3.89). There was no association with spontaneous preterm birth. The use of boosted PI regimens was associated with medical and obstetrical complications, suggesting that the association with iatrogenic preterm delivery was mediated by these complications.

A secondary analysis of a randomized clinical trial conducted in Botswana with pregnant women with CD4 cell counts >200 cells/mm\textsuperscript{3} found an increased rate of preterm birth in women randomized to a lopinavir/ritonavir PI-based cART regimen compared to a triple nucleoside-based cART regimen (21.4% vs. 11.8%, \textit{P} = 0.003).\textsuperscript{20} In a population-based observational study of 33,148 women from 6 sites in Botswana, which included 9,504 HIV-infected women, maternal HIV was significantly associated with increased risk of stillbirth, preterm birth, and small for gestational age (SGA).\textsuperscript{21} HIV-infected women initiating cART prior to conception compared to all other women were more likely to have preterm birth (AOR 1.2; 95% CI, 1.1–1.4), SGA (AOR 1.8; 95% CI, 1.6–2.1), and stillbirth (AOR 1.5; 95% CI, 1.2–1.8). Among HIV-infected women initiating ARV drugs during pregnancy, use of cART compared to use of zidovudine monotherapy was associated with higher odds of preterm birth (AOR 1.4; 95% CI, 1.2–1.8), SGA (AOR 1.5; 95% CI, 1.2–1.9), and stillbirth (AOR 2.5; 95% CI, 1.6–3.9). However, adverse pregnancy outcomes were also associated with maternal hypertension.

Clinicians should be aware of a possible increased risk of preterm birth with use of cART. Given the clear benefits for maternal health and reduction in perinatal transmission, these agents should not be withheld due to concern for increased risk of preterm delivery. Until more information is available, HIV-infected pregnant women receiving cART should continue their provider-recommended regimens and receive regular monitoring for pregnancy complications, including preterm birth.\textsuperscript{22}
<table>
<thead>
<tr>
<th>Study Location(s); Dates of Study</th>
<th>Total Number of Pregnancies/Total on ARV Drugs</th>
<th>Types of ARV Regimens Compared (Numbers)</th>
<th>Association Noted Between PI-Containing or Other Multi-ARV Regimens and PTD</th>
<th>Notes</th>
</tr>
</thead>
</table>
| European Collaborative Study and Swiss Mother and Child HIV Cohort Study; 1986–20001                                                                                   | 3,920/896                                                                                             | • Mono (573)  
• Multi, no PI (215)  
• Multi-PI (108)                                                                                     | • YES (compared with no ARV)  
• Multi: 1.82 (1.13–2.92)  
• Multi-PI: 2.60 (1.43–4.7)                                                                 | • Increase in PTD if ARV begun before pregnancy versus in third trimester |
| United States; 1990–19981                                                                                                                                     | 3,266/2,123                                                                                           | • Mono (1,590)  
• Multi (396)  
• Multi-PI (137)                                                                                       | • NO (compared with mono)  
• Multi: 0.95 (0.60–1.48)  
• Multi-PI: 1.45 (0.81–2.50)                                                                 | • 7 prospective clinical studies                                                                 |
| European Collaborative Study; 1986–20042                                                                                                                       | 4,372/2,033                                                                                           | • Mono (704)  
• Dual (254)  
• Multi (1,075)                                                                                       | • YES (compared with mono/dual)  
• Multi in pregnancy: 1.88 (1.34–2.65)  
• Multi pre-pregnancy: 2.05 (1.43–2.95)                                              | N/A                                                                                          |
| United States; 1990–20022                                                                                                                                     | 2,543/not given                                                                                     | Early (<25 Weeks):  
• Mono (621)  
• Multi (≥2 without PI or NNRTI) (198)  
• Multi (with PI or NNRTI) (357)  
Late (≥32 Weeks):  
• Mono (932)  
• Multi (≥2 without PI or NNRTI) (258)  
• Multi (with PI or NNRTI) (588)                                                                 | • NO (compared with mono)  
• No association between any ARV and PTD                                                                 | PTD decreased with ARV compared with no ARV.                                         |
| United States; 1990–200223                                                                                                                                   | 1,337/999                                                                                             | • Mono (492)  
• Multi (373)  
• Multi-PI (134)                                                                                      | • YES (compared with other multi)  
• Multi-PI: 1.8 (1.1–3.03)                                                                 | • Multi-PI reserved for advanced disease, those who failed other multi-ARV regimens. |
| Brazil, Argentina, Mexico, Bahamas; 2002–200524                                                                                                                | 681/681                                                                                               | • Mono/dual NRTI (94)  
• Multi-NNRTI (257)  
• Multi-PI (330)                                                                                      | • NO (compared with mono/dual NRTI)  
• No association between any ARV regimen and PTD                                                        | • All on ARV for at least 28 days during pregnancy  
• Preeclampsia/eclampsia, cesarean delivery, diabetes, low BMI associated with PTD |

Table 5. Results of Studies Assessing the Association Between Antiretroviral Regimens and Preterm Delivery (page 1 of 3)
<table>
<thead>
<tr>
<th>Study Location(s); Dates of Study</th>
<th>Total Number of Pregnancies/ Total on ARV Drugs</th>
<th>Types of ARV Regimens Compared (Numbers)</th>
<th>Association Noted Between PI-Containing or Other Multi-ARV Regimens and PTD</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meta-analysis, Europe and United States; 1986–2004⁴</td>
<td>11,224/not given</td>
<td>• Multi-no PI (including dual) or multi-PI (2,556)</td>
<td>• YES (only comparing PI with multi) • PI versus multi-no PI: 1.35 (1.08–1.70)</td>
<td>• 14 studies, 5 in PTD-ARV comparison • No overall increase in PTD with antepartum ARV • PTD increased in those on ARV pre-pregnancy and in first trimester compared with later use.</td>
</tr>
<tr>
<td>Italy; 2001–2006⁷</td>
<td>419/366</td>
<td>• Multi-PI second trimester (97) • Multi-PI third trimester (146)</td>
<td>• YES</td>
<td>• Multivariate association also with hepatitis C</td>
</tr>
<tr>
<td>United States; 1989–2004⁶</td>
<td>8,793/6,228</td>
<td>• Mono (2,621) • Dual (1,044) • Multi-no PI (1,781) • Multi-PI (782)</td>
<td>• YES (compared with dual) • Multi-PI associated with PTD: 1.21 (1.04–1.40)</td>
<td>• Lack of antepartum ARV also associated with PTD • PTD and low birth weight decreased over time.</td>
</tr>
<tr>
<td>United Kingdom, Ireland; 1990–2005⁵</td>
<td>5,009/4,445</td>
<td>• Mono/dual (1,061) • Multi-NNRTI or multi-PI (3,384)</td>
<td>• YES (compared with mono/dual) • Multi: 1.51 (1.19–1.93)</td>
<td>• Similar increased risk with PI or no-PI multi • No association with duration of use</td>
</tr>
<tr>
<td>Germany, Austria; 1995–2001⁸</td>
<td>183/183</td>
<td>• Mono (77) • Dual (31) • Multi-PI (21) • Multi-NNRTI (54)</td>
<td>• YES (compared with mono) • Multi-PI: 3.40 (1.13–10.2)</td>
<td>N/A</td>
</tr>
<tr>
<td>United States; 2002–2007⁷⁶</td>
<td>777/777</td>
<td>• Mono (6) • Dual (11) • Multi-no PI (202) • Multi-PI (558)</td>
<td>• NO (compared PI with all non-PI) • Multi-PI: 1.22 (0.70–2.12)</td>
<td>• All started ARV during pregnancy. • Analyzed only spontaneous PTD</td>
</tr>
<tr>
<td>Swiss Mother and Child HIV Cohort Study; 1985–2007¹³</td>
<td>1,180/941</td>
<td>• Mono (94) • Dual (53) • Multi (PI or no PI) (409) • Multi-PI (385)</td>
<td>• YES (compared with no ARV) • Multi: 2.5 (1.4–4.3)</td>
<td>• No association of mono/dual with PTD compared with no ARV • No confounding by duration of ARV or maternal risk factors</td>
</tr>
</tbody>
</table>
Table 5. Results of Studies Assessing the Association Between Antiretroviral Regimens and Preterm Delivery (page 3 of 3)

<table>
<thead>
<tr>
<th>Study Location(s); Dates of Study</th>
<th>Total Number of Pregnancies/ Total on ARV Drugs</th>
<th>Types of ARV Regimens Compared (Numbers)</th>
<th>Association Noted Between PI-Containing or Other Multi-ARV Regimens and PTD</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Botswana; 2006–2008<sup>20</sup> | 530/530                                        | • Lopinavir/ritonavir plus zidovudine plus lamivudine (267)  
• Abacavir plus zidovudine plus lamivudine (263)  | • YES  
• Multi-PI versus multi-NRTI: 2.03 (1.26–3.27)  | • Secondary analysis of data from randomized, controlled clinical trial of ARV begun at 26–34 weeks for prevention of perinatal transmission  
• All CD4 cell counts >200 cells/mm<sup>3</sup> |
| Botswana; 2007–2010<sup>25</sup> | 4,347/3,659                                    | • ARV, regimen unspecified (70)  
• Mono (2,473)  
• Multi, 91% NNRTI (1,116)  | • NO  
• No association between multi-cART and very PTD (<32 weeks’ gestation)  | • Observational multi-ART before conception associated with very small for gestational age and maternal hypertension during pregnancy |
| Spain; 2000–2008<sup>11</sup>  | 803/739                                        | • Mono/dual (32)  
• Multi-no PI (281)  
• Multi-PI (426)  | • NO  
• No association between ARV and PTD  | • Greatest PTD risk if no antepartum ARV received |
| Spain; 1986–2010<sup>17</sup>  | 519/371                                        | • Mono/dual NRTI (73)  
• All multi (298)  
• Multi-PI (178)  | • NO (compared with no ARV plus mono/dual)  
• Spontaneous PTD not associated with multi-ARV or multi-PI before or during pregnancy  | • Iatrogenic PTD associated with multi-ARV given in second half of pregnancy and with prior PTD |
| Botswana; 2009–2011<sup>21</sup> | 9,504/7,915                                    | • Mono (4,625)  
• All multi (3,290)  
• Multi-PI (312)  | • YES (multi-ARV before and during pregnancy compared to mono): 1.2 (1.1–1.4) and 1.4 (1.2–1.8)  
• YES (multi-PI compared to multi-no PI before pregnancy): 2.0 (1.1–3.6)  | • cART group classified by initiation before and during pregnancy |
| United States; 2007–2010<sup>18</sup> | 1,869/1,810                                    | • Mono/dual (138)  
• Multi-NRTI (193)  
• Multi-NNRTI (160)  
• Multi-PI (1,319)  | • YES (compared with no ARV in first trimester)  
• Multi-PI in first trimester vs. none in first trimester  
• PTD 1.55 (1.16–2.07); spontaneous PTD 1.59 (1.10–2.30)  | N/A |

Key to Acronyms: ARV = antiretroviral; BMI = body mass index; dual = two ARV drugs; mono = single ARV drug; multi = three or more ARV drugs; multi-PI = combination ARV with PI; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PTD = preterm delivery
References


Antiretroviral (ARV) drug recommendations for HIV-infected, pregnant women have been based on the concept that drugs of known benefit to women should not be withheld during pregnancy unless there are known adverse effects to the mother, fetus, or infant and unless these adverse effects outweigh the benefits to the woman. Pregnancy should not preclude the use of optimal drug regimens. The decision to use any ARV drug during pregnancy should be made by a woman after discussing with her health care provider the known and potential benefits and risks to her and her fetus.

The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission (the Panel) reviews clinical trial data published in peer-reviewed journals and data prepared by manufacturers for Food and Drug Administration review related to treatment of HIV-infected adult women, both pregnant and non-pregnant. The durability, tolerability, and simplicity of a medication regimen are particularly important for ensuring adherence and preserving future treatment options. Regimen selection should be individualized and the following factors should be considered:

- Potential teratogenic effects and other short- and long-term adverse effects on fetuses or newborns including preterm birth, mutagenicity, and carcinogenicity,
- Experience with use in pregnancy,
- Potential drug interactions with other medications,
- Results of genotypic resistance testing and prior antiretroviral exposure,
- Pharmacokinetic (PK) changes in pregnancy and degree of placental transfer,
- Potential adverse maternal drug effects that may be exacerbated during pregnancy,
- Comorbidities,
- Ability of patient to adhere to regimen, and
- Convenience.

Information used by the Panel for recommendations on specific drugs or regimens for pregnant women includes:

- Data from randomized clinical trials and prospective cohort studies that demonstrate durable viral suppression as well as immunologic and clinical improvement;
- Incidence rates and descriptions of short- and long-term drug toxicity of ARV regimens, with special attention to maternal toxicity and potential teratogenicity and fetal safety;
- Specific knowledge about drug tolerability and simplified dosing regimens;
- Known efficacy of ARV drug regimens in reducing mother-to-child transmission of HIV;
Physiologic changes that occur during pregnancy can affect drug absorption, distribution, biotransformation, and elimination, thereby also affecting requirements for drug dosing and potentially altering the susceptibility of pregnant women to drug toxicity. During pregnancy, gastrointestinal transit time becomes prolonged; body water and fat increase throughout gestation and are accompanied by increases in cardiac output, ventilation, and liver and renal blood flow; plasma protein concentrations decrease; renal sodium reabsorption increases; and changes occur in cellular transporters and drug metabolizing enzymes in the liver and intestine. Placental transport of drugs, compartmentalization of drugs in the embryo/fetus and placenta, biotransformation of drugs by the fetus and placenta, and elimination of drugs by the fetus also can affect drug PK in the pregnant woman.

Currently available data on the PKs and dosing of ARV drugs in pregnancy are summarized in Table 7. In general, the PKs of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are similar in pregnant and non-pregnant women (although data on etravirine are limited), whereas protease inhibitor (PI) PKs are more variable, particularly in later pregnancy. Current data suggest that with standard adult dosing, plasma concentrations of nelfinavir and lopinavir/ritonavir, atazanavir, and darunavir are reduced during the second and/or third trimesters (see Table 7). The need for a dose adjustment depends on the PI, an individual patient’s treatment experience, and use (if any) of concomitant medications with potential for drug interactions.

Raltegravir levels in the third trimester were quite variable but not significantly different than postpartum or historical data in non-pregnant individuals. Data on enfuvirtide, maraviroc, dolutegravir, and elvitegravir in pregnancy are too limited to allow recommendations on dosing.

Although clinical data are more limited on ARV drugs in pregnant women than in non-pregnant individuals, sufficient data exist on which to base recommendations related to drug choice for many of the available ARV drugs. Drugs and drug regimens for pregnant antiretroviral-naive women are classified as preferred, alternative, insufficient data to recommend use, and not recommended (Table 6).

Categories of ARV regimens include:

- **Preferred**: Drugs or drug combinations are designated as preferred for use in ARV-naive pregnant women when clinical trial data in adults have demonstrated optimal efficacy and durability with acceptable toxicity and ease of use; pregnancy-specific PK data are available to guide dosing; and no established association with teratogenic effects or clinically significant adverse outcomes for mothers, fetuses, or newborns have been reported. Drugs in the preferred category may have toxicity concerns based on non-human data that have not been verified or established in humans. Therefore, it is important to read the full discussion of each drug in the Guidelines before administering any of these medications to your patients (also see Appendix B: Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy). For example, efavirenz is now listed in the preferred category, but only with initiation after 8 weeks’ gestation because of unresolved questions regarding teratogenicity.

- **Alternative**: Drugs or drug combinations are designated as alternatives for initial therapy in ARV-naive pregnant women when clinical trial data in adults show efficacy but any one or more of the following conditions apply: experience in pregnancy is limited; data are lacking on teratogenic effects on the fetus; or the drug or regimen is associated with dosing, tolerability, formulation, administration, or interaction issues.

- **Insufficient Data to Recommend**: The drugs and drug combinations in this category are approved for use in adults but lack pregnancy-specific PK or safety data or such data are too limited to make a recommendation for use in ARV-naive pregnant women.

- **Not Recommended**: Drugs and drug combinations listed in this category are not recommended for therapy in pregnant women because of inferior virologic response, potentially serious maternal or fetal safety concerns, or pharmacologic antagonism or are not recommended for ARV-naive populations regardless of pregnancy status.
In pregnant women, as in non-pregnant adults, a combination ARV treatment (cART) regimen with at least three agents is recommended. Recommendations for choice of ARV drug regimen during pregnancy must be individualized according to a pregnant woman’s specific ARV history, the results of drug-resistance assays, and the presence of comorbidities. Women receiving cART may become pregnant and present for obstetrical care. In general, women who are already on a fully suppressive regimen should continue their regimens (see HIV-Infected Pregnant Women Who Are Currently Receiving Antiretroviral Therapy).

Other HIV-infected women may not be receiving cART at the time they present for obstetrical care. Some women have never received ARV drugs in the past and some may have been treated in previous pregnancies. The following sections provide detailed discussions of recommendations based on maternal ARV history and current and previous resistance testing.

For ARV-naive women, a cART regimen including two NRTIs combined with a PI with low-dose ritonavir or an NNRTI or an integrase inhibitor is preferable (Table 6).

### NRTIs and Pregnancy

Nucleoside reverse transcriptase inhibitor (NRTI) drugs are well-tolerated medications in general. However, NRTIs are known to induce some level of mitochondrial dysfunction because the drugs have varying affinity for mitochondrial gamma DNA polymerase. This affinity can interfere with mitochondrial replication, resulting in mitochondrial DNA (mtDNA) depletion and dysfunction.\(^{14-16}\) These toxicities may be of particular concern for pregnant women and infants with in utero exposure to NRTI drugs, both because the intrauterine environment may affect later disease development in the child (fetal epigenetic programming),\(^{17,18}\) and because mitochondria are exclusively inherited from the maternal ovum.\(^{19}\) The degrees to which these theoretical concerns, and even documented mitochondrial abnormalities, are clinically relevant is not yet known with certainty, but are very likely to be outweighed by the importance of maternal and infant ARV use to prevent perinatal HIV transmission.\(^{20,21}\)

Uncommon clinical disorders linked to mitochondrial toxicity include neuropathy, myopathy, cardiomyopathy, pancreatitis, hepatic steatosis, and lactic acidosis. Among these disorders, symptomatic lactic acidosis and hepatic steatosis may have a female preponderance.\(^{22,23}\) These syndromes have similarities to two rare but life-threatening syndromes that occur during pregnancy, most often during the third trimester: the hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome, and acute hepatic steatosis (with or without lactic acidosis). The frequency of HELLP syndrome or lactic acidosis and hepatic steatosis in pregnant HIV-infected women receiving NRTI drugs is unknown, but a small number of cases have been reported, including several in which didanosine and stavudine were used in combination during pregnancy. Nonfatal cases of lactic acidosis also have been reported in pregnant women receiving combination didanosine/stavudine.\(^{24}\) Thus, clinicians should not prescribe combination didanosine/stavudine for pregnant (or even non-pregnant) adults (see Adult and Adolescent ARV Guidelines).

Some studies have reported that NRTI use in pregnant women is associated with depletion of mtDNA in the placenta, albeit without evidence of ultrastructural damage to placental cells; altered maternal and fetal mitochondrial protein synthesis; and reduced levels of fetal mtDNA.\(^{25,26}\) However, no adverse clinical outcomes were linked to these findings.

For ARV-naive pregnant women, abacavir in combination with lamivudine is considered a preferred dual NRTI combination. This combination offers the advantage of once daily dosing and is well tolerated in pregnancy.\(^{27}\) Testing for the HLA-B*5701 allele should be performed and documented as negative before starting abacavir, and women should be educated about symptoms of hypersensitivity reactions.

Tenofovir disoproxil fumarate (tenofovir) with emtricitabine or lamivudine is the NRTI component in some preferred regimens for non-pregnant adults and, based on increased experience with use in pregnancy, once-daily dosing, enhanced activity against hepatitis B, and less frequent toxicity compared to zidovudine/ lamivudine, is considered a preferred combination in pregnancy. Although there have been concerns about
bone and growth abnormalities in infants exposed to tenofovir *in utero*, the duration and clinical significance of study findings require further evaluation (see Tenofovir Disoproxil Furmarate).

Based on efficacy studies in preventing perinatal transmission and extensive experience with safe use in pregnancy, zidovudine/lamivudine also remains a preferred dual NRTI combination for ARV-naive pregnant women.

**NNRTIs and Pregnancy**

Efavirenz is an alternative NNRTI for non-pregnant adults. Although increasing data on use of efavirenz in pregnancy are reassuring, because of concerns regarding potential teratogenicity, efavirenz is not recommended for initiation in ARV-naive women in the first 8 weeks of pregnancy (see Teratogenicity and HIV-Infected Pregnant Women Who are Currently Receiving Antiretroviral Treatment).

Efavirenz remains a preferred agent for initial therapy in ARV-naive pregnant women because of extensive experience with use in pregnancy and because of its availability in a once-daily single-pill regimen which can facilitate better adherence. Efavirenz-based ARV regimens should be initiated after the first eight weeks of pregnancy with accurate dating parameters. Rilpivirine is part of an alternative regimen for non-pregnant adults with pre-treatment HIV RNA <100,000 copies/mL and CD4 T lymphocyte cell count >200 cells/mm³ and there is sufficient data from use in pregnancy to recommend it similarly as an alternative agent for ARV-naive pregnant women. Nevirapine is not recommended for ARV-naive pregnant women or for non-pregnant adults because of greater potential for adverse events, complex lead-in dosing, and low barrier to resistance. Safety and PK data on etravirine in pregnancy are insufficient to recommend use of these NNRTI drugs in ARV-naive women.

**PIs and Pregnancy**

Atazanavir/ritonavir and darunavir/ritonavir are the preferred PI drugs for use in ARV-naive pregnant women, based on efficacy studies in adults and experience with use in pregnancy (see Table 7 for dosing considerations). The alternative PI is lopinavir/ritonavir for which there is extensive clinical experience and PK data in pregnancy, but which requires twice daily dosing in pregnancy and can cause issues with nausea. PK data and extensive clinical experience do exist for nelfinavir in pregnancy, but the rate of virologic response to nelfinavir-based regimens was lower than lopinavir/ritonavir or efavirenz-based regimens in clinical trials of initial therapy in non-pregnant adults. Because of its lower antiviral activity, nelfinavir use is not recommended. Saquinavir is not recommended in ARV-naive pregnant women because it requires a baseline electrocardiogram due to potential PR and QT prolongation, has a high pill burden, and is not recommended for use in initial therapy for non-pregnant adults. Indinavir may be associated with nephrolithiasis and has a higher pill burden than many other PI drugs; therefore, it is also not recommended for use in ARV-naive pregnant women. Both atazanavir and indinavir are associated with increased indirect bilirubin levels, which theoretically may increase the risk of hyperbilirubinemia in neonates although pathologic elevations have not been seen in studies to date. In an analysis from PHACS, *in utero* exposure to atazanavir compared to other drugs was associated with risk of late language emergence at 12 months, but that was no longer significant at 24 months. Data on use in pregnancy are too limited to recommend routine use of fosamprenavir and tipranavir/ritonavir in pregnant women, although they can be considered for women who are intolerant of other agents or who require tipranavir/ritonavir because of resistance.

**Entry and Fusion Inhibitors and Pregnancy**

Safety and PK data in pregnancy are insufficient to recommend use of the entry inhibitors enfuvirtide and maraviroc in ARV-naive women during pregnancy. Use of these agents can be considered for women who have failed therapy with several other classes of ARV drugs after consultation with HIV and obstetric specialists.
Integrase Inhibitors and Pregnancy

PK, safety and other data on the use of the integrase inhibitor raltegravir during pregnancy are available and increasing; cART regimens including raltegravir can be considered as preferred regimens in ARV-naive pregnant women as they are for ARV-naive non-pregnancy adults. Clinical trial data from non-pregnant adults suggest a more rapid viral decay with the use of raltegravir compared to efavirenz. Case series have reported rapid viral decay with the use of raltegravir initiated late in pregnancy to achieve viral suppression and reduce the risk of perinatal HIV transmission, but no comparative data are available in pregnancy. The rate of viral decay with raltegravir compared to efavirenz in late-presenting pregnant women is currently under investigation. A case report of marked elevation of liver transaminases after initiation of raltegravir in late pregnancy, which resolved rapidly after stopping the drug, suggests that monitoring of transaminases may be indicated with use of this strategy. There are currently no data on the use of dolutegravir or elvitegravir in pregnancy; thus these drugs cannot be recommended for ARV-naive pregnant women at this time.

Pharmacologic Boosters

There are currently no data on the use of cobicistat in pregnancy; thus this drug cannot be recommended for ARV-naive pregnant women at this time.

References


HIV-Infected Pregnant Women Who Have Never Received Antiretroviral Drugs (Antiretroviral Naive) (Last updated August 6, 2015; last reviewed August 6, 2015)

Panel’s Recommendations

- All HIV-infected pregnant women should receive combination antiretroviral therapy (cART) to reduce the risk of perinatal transmission of HIV (AI). The choice of regimen should take into account current adult treatment guidelines, what is known about the use of specific drugs in pregnancy, and the risk of teratogenicity (see Table 6 and Table 7).

- Consideration should be given to initiating cART as soon as HIV is diagnosed during pregnancy; earlier viral suppression is associated with lower risk of transmission. This decision may be influenced by CD4 T lymphocyte count, HIV RNA levels, and maternal conditions (e.g., nausea and vomiting) (AIII). The benefits of early cART must be weighed against potential fetal effects of drug exposure.

- Antiretroviral drug-resistance studies should be performed to guide selection of antiretroviral regimens in women whose HIV RNA levels are above the threshold for resistance testing (i.e., >500 to 1,000 copies/mL) unless drug-resistance studies have already been performed (see Antiretroviral Drug Resistance and Resistance Testing in Pregnancy) (AI). If cART is initiated before the results of the drug-resistance assays are available, the antiretroviral regimen should be modified, if necessary, based on the resistance assay results (BII).

- If there is no evidence of resistance, cART regimens that are preferred for the treatment of antiretroviral-naive HIV-infected pregnant women include: a dual nucleoside reverse transcriptase inhibitor combination (abacavir/lamivudine, tenofovir disoproxil fumarate/emtricitabine or lamivudine, or zidovudine/lamivudine) and either a ritonavir-boosted protease inhibitor (atazanavir/ritonavir) or darunavir/ritonavir), a non-nucleoside reverse transcriptase inhibitor (efavirenz initiated after 8 weeks of pregnancy), or an integrase inhibitor (raltegravir) (see Table 6) (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic evaluation. They should be counseled about and offered combination antiretroviral therapy (cART) containing at least 3 drugs for their own health and for prevention of perinatal transmission of HIV, consistent with the principles of treatment for non-pregnant adults. Use of a cART regimen that successfully reduces plasma HIV RNA to undetectable levels substantially lowers the risk of perinatal transmission of HIV, lessens the need for consideration of elective cesarean delivery as an intervention to reduce risk of transmission, and reduces risk of antiretroviral (ARV) drug resistance in the mother. In an analysis of perinatal transmission in a total of 12,486 infants delivered by HIV-infected women between 2000 and 2011 in the United Kingdom and Ireland, the overall perinatal transmission rate declined from 2.1% in 2000–2001 to 0.46% in 2010–2011. The transmission risk was significantly lower (0.09%) in women with viral loads <50 copies/mL compared with a risk of 1.0% in women with viral loads of 50–399 copies/mL, regardless of the type of ARV regimen or mode of delivery.2 The continued decline in perinatal transmission rates was attributed to increasing number of women on cART at the time of conception and reductions in the proportion of women either initiating cART late in pregnancy or never receiving cART prior to delivery. Similar data from Canada in 1,707 HIV-infected pregnant women followed between 1997 and 2010 showed perinatal transmission was 1% in all mothers receiving cART and 0.4% if more than 4 weeks of cART was received.3

ARV drug-resistance testing should be performed before starting an ARV regimen if plasma HIV RNA levels are above the threshold for resistance testing (that is, >500 to 1,000 copies/mL). For details regarding genotypic and phenotypic resistance testing, see Adult and Adolescent Antiretroviral Guidelines. Given the association of earlier viral suppression with lower risk of transmission as discussed above, during pregnancy, cART should be initiated as soon as HIV is diagnosed without waiting for the results of resistance testing, with modification of the regimen, if required, when test results return. Because clinically significant resistance to protease inhibitors (PI) is less common than resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) in ARV-naive...
individuals, a PI-based cART regimen generally should be considered in this situation.

Table 6 outlines the ARV regimens that are preferred for treatment of HIV-infected pregnant women who have never received ARV drugs. These recommendations are based on available data indicating acceptable toxicity profiles, ease of use, pharmacokinetic data in pregnancy, and lack of evidence of teratogenic effects or established adverse outcomes for mother, fetus or newborn in addition to optimal ARV efficacy and durability. Preferred regimens include a dual nucleoside reverse transcriptase inhibitor (NRTI) combination (abacavir/lamivudine, tenofovir disoproxil fumarate (tenofovir)/emtricitabine or lamivudine, or zidovudine/lamivudine) in combination with either a ritonavir-boosted PI (atazanavir/ritonavir or darunavir/ritonavir), an NNRTI (efavirenz initiated after 8 weeks of pregnancy) or an integrase inhibitor (raltegravir). Alternative regimens include those demonstrated to be effective in adults but with more limited data on use in pregnancy, lack of or incomplete data on teratogenicity, and dosing, formulation, toxicity or interaction issues. Selection of these regimens should be based on individual patient characteristics and needs (see Table 7).

Susceptibility of fetuses to the potential teratogenic effects of drugs is dependent on multiple factors, including the gestational age of the fetus at exposure (see the Teratogenicity section). Although fetal effects of ARV drugs are not fully known, in general, reports of birth defects in fetuses/infants of women enrolled in observational studies who receive ARV regimens during pregnancy have been reassuring. There have been no differences in the rates of birth defects for first-trimester compared with either later gestational exposures or with rates reported in the general population.4-7 The decision about when to initiate cART should be carefully considered by health care providers and their patients. The discussion should include an assessment of a woman’s health status and the benefits and risks to her health and the potential risks and benefits to the fetus.

Although most perinatal transmission events occur late in pregnancy or during delivery, recent analyses suggest that early control of viral replication may be important in preventing transmission. In a French study, lack of early and sustained control of maternal viral load appeared strongly associated with residual perinatal transmission of HIV.8 That study evaluated risk factors for perinatal transmission in women with HIV RNA <500 copies/mL at the time of delivery; overall HIV transmission was 0.5%. Women who transmitted were less likely to have received ARV drugs at the time of conception than nontransmitters and were less likely to have HIV RNA <500 copies/mL at 14, 28, and 32 weeks’ gestation. By multivariate analysis, plasma viral load at 30 weeks’ gestation was significantly associated with transmission. Among women starting ARV drugs during pregnancy, the gestational age at initiation of therapy did not differ between groups (30 weeks), but viral load tended to decrease earlier in the nontransmitters, although this was not statistically significant. The number of patients initiating therapy during pregnancy was too small to assess whether initiation of ARV drugs in the first trimester was associated with lower rates of transmission. These data suggest that early and sustained control of HIV viral replication is associated with decreasing residual risk of transmission and favor initiating cART sufficiently early in ARV-naïve women to suppress viral replication by the third trimester. Other studies have demonstrated that baseline viral load is significantly associated with the likelihood of viral suppression by delivery, and thus, prompt initiation of cART would be particularly important in HIV-infected pregnant women who have high baseline viral loads.9-11 However, the potential benefits of earlier initiation of cART must be balanced against the unknown long-term outcome of first-trimester ARV exposure to the fetus.

cART is recommended for all HIV-infected pregnant women, regardless of viral load. Although rates of perinatal transmission are low in women with undetectable or low HIV RNA levels, there is no threshold below which lack of transmission can be ensured.12-14 The mechanism by which ARV drugs reduce perinatal transmission of HIV is multifactorial. Although lowering maternal antenatal viral load is an important component of prevention in women with higher viral load, ARV prophylaxis is effective even in women with low viral load.15-19 Additional mechanisms of protection include pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis of the infant. With PrEP, passage of the ARV drug across the placenta results in presence of drug levels sufficient for inhibition of viral replication in the fetus, particularly during the birth process when there is intensive viral exposure. Therefore, whenever possible, cART regimens initiated during pregnancy should include zidovudine or another NRTI with high transplacental passage, such as lamivudine, emtricitabine, tenofovir, or abacavir (see

---

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

C-26

Table 7). With post-exposure prophylaxis, ARV drugs are administered to the infant after birth.

Some women may wish to restrict fetal exposure to ARV drugs while reducing the risk of HIV transmission to their infants. Use of zidovudine alone during pregnancy for prophylaxis of perinatal transmission is not optimal, but it could be an option for women with low viral loads (i.e., <1,000 copies/mL) on no ARV drugs. In the UK study discussed above, transmission rates were 0.7% for women receiving a triple-ARV drug regimen combined with planned cesarean delivery or with planned vaginal delivery and 0.5% in 464 women with HIV RNA levels <10,000 copies/mL who received single-drug prophylaxis with zidovudine combined with planned cesarean delivery, not significantly different between groups. Zidovudine single-drug prophylaxis is recommended in the British HIV Association guidelines for women with CD4 T lymphocyte counts >350 cells/mm³ and HIV RNA levels <10,000 copies/mL and wild-type virus who do not require treatment for their own health. Time-limited administration of zidovudine during the second and third trimesters is less likely to induce development of resistance in women with low viral loads than in those with higher viral loads. This lower rate of resistance is likely because of the low level of viral replication and the short duration of exposure. Women’s choices after counseling to use or not use ARV drugs during pregnancy should be respected.

Raltegravir has been suggested for use in late pregnancy in women who have high viral loads because of its ability to rapidly suppress viral load (approximately 2-log copies/mL decrease by Week 2 of therapy). Two recent case series have reported the effect of adding raltegravir to cART regimens. In one, 4 women diagnosed with HIV infection in the third trimester experienced a mean viral load decline per week of 1.12 log after raltegravir was added to a standard ARV regimen. In the second publication, raltegravir was either initiated as part of a combination ARV regimen in nine ARV-naive women or added to an existing ARV regimen in five women who conceived on cART but had persistent viremia. Raltegravir was initiated at a gestational age of 34 weeks or later. The median exposure time to raltegravir was 17 days and the mean viral load decline was 2.6 log. Although no raltegravir-related side effects were noted in these reports, marked elevations in hepatic transaminases were reported in a single HIV-infected pregnant woman when raltegravir was added to an ARV regimen. Because the efficacy and safety of this approach has only been described in anecdotal reports, it cannot be routinely recommended at this time for women who are ARV-naive.

The cART regimen initiated during pregnancy can be modified after delivery to include simplified regimens that were not used in pregnancy because pregnancy safety data were insufficient. Decisions regarding continuation of an ARV regimen or which specific ARV agents to use should be made by women in consultation with their HIV care providers, taking into account current recommendations and life circumstances (see General Principles Regarding Use of Antiretroviral Drugs during Pregnancy).

References


Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

C-28


Table 6. What to Start: Initial Combination Regimens for Antiretroviral-Naive Pregnant Women

These recommendations are for pregnant women who have never received antiretroviral therapy (ART) previously (i.e., antiretroviral-naive) and are predicated on lack of evidence of resistance to regimen components. See Table 7 for more information on specific drugs and dosing in pregnancy. Within each drug class, regimens are listed alphabetically, and the order does not indicate a ranking of preference. It is recommended that women who become pregnant while on a stable ARV regimen with viral suppression remain on that same regimen.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preferred Regimens</strong></td>
<td>Regimens with clinical trial data in adults demonstrating optimal efficacy and durability with acceptable toxicity and ease of use, PK data available in pregnancy, and no evidence to date of teratogenic effects or established adverse outcomes for mother/fetus/newborn. To minimize the risk of resistance, a PI regimen is preferred for women who may stop ART during the postpartum period.</td>
</tr>
<tr>
<td><strong>Preferred Two-NRTI Backbone</strong></td>
<td>Available as FDC. Can be administered once daily. ABC should not be used in patients who test positive for HLA-B*5701 because of risk of hypersensitivity reaction. ABC/3TC with ATV/r or with EFV is not recommended if pretreatment HIV RNA &gt;100,000 copies/mL.</td>
</tr>
<tr>
<td>ABC/3TC</td>
<td></td>
</tr>
<tr>
<td>TDF/FTC or 3TC</td>
<td>TDF/FTC available as FDC. Either TDF/FTC or TDF and 3TC can be administered once daily. TDF has potential renal toxicity, thus TDF-based dual NRTI combinations should be used with caution in patients with renal insufficiency.</td>
</tr>
<tr>
<td>ZDV/3TC</td>
<td>Available as FDC. NRTI combination with most experience for use in pregnancy but has disadvantages of requirement for twice-daily administration and increased potential for hematologic toxicities.</td>
</tr>
<tr>
<td><strong>Preferred PI Regimens</strong></td>
<td></td>
</tr>
<tr>
<td>ATV/r plus a Preferred Two-NRTI Backbone</td>
<td>Once-daily administration. Extensive experience in pregnancy. Maternal hyperbilirubinemia</td>
</tr>
<tr>
<td>DRV/r plus a Preferred Two-NRTI Backbone</td>
<td>Better tolerated than LPV/r. PK data available. Increasing experience with use in pregnancy. Must be used twice daily in pregnancy.</td>
</tr>
<tr>
<td><strong>Preferred NNRTI Regimen</strong></td>
<td></td>
</tr>
<tr>
<td>EFV plus a Preferred Two-NRTI Backbone</td>
<td>Concern because of birth defects seen in primate study; risk in humans is unclear (see Teratogenicity and Table 7). Postpartum contraception must be ensured. Preferred regimen in women who require co-administration of drugs with significant interactions with PIs or the convenience of co-formulated, single-tablet, once-daily regimen.</td>
</tr>
<tr>
<td><strong>Preferred Integrase Inhibitor Regimen</strong></td>
<td></td>
</tr>
<tr>
<td>RAL plus a Preferred Two-NRTI Backbone</td>
<td>PK data available and increasing experience in pregnancy. Rapid viral load reduction. Useful when drug interactions with PI regimens are a concern. Twice-daily dosing required.</td>
</tr>
<tr>
<td><strong>Alternative Regimens</strong></td>
<td>Regimens with clinical trial data demonstrating efficacy in adults but one or more of the following apply: experience in pregnancy is limited, data are lacking or incomplete on teratogenicity, or regimen is associated with dosing, formulation, toxicity, or interaction issues</td>
</tr>
<tr>
<td><strong>PI Regimens</strong></td>
<td></td>
</tr>
<tr>
<td>LPV/r plus a Preferred Two-NRTI Backbone</td>
<td>Abundant experience and established PK in pregnancy. More nausea than preferred agents. Twice-daily administration. Once-daily LPV/r is not recommended for use in pregnant women.</td>
</tr>
<tr>
<td><strong>NNRTI Regimen</strong></td>
<td></td>
</tr>
<tr>
<td>RPV/TDF/FTC (or RPV plus a Preferred Two-NRTI Backbone)</td>
<td>RPV not recommended with pretreatment HIV RNA &gt;100,000 copies/mL or CD4 cell count &lt;200 cells/mm³. Do not use with PPIs. PK data available in pregnancy but relatively little experience with use in pregnancy. Available in co-formulated single-pill once-daily regimen.</td>
</tr>
</tbody>
</table>

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States
Table 6. What to Start: Initial Combination Regimens for Antiretroviral-Naive Pregnant Women

<table>
<thead>
<tr>
<th>Drug</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Insufficient Data in Pregnancy to Recommend Routine Use in ART-Naive Women</strong></td>
<td>Drugs that are approved for use in adults but lack adequate pregnancy-specific PK or safety data</td>
</tr>
<tr>
<td>DTG</td>
<td>No data on use of DTG in pregnancy</td>
</tr>
<tr>
<td>EVG/COBI/TDF/FTC Fixed Drug Combination</td>
<td>No data on use of EVG/COBI component in pregnancy.</td>
</tr>
<tr>
<td>FPV</td>
<td>Limited data on use in pregnancy.</td>
</tr>
<tr>
<td>MVC</td>
<td>MVC requires tropism testing before use. Few case reports of use in pregnancy.</td>
</tr>
<tr>
<td>COBI</td>
<td>No data on use of COBI (including co-formulations with ATV or DRV) in pregnancy.</td>
</tr>
<tr>
<td><strong>Not Recommended</strong></td>
<td>Drugs whose use is not recommended because of toxicity, lower rate of viral suppression or because not recommended in ART-naive populations</td>
</tr>
<tr>
<td>ABC/3TC/ZDV</td>
<td>Generally not recommended due to inferior virologic efficacy.</td>
</tr>
<tr>
<td>d4T</td>
<td>Not recommended due to toxicity.</td>
</tr>
<tr>
<td>ddl</td>
<td>Not recommended due to toxicity.</td>
</tr>
<tr>
<td>IDV/r</td>
<td>Nephrolithiasis, maternal hyperbilirubinemia.</td>
</tr>
<tr>
<td>NFV</td>
<td>Lower rate of viral suppression with NFV compared to LPV/r or EFV in adult trials.</td>
</tr>
<tr>
<td>RTV</td>
<td>RTV as a single PI is not recommended because of inferior efficacy and increased toxicity.</td>
</tr>
<tr>
<td>SQV/r</td>
<td>Not recommended based on potential toxicity and dosing disadvantages. Baseline ECG is recommended before initiation of SQV/r because of potential PR and QT prolongation; contraindicated with pre-existing cardiac conduction system disease. Limited data in pregnancy. Large pill burden. Twice daily dosing required.</td>
</tr>
<tr>
<td>ETR</td>
<td>Not recommended in ART-naive populations</td>
</tr>
<tr>
<td>NVP</td>
<td>Not recommended because of greater potential for adverse events, complex lead-in dosing, and low barrier to resistance. NVP should be used with caution when initiating ART in women with CD4 cell count &gt;250 cells/mm³. Use NVP and ABC together with caution; both can cause hypersensitivity reactions within the first few weeks after initiation.</td>
</tr>
<tr>
<td>T20</td>
<td>Not recommended in ART-naive populations</td>
</tr>
<tr>
<td>TPV/r</td>
<td>Not recommended in ART-naive populations</td>
</tr>
</tbody>
</table>

**Key to Acronyms:**
- 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; ATV/r = atazanavir/ritonavir; CD4 = CD4 T lymphocyte cell; COBI = cobicistat; d4T = stavudine; ddl = didanosine; DTG = dolutegravir; DRV/r = darunavir/ritonavir; ECG = electrocardiogram; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; FDC = fixed-dose combination; FPV = fosamprenavir; FTC = emtricitabine; IDV/r = indinavir/ritonavir; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NFV = nelfinavir; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PPI = proton pump inhibitor; PK = pharmacokinetic; RAL = raltegravir; RPV = rifampin; RTV = ritonavir; SQV/r = saquinavir/ritonavir; T20 = enfuvirtide; TDF = tenofovir disoproxil fumarate; TPV = tipranavir; ZDV = zidovudine
In general, HIV-infected pregnant women receiving combination antiretroviral therapy (cART) who present for care during the first trimester should continue treatment during pregnancy, assuming the regimen is tolerated and effective in suppressing viral replication (HIV-1 viral load less than lower limits of detection of the assay) (AII).

The Panel recommends that efavirenz be continued in pregnant women receiving efavirenz-based cART who present for antenatal care in the first trimester, provided the regimen is achieving virologic suppression (CII).

HIV antiretroviral drug-resistance testing should be performed to assist in the selection of active drugs when changing antiretroviral regimens in pregnant women on therapy with virologic failure and HIV RNA levels >1,000 copies/mL (AII). In individuals with HIV RNA levels >500 but <1,000 copies/mL, testing may be unsuccessful but should still be considered (BII) (see Lack of Viral Suppression).

Women who have been receiving combination antiretroviral therapy (cART) for their HIV infection should continue treatment during pregnancy, assuming it is effective in suppressing viral replication and well-tolerated. Discontinuation of therapy could lead to an increase in viral load with possible decline in immune status and disease progression as well as adverse consequences for the fetus, including increased risk of HIV transmission. Continuation of cART is recommended when pregnancy is identified in HIV-infected women receiving cART.

HIV-infected women receiving cART who present for care during the first trimester should be counseled regarding the benefits and potential risks of administration of antiretroviral (ARV) drugs during this period. Providers should emphasize that continuation of cART is recommended. There are concerns regarding efavirenz use in the first trimester and potential for neural tube defects, based on non-human primate data and retrospective case reports (for more details see Teratogenicity). However, a recent meta-analysis including data on 2,026 women with first-trimester efavirenz exposure from 21 prospective studies did not find an increased relative risk (RR) of overall birth defects in infants born to women receiving efavirenz-based versus non-efavirenz-based regimens (RR 0.78, 95% confidence interval [CI], 0.56–1.08). One neural tube defect was identified, resulting in an incidence of 0.05% (95% CI, <0.01 to 0.28) similar to the incidence of neural tube defects in the general population. Although a 2- to 3-fold increased incidence of a rare outcome (e.g., neural tube defects [0.02% to 0.2% incidence in the United States]) cannot be ruled out given the limited data on first-trimester efavirenz exposure, the available data suggest that first-trimester exposure is not associated with a large (i.e., 10-fold or more) increase in risk of neural tube defects.

The risk of neural tube defects is restricted to the first 5 to 6 weeks of pregnancy. Pregnancy is rarely recognized before 5 to 6 weeks, and changes in ARV drugs during pregnancy may be associated with lack of virologic suppression at the end of pregnancy and increased risk of perinatal transmission. The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission recommends that efavirenz be continued in pregnant women receiving efavirenz-based cART who present for antenatal care in the first trimester, provided that the ARV regimen is resulting in virologic suppression.

Resistence testing should be performed in pregnant women on cART when a change in active drugs is being considered because of virologic failure with HIV RNA levels >1,000 copies/mL. In individuals with HIV RNA levels >500 but <1,000 copies/mL, testing may be unsuccessful but it still should be considered. The results can be used to select a new regimen with a greater likelihood of suppressing viral replication to undetectable levels.
Pregnant women for whom nevirapine-containing regimens result in virologic suppression and who are tolerating therapy may be continued on that regimen, regardless of current CD4 T lymphocyte (CD4) cell count. Although hepatic toxicity is a concern in women starting a nevirapine-containing regimen who have CD4 cell counts >250 cells/mm$^3$, an increased risk of hepatic toxicity has not been seen in women continuing nevirapine-based therapy that has resulted in CD4 counts >250 cell/mm$^3$.

References


During a previous pregnancy, HIV-infected women may have received antiretroviral (ARV) drugs solely for prevention of perinatal transmission. At any time in the past, they also may have discontinued ARV drugs given to them for treatment of their own disease. A small number of clinical trials or observational studies have generated information about effectiveness of combination antiretroviral therapy (cART) in individuals who previously received ARV prophylaxis. Long-term data are limited about outcomes with therapy containing nevirapine initiated after the use of peripartum single-dose nevirapine. Diminished viral and clinical response to nevirapine-based cART has been observed if cART was initiated within 12 to 24 months after single-dose nevirapine exposure. Adding other ARV drugs to single-dose nevirapine (such as use of an ARV tail) decreases rates of nevirapine resistance (see Antiretroviral Drug Resistance and Resistance Testing in Pregnancy). There is concern that time-limited use of ARV drugs during pregnancy for prophylaxis of perinatal transmission may lead to genotypic resistance and, thus, reduced efficacy of these ARV drugs when used either for HIV therapy or during a subsequent pregnancy for prevention of perinatal transmission. Rates of resistance appear to be low, based on standard genotyping, after prophylaxis for prevention of perinatal transmission with cART consisting of zidovudine, lamivudine, and nevirapine. However, minority populations of virus with resistance to nevirapine or lamivudine have been detected using sensitive allele-specific polymerase chain reaction (PCR) techniques, particularly in women whose virus was inadequately suppressed during prophylaxis. Rates of minor, drug-resistant variants may be lower in women given longer or more complex ARV tails after stopping pregnancy-limited nevirapine-based cART. Only limited data are available on the impact of these resistance-conferring minority variants on prediction of virologic or clinical failure of subsequent cART, and the PCR-based assays are not widely available. However, in the OCTANE/A5208 study, while the presence of low-frequency minority viral variants with nevirapine resistance was associated with higher rates of viral failure in women starting nevirapine-based cART after receiving single-dose nevirapine for prevention of perinatal transmission, low-frequency minority
variants were not associated with higher rates of nevirapine-cART failure in women who had not had prior single-dose nevirapine exposure. Both standard and sensitive genotyping techniques appear to show a low rate of resistance to protease inhibitors (PIs) after pregnancy-limited use of PI-based combination ARV regimens for prophylaxis, but these results reflect assessments in only small numbers of women.

Treatment failure has not been demonstrated with reinitiation of cART regimens following prophylactic use in pregnancy for prevention of transmission. In ACTG 5227, 52 women who had previously received cART regimens for prevention of perinatal transmission, had no evidence of HIV drug resistance, and had an indication for restarting cART were prescribed a fixed-dose combination of efavirenz plus tenofovir disoproxil fumarate/emtricitabine once daily. After 6 months of therapy, 81% achieved plasma viral loads below the limit of detection; the virologic suppression rate was similar regardless of the drug class of the prior cART regimen and whether women had received such ARV regimens in one or more than one previous pregnancy. Data from the French Perinatal Cohort assessed virologic suppression with a PI-based cART regimen administered for prevention of perinatal transmission to women who had received ARV prophylaxis during a previous pregnancy. No differences in rates of undetectable viral load at delivery were noted among ARV-naive women when compared with those with previous prophylaxis or according to type of previous prophylaxis regimens received. In addition, the National Study of HIV in Pregnancy and Childhood in the United Kingdom and Ireland found no increased risk of perinatal transmission in sequential pregnancies compared with one pregnancy at a time when most women received interventions for prevention of perinatal HIV transmission.

However, in a subsequent comparison between 5,372 ARV-naive pregnant women and 605 women who had previously received ARV but were on no ARV prior to the current pregnancy, ARV-experienced women had a slight increase in the risk of detectable viral load at delivery after receiving antenatal cART (aOR 1.27; 95% CI, 1.01–1.60). This risk was confined to those ARV-experienced women who received non-nucleoside reverse transcriptase inhibitor (NNRTI)-based as opposed to PI-based therapy. Sufficiently large, prospective, observational studies and clinical trials are lacking by which we can definitively assess the effect of pregnancy-limited ARV prophylaxis on virologic outcomes of subsequent ARV therapy.

It is reasonable to use results of initial resistance testing, if available, to make preliminary decisions about ARV regimens in women whose only previous exposure to ARV drugs was during pregnancy. However, interpretation of resistance testing after discontinuation of ARV drugs can be complex because drug-resistance testing is most accurate if performed while an individual is taking the ARV regimen or within 4 weeks of treatment discontinuation. In the absence of selective drug pressure, resistant virus may revert to wild-type virus, and although detection of drug-resistance mutations is informative for choosing a regimen, a negative finding does not rule out the presence of archived drug-resistant virus that could re-emerge once drugs are reinitiated. Therefore, when selecting a new regimen for use, all information including regimens received, viral response, laboratory testing (including HLA-B*5701 results), any tolerance or adherence problems, and the results of resistance testing should be taken into consideration.

Before genotype results are available, starting cART while genotype results are pending is particularly relevant after the first trimester as duration of cART ≥24 weeks has been associated with reduced transmission rates compared to shorter duration of cART. If cART is initiated before results are available the regimen should be modified, if necessary, based on resistance assay results. Careful monitoring of virologic response to the chosen ARV regimen is important.

If the chosen regimen produces an insufficient viral response, decisions about switching regimens should be guided by repeat resistance testing and assessment of medication adherence including, if available, relevant pharmacokinetic studies. These measures should be undertaken in consultation with an HIV treatment specialist.

Women may choose to discontinue cART for a variety of reasons, and the length of time between treatment termination and pregnancy may vary. In these cases, careful clinical and laboratory assessments are necessary before therapy is reinitiated during pregnancy. The evaluations should include a review of a woman’s prior history of virologic response and medication toxicity and her adherence to therapy. The
appropriate choice of ARV regimen to be initiated during pregnancy will vary according to a woman’s history of cART; the indication for stopping therapy; the effect of prior therapy on clinical, virologic, and immunologic status; and the results of past and current testing for resistance and for HLA-B*5701. It may be possible, for example, to restart the same regimen in a woman with a history of prior cART associated with successful suppression of viral load who then stopped all drugs simultaneously (or staggered discontinuation, if therapy was NNRTI-based) and who has no evidence of resistance. On the other hand, even health care providers experienced in HIV care may have difficulty with the selection of appropriate ARV regimens for women with advanced HIV disease, a history of extensive prior cART, or previous significant toxicity or nonadherence to ARV drugs. In such cases, restarting the prior regimen for a week or two before performing a resistance assay may yield more accurate results. In addition to obtaining genotypic resistance testing, it is strongly recommended that specialists in the treatment of HIV infection be consulted early during the pregnancy about the choice of a suitable cART regimen.

References


## Monitoring of the Woman and Fetus During Pregnancy

### Panel's Recommendations

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Rating of Evidence</th>
<th>Rating of Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma HIV RNA levels should be monitored at the initial visit (AI); 2 to 4 weeks after initiating (or changing) antiretroviral drug regimens (BI); monthly until RNA levels are undetectable (BII); and then at least every 3 months during pregnancy (BIII). HIV RNA levels also should be assessed at approximately 34 to 36 weeks’ gestation to inform decisions about mode of delivery (see Transmission and Mode of Delivery) and to inform decisions about optimal treatment of the newborn (see Infant ARV Prophylaxis) (AI).</td>
<td>BI</td>
<td>AI</td>
</tr>
<tr>
<td>CD4 T lymphocyte (CD4) cell count should be monitored at the initial antenatal visit (AI) and at least every 3 months during pregnancy (BII). Monitoring of CD4 cell count can be performed every 6 months in patients on combination antiretroviral therapy (cART) with consistently suppressed viral load who have CD4 counts well above the threshold for opportunistic infection risk (CII).</td>
<td>BII</td>
<td>BI</td>
</tr>
<tr>
<td>Genotypic antiretroviral drug-resistance testing should be performed at baseline in all HIV-infected pregnant women with HIV RNA levels &gt;1,000 copies/mL (AI). In individuals with HIV RNA levels &gt;500 but &lt;1,000 copies/mL, testing may be unsuccessful but should still be considered (BII). Tests should be performed whether the women are antiretroviral-naïve or currently on therapy (BII).</td>
<td>CII</td>
<td>AIII</td>
</tr>
<tr>
<td>HIV drug-resistance studies should be performed before modifying antiretroviral regimens for those entering pregnancy with detectable HIV RNA levels that are above the threshold for resistance testing (i.e., &gt;500 to 1,000 copies/mL) while receiving antiretroviral drugs. They should also be performed on women who have suboptimal viral suppression after starting ARV drugs during pregnancy (AI).</td>
<td>CII</td>
<td>AI</td>
</tr>
<tr>
<td>Monitoring for complications of antiretroviral drugs during pregnancy should be based on what is known about the adverse effects of the drugs a woman is receiving (AI).</td>
<td>CII</td>
<td>AIII</td>
</tr>
<tr>
<td>HIV-infected women taking cART during pregnancy should undergo standard glucose screening at 24 to 28 weeks’ gestation (AIII). Some experts would perform earlier glucose screening in women receiving ongoing protease inhibitor-based regimens initiated before pregnancy, similar to recommendations for women with risk factors for glucose intolerance (BII). For further information on protease inhibitors see Combination Antiretroviral Drug Regimens and Pregnancy Outcome.</td>
<td>BIII</td>
<td>AIII</td>
</tr>
<tr>
<td>Early ultrasound is recommended to confirm gestational age and, if scheduled cesarean delivery is necessary, to guide timing of the procedure (see Transmission and Mode of Delivery) (AI).</td>
<td>AIII</td>
<td>AIII</td>
</tr>
<tr>
<td>In women on effective cART, no perinatal transmissions have been reported after amniocentesis, but a small risk of transmission cannot be ruled out. Amniocentesis should be performed on HIV-infected women only after initiation of an effective cART regimen and, ideally, when HIV RNA levels are undetectable (BII). In women with detectable HIV RNA levels in whom amniocentesis is deemed necessary, consultation with an expert should be considered (BII).</td>
<td>BIII</td>
<td>AI</td>
</tr>
</tbody>
</table>

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

More frequent viral load monitoring is recommended in pregnant than non-pregnant individuals because of the importance of rapid and persistent viral suppression in preventing perinatal HIV transmission. In individuals who are adherent to their antiretroviral (ARV) regimen and do not harbor resistance mutations to the prescribed drugs, viral suppression is generally achieved in 12 to 24 weeks—although it may take longer in some patients and may be dependent on starting viral load. Most patients with adequate viral response at 24 weeks of treatment have had at least a 1 log viral load decrease within 1 to 4 weeks after starting therapy.1,2 Viral load should be monitored in HIV-infected pregnant women at the initial visit, 2 to 4 weeks after initiating or changing ARV regimens, monthly until undetectable, and at least every 3 months thereafter. If adherence is a concern, more frequent monitoring is recommended because of the potential increased risk of perinatal HIV infection associated with detectable HIV viremia during pregnancy.

Viral load also should be assessed at approximately 34 to 36 weeks’ gestation to inform decisions about mode of delivery and about optimal treatment of the newborns (see Transmission and Mode of Delivery).

In HIV-infected pregnant women, CD4 T lymphocyte (CD4) cell count should be monitored at the initial visit and at least every 3 months during pregnancy. CD4 cell counts can be performed every 6 months in patients who are clinically stable with consistently suppressed viral load who have CD4 counts well above...
Whenever feasible, ARV drug-resistance testing should be performed before initiation of ARV drugs if HIV RNA levels are above the threshold for resistance testing, but therapy should not be delayed once the blood is drawn and results are pending. If the results demonstrate resistance, then the regimen can subsequently be adjusted. Testing also should be performed on women taking an ARV regimen who have suboptimal viral suppression or who have persistent viral rebound to detectable levels after prior viral suppression on an ARV regimen (see Antiretroviral Drug Resistance and Resistance Testing in Pregnancy). Drug-resistance testing in the setting of virologic failure should be performed while patients are receiving ARV drugs or within 4 weeks after discontinuation of drugs. Even if more than 4 weeks have elapsed since the ARVs were discontinued, resistance testing can still provide useful information to guide therapy, though it may not detect previously selected resistance mutations. Genotypic testing is preferable to phenotypic testing because it costs less, has a faster turnaround time, and is more sensitive for detection of mixtures of wild-type and resistant virus.

Monitoring for potential complications of ARV drugs during pregnancy should be based on what is known about the adverse effects of the drugs a woman is receiving. For example, routine hematologic monitoring is recommended for women receiving zidovudine-containing regimens and routine renal monitoring should be recommended for women on tenofovir. Liver function should be monitored in all women receiving ARV drugs. Hepatic dysfunction has been observed in pregnant women on protease inhibitors (PI), and hepatic steatosis and lactic acidosis in pregnancy have been related to nucleoside reverse transcriptase inhibitor use.

Women with CD4 cell counts >250 cells/mm$^3$ were thought to be at risk of developing symptomatic, rash-associated hepatotoxicity within the first 18 weeks after initiation of nevirapine therapy. However, recent data either do not demonstrate the same association between nevirapine toxicity and CD4 cell counts among pregnant women, or demonstrate only a weak association. Additional data from a 2010 study suggest that abnormal liver transaminase levels at baseline may be more predictive of risk of nevirapine toxicity than CD4 cell count. Transaminase levels should be monitored more frequently and carefully in pregnant women initiating therapy with nevirapine, and they should also be watched for clinical symptoms of potential hepatotoxicity. The drug can be used cautiously with careful monitoring in women with mildly abnormal liver function tests at the time of ARV drug initiation.

Pregnancy increases the risk of hyperglycemia. PI drugs have been associated with increased risk of hyperglycemia, new-onset diabetes mellitus, exacerbation of existing diabetes mellitus, and diabetic ketoacidosis. However, the majority of studies in HIV-infected pregnant women have not shown an increased risk of glucose intolerance with PI-based regimens during pregnancy. A prospective study including detailed evaluations for glucose intolerance and insulin resistance among HIV-infected pregnant women did not find differences between women on PI-containing and non-PI-containing regimens. In both groups, the rate of impaired glucose tolerance was high (38%); but, this may be related to high body mass index and race/ethnicity among trial subjects. HIV-infected women receiving cART during pregnancy should receive the standard glucose screening at 24 to 28 weeks’ gestation that is recommended for all pregnant women. Some experts would perform earlier glucose screening in women receiving ongoing PI-based cART initiated before pregnancy, similar to recommendations for women with risk factors for glucose intolerance.

Accurate estimation of date of delivery is critical to planning elective cesarean deliveries at 38 weeks’ gestation to prevent perinatal transmission in HIV-infected women with elevated HIV RNA viral loads. Therefore, first-trimester ultrasound is recommended to confirm gestational age and to provide the most accurate estimation of gestational age at delivery (see Transmission and Mode of Delivery). In patients who are not seen until later in gestation, second-trimester ultrasound can be used for both anatomical survey and determination of gestational age.

Although data are still somewhat limited, the risk of HIV transmission does not appear to be increased with amniocentesis or other invasive diagnostic procedures in women receiving effective cART resulting in viral suppression. This is in contrast to the era before effective cART, during which invasive procedures such as
amniocentesis and chorionic villus sampling (CVS) were associated with a 2- to 4-fold increased risk of perinatal transmission of HIV. Although no transmissions have occurred among 159 cases reported to date of amniocentesis or other invasive diagnostic procedures among women on effective cART, a small increase in risk of transmission cannot be ruled out. HIV-infected women who have indications for invasive testing in pregnancy (e.g., abnormal ultrasound or aneuploidy screening) should be counseled about the potential risk of transmission of HIV along with other risks of the procedure and allowed to make an informed decision about testing. Some experts consider CVS and cordocentesis too risky to offer to HIV-infected women, and they recommend limiting invasive procedures to amniocentesis. At a minimum, HIV-infected pregnant women should receive effective cART before undergoing any invasive prenatal testing and, ideally, have an undetectable HIV RNA level at the time of the procedure. Consideration can also be given to noninvasive testing using cell-free fetal DNA to reduce the need for amniocentesis. In women with detectable HIV RNA levels for whom amniocentesis is deemed necessary, consultation with an expert should be considered.

References


Panel’s Recommendations

- HIV drug-resistance studies should be performed before starting antiretroviral (ARV) regimens in all ARV-naive pregnant women whose HIV RNA levels are above the threshold for resistance testing (i.e., >500 to 1,000 copies/mL) unless they have already been tested for ARV resistance (AII).
- HIV drug-resistance studies should be performed before modifying ARV regimens for those entering pregnancy with detectable HIV RNA levels that are above the threshold for resistance testing (i.e., >500 to 1,000 copies/mL) while receiving ARV drugs or who have suboptimal virologic response to ARV drugs started during pregnancy (AII).
- Combination antiretroviral therapy (cART) should be initiated in pregnant women prior to receiving results of ARV-resistance studies. The ARV regimen should be modified, if necessary, based on the results of the resistance assay (BII).
- Documented zidovudine resistance does not affect the indications for use of intrapartum zidovudine (BIII).
- The optimal prophylactic regimen for newborns of women with ARV resistance is unknown. Therefore, ARV prophylaxis for an infant born to a woman with known or suspected drug resistance should be determined in consultation with a pediatric HIV specialist, preferably before delivery (see Infant Antiretroviral Prophylaxis) (AIII).
- HIV-infected pregnant women should be given cART to maximally suppress viral replication, which is the most effective strategy for preventing development of resistance and minimizing risk of perinatal transmission (AII).
- All pregnant and postpartum women should be counseled about the importance of adherence to prescribed ARV medications to reduce the potential for development of resistance (AII).
- To minimize development of resistance, pregnant women who receive a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based CART regimen that is discontinued after delivery should receive either dual nucleoside analogue reverse transcriptase inhibitor agents alone (AII) or with a protease inhibitor (BII) for 7 to 30 days (AII) after stopping the NNRTI drug. The optimal interval between stopping an NNRTI and the other ARV drugs is unknown (see Stopping Antiretroviral Drugs During Pregnancy and Postpartum Follow-Up of HIV-Infected Women).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Indications for Antiretroviral Drug-Resistance Testing in HIV-Infected Pregnant Women

Because identification of baseline resistance mutations allows for the selection of more effective and durable antiretroviral (ARV) regimens, genotypic resistance testing (in addition to a comprehensive history of ARV drug use) is recommended:

- Before initiating combination antiretroviral therapy (cART) in ARV-naive HIV-infected pregnant women with HIV RNA levels above the threshold for resistance testing (i.e., >500 to 1,000 copies/mL) who have not been previously tested for ARV resistance
- Before initiating cART in HIV-infected pregnant women who have received ARVs for prevention of perinatal transmission in prior pregnancies if HIV RNA levels are above the threshold for resistance testing (i.e., >500 to 1,000 copies/mL)
- Before modifying ARV regimens in HIV-infected pregnant women entering pregnancy with detectable HIV RNA levels that are above the threshold for resistance testing (i.e., >500 to 1,000 copies/mL) while receiving cART or who have suboptimal virologic response to ARV drugs started during pregnancy

In most settings, the results of resistance testing guide selection of the initial ARV regimen. However, given the association of earlier viral suppression with lower risk of perinatal transmission, in ARV-naive pregnant women, cART should be initiated without waiting for the results of resistance testing, with modification of
the regimen, if required, when test results return (see HIV-Infected Pregnant Women Who Have Never Received Antiretroviral Drugs (Antiretroviral Naive) section).

**Incidence and Significance of Antiretroviral Drug Resistance in Pregnancy**

The development of ARV drug resistance is one of the major factors leading to therapeutic failure in HIV-infected individuals. In addition, pre-existing resistance to a drug in a cART regimen may diminish the regimen’s efficacy in preventing perinatal transmission. Infant treatment options also may be limited if maternal drug resistance is present or develops and resistant virus is transmitted to the fetus.

Several factors unique to pregnancy may increase the risk of development of resistance. If a non-nucleoside reverse transcriptase inhibitor (NNRTI), with its long half-life and low genetic barrier to resistance, is combined with two nucleoside analogue drugs (which have much shorter half-lives) in the maternal ARV regimen, simultaneous postpartum discontinuation of all regimen components may result in prolonged NNRTI levels (at subtherapeutic levels) without detectable levels of the other drugs, which may increase the risk of development of NNRTI resistance (see Stopping Antiretroviral Drugs During Pregnancy). Issues relating to discontinuation of NNRTI-based cART are discussed in Prevention of Antiretroviral Drug Resistance. Problems such as nausea and vomiting in early pregnancy may compromise adherence and increase the risk of resistance in women receiving ARV drugs. Pharmacokinetic changes during pregnancy, such as increased plasma volume and renal clearance, may lead to subtherapeutic drug levels, increasing the risk that resistance will develop.

**Impact of Resistance on the Risk of Perinatal Transmission of HIV and Maternal Response to Subsequent Therapy**

**Perinatal Transmission**

Perinatal transmission of resistant virus has been reported but appears to be unusual. There is little evidence that the presence of resistance mutations increases the risk of transmission when current recommendations for ARV management in pregnancy are followed. A sub-study of the Women and Infants Transmission Study followed pregnant women receiving zidovudine alone for treatment of HIV infection in the early 1990s. In this study, detection of zidovudine resistance conferred an increased risk of transmission when analysis was adjusted for duration of membrane rupture and total lymphocyte count; however, women in this cohort had characteristics that would indicate a need for cART under the current Department of Health and Human Services recommendations for maternal health and for prevention of perinatal transmission. When transmitting mothers had mixed viral populations of wild-type virus and virus with low-level zidovudine resistance, only wild-type virus was detected in their infants, and other studies have suggested that drug-resistance mutations may diminish viral fitness, possibly leading to a decrease in transmissibility. In another study, prevalence of ARV drug resistance among HIV-infected newborns in New York State was examined. Eleven (12.1%) of 91 infants born between 1989 and 1999 and 8 (19%) of 42 infants born between 2001 and 2002 had mutations associated with decreased drug susceptibility. However, perinatal exposure to ARVs was not found to be a significant risk factor for the presence of resistance during either time period. Neither resistance to NNRTI drugs that develops as a result of exposure to single-dose nevirapine nor exposure to single-dose nevirapine in a prior pregnancy has been shown to affect perinatal transmission rates.

**Maternal Response to Subsequent Treatment Regimens**

Few studies have evaluated response to subsequent therapy in women who receive current cART regimens for both treatment and prophylaxis and then choose to discontinue the drugs postpartum. In theory, however, resistance should not occur if the regimen that was discontinued had fully suppressed viral replication. The French Perinatal Cohort evaluated the association between exposure to ARV drugs to prevent perinatal transmission during a previous pregnancy and presence of a detectable viral load with exposure to ARV drugs during the current pregnancy in women followed between 2005 and 2009. In 1,166 women not receiving ARVs at the time of conception, 869 were ARV-naive and 247 had received ARV drugs to prevent
perinatal transmission during a previous pregnancy. Previous ARV prophylaxis was protease inhibitor (PI)-based in 48%, non-PI-based in 4%, nucleoside reverse transcriptase inhibitor (NRTI) dual ARVs in 19%, and zidovudine as a single ARV in 29%. A PI-based ARV regimen was initiated in 90% of the women during the current pregnancy; in multivariate analysis, previous ARV exposure in a prior pregnancy was not associated with detectable viral load in the current pregnancy. A separate study (ACTG A5227) evaluated viral suppression in 52 women with prior combination ARV exposure to prevent perinatal transmission who had stopped ARVs at least 24 weeks before study entry and were now initiating cART (efavirenz, tenofovir disoproxil fumarate, and emtricitabine) for treatment.10 None of the women had prior or recent resistance detected on standard bulk genotyping. Viral suppression was observed in 81% of women after 24 weeks of follow-up, with no difference in response by number of prior ARV exposures to prevent perinatal transmission or the drug class of prior exposure. Recent clinical series have confirmed this observation.11,12

Management of Antiretroviral Drug Resistance during Pregnancy

For women who have documented zidovudine resistance and whose antepartum regimen does not include zidovudine, intravenous (IV) zidovudine still should be given during labor when indicated (i.e., HIV RNA >1,000 copies/mL near delivery; see Intrapartum Antiretroviral Drug Therapy/Prophylaxis). Other ARVs should be continued orally during labor to the extent possible. The rationale for including zidovudine intrapartum when a woman is known to harbor virus with zidovudine resistance is based on several factors. Data thus far have suggested that only wild-type virus appears to be transmitted to infants by mothers who have mixed populations of wild-type virus and virus with low-level zidovudine resistance.4 Other studies have suggested that drug-resistance mutations may diminish viral fitness and possibly decrease transmissibility. The efficacy of the zidovudine prophylaxis appears to be based not only on a reduction in maternal HIV viral load but also on pre- and post-exposure prophylaxis in the infant.13-15 Zidovudine crosses the placenta readily and has a high maternal-to-cord-blood ratio. In addition, zidovudine is metabolized to the active triphosphate within the placenta,16,17 which may provide additional protection against transmission. Metabolism to the active triphosphate, which is required for activity of all nucleoside analogue agents, has not been observed within the placenta with other nucleoside analogues that have been evaluated (didanosine and zalcitabine). Zidovudine penetrates the central nervous system (CNS) better than other nucleoside analogues except stavudine, which has similar CNS penetration; this may help eliminate a potential reservoir for transmitted HIV in the infant.18,19 Thus, intrapartum IV administration of zidovudine, when indicated, currently is recommended even in the presence of known resistance because of the drug’s unique characteristics and its proven record in reducing perinatal transmission.

The optimal prophylactic regimen for newborns of women with ARV drug-resistant virus is unknown. Therefore, ARV prophylaxis for infants born to women with known or suspected drug-resistant virus should be determined with a pediatric HIV specialist, preferably before delivery (see Infant Antiretroviral Prophylaxis). There is no evidence that neonatal prophylaxis regimens customized based on the presence of maternal drug resistance are more effective than standard neonatal prophylaxis regimens.

Prevention of Antiretroviral Drug Resistance

The most effective way to prevent development of ARV drug resistance in pregnancy is to use and adhere to an effective cART regimen to achieve maximal viral suppression.

Several studies have demonstrated that women’s adherence to cART may worsen in the postpartum period.20-25 Clinicians caring for postpartum women receiving cART should specifically address adherence, including evaluating specific factors that facilitate or impede adherence. A systematic review has identified viral load monitoring as a means of enhancing adherence.26

Because of the prolonged half-life of NNRTI drugs, if an NNRTI-based ARV regimen is stopped postpartum, there is a risk of development of NNRTI-resistance mutations if all drugs in the regimen are stopped simultaneously. This has been demonstrated for nevirapine and efavirenz but may also be a problem with newer NNRTI drugs with long half-lives, such as etravirine and rilpivirine. Several studies have shown that
development of NNRTI resistance is significantly decreased (but not eliminated) when zidovudine/lamivudine is given intrapartum and administered for 3 to 7 days postpartum in women who have received single-dose intrapartum nevirapine.27-30 Other regimens (e.g., tenofovir/emtricitabine, zidovudine/didanosine, zidovudine/didanosine/lamivudine/lopinavir/ritonavir) given for 7 to 30 days postpartum following maternal single-dose nevirapine have also been shown to be very effective in reducing the development of NNRTI resistance.29,31,32,33,34,35 These data suggest that the NRTI components of an NNRTI-based regimen should be continued for 7 to 30 days after discontinuation of the NNRTI to minimize the risk of resistance. An alternative, equally effective strategy is to substitute a PI for the NNRTI and to continue the PI with dual NRTIs for a period of time.36 The optimal duration for continuation of either dual nucleosides or the substituted PI-based regimen after stopping the NNRTI is unknown.37 NNRTI drugs have long half-lives, and drug levels can persist for up to 1 to 3 weeks after stopping the drugs; efavirenz levels persist longer than nevirapine levels.38,39 Despite the use of various multiple-drug regimens, ARV drug resistance may still develop in some women.37 More research is needed on the optimal duration of time and regimen to cover this period of prolonged NNRTI exposure to prevent the emergence of resistance after discontinuation of an NNRTI-based ARV regimen.

References


Lack of Viral Suppression  (Last updated August 6, 2015; last reviewed August 6, 2015)

Virologic suppression is defined as a confirmed HIV RNA level below the lower limits of detection of an ultrasensitive assay, and virologic failure is the inability to achieve or maintain an HIV RNA level <200 copies/mL.

The lack of virologic suppression by late pregnancy may indicate virologic failure but may also represent inadequate time on therapy. Baseline HIV RNA levels have been shown to affect the time to response in both pregnant and non-pregnant individuals, with no difference in response between pregnant and non-pregnant women.\(^1,2\) HIV RNA levels should be assessed 2 to 4 weeks after an antiretroviral (ARV) drug regimen is initiated or changed to provide an initial assessment of effectiveness.\(^3\) Most patients with an adequate viral response at 24 weeks of treatment have had at least a 1 log copies/mL HIV RNA decrease within 1 to 4 weeks after starting therapy.\(^3\) In a retrospective multicenter cohort of 378 pregnant women, 77.2% achieved HIV RNA <50 copies/mL by delivery, with success of viral suppression varying by baseline HIV RNA level. With baseline <10,000 copies/mL, gestational age at initiation did not affect success up to 26.3 weeks. With baseline >10,000 copies/mL, however, delaying initiation past 20.4 weeks significantly reduced the ability to achieve maximal suppression at delivery.\(^1\) In data on 1,070 HIV-infected treatment-naive pregnant women participating in IMPAACT P1025, a prospective cohort study, initiation of combination antiretroviral therapy (cART) at >32 weeks’ gestation was also associated with a significantly higher risk of having viral load >400 copies/mL at delivery.\(^4\) Because maternal antenatal HIV RNA level correlates with risk of perinatal transmission of HIV, suppression of HIV RNA to undetectable levels should be achieved as rapidly as possible.

A three-pronged approach is indicated for management of women on ARV regimens who have suboptimal suppression of HIV RNA, taking into account time on therapy. They should be:

- Evaluated for resistant virus (if plasma HIV RNA is above the threshold for resistance testing, generally >500 or >1,000 copies/mL);
- Assessed for adherence, tolerability, incorrect dosing, or potential problems with absorption (e.g., nausea/vomiting, lack of attention to food requirements); and
- Considered for ARV regimen modification.

The role of therapeutic drug monitoring in reducing the risk of virologic failure is still undefined.\(^5,6\) Experts in the care of ARV-experienced adults should be consulted, particularly if a change in drug regimen is necessary. Hospitalization can be considered for directly observed drug administration, adherence education, and treatment of comorbidities such as nausea and vomiting.\(^7\)
Among 662 pregnancies followed in Italy between 2001 and 2008, treatment modification during pregnancy was independently associated with an HIV-1 RNA level >400 copies/mL in late pregnancy (adjusted odds ratio, 1.66; 95% confidence interval, 1.07–2.57; P = 0.024), highlighting the importance of using potent and well-tolerated regimens during pregnancy to maximize effectiveness and minimize the need to modify treatment.8

A recent systematic review and meta-analysis of adherence to cART during and after pregnancy in low-, middle-, and high-income countries (27% of studies were from the United States) found that a pooled estimate of 63.5% of pregnant women on cART had adequate (>80%) adherence to cART.9 Evaluation of and support for adherence during pregnancy is critical to achievement and maintenance of maximal viral suppression.

The addition of raltegravir in late pregnancy has been suggested for women who have high viral loads and/or in whom multiple drug-resistant mutations have resulted in incomplete suppression of viremia because of the ability of raltegravir to rapidly suppress viral load (approximately 2 log copies/mL decrease by Week 2 of therapy).10-13 However, the efficacy and safety of this approach have not been evaluated, and only anecdotal reports are available. In the setting of a failing regimen related to non-adherence and/or resistance, there are concerns that the addition of a single agent may further increase risk of resistance and potential loss of future effectiveness with raltegravir. A recent report found a 10- to 23-fold increase in transaminase levels following introduction of a raltegravir-containing regimen in late pregnancy, with return to normal levels after raltegravir discontinuation.14 At the current time, this approach cannot be routinely recommended.

Scheduled cesarean delivery is recommended for HIV-infected pregnant women who have HIV RNA levels >1,000 copies/mL.15,16

References


Stopping Antiretroviral Drugs during Pregnancy

Panel's Recommendations

- HIV-infected women receiving combination antiretroviral therapy who present for care during the first trimester should continue treatment during pregnancy (AII).
- If an antiretroviral drug regimen is stopped acutely for severe or life-threatening toxicity, pregnancy-induced hyperemesis unresponsive to antiemetics, or other acute illnesses that preclude oral intake, all antiretroviral drugs should be stopped simultaneously and ARV therapy should be reinitiated as soon as possible (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Discontinuation of antiretroviral (ARV) drug regimens during pregnancy may be indicated in some situations, including serious drug-related toxicity, pregnancy-induced hyperemesis unresponsive to antiemetics, or acute illnesses or planned surgeries that preclude oral intake. Other reasons for discontinuation of ARV drug regimens during pregnancy include lack of available medication or patient request. If an ARV drug regimen must be stopped for any reason, all ARV drugs should be stopped simultaneously and ARV therapy should then be reinitiated simultaneously as soon as possible, whether restarting the same regimen or a new regimen (e.g., based on toxicity attributed to drug in original regimen).

HIV-infected women receiving combination antiretroviral therapy (cART) who present for care during the first trimester should continue treatment during pregnancy. Discontinuation of therapy could lead to an increase in viral load with possible decline in immune status and disease progression as well as adverse consequences for the fetus, including increased risk of in utero transmission of HIV. An analysis from a prospective cohort of 937 HIV-infected mother-child pairs found that interruption of cART during pregnancy, including interruption in the first and third trimesters, was independently associated with perinatal transmission. In the first trimester, the median time at interruption was 6 weeks’ gestation and length of time without therapy was 8 weeks (interquartile range [IQR], 7–11 weeks); in the third trimester, the median time at interruption was 32 weeks and length of time without therapy was 6 weeks (IQR, 2–9 weeks). Although the perinatal transmission rate for the entire cohort was only 1.3%, transmission occurred in 4.9% (95% CI, 1.9% to 13.2%; adjusted odds ratio [AOR] 10.33; P = .005) with first-trimester interruption and 18.2% (95% CI, 4.5% to 72.7%; AOR 46.96; P = .002) with third-trimester interruption.1 Although the use of efavirenz should be avoided during the first trimester when possible, therapy should not be interrupted in women receiving an efavirenz-based regimen who present in the first 8 weeks of pregnancy, provided the regimen produces viral suppression and is well tolerated (see HIV-Infected Pregnant Women Who Are Currently Receiving Antiretroviral Therapy).

Continuation of all drugs during the intrapartum period generally is recommended. Women who are having elective cesarean delivery can take oral medications before the procedure and restart drugs following surgery. Because most drugs are given once or twice daily, it is likely that no doses would be missed or that at most the postpartum dose would be given a few hours late.

When short-term drug interruption is indicated, all ARV drugs should generally be stopped simultaneously and reinitroduced simultaneously as soon as possible. This can be problematic with drugs (e.g., NVP, EFV) that have long half-lives and low thresholds for developing HIV viral resistance. However, in conditions such as serious or life-threatening toxicity, severe pregnancy-induced hyperemesis unresponsive to antiemetics, or other acute illnesses precluding oral intake, the clinician has no choice but to stop all therapy at the same time. In the rare case in which a woman has limited oral intake that does not meet food requirements for certain ARV agents, decisions about the ARV regimen administered during the antepartum or intrapartum...
period should be made on an individual basis and in consultation with an HIV treatment expert.

Efavirenz can be detected in blood for longer than 3 weeks after discontinuation; if an efavirenz-containing regimen must be stopped for more than a few days due to toxicity, consideration should be given to assessing for rebound viremia and potential drug resistance. Nevirapine is rarely used during pregnancy in the United States anymore; however, if it is included in a regimen that has been discontinued for more than 7 days, a 2-week dose escalation is recommended when it is re-introduced.

References


### Panel’s Recommendations

- All HIV-infected pregnant women should be screened during the current pregnancy for hepatitis B virus (HBV) and hepatitis C virus, unless they are known to be coinfected (see [HIV/Hepatitis C Virus Coinfection](#) (AII)).
- All HIV-infected pregnant women who screen negative for HBV (i.e., HBV surface antigen-negative, HBV core antibody-negative, and HBV surface antibody-negative) should receive the HBV vaccine series (AII).
- Women with chronic HBV infection who have not already received the hepatitis A virus (HAV) vaccine series should be screened for immunity to HAV because they are at increased risk of complications from coinfection with other viral hepatitis infections (AII).
- Women with chronic HBV infection who are hepatitis A immunoglobulin G antibody-negative should receive the HAV vaccine series if they have never received it (AII).
- The management of HIV/HBV coinfection in pregnancy is complex and consultation with an expert in HIV and HBV is strongly recommended (AIII).
- Interferon alfa and pegylated interferon alfa are not recommended during pregnancy (AII).
- All pregnant women with HIV/HBV coinfection should receive combination antiretroviral therapy (cART). Antepartum cART in HIV/HBV-coinfected pregnant women should include tenofovir disoproxil fumarate plus lamivudine or emtricitabine (AII).
- Pregnant women with HIV/HBV coinfection receiving antiretroviral drugs should be counseled about signs and symptoms of liver toxicity, and liver transaminases should be assessed 1 month following initiation of antiretroviral drugs and at least every 3 months thereafter during pregnancy (BIII).
- If antiretroviral drugs are discontinued postpartum in women with HIV/HBV coinfection, frequent monitoring of liver function tests for potential exacerbation of HBV infection is recommended, with prompt re-initiation of treatment for both HIV and HBV if a flare is suspected (BIII).
- Decisions concerning mode of delivery in HIV/HBV-coinfected pregnant women should be based on standard obstetric and HIV-related indications alone; HBV coinfection does not necessitate cesarean delivery, if not otherwise indicated (see [Intrapartum Care](#) (AIII)).
- Within 12 hours of birth, infants born to women with HBV infection should receive hepatitis B immune globulin and should initiate the HBV vaccine series (AII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

For additional information on hepatitis B virus (HBV) and HIV, see [HIV/Hepatitis B (HBV) Coinfection](#) in the [Adult and Adolescent Antiretroviral Guidelines](#) and [Hepatitis B Virus Infection](#) in the [Adult Opportunistic Infections Guidelines](#). The management of HIV/HBV coinfection in pregnancy is complex and consultation with an expert in HIV and HBV infection is strongly recommended.

### Screening and Vaccination

All HIV-infected women should be screened for HBV and hepatitis C virus (HCV) at entry into general HIV care. All HIV-infected pregnant women should be screened for HBV and HCV during each pregnancy, unless they are known to be coinfected. Screening for HBV should include hepatitis B surface antigen [HBsAg], hepatitis B core antibody [anti-HBc], and hepatitis B surface antibody [anti-HBs]. Women who test positive for HBsAg should have follow-up testing that includes liver function tests, prothrombin time, HB e antigen, HB e antibody, and HBV DNA. The male partners of all HIV/HBV-coinfected women should be referred to their own providers for both HIV and HBV counseling and testing, and for HBV vaccination if HBV susceptible, to prevent horizontal transmission of HIV as well as HBV from women to their male partners.

A positive test for anti-HBc alone can be false-positive; alternatively, it may signify remote exposure with subsequent loss of anti-HBs antibody or longstanding chronic HBV infection with loss of surface antigen.

---

For additional information on hepatitis B virus (HBV) and HIV, see [HIV/Hepatitis B (HBV) Coinfection](#) in the [Adult and Adolescent Antiretroviral Guidelines](#) and [Hepatitis B Virus Infection](#) in the [Adult Opportunistic Infections Guidelines](#). The management of HIV/HBV coinfection in pregnancy is complex and consultation with an expert in HIV and HBV infection is strongly recommended.

### Screening and Vaccination

All HIV-infected women should be screened for HBV and hepatitis C virus (HCV) at entry into general HIV care. All HIV-infected pregnant women should be screened for HBV and HCV during each pregnancy, unless they are known to be coinfected. Screening for HBV should include hepatitis B surface antigen [HBsAg], hepatitis B core antibody [anti-HBc], and hepatitis B surface antibody [anti-HBs]. Women who test positive for HBsAg should have follow-up testing that includes liver function tests, prothrombin time, HB e antigen, HB e antibody, and HBV DNA. The male partners of all HIV/HBV-coinfected women should be referred to their own providers for both HIV and HBV counseling and testing, and for HBV vaccination if HBV susceptible, to prevent horizontal transmission of HIV as well as HBV from women to their male partners.

A positive test for anti-HBc alone can be false-positive; alternatively, it may signify remote exposure with subsequent loss of anti-HBs antibody or longstanding chronic HBV infection with loss of surface antigen.
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

C-54

(“occult” HBV infection, which can be confirmed by detection of HBV DNA). Some experts recommend that HIV-infected individuals with anti-HBc alone be tested for HBV DNA to inform decisions about vaccination for HBV and treatment with antiretroviral (ARV) drugs. It may also be important to check HBV DNA levels in women with isolated anti-HBc before ARVs are initiated because of the risk of a paradoxical exacerbation of HBV and the occurrence of immune reconstitution inflammatory syndrome (IRIS). HIV-infected pregnant women with isolated anti-HBc and occult HBV infection typically have very low levels of HBV DNA and are thought to be at extremely low risk of transmitting HBV to their infants.

HIV-infected pregnant women who screen negative for HBV (i.e., HBsAg-negative, anti-HBc-negative, and anti-HBs-negative) should receive the HBV vaccine series. HIV-infected women with remote HBV infection and current isolated anti-HBc antibody (negative HBV DNA, HBsAg, and anti-HBs) may have lost immunity to HBV and should be vaccinated. Data indicate no apparent risk to developing fetuses of adverse events from hepatitis B vaccine, and current vaccines contain noninfectious HBsAg.

Household contacts of HBV-infected women should also be tested for HBV, and if negative, receive the HBV vaccine series. Anti-HBs titers should be obtained 1 month after completion of the vaccine series in HIV-infected patients; if anti-HBs titers are below 10 IU/mL, a second vaccine series is recommended.

Because of the added risk of hepatic decompensation from acute infection with hepatitis A virus (HAV) in individuals with chronic HBV or HCV, women who are found to have HBV infection should also be screened for HAV using antibody testing for immunoglobulin G (IgG). If HAV IgG is negative, and if the HAV vaccine was not given previously, HIV/HBV-coinfected women should receive the HAV vaccine series. Women who have already received the HAV vaccine series do not need to repeat it because they are protected but may have undetectable HAV IgG levels. Although the safety of HAV vaccination during pregnancy has not been determined, HAV vaccine is produced from inactivated HAV and the theoretical risk to the developing fetus is expected to be low.

**Therapy for HIV and Hepatitis B Virus in Pregnancy**

A combination antiretroviral therapy (cART) regimen that includes drugs active against both HIV and HBV is recommended for all individuals with HIV/HBV coinfection who require HBV treatment or who are starting ARV drugs, including all pregnant women. Initiation of cART may be associated with reactivation of HBV and development of IRIS, particularly in patients with high HBV DNA levels.

In addition, use of ARV drugs with anti-HBV activity during pregnancy lowers HBV viremia, potentially increasing the efficacy of neonatal hepatitis B immune globulin (HBIG) and hepatitis B vaccine in prevention of perinatal transmission of HBV. High maternal HBV DNA levels are strongly correlated with perinatal HBV transmission and with failures of HBV passive-active immunoprophylaxis. Several small studies and a recent meta-analysis suggest that lamivudine or telbivudine may reduce the risk of perinatal transmission of HBV if given during the third trimester to HBV-infected, HIV-seronegative women with high HBV DNA viremia. Although a high HBV viral load clearly is important, it is not the only factor predisposing to failure of HBV prophylaxis. In a study of 2,048 HIV-infected pregnant women in Malawi, 5% (103 women) were HBsAg-positive, 70 of whom were also HBV DNA-positive. Nearly 10% of infants born to HBV/HIV co-infected mothers had HBV DNA detected by age 48 weeks despite being immunized at ages 6, 10, and 14 weeks per standard-of-care health practices in this population.

Lamivudine, tenofovir disoproxil fumarate (tenofovir), and emtricitabine have activity against both HIV and HBV. Tenofovir with emtricitabine or lamivudine is the preferred dual nucleoside reverse transcriptase inhibitor backbone in women who are HIV/HBV-coinfected (see Table 6). These agents are recommended for use in pregnancy (see Table 6). Please see individual drug sections for tenofovir, emtricitabine, and lamivudine for detailed review of safety, pharmacologic, and other clinical data for use in pregnancy.

Several other antivirals with activity against HBV, including entecavir, adefovir, and telbivudine, have not been well evaluated in pregnancy. Entecavir is associated with skeletal anomalies in rats and rabbits but only
at doses high enough to cause toxicity to the mother. Fewer than 57 cases of exposure to each of these drugs during the first trimester have been reported to the Antiretroviral Pregnancy Registry prospectively, with no increased risk of birth defects. Telbivudine was given to 135 HBV-positive, HIV-seronegative women during the third trimester and was well tolerated, and perinatal transmission of HBV was lower in telbivudine-treated mothers than in the controls not on telbivudine (0% vs. 8%; \( p = 0.002 \)). In 2 separate meta-analyses of the effects of telbivudine in late pregnancy in women infected with HBV alone, telbivudine was effective in interrupting intrauterine HBV infection without significant adverse effects or complications. For HIV/HBV coinfected pregnant women, both entecavir and telbivudine should be administered only in addition to a fully suppressive cART regimen for HIV. Because these other anti-HBV drugs also have weak activity against HIV, they may select for anti-HIV drug resistance in the absence of fully suppressive cART regimen as well as confer the potential for developing cross-resistance to other ARV drugs (e.g., entecavir can select for the M184V mutation, which confers HIV resistance to lamivudine and emtricitabine). Although adefovir does not have significant anti-HIV activity, it is not recommended for treatment of HBV because it is less potent and has a higher risk of selecting for resistance mutations than the preferred HBV nucleos(t)ides. Cases of exposure during pregnancy to any of the ARV drugs and HBV drugs listed should be reported to the Antiretroviral Pregnancy Registry (800-258-4263; http://www.apregistry.com).

Interferon alfa and pegylated interferon alfa are not recommended for use in pregnancy and should be used only if the potential benefits outweigh the potential risks. Although interferons are not teratogenic, they are abortifacient at high doses in monkeys and should not be used in pregnant women because of their direct antigrowth and antiproliferative effects.

**Monitoring of HIV/Hepatitis B Virus-Infected Women during Pregnancy**

Following initiation of ARV drugs, an elevation in hepatic enzymes can occur in HIV/HBV-coinfected women—particularly those with low CD4 T lymphocyte counts at the time of treatment initiation—as a result of an immune-mediated flare in HBV disease triggered by immune reconstitution with effective HIV therapy. HBV infection also can increase hepatotoxic risk of certain ARV drugs, specifically protease inhibitors and nevirapine. Pregnant women with HIV/HBV coinfection should be counseled about signs and symptoms of liver toxicity, and transaminases should be assessed 1 month following initiation of ARV drugs and at least every 3 months thereafter. If hepatic toxicity occurs, it may be necessary to consider substituting a less hepatotoxic regimen or, if clinical symptoms or significant elevations of transaminases occur, drugs may need to be temporarily discontinued. Differentiating between a flare in HBV disease due to immune reconstitution and drug toxicity often can be difficult, and consultation with an expert in HIV and HBV coinfection is strongly recommended. Because tenofovir has potential to cause renal toxicity, kidney function also should be monitored regularly in pregnant women as in non-pregnant adults.

Following delivery, considerations regarding continuation of the ARV drug regimen are the same as for other non-pregnant individuals (see General Principles Regarding Use of Antiretroviral Drugs During Pregnancy). Therefore, once HBV therapy with nucleos(t)ide analogs is initiated, treatment is recommended to be continued indefinitely. Discontinuation of agents with anti-HBV activity may be associated with hepatocellular damage resulting from reactivation of HBV. Frequent monitoring of liver function tests for potential HBV flare is recommended in women with HIV/HBV coinfection who choose to stop their ARV drugs postpartum, with prompt reinitiation of treatment for both HIV and HBV if a flare is suspected.

**Mode of Delivery**

Decisions concerning mode of delivery in HIV/HBV-coinfected pregnant women should be based on standard obstetric and HIV-related indications alone (see Intrapartum Care). There are no data on the role of cesarean delivery in reducing perinatal transmission of HBV in HIV/HBV-coinfected women or when HBV-infected women receive antiviral therapy active against HBV. Current guidelines for HBV-monoinfected women advise that cesarean delivery is not indicated to prevent perinatal transmission of HBV.
Treatment of HIV/HBV coinfected pregnant women with cART that includes tenofovir and emtricitabine will result in low or suppressed HBV viral loads near delivery, which should further reduce risk of HBV perinatal transmission.

**Evaluation and Management of Hepatitis B Virus-Exposed Infants**

Within 12 hours of birth, all infants born to mothers with chronic HBV infection should receive HBIG and the first dose of the HBV vaccination series. **For infants weighing ≥2,000 g at birth,** the second and final doses of the vaccine series should be administered at ages 1 and 6 months, respectively. **For infants with birth weights <2,000 g at birth,** do not count the birth dose as part of the vaccine series and administer three additional doses at ages 1, 2–3, and 6 months. This regimen is >95% effective in preventing HBV infection in these infants.

Post-vaccination testing for anti-HBs and HBsAg should be performed after completion of the vaccine series, at age 9 months to 18 months. Testing should not be performed before age 9 months to avoid detection of anti-HBs from HBIG administered during infancy and to maximize the likelihood of detecting late HBV infection. Anti-HBc testing of infants is not recommended because passively acquired maternal anti-HBc might be detected in infants born to HBV-infected mothers up to age 24 months. HBsAg-negative infants with anti-HBs levels >10 mIU/mL are protected and need no further medical management. HBsAg-negative infants with anti-HBs levels <10 mIU/mL should be revaccinated with a second three-dose series and retested 1 to 2 months after the final dose of vaccine.

**References**


### Panel’s Recommendations

- All HIV-infected pregnant women should be screened during the current pregnancy for hepatitis B virus (HBV) and hepatitis C virus (HCV), unless they are known to be coinfected (see [HIV/Hepatitis B Virus Coinfection](#) section) (AII).
- Screening for HCV infection should use the most sensitive immunoassays licensed for detection of antibody to HCV (anti-HCV) in blood (AII).
- All HIV-infected pregnant women who screen negative for HBV (i.e., HBV surface antigen-negative, HBV core antibody-negative, and HBV surface antibody-negative) should receive the HBV vaccine series (AII).
- Women with chronic HBV or HCV infection should also be screened for hepatitis A virus (HAV) because they are at increased risk of complications from coinfection with other viral hepatitis infections (AII).
- Women with chronic HCV who are negative for hepatitis A immunoglobulin G should receive the HAV vaccine series if they have never received it (AII).
- The management of HIV/HCV coinfection in pregnancy is complex because currently approved medications for HCV are not recommended during pregnancy, and no safety data exist for use of the recently approved HCV oral medications in pregnant women (AII). If considering treatment of HCV in an HIV-coinfected pregnant woman, consultation with an expert in HIV and HCV is strongly recommended (AII).
- Interferon alfa and pegylated interferon alfa are not recommended and ribavirin is contraindicated during pregnancy (AII).
- Recommendations for antiretroviral drug use during pregnancy are the same for HIV-infected women whether or not they have chronic HCV (BII).
- Pregnant women with HIV/HCV coinfection receiving antiretroviral drugs should be counseled about signs and symptoms of liver toxicity, and liver transaminases should be assessed 1 month following initiation of antiretroviral drugs and at least every 3 months thereafter during pregnancy (BII).
- Decisions concerning mode of delivery in HIV/HCV-coinfected pregnant women should be based on standard obstetric and HIV-related indications alone; HCV coinfection does not necessitate cesarean delivery, if not otherwise indicated (see [Intrapartum Care](#)) (AII).
- Infants born to women with HIV/HCV coinfection should be evaluated for HCV infection with anti-HCV antibody testing after age 18 months (AII). Infants who screen positive should undergo confirmatory HCV RNA testing. If earlier diagnosis is desired, HCV RNA virologic testing can be done after age 2 months (AII). Because HCV viremia can be intermittent, 2 negative HCV RNA tests at or after age 2 months, including 1 at or after age 12 months, are needed to definitively exclude HCV infection (BII). Children are considered to be HCV-infected if they have two or more positive HCV RNA results at any age, or are HCV antibody-positive beyond age 18 months (AII).

### Rating of Recommendations:

- A = Strong
- B = Moderate
- C = Optional

### Rating of Evidence:

- I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints
- II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes
- III = Expert opinion

For additional information on hepatitis C virus (HCV) and HIV, see [HIV/Hepatitis C Coinfection](#) in the [Adult and Adolescent Antiretroviral Guidelines](#) and [Hepatitis C Virus Infection](#) in the [Adult Opportunistic Infections Guidelines](#). The American Association for the Study of Liver Diseases, the Infectious Diseases Society of America, and International Antiviral Society-USA recently updated their HCV treatment guidelines to add newly approved interferon-free direct-acting antiviral regimens and to provide more information about treating patients with HIV/HCV coinfection and decompensated liver disease. The guidelines are available online at [HCVguidelines.org](http://hcvguidelines.org). The management of HIV/HCV coinfection in pregnancy is complex and consultation with an expert in HIV and HCV infection is strongly recommended, particularly if treatment of HCV infection during pregnancy is being considered.
Screening and Vaccination

All HIV-infected women should be screened for hepatitis B virus (HBV) and HCV at entry into general HIV care. HIV-infected women should be rescreened for HBV and HCV during each pregnancy, unless they are known to be coinfected. HCV coinfection is not uncommon in HIV-infected women, particularly those infected via parenteral use of drugs; among HIV-infected pregnant women in a European cohort, the observed HCV seroprevalence rate was 12%. The male partners of all HIV/HCV-coinfected patients should be referred for both HIV and hepatitis counseling and testing to prevent horizontal transmission of HIV as well as HCV from woman to their male partners.

Although current HCV treatment guidelines recommend therapy for all HCV-infected patients with estimated life expectancies >12 months, currently available anti-HCV treatments lack sufficient safety data to be recommended during pregnancy. In addition, the risks of perinatal HCV transmission are much lower than of perinatal HIV transmission, and many infected children will clear HCV infection spontaneously, making the balance of risks and benefits for treating HCV in pregnancy very different than for treating HIV in pregnancy.

The primary reasons for HCV testing during pregnancy, therefore, are:

1) To identify HCV-infected women at a time when they are engaged with the health system, so that HCV treatment can be offered after delivery (ideally before a subsequent pregnancy, if planned);
2) To be aware of increased risk of HCV-related hepatotoxicity related to antiretroviral (ARV) use in HIV/HCV coinfected women;
3) To ensure vaccination against other viral hepatitides (hepatitis A virus [HAV] and HBV) when needed; and
4) To ensure appropriate follow-up and evaluation of HCV-exposed infants.

Screening for chronic HCV infection using a sensitive immunoassay for HCV antibody is recommended for all HIV-infected individuals, including pregnant women. False-negative anti-HCV immunoassay results can occur in HIV-infected individuals, particularly those with very low CD4 T lymphocyte (CD4) cell counts or very recent infection, but it is uncommon with the more sensitive immunoassays. If HCV infection is suspected despite a negative HCV antibody screen, a quantitative HCV RNA assay can be performed.

Individuals who have a positive HCV antibody test should undergo confirmatory testing for plasma HCV RNA using a commercially available quantitative diagnostic assay. Testing for HCV RNA also should be performed on individuals whose serologic test results are indeterminate or negative but in whom HCV infection is suspected because of elevated aminotransaminase levels or risk factors such as a history of injection drug use.

HIV/HCV-coinfected women who screen negative for HBV (i.e., hepatitis B surface antigen [HBsAg]-negative, hepatitis B core antibody-negative, and hepatitis B surface antibody-negative) should receive the HBV vaccine series. Data indicate no apparent risk to developing fetuses of adverse events from hepatitis B vaccination, and current vaccines contain noninfectious HBsAg and should cause no risk to fetuses.

Because of the added risk of hepatic decompensation from acute infection with HAV in individuals with chronic HCV, women with HCV infection should also be screened for HAV, using antibody testing for immunoglobulin G (IgG). If HAV IgG is negative, and if the HAV vaccine was not given previously, HIV/HCV-coinfected women should receive the HAV vaccine series. Post-vaccination serologic testing is not indicated because many commercially available HAV antibody assays do not have the sensitivity to detect low HAV antibody concentrations after vaccination. Although the safety of HAV vaccination during pregnancy has not been determined, HAV vaccine is produced from inactivated HAV and the theoretical risk to the developing fetus is expected to be low.
Impact of Hepatitis C Virus on HIV Management

Few data exist on the optimal management of HIV-infected pregnant women with HCV coinfection. Recommendations for ARV drug use during pregnancy for treatment of HIV and prevention of perinatal transmission are the same for women who have HIV/HCV co-infection as for those infected only with HIV (see HIV/Hepatitis C Coinfection in the Adult and Adolescent Antiretroviral Guidelines).

Hepatitis C Virus-Specific Therapy in Pregnancy

Currently available anti-HCV treatments—both oral and parenteral—lack sufficient safety data to be recommended during pregnancy. Until recently, most anti-HCV therapy included both interferon and ribavirin. Interferons are not recommended for use in pregnancy because they are abortifacient at high doses in monkeys and have direct antitumor and antiproliferative effects. Ribavirin is contraindicated (Food and Drug Administration [FDA] Pregnancy Category X) because of teratogenicity at low doses in multiple animal species. Ribavirin-associated defects in animals include limb abnormalities, craniofacial defects, anencephaly, and anophthalmia. Concerns have been raised about potential mutagenic effects of ribavirin in the offspring of men taking ribavirin before conception because of possible accumulation of ribavirin in spermatozoa. However, in a small number of inadvertent pregnancies occurring in partners of men receiving ribavirin therapy, no adverse outcomes were reported. Pregnancies that occur in women taking ribavirin should be reported to the Ribavirin Pregnancy Registry (800-593-2214 or http://www.ribavirinpregnancyregistry.com).

Newer interferon-free and ribavirin-free regimens have recently been approved for treatment of HCV. As of June 2015, these regimens included the protease inhibitor (PI) simeprevir (Pregnancy Category C), the nucleotide analogue NS5B polymerase inhibitor sofosbuvir (Pregnancy Category B), the NS5A inhibitor ledipasvir (Pregnancy Category B), and a fixed-dose combination (Pregnancy Category B) of both ledipasvir/sofosbuvir and paritaprevir (NS3/4A PI)/ritonavir/ombitasvir (NS5A PI) plus twice-daily dasabuvir (NS5B polymerase inhibitor), given with and without ribavirin, depending on HCV genotype. However, these medications are not yet recommended for use in pregnancy because of the lack of data on their use in pregnancy. In addition, potential drug interactions between these newer anti-HCV drugs and ARV drugs, particularly certain protease inhibitor (PI) regimens and non-nucleoside reverse transcriptase inhibitors, may reduce the effectiveness of these medications if used together or increase exposure to tenofovir disoproxil fumarate if included in the regimen. For more detailed information on drug interactions and newly approved medications, see Adult and Adolescent Antiretroviral Guidelines, Adult Opportunistic Infections Guidelines and the HCV treatment guidelines (http://www.hcvguidelines.org).

Pregnancy does not appear to influence the course of HCV infection and women with chronic HCV generally do quite well during pregnancy, provided that their infections have not progressed to decompensated cirrhosis.

In a majority of studies, the incidence of perinatal HCV transmission increases if the mother is coinfected with HIV, with transmission rates between 10% and 20% reported primarily among women not treated with combination antiretroviral therapy (cART). These higher transmission rates are likely related to an increase in HCV viremia and/or other HIV-related impact on HCV disease activity. However, early and sustained control of HIV viremia with cART may reduce HCV transmission to infants. A European study of perinatal transmission of HCV found that use of effective cART for HIV was associated with a strong trend toward reduction in HCV transmission (odds ratio 0.26, 95% confidence interval, 0.07–1.01). Maternal HIV/HCV coinfection also may increase the risk of perinatal transmission of HIV. Therefore, cART is recommended for all HIV/HCV-coinfected pregnant women, regardless of CD4 cell count or HIV viral load.

Monitoring of HIV/ Hepatitis C Virus-Infected Women during Pregnancy

An elevation in hepatic enzymes following initiation of cART can occur in HIV/HCV-coinfected women—particularly in those with low CD4 cell counts at treatment initiation—as a result of an immune-mediated flare in HCV disease triggered by immune reconstitution with effective cART. HCV infection may increase the...
hepatotoxic risk of certain ARV agents, specifically PIs and nevirapine. Pregnant women with HIV/HCV coinfection should be counseled about signs and symptoms of liver toxicity, and transaminase levels should be assessed 1 month after initiation of ARV drugs and then every 3 months thereafter. If hepatic toxicity occurs, consideration may need to be given to substituting a less hepatotoxic drug regimen, and if clinical symptoms or significant elevations of transaminases occur, drugs may need to be temporarily discontinued. Differentiating between a flare in HCV disease associated with immune reconstitution and drug toxicity often can be difficult; therefore, consultation with an expert in HIV and HCV coinfection is strongly recommended.

**Mode of Delivery**

As with transmission of HIV, risk of perinatal transmission of HCV may be increased by use of internal fetal monitoring, amniocentesis, and rupture of membranes for more than 6 hours. The majority of studies of elective cesarean delivery in HCV-infected women with or without HIV coinfection have found that the procedure does not reduce the risk of perinatal transmission of HCV. Thus, the general recommendations for intrapartum management are the same in women with HIV/HCV coinfection as in those with HIV infection alone (see [Intrapartum Care](#)).

**Evaluation of HCV-Exposed Infants**

Infants born to women with HIV/HCV coinfection should be assessed for HCV infection with anti-HCV antibody testing after age 18 months. Infants who screen positive should undergo confirmatory HCV RNA testing. HCV RNA virologic testing can be done after age 2 months, if earlier diagnosis is indicated or desirable. Because HCV viremia can be intermittent, two negative HCV RNA tests at or after age 2 months, including one at or after age 12 months, are needed to definitively exclude HCV infection. Children are considered to be HCV-infected if they have two or more positive HCV RNA polymerase chain reaction results at any age, or are HCV antibody-positive beyond age 18 months.

**References**

10. Tovo PA, Palomba E, Ferraris G, et al. Increased risk of maternal-infant hepatitis C virus transmission for women...


HIV-2 infection is endemic in West African countries including Ivory Coast, Ghana, Cape Verde, Gambia, Mali, Senegal, Liberia, Guinea, Burkina Faso, Nigeria, Mauritania, Sierra Leone, Guinea Bissau, Niger, Sao Tome, and Togo; Angola; Mozambique; and in parts of India.1-4 It also occurs in countries such as France and Portugal, which have large numbers of immigrants from these regions.5 HIV-2 remains rare in the United States. Between 1998 and 2010, 242 HIV-2 cases were reported to the Centers for Disease Control and Prevention (CDC), with 166 cases meeting criteria for HIV-2 diagnosis. These 166 cases constituted only 0.01% of the more than 1.4 million U.S. cases of HIV infection.6 Of the 50 women aged 15 to 44 years at diagnosis, 24 (48%) were pregnant at or after HIV-2 diagnosis.6 HIV-2 infection should be suspected in pregnant women who are from—or have partners from—countries in which the disease is endemic who have positive results on an HIV-1/HIV-2 antibody or HIV-1/HIV-2 antigen/antibody immunoassay. They should be tested with a supplemental HIV-1/HIV-2 antibody differentiation assay. If they are indeed HIV-2 infected it would show negative HIV-1 antibodies and positive HIV-2 antibodies.7

A regimen with two nucleoside reverse transcriptase inhibitors and a boosted protease inhibitor currently is recommended for HIV-2-infected pregnant women who require treatment for their own health because they have significant clinical disease or CD4 T lymphocyte cell (CD4) counts <500 cells/mm³ (AII).

Lopinavir/ritonavir plus zidovudine/lamivudine or abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine is the preferred combination antiretroviral therapy regimen for HIV-2-infected pregnant women who require treatment (AII).

Optimal prophylactic regimens have not been defined for HIV-2-infected pregnant women who do not require treatment for their own health (i.e., CD4 counts >500 cells/mm³ and no significant clinical disease). Experts have recommended the following approaches:

- A boosted protease inhibitor-based regimen (two nucleoside reverse transcriptase inhibitors plus lopinavir/ritonavir) for prophylaxis, with the drugs stopped postpartum (BII); or
- Zidovudine prophylaxis alone during pregnancy and intrapartum (BII).

Non-nucleoside reverse transcriptase inhibitors and enfuvirtide are not active against HIV-2 and should not be used for treatment or prophylaxis (AII).

All infants born to HIV-2-infected mothers should receive the standard 6-week zidovudine prophylactic regimen (BIII).

In the United States, where safe infant formula is readily available, breastfeeding is not recommended for infants of HIV-2-infected mothers (AII).

In 2014, the CDC released a new HIV Testing Algorithm, which may enhance the diagnosis of HIV-2. The first step in that algorithm is performance on serum or plasma of an HIV-1/HIV-2 antigen/antibody combination assay (e.g., Abbott Architect HIV Ag/Ab combo assay, BioRad GS Combo Ag/Ab EIA, Alere Determine).10 This test does not distinguish between antibodies to HIV-1 and HIV-2. Specimens which are reactive on this test must be tested with a Food and Drug Administration (FDA)-approved second-generation antibody assay to
distinguish HIV-1 from HIV-2 antibodies. There are two HIV-2 antibody supplemental tests now approved by FDA that can be used as part of the CDC recommended HIV laboratory testing algorithm: Multispot HIV-1/HIV-2 Rapid Test (Bio-Rad Laboratories) and GeeniuS (Bio-Rad Laboratories). Viral load assays for HIV-2 are not commercially available, but may be available under research protocols. The University of Washington [11] and the New York State Department of Health [12] offer HIV-2 viral load assays. All HIV-2 cases should be reported to the HIV surveillance program of the state or local health department, which can arrange for additional confirmatory testing for HIV-2 by the CDC. [13] No validated HIV-2 genotype or phenotype resistance assays are available in the United States. Recently, European experts developed a rule set and an automated tool for HIV-2 drug resistance analyses that is freely available on the Internet (see [14]).

HIV-2 has a longer asymptomatic phase than HIV-1, with a slower progression to AIDS. The most common mode of HIV-2 transmission is through heterosexual sex. HIV-2 is less infectious than HIV-1, with a 5-fold lower rate of sexual transmission and 20- to 30-fold lower rate of vertical transmission. [3,15,16] Several studies confirm that rates of perinatal transmission of HIV-2 are low with and without interventions (0% to 4%), which may be a result of reduced plasma viral loads and less cervical viral shedding, compared with that seen in HIV-1-infected women. [17-20] HIV-2 also can be transmitted through breastfeeding. HIV-2 infection does not protect against HIV-1 and dual infection, which carries the same prognosis as HIV-1 mono-infection, can occur. [21]

Few data exist on which to base treatment decisions or strategies for prevention of perinatal transmission in patients infected with HIV-2. In a systematic review of non-pregnant, HIV-2-infected patients from 1996–2012, Ekouevi, et al. noted a heterogeneity of treatment outcomes among HIV-2-infected patients initiating combination antiretroviral therapy, especially in resource-limited settings. [22] Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and enfuvirtide are not active against HIV-2 and should not be used for treatment or prophylaxis. [23,24] HIV-2 has variable sensitivity to protease inhibitors (PIs), with lopinavir, saquinavir, and darunavir having the most activity. [25] The integrase inhibitors raltegravir and elvitegravir also appear to be effective against HIV-2. [3,26-29] The CCR5 antagonist maraviroc appears active against some strains of HIV-2, although there are no approved assays to determine HIV-2 co-receptor tropism. [30,31] HIV-2 drug resistance has been documented with various antiretroviral (ARV) drugs. [32,33]

The care of HIV-2-infected pregnant women has been based on expert opinion. A regimen with two nucleoside reverse transcriptase inhibitors and a boosted PI currently is recommended for HIV-2-infected pregnant women who require treatment for their own health because they have significant clinical disease or CD4 T lymphocyte (CD4) cell counts <500 cells/mm³. [34] Based on efficacy and available data on safety in HIV-1-infected pregnant women, lopinavir/ritonavir plus zidovudine/lamivudine or abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine or lamivudine is preferred. [35,36] NNRTIs should not be used because they are not active against HIV-2.

For HIV-2-infected pregnant women with CD4 cell counts >500 cells/mm³ and no significant clinical disease, who do not require treatment for their own health, some experts would use a boosted PI-based regimen for prophylaxis and stop the drugs postpartum. [18] Single-drug prophylaxis with zidovudine alone has also been considered by other experts for prevention of perinatal transmission because HIV-2 has a significantly lower risk of perinatal transmission than HIV-1. [18] However, this may not be an optimal choice as there seems to be a low genetic barrier to resistance in HIV-2, with as few as two mutations conferring full zidovudine resistance. [35,37] All infants born to mothers infected with HIV-2 should receive the standard 6-week zidovudine prophylactic regimen. [36] The possible risks and benefits of ARV prophylaxis should be discussed with the mothers.

Pregnant women who have HIV-1/HIV-2 coinfection should be treated according to the guidelines for HIV-1-monoinfected patients, making sure that the ARV regimen chosen is also appropriate for HIV-2.

Other than the standard obstetric indications, no data exist regarding the role of elective cesarean delivery in women who are infected with HIV-2. The risk to infants from breastfeeding is lower for HIV-2 than for HIV-1. [38] Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

C-65
1, but breastfeeding should be avoided in the United States and other resource-rich countries where safe infant formula is readily available.  

Infants born to HIV-2-infected mothers should be tested for HIV-2 infection with HIV-2-specific virologic assays at time points similar to those used for HIV-1 testing.  

HIV-2 virologic assays are not commercially available, but the National Perinatal HIV Hotline (888-448-8765) can provide a list of sites that perform this testing.

Testing of infants at age 18 months (e.g., with the Bio-Rad Laboratories Multispot HIV-1/HIV-2 test) also is recommended to confirm clearance of HIV-2 antibodies.

References


Pregnancy in Women with Perinatal HIV Infection  (Last updated August 6, 2015; last reviewed August 6, 2015)

With the availability of potent combination antiretroviral therapy (cART), morbidity and mortality have significantly declined in HIV-infected individuals, including those with perinatally acquired HIV. An increasing number of those with perinatal HIV infection are now reaching childbearing age and becoming pregnant or fathering children. A significant number of these pregnancies are unintended.1-3 The components of prenatal care and general principles of cART and HIV management do not differ between pregnant women who were perinatally infected and those who acquired HIV infection in other ways. However, there are some unique challenges in this population related to reproductive health care needs and the prevention of perinatal transmission. Adherence to cART historically has been an issue for women with longstanding HIV infection and is a key challenge in caring for perinatally infected women. In addition, because most perinatally infected pregnant women are adolescents and young adults, they may be at higher risk of certain pregnancy complications such as preterm delivery, low birthweight, and preeclampsia.4,6

Perinatally infected women may be at risk of drug resistance due to extensive cART exposure prior to pregnancy, including exposure to suboptimal mono- or dual-therapy regimens as children.7 The choice of the best cART regimen to prevent perinatal transmission and for maternal treatment is crucial to the management of perinatally infected pregnant women. Optimal cART regimens should be selected on the basis of resistance testing, prior cART history, and the same guiding principles used for heavily ART-experienced adults. Given challenges to adherence in perinatally infected pregnant adolescents, whenever possible, consideration should be given to regimens that optimize dosing intervals and minimize pill burden. Consultation with experts in HIV and pregnancy is recommended.

Several studies comparing perinatally and horizontally infected (e.g., through sexual contact or injection drug use) pregnant women have reported that perinatally infected women were more likely to have lower median CD4 T lymphocyte counts, detectable viral loads, and genotypic drug resistances (40% vs 12%).7,8 In a retrospective analysis of 37 pregnancies among perinatally infected women and 40 pregnancies among age-matched horizontally infected women delivering during the same time period, the viral load decline achieved during pregnancy in the perinatally infected women was not sustained during postpartum follow-up in contrast to the horizontally infected women. During extended follow-up of 4 years, there were 4 deaths due to AIDS-related complications in the perinatally infected women and none in the horizontally infected women.8 Although genotypic mutations were more common in perinatally infected women, loss of viral suppression resulting in progression of disease postpartum is more likely related to adherence highlighting the need for special focus on adherence interventions after delivery.

Although data are limited, some studies have suggested that perinatally infected women may have elevated rates of preterm and small-for-gestational-age (SGA) infants compared to women with horizontal HIV infection. However, other studies have not reported this. Williams et al. reported a 31% incidence of preterm delivery and/or premature rupture of membranes in a cohort of 10 perinatally infected pregnant women.9 In a cohort of 79 pregnant women (17 with perinatal and 62 with horizontal infection) with 87 live births, Jao et al. reported a four-fold increased risk for SGA births among women infected perinatally versus women infected horizontally.10 Munjal et al. reported that perinatally infected women were more likely to deliver at an earlier gestational age and that their newborns had a lower average birthweight.8 In contrast, Agwu found no differences in adverse pregnancy outcomes in 96 pregnancies between perinatally and horizontally infected women; however, there were high rates of preterm births in both groups (29.4% among women with perinatal infection and 36.3% among those with horizontal infection).11 Badell et al. also did not find differences in birth outcomes between 20 women with perinatal infection and 80 with horizontal infection.7 Several studies have suggested that perinatally infected pregnant women are more likely to have a cesarean delivery (most commonly related to prevention of HIV infection due to lack of optimal viral load suppression).8,9 The young age of these women and their likelihood of future pregnancies and possibly cesarean deliveries raise concerns regarding the potential for increased risk of adverse obstetric outcomes in the future.
Reassuringly, despite prolonged HIV infection in perinatally infected women, receipt of multiple cART regimens, and increased likelihood of having drug-resistant virus, when appropriate ART and prenatal management occurs and optimal viral load suppression is attained the risk of perinatal transmission does not appear to be increased in this population.7-9,12-14

Among perinatally infected adolescents, pregnancy may create additional burdens in the transition from pediatric/adolescent HIV care to adult care. Psychosocial challenges may be magnified due to the presence of a lifelong chronic illness, high rates of depression,15 and frequent loss of one or both parents. Attention to developmentally appropriate adherence counseling is critical. A systematic review and meta-analysis of 50 eligible studies on cART adherence in HIV-infected individuals aged 12 years to 24 years, in which adequate adherence was defined as >85% by self-report or undetectable viral load, reported 62.3% adherence overall among HIV-infected youth, with youth from U.S. studies having lowest average rate of adherence, at 53%.16 Co-management between adolescent physicians and the prenatal team case managers may be helpful. Inclusion of developmentally appropriate risk-reduction interventions, integration of reproductive health counseling and pregnancy prevention, inclusion of perinatally infected males in guidance for planning future pregnancies, developmentally appropriate skill building to support disclosure, and consistent condom use are also important.

References


**Acute HIV Infection** *(Last updated August 6, 2015; last reviewed August 6, 2015)*

### Panel’s Recommendations

- When acute retroviral syndrome is suspected in pregnancy or during breastfeeding, a plasma HIV RNA test should be obtained in conjunction with a routine HIV antibody screening test or an antigen/antibody immunoassay test (see Identifying, Diagnosing, and Managing Acute HIV-1 Infection in the Adult and Adolescent Antiretroviral Guidelines, [http://www.cdc.gov/hiv/pdf/HIVtestingAlgorithmRecommendation-Final.pdf](http://www.cdc.gov/hiv/pdf/HIVtestingAlgorithmRecommendation-Final.pdf)) *(AII)*.

- Repeat HIV testing in the third trimester is recommended for pregnant women with initial negative HIV antibody tests who are known to be at risk of acquiring HIV, are receiving care in facilities that have an HIV incidence in pregnant women of at least 1 per 1,000 per year, are incarcerated, or who reside in jurisdictions with elevated HIV incidence (see Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings and [http://www.cdc.gov/hiv/pdf/HIVtestingAlgorithmRecommendation-Final.pdf](http://www.cdc.gov/hiv/pdf/HIVtestingAlgorithmRecommendation-Final.pdf)) *(AII)*.

- All pregnant women with acute or recent HIV infection should start a combination antiretroviral drug regimen as soon as possible to prevent perinatal transmission, with the goal of suppressing plasma HIV RNA to below detectable levels *(AI)*.

- In women with acute HIV infection, baseline genotypic resistance testing should be performed simultaneously with initiation of the combination antiretroviral regimen, and the antiretroviral regimen should be adjusted, if necessary, to optimize virologic response *(AII)*.

- Because clinically significant resistance to protease inhibitors (PIs) is less common than resistance to non-nucleoside reverse transcriptase inhibitors in antiretroviral-naive individuals, a ritonavir-boosted, PI-based regimen should be initiated *(AII)*.

### Rating of Recommendations: A = Strong; B = Moderate; C = Optional

### Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Primary or acute HIV infection in pregnancy or during breastfeeding is associated with an increased risk of perinatal transmission of HIV and may represent a significant proportion of residual perinatal transmission in the United States.¹

In North Carolina, from 2002 to 2005, 5 of 15 women found to have acute HIV infection on nucleic acid amplification testing of pooled HIV antibody-negative specimens were pregnant at the time of testing.² All 5 women received antiretroviral (ARV) drugs and delivered HIV-uninfected infants. From 2002 to 2006, of 3,396 HIV-exposed neonates born in New York State, 22% (9 of 41) of infants born to mothers who acquired HIV during pregnancy became infected with HIV, compared with 1.8% of those born to mothers who did not acquire HIV during pregnancy (OR 15.19; 95% CI, 3.98–56.30).³ A case series from China reported a perinatal transmission rate of 35.8% in 106 breastfeeding infants of mothers who acquired HIV postnatally through blood transfusion.⁴ The high rate of transmission associated with acute infection likely is related to the combination of the high viral load in plasma, breast milk, and the genital tract associated with acute infection⁵ and the fact that the diagnosis is easy to miss, which results in lost opportunities for implementation of prevention interventions.

Health care providers should maintain a high level of suspicion of acute HIV infection in women who are pregnant or breastfeeding and have a compatible clinical syndrome, even when they do not report high-risk behaviors, because it is possible that their sexual partners are practicing high-risk behaviors of which the women are unaware.

An estimated 40% to 90% of patients with acute HIV infection will experience symptoms of acute retroviral syndrome, characterized by fever, lymphadenopathy, pharyngitis, skin rash, myalgias/arthritis, and other symptoms.⁶⁷ Providers often do not recognize acute HIV infection, however, because the symptoms are similar to those of other common illnesses and individuals with the condition also can be asymptomatic. Combination antiretroviral therapy (cART) is currently recommended for all adults and adolescents with HIV...
infection, including those with acute or recent infection. Whether treatment of acute or recent HIV infection results in long-term virologic, immunologic, or clinical benefit is unknown.

When acute retroviral syndrome is suspected in pregnancy or during breastfeeding, a plasma HIV RNA test should be obtained in conjunction with a routine HIV antibody screening test or an antigen/antibody immunoassay test. Updated guidance for HIV testing recommends initial testing for HIV with a Food and Drug Administration-approved antigen/antibody combination (fourth generation) immunoassay that detects HIV-1 and HIV-2 antibodies and HIV-1 p24 antigen. These tests are used to screen for established infection with HIV-1 or HIV-2 and for acute HIV-1 infection. These fourth-generation tests have the advantage of a shorter window to detect infection (2 weeks compared with 4 weeks by Western Blot testing). A second rapid test with a different assay should be performed to confirm any positive test. The fourth-generation tests are becoming increasingly available and will likely result in improved detection of acute and early HIV infection (see Acute and Recent HIV in the Adult and Adolescent Antiretroviral Guidelines and http://www.cdc.gov/hiv/pdf/HIVtestingAlgorithmRecommendation-Final.pdf). Confirmatory serologic testing should be performed within 3 months on patients whose acute HIV infection is diagnosed with virologic testing but who are antibody-negative or whose antibody levels cannot be determined.

Recent HIV infection also can be detected by repeat HIV testing later in pregnancy in women whose initial HIV test earlier in pregnancy was negative. A report from the Mother-Infant Rapid Intervention at Delivery study found that 6 (11%) of 54 women whose HIV was identified with rapid HIV testing during labor had primary infection. In the United States, of 10,308 HIV-infected pregnant women who delivered live infants from 2005 to 2010 in 15 areas conducting Enhanced Perinatal Surveillance (EPS), 124 (1.2%) were identified as seroconverting during pregnancy. The rate of perinatal transmission was eight times higher among women who seroconverted during pregnancy (12.9%) than in those who became infected prior to pregnancy (1.6%) (P < 0.0001). Repeat HIV testing in the third trimester is recommended for pregnant women known to be at risk of HIV, who receive care in facilities with an HIV incidence of at least 1 case per 1,000 pregnant women per year, who are incarcerated, or who reside in jurisdictions with elevated HIV incidence (see Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings and http://www.cdc.gov/hiv/pdf/HIVtestingAlgorithmRecommendation-Final.pdf).

In pregnant or breastfeeding women, acute or recent HIV infection is associated with a high risk of perinatal transmission of HIV. All HIV-infected pregnant women with acute or recent infection should start a combination ARV regimen as soon as possible, with the goal of preventing perinatal transmission by optimal suppression of plasma HIV RNA below detectable levels. Data from the United States and Europe demonstrate that in 6% to 16% of patients, transmitted virus may be resistant to at least one ARV drug. Therefore, baseline genotypic resistance testing should be performed to guide selection or adjustment of an optimal ARV drug regimen. If results of resistance testing or the source virus’s resistance pattern are known, that information should be used to guide selection of the drug regimen, but initiation of the combination ARV regimen should not be delayed. Because clinically significant resistance to protease inhibitors (PIs) is less common than resistance to non-nucleoside reverse transcriptase inhibitors in ARV-naive persons, a PI-based ARV drug regimen generally should be initiated. Choice of regimen should be based on recommendations for use of ARV drugs in pregnancy (see Table 6 and Table 7). Following delivery, considerations regarding continuation of the ARV regimen for treatment are the same for mothers as for other non-pregnant individuals.

When acute HIV infection is diagnosed during pregnancy, and particularly if it is documented in late pregnancy, cesarean delivery is likely to be necessary because there may be insufficient time to fully suppress a patient’s viral load. In nursing mothers in whom seroconversion is suspected, breastfeeding should be interrupted and it should not resume if infection is confirmed (see Breastfeeding in Infants of Mothers Diagnosed with HIV Infection in Infant Antiretroviral Prophylaxis). Women can continue to express and store breast milk while awaiting confirmation of infection status. In such a situation, given the high risk of transmission to the infant with acute maternal infection, consultation with a pediatric HIV specialist regarding appropriate infant management is strongly recommended.
All women who are pregnant or breastfeeding should be counseled about prevention of acquisition of HIV (see Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis and Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States). Several studies suggest that pregnancy may be a time of increased risk of transmission of HIV even when controlling for sexual risk behaviors. It is hypothesized that the heightened risk may be attributable to hormonal changes that affect the genital tract mucosa or immune responses. Although no reliable data on HIV serodiscordance rates in the United States exist, data on women from sub-Saharan Africa show that women in serodiscordant relationships may be particularly vulnerable to acquisition of HIV. All women should be asked if they know the HIV status of their partner. HIV testing of the sexual partners of pregnant women should be encouraged; initiation of cART is recommended for partners who are identified to be HIV-infected to reduce the risk of HIV acquisition by the woman. Furthermore, the importance of using condoms should be reinforced in pregnant and breastfeeding women who may be at risk of acquisition of HIV, including those whose partners are HIV-infected, and the potential use of pre- or post-exposure antiretroviral prophylaxis also should be emphasized (see Reproductive Options for HIV-Concordant and Serodiscordant Couples).

References


Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States
Intrapartum Antiretroviral Therapy/Prophylaxis

Panel’s Recommendations

- Women should continue their antepartum combination antiretroviral therapy (cART) drug regimen on schedule as much as possible during labor and before scheduled cesarean delivery (AIII).
- Intravenous (IV) zidovudine should be administered to HIV-infected women with HIV RNA >1,000 copies/mL (or unknown HIV RNA) near delivery (AI), but is not required for HIV-infected women receiving cART regimens who have HIV RNA ≤1,000 copies/mL during late pregnancy and near delivery and no concerns regarding adherence to the cART regimen (BII). Scheduled cesarean delivery at 38 weeks’ gestation (compared to 39 weeks for most indications) is recommended for women who have HIV RNA >1,000 copies/mL near delivery (see Transmission and Mode of Delivery) (AI).
- Women who present in labor with unknown HIV status should undergo expedited HIV testing (AII). If the results are positive, a confirmatory HIV test should be done as soon as possible and maternal (IV zidovudine)/infant (combination antiretroviral [ARV] prophylaxis) ARV drugs should be initiated pending results of the confirmatory test (AII). If the maternal confirmatory HIV test is positive, infant ARV drugs should be managed as discussed in the Infant Antiretroviral Prophylaxis section (AI); if the maternal confirmatory HIV test is negative, the maternal and infant ARV drugs should be stopped.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Women Who Have Received Antepartum Antiretroviral Drugs

Use of Intravenous Zidovudine During Labor

The PACTG 076 zidovudine regimen included a continuous intravenous (IV) infusion of zidovudine during labor for all women. Combination antiretroviral therapy (cART) regimens are now recommended for all pregnant women for treatment and prevention of perinatal transmission of HIV; the additional benefit of IV zidovudine in women receiving combination regimens has not been evaluated in randomized clinical trials.

The French Perinatal Cohort evaluated transmission in >11,000 HIV-infected pregnant women receiving antiretroviral (ARV) drugs (10% zidovudine alone, 18% dual ARV, and 72% triple ARV) who delivered between 1997 and 2010, stratified by viral load at delivery; 95% received IV intrapartum zidovudine. The overall rate of perinatal transmission was 0.9% (95/10,239) with IV zidovudine and 1.8% (9/514, \(P = 0.06\)) without IV zidovudine. Among women with HIV RNA <1,000 copies/mL at delivery, no transmission occurred among 369 who did not receive IV zidovudine compared to a rate of 0.6% (47/8,132, \(P > 0.20\)) among those receiving IV zidovudine. Among women with HIV RNA >1,000 copies/mL, the risk of transmission was increased without IV zidovudine (10.2%) compared to 2.5% with IV zidovudine (\(P < 0.01\)) if neonates received only zidovudine for prophylaxis, but was not different (4.8% vs. 4.1%, \(P = 0.83\)) without or with intrapartum zidovudine if the neonate received intensified prophylaxis with two or more ARV drugs. In a cohort of 717 women delivering between 1996 and 2008 in Miami, the majority of whom were receiving a cART regimen and had HIV RNA <1,000 copies/mL at delivery, lack of receipt of IV zidovudine during labor was not associated with an increased risk of transmission. Among a European cohort of infants considered at high risk of transmission, lack of IV zidovudine in labor was associated with transmission on univariate analysis but was not significantly associated once adjusted for maternal HIV RNA and other factors (adjusted odds ratio with IV zidovudine 0.79; 95% confidence interval, 0.55–1.15; \(P = 0.23\)). In a cohort of Irish women receiving cART for at least 4 weeks before delivery with HIV RNA <1,000 copies/mL, no transmission occurred among 61 who received either no zidovudine in labor or <4 hours of IV zidovudine.

Based on these studies, IV zidovudine is not required for HIV-infected women receiving cART with HIV RNA ≤1,000 copies/mL in late pregnancy and/or near delivery and for whom there are no concerns about
adherence to or tolerance of their cART regimens; IV zidovudine should continue to be administered to HIV-infected women with HIV RNA >1,000 copies/mL near delivery (or unknown HIV RNA levels), regardless of antepartum regimen.

Previously, these guidelines specified that the threshold for not requiring intrapartum IV zidovudine was <400 copies/mL. However, based on more recent studies that have used a threshold of 1,000 copies/mL, a threshold of ≤1,000 copies/mL is now recommended for consideration to not administer IV zidovudine. This recommendation is now consistent with the mode of delivery recommendations that specify that a scheduled cesarean delivery is not recommended for women receiving cART with plasma HIV RNA levels ≤1,000 copies/mL. However, regardless of viral load, the clinician may elect to use intrapartum IV zidovudine based on clinical judgement.

In women with HIV RNA >1,000 copies/mL undergoing a scheduled cesarean delivery for prevention of transmission, IV zidovudine administration should begin 3 hours before the scheduled operative delivery. This recommendation is based on a pharmacokinetic (PK) study of zidovudine given orally during pregnancy and as a continuous infusion during labor. Maternal zidovudine levels were measured at baseline, after the initial IV loading dose, and then every 3 to 4 hours until delivery, and in cord blood. Systemic and intracellular zidovudine levels increased from baseline but appeared to stabilize after 3 hours of infusion; cord blood zidovudine levels were associated with maternal levels and maternal infusion duration. If cesarean delivery is being performed for other indications and maternal viral load is ≤1,000 copies/mL near the time of delivery, administration of IV zidovudine is not required.

If zidovudine was not used in the antenatal cART regimen because of known or suspected zidovudine resistance, intrapartum use of the drug is still recommended in women with HIV RNA >1,000 copies/mL near delivery, except in women with documented histories of hypersensitivity. This intrapartum use of the drug is recommended because of the unique characteristics of zidovudine and its proven record in reducing perinatal transmission, even in the presence of maternal resistance to the drug (see Antiretroviral Drug Resistance and Resistance Testing in Pregnancy). In some international studies, oral rather than IV zidovudine has been administered during labor. Data are limited on the PKs of oral compared with IV zidovudine during labor. In studies of oral dosing in labor, levels were lower than with IV dosing, and PK parameters suggested erratic absorption during labor. Therefore, in women with HIV RNA >1,000 copies/mL near delivery for whom zidovudine is recommended, IV would be preferred to oral administration in the United States; in situations where IV administration is not possible, oral administration of zidovudine using a 600-mg loading dose and 400 mg every 3 hours can be considered.

Continuation of Antenatal Antiretroviral Drugs during Labor

Women who are receiving an antepartum cART regimen should continue that regimen on schedule as much as possible during the intrapartum period to provide maximal virologic effect and to minimize the chance of development of drug resistance. If the woman’s HIV-1 RNA level is >1,000 copies/mL and oral zidovudine is part of the antepartum regimen, the oral zidovudine component of the regimen can be held while she receives IV zidovudine. When cesarean delivery is planned, oral medications can be continued preoperatively with sips of water. Medications requiring food ingestion for absorption can be taken with liquid dietary supplements, contingent on consultation with the attending anesthesiologist in the preoperative period. If the maternal ARV regimen must be interrupted temporarily (meaning for less than 24 hours) during the peripartum period, all drugs should be stopped and reinstituted simultaneously to minimize the chance that resistance will develop.

Women Who Have Received Antepartum Antiretroviral Drugs But Have Suboptimal Viral Suppression Near Delivery

Women who have received cART regimens may not achieve complete viral suppression by the time of delivery because of factors such as poor adherence, viral resistance, or late entry into care. Regardless of the
reason, all women who have HIV RNA levels >1,000 copies/mL near the time of delivery should be offered a scheduled cesarean delivery at 38 weeks, which may significantly reduce the risk of transmission (see Transmission and Mode of Delivery).

Women with incomplete viral suppression at the time of delivery should receive IV zidovudine along with their other ARVs orally, as described above. In certain high-risk situations, additional medications for prophylaxis in infants may be warranted, such as in cases where maternal HIV RNA levels are high at or near the time of delivery, especially if delivery is not a scheduled cesarean (see Infant Antiretroviral Prophylaxis and Table 8).

**Women Who Have Not Received Antepartum Antiretroviral Drugs**

**Women Who Present in Labor without Documentation of HIV Status**

All women without documentation of HIV status at the time of labor should be screened with expedited HIV testing unless they decline (opt-out screening). Expedited HIV testing is also recommended for women presenting in labor who tested negative for HIV in early pregnancy but are at increased risk of HIV infection and were not retested in the third trimester. Factors that may increase risk of infection include diagnosis of a sexually transmitted disease, illicit drug use or exchange of sex for money or drugs, multiple sexual partners during pregnancy, a sexual partner at risk of HIV infection, signs/symptoms of acute HIV infection, or living in a region with an elevated incidence of HIV in women of childbearing age.

**Expedited** HIV testing should be available on a 24-hour basis at all facilities with a maternity service and/or neonatal intensive care unit (NICU). Statutes and regulations regarding expedited testing vary from state to state (see [http://nccc.ucsf.edu/clinical-resources/hiv-aids-resources/state-hiv-testing-laws/](http://nccc.ucsf.edu/clinical-resources/hiv-aids-resources/state-hiv-testing-laws/) for a review of state HIV testing laws). Current information on expedited testing also should be available at all facilities with a maternity service and/or NICU.

Women with positive expedited HIV antibody tests should be presumed to be infected until standard HIV confirmatory testing clarifies their infection status (see Antiretroviral Drug Resistance and Resistance Testing in Pregnancy). IV zidovudine should be started immediately in all women with positive expedited HIV tests in labor to prevent perinatal transmission of HIV, as discussed below.

In the postpartum period, along with confirmatory HIV testing, these women should receive appropriate assessments as soon as possible to determine their health status, including CD4 T lymphocyte cell count, HIV-1 RNA viral load, and HIV genotype for resistance. Arrangements also should be made for establishing HIV care and providing ongoing psychosocial support after discharge.

**Choice of Intrapartum/Postpartum Antiretroviral Regimen for Women without Antepartum Antiretroviral Therapy**

All HIV-infected women who have not received antepartum ARV drugs should have IV zidovudine started immediately to prevent perinatal transmission of HIV. Although intrapartum/neonatal ARV medications will not prevent perinatal transmission that occurs before labor, most transmission occurs near to or during labor and delivery. Pre-exposure prophylaxis for the fetus can be provided by giving mothers a drug that rapidly crosses the placenta, producing fetal systemic ARV drug levels during intensive exposure to HIV in maternal genital secretions and in blood during birth. In general, zidovudine and other nucleoside reverse transcriptase inhibitor drugs and non-nucleoside reverse transcriptase inhibitors cross the placenta well, whereas protease inhibitors do not (see Table 7).

A large international trial (NICHD-HPTN 040/PACTG 1043) demonstrated that adding ARV agents to the neonatal portion of the intrapartum/neonatal zidovudine regimen can further reduce perinatal transmission of HIV for mothers who have received no antepartum ARV drugs (see Infant Antiretroviral Prophylaxis). In this study, women who had not received antepartum ARV drugs received IV zidovudine if they were identified in labor or no zidovudine when diagnosed immediately postpartum; their infants received either 6 weeks of...
zidovudine alone or zidovudine in combination with other agents. The combination infant regimens resulted in a 50% reduction in transmission compared with zidovudine alone.\textsuperscript{9} Therefore, based on the efficacy of the neonatal regimen and no benefit seen with the addition of maternal single-dose nevirapine to a regimen of maternal short-course zidovudine and infant single-dose nevirapine in the Mashi trial, no additional intrapartum drugs, including intrapartum maternal single-dose nevirapine, are recommended for a woman in this situation.\textsuperscript{10} Women diagnosed with HIV infection during labor or the early postpartum period should be counseled against breastfeeding in the United States, where replacement feeding is affordable, feasible, acceptable, sustainable, and safe.

**References**


**Transmission and Mode of Delivery** *(Last updated August 6, 2015; last reviewed August 6, 2015)*

### Panel’s Recommendations

- Scheduled cesarean delivery at 38 weeks’ gestation to minimize perinatal transmission of HIV is recommended for women with HIV RNA levels >1000 copies/mL or unknown HIV levels near the time of delivery, irrespective of administration of antepartum antiretroviral drugs (AII). Scheduled cesarean delivery performed solely for prevention of perinatal transmission in women receiving combination antiretroviral therapy with HIV RNA ≤1000 copies/mL is not routinely recommended due to the low rate of perinatal transmission in this group and the potential for increased complications following cesarean delivery in HIV-infected women (AII). In women with HIV RNA levels ≤1000 copies/mL, cesarean delivery performed for standard obstetrical indications should be scheduled at 39 weeks’ gestation (AII).

- Because there is insufficient evidence to determine whether cesarean delivery after rupture of membranes or onset of labor reduces the risk of perinatal HIV transmission, management of women originally scheduled for cesarean delivery who present with ruptured membranes or in labor must be individualized at the time of presentation (BII). In these circumstances, consultation with an expert in perinatal HIV (e.g., telephone consultation with the National Perinatal HIV/AIDS Clinical Consultation Center at (888) 448-8765) may be helpful in rapidly developing an individualized plan.

- Women with HIV infection should be counseled that HIV infection may put them at higher risk of surgical complications of cesarean delivery (AII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

---

### Basis for Current Recommendations

Scheduled cesarean delivery, defined as cesarean delivery performed before the onset of labor and before rupture of membranes, is recommended for prevention of perinatal transmission of HIV in women with HIV RNA levels >1000 copies/mL near delivery and for women with unknown HIV RNA levels.

This recommendation is based on findings from a multicenter, randomized clinical trial and from a large individual patient data meta-analysis. These two studies were conducted at a time when the majority of HIV-infected women received no antiretroviral (ARV) medications or zidovudine as a single drug and before the availability of viral load information. Study results have since been extrapolated to make current recommendations about the mode of delivery in an era when combination antiretroviral therapy (cART) during pregnancy is recommended and viral load information is readily available.

In the randomized clinical trial, 1.8% of infants born to women randomized to undergo cesarean delivery were HIV-infected compared with 10.5% of infants born to women randomized to vaginal delivery (P < .001). When adjusted for ARV use in pregnancy (zidovudine alone), scheduled cesarean delivery lowered risk of HIV transmission by 80%, although the results were no longer statistically significant (odds ratio [OR] 0.2; 95% CI, 0–1.7). The protective effect remained for scheduled delivery (adjusted OR [AOR] 0.3; 95% CI, 0.1–0.8) but not for emergency cesarean delivery (AOR 1.0; 95% CI, 0.3–3.7) when the data were analyzed by actual mode of delivery rather than by the group to which women were allocated. Results from a large meta-analysis of individual patient data from 15 prospective cohort studies also demonstrated the benefit of scheduled cesarean delivery, with a 50% reduction in risk.

### HIV RNA Level of >1000 copies/mL as a Threshold for Recommendation of Scheduled Cesarean Delivery

The American College of Obstetricians and Gynecologists (ACOG) recommends that women with HIV RNA >1000 copies/mL be counseled regarding the potential benefits of scheduled cesarean delivery. Initially, the threshold of 1000 copies/mL was based largely on data from the Women and Infants Transmission Study, a large prospective cohort study that reported no HIV transmission among 57 women with HIV RNA levels less than 1000 copies/mL. Studies reported since then have demonstrated that HIV transmission can occur in infants born to women with low viral loads.
In an analysis of 957 women with plasma viral loads ≤1000 copies/mL, cesarean delivery (scheduled or urgent) reduced the risk of HIV transmission when adjusting for potential confounders including receipt of maternal ARV medications (AOR 0.30; \( P = 0.022 \)); however, zidovudine alone was the regimen primarily used as prophylaxis.\(^5\) Among infants born to 834 women with HIV RNA ≤1000 copies/mL receiving ARV medications, 8 (1%) were HIV-infected. In a report from a comprehensive national surveillance system in the United Kingdom and Ireland, 3 (0.1%) of 2,309 and 12 (1.2%) of 1,023 infants born to women with HIV RNA levels <50 copies/mL and 50 to 999 copies/mL, respectively, were HIV infected.\(^6\)

The recent studies demonstrate that transmission can occur even at very low HIV RNA levels. However, given the low rate of transmission in this group, it is unclear whether scheduled cesarean delivery confers any additional benefit in reducing transmission. Furthermore, there is evidence that complication rates for cesarean deliveries are higher in HIV-infected women compared with HIV-infected women.\(^7\) Therefore, decisions about mode of delivery for women receiving cART with HIV RNA levels ≤1000 copies/mL should be individualized based on discussion between the obstetrician and the mother. Women should be informed that there is no evidence of benefit for scheduled cesarean delivery performed solely for prevention of perinatal transmission in women receiving cART with HIV RNA ≤1000 copies/mL and that it is not routinely recommended in this group.

**Scheduled Cesarean Delivery in the Combination Antiretroviral Therapy Era**

In surveillance data from the United Kingdom and Ireland, pregnant women receiving cART (i.e., at least 3 drugs) had transmission rates of about 1%, unadjusted for mode of delivery.\(^6\) Given the low transmission rates achievable with use of maternal cART, the benefit of scheduled cesarean delivery is difficult to evaluate. Both the randomized clinical trial\(^1\) and meta-analysis\(^2\) documenting the benefits of cesarean delivery included mostly women who were receiving either no ARVs or zidovudine alone. However, other data partially address this issue.

In a report on births to HIV-infected women from the United Kingdom and Ireland between 2000 and 2011, perinatal transmission rates in women on cART with HIV RNA<1,000 copies/mL with planned cesarean delivery (13/3,814; 0.3%) were not significantly different than those in similar women with planned vaginal delivery (6/2,238; 0.3%).\(^8\) Similarly, data from the French Perinatal Cohort showed no difference in transmission rates between vaginal delivery and planned cesarean delivery among women on cART with suppressed viral loads, 0.3% in both. For preterm deliveries with HIV RNA <1,000 copies/mL, transmission rates were slightly higher among planned vaginal deliveries but the numbers were small and the differences were not statistically significant (1/9 [11.1%] vs. 1/17 [5.9%] for HIV RNA 400–1000 copies/mL; 1/39 [2.6%] vs. 1/56 [1.8%] for HIV RNA 50–400 copies/mL; 1/189 [0.5%] vs. 0/143 [0%] for HIV RNA <50 copies/mL, for planned vaginal deliveries and elective cesarean deliveries, respectively).\(^9\) Therefore, no evidence to date suggests any benefit from scheduled cesarean delivery in women who have been receiving cART for several weeks and who have achieved virologic suppression.

When the delivery method selected is scheduled cesarean delivery and the maternal viral load is >1000 copies/mL, a 1-hour loading dose followed by a continuous intravenous (IV) zidovudine infusion for 2 hours (3 hours total) before scheduled cesarean delivery should be administered. In a study of the pharmacokinetics of IV zidovudine in 28 pregnant women, the ratio of cord blood-to-maternal-zidovudine levels increased significantly in women who received IV zidovudine for 3 to 6 hours compared with <3 hours before delivery (1.0 vs. 0.55, respectively)\(^10\) This suggests that an interval of at least 3 hours may provide adequate time to reach equilibrium across the placenta, although the relationship between specific cord blood zidovudine levels or cord blood-to-maternal-zidovudine levels and efficacy in preventing perinatal transmission of HIV is unknown.

Because unscheduled cesarean delivery is performed for both maternal and fetal indications, when an unscheduled cesarean delivery is indicated in a woman who has a viral load >1000 copies/mL, consideration can be given to shortening the interval between initiation of IV zidovudine administration and delivery. For example, some experts recommend administering the 1-hour loading dose of IV zidovudine and not waiting to complete additional administration before proceeding with delivery.
Women Presenting Late in Pregnancy

HIV-infected women who present late in pregnancy and are not receiving ARV drugs may not have HIV RNA results available before delivery. Without current therapy, HIV RNA levels are unlikely to be ≤1000 copies/mL at baseline. Even if cART was begun immediately, reduction in plasma HIV RNA to undetectable levels usually takes several weeks, depending on the kinetics of viral decay for a particular drug regimen. In this instance, scheduled cesarean delivery is likely to provide additional benefit in reducing the risk of perinatal transmission of HIV for women, unless viral suppression can be documented before 38 weeks’ gestation.

Timing of Scheduled Cesarean Delivery

For the general obstetric population, ACOG recommends that scheduled cesarean delivery not be performed before 39 weeks’ gestation because of the risk of iatrogenic prematurity. However, in cases of cesarean delivery performed to prevent transmission of HIV, ACOG recommends scheduling cesarean delivery at 38 weeks’ gestation in order to decrease the likelihood of onset of labor or rupture of membranes before delivery. In all women undergoing repeat cesarean delivery, the risk of any neonatal adverse event—including neonatal death, respiratory complications, hypoglycemia, newborn sepsis, or admission to the neonatal intensive care unit—is 15.3% at 37 weeks, 11.0% at 38 weeks, and 8.0% at 39 weeks. Gestational age should be determined by best obstetrical dating criteria, including last menstrual period and early ultrasound for dating purposes. Amniocentesis to document lung maturity should be avoided when possible in HIV-infected women and is rarely indicated before scheduled cesarean section for prevention of HIV transmission.

Among 1,194 infants born to HIV-infected mothers, 9 (1.6%) infants born vaginally had respiratory distress syndrome (RDS) compared with 18 (4.4%) infants born by scheduled cesarean delivery ($P <0.001$). There was no statistically significant association between mode of delivery and infant RDS in an adjusted model that included infant gestational age and birth weight. Although newborn complications may be increased in planned births <39 weeks’ gestation, the benefits of planned cesarean delivery at 38 weeks are generally thought to outweigh the risks if the procedure is performed for prevention of HIV transmission. When scheduled cesarean delivery is performed in HIV-infected women for an indication other than decreasing HIV transmission, cesarean delivery should be scheduled at 39 weeks, based on ACOG guidelines.

Risk of Maternal Complications

Administration of perioperative antimicrobial prophylaxis is recommended for all women to decrease maternal infectious morbidity associated with cesarean delivery. Most studies have demonstrated that HIV-infected women have increased rates of postoperative complications, mostly infectious, compared with HIV-uninfected women and that risk of complications is related to degree of immunosuppression and the receipt of suppressive cART. Furthermore, a Cochrane review of six studies of HIV-infected women concluded that urgent cesarean delivery was associated with the highest risk of postpartum morbidity, scheduled cesarean delivery was intermediate in risk, and vaginal delivery had the lowest risk of morbidity. Complication rates in most studies were within the range reported in populations of HIV-uninfected women with similar risk factors and not of sufficient frequency or severity to outweigh the potential benefit of reduced perinatal HIV transmission. A recent U.S. study of nationally representative data from a large administrative database demonstrated that even in the era of cART infectious complications, surgical trauma, prolonged hospitalization, and in-hospital deaths remain higher among HIV-infected women compared to HIV-uninfected women. The rate of any complication associated with cesarean delivery was 117 per 1,000 deliveries among HIV-infected women compared with 67 per 1,000 deliveries among HIV-uninfected women. Therefore, HIV-infected women should be counseled regarding the specific risks associated with undergoing cesarean delivery in the setting of HIV infection.

Management of Women Who Present in Early Labor or With Ruptured Membranes

Few data are available to address the question of whether performing cesarean delivery after the onset of labor or membrane rupture decreases risk of perinatal transmission of HIV. Most studies have shown a similar risk of transmission for cesarean delivery performed for obstetric indications after labor and...
membrane rupture as for vaginal delivery. In one study, the HIV transmission rate was similar in women undergoing emergency cesarean delivery and those delivering vaginally (1.6% vs. 1.9%, respectively). A meta-analysis of HIV-infected women, most of whom were on zidovudine as a single drug or receiving no ARV medications, demonstrated a 2% increased transmission risk for every additional hour of ruptured membranes. However, it is not clear how soon after the onset of labor or the rupture of membranes the benefit of cesarean delivery is lost.

Because it is not clear whether cesarean delivery after rupture of membranes or onset of labor reduces the risk of perinatal HIV transmission, management of women originally scheduled for cesarean delivery who present with ruptured membranes or in labor must be individualized at the time of presentation. In these circumstances, consultation with an expert in perinatal HIV may be helpful. Because the delivery plan in the setting of labor or ruptured membranes must be made quickly, telephone consultation with a 24-hour, 7-day-a-week hotline (e.g., the National Perinatal HIV/AIDS Clinical Consultation Center (888) 448-8765) may be helpful in rapidly developing an individualized plan.

The ARV drug regimen should be continued and IV zidovudine initiated, if previously planned.

When membrane rupture occurs before 37 weeks’ gestation, decisions about timing of delivery should be based on best obstetrical practices, taking into account risks to the infant of prematurity and of HIV transmission. Steroids should be given, if appropriate, to accelerate fetal lung maturity because no data exist to suggest that these recommendations need to be altered for HIV-infected women. When the decision is made to deliver, route of delivery should be according to obstetrical indications.

References


*Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States*
### Other Intrapartum Management Considerations

(Last updated August 6, 2015; last reviewed August 6, 2015)

If spontaneous rupture of membranes occurs before or early during the course of labor, interventions to decrease the interval to delivery (e.g., administration of oxytocin) can be considered in HIV-infected women with viral suppression and no indications for cesarean delivery. Artificial rupture of membranes should be avoided unless there is a clear obstetric indication in women with intact membranes and detectable viral loads who present in labor and will be allowed to proceed to vaginal delivery. Data are limited on artificial rupture of membranes in women with undetectable viral loads and planned vaginal delivery. Data on the association of duration of membrane rupture and perinatal transmission in the era of effective combination antiretroviral therapy (cART) are more reassuring on this issue. A recent prospective cohort study of 707 HIV-infected pregnant women on cART included 493 women with delivery HIV-RNA <1,000 copies/mL with no cases of perinatal transmission with up to 25 hours of membrane rupture; logistic regression found that HIV viral load >10,000 copies/mL was the only independent risk factor for transmission.\(^1\) In general, the procedure should be performed only for clear obstetric indications because of the potential, albeit small, of an increased risk of HIV transmission.

Obstetric procedures that increase the risk of fetal exposure to maternal blood, such as invasive fetal monitoring, have been implicated in increasing vertical transmission rates by some, but not all, investigators, primarily in studies performed in the pre-cART era.\(^2\)\(^-\)\(^5\) Data are limited on use of fetal scalp electrodes in labor in women receiving suppressive antiretroviral (ARV) regimens who have undetectable viral loads; routine use of fetal scalp electrodes for fetal monitoring should be avoided in the setting of maternal HIV infection unless there are clear obstetric indications.

Similarly, data are limited to those obtained in the pre-cART era regarding the potential risk of perinatal transmission of HIV associated with operative vaginal delivery with forceps or the vacuum extractor and/or use of episiotomy.\(^3\)\(^,\)\(^5\) These procedures should be performed only if there are clear obstetric indications. Delayed cord clamping has been associated with improved iron status in both term and preterm infants and benefits such as decreased risk of intraventricular hemorrhage in preterm births to HIV-uninfected mothers.\(^6\)\(^,\)\(^7\) Even though HIV-specific data on the practice are lacking, there is no reason to modify it in HIV-infected mothers.

### Panel's Recommendations

| Rating of Recommendations: A = Strong; B = Moderate; C = Optional |
| Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion |

- The following should generally be avoided because of a potential increased risk of transmission, unless there are clear obstetric indications:
  - Artificial rupture of membranes (BIII)
  - Routine use of fetal scalp electrodes for fetal monitoring (BIII)
  - Operative delivery with forceps or a vacuum extractor and/or episiotomy (BIII)

- The antiretroviral drug regimen a woman is receiving should be taken into consideration when treating excessive postpartum bleeding resulting from uterine atony:
  - In women who are receiving a cytochrome P450 (CYP) 3A4 enzyme inhibitor such as a protease inhibitor, methergine should be used only if no alternative treatments for postpartum hemorrhage are available and the need for pharmacologic treatment outweighs the risks. If methergine is used, it should be administered in the lowest effective dose for the shortest possible duration (BIII).
  - In women who are receiving a CYP3A4 enzyme inducer such as nevirapine, efavirenz, or etravirine, additional uterotonic agents may be needed because of the potential for decreased methergine levels and inadequate treatment effect (BIII).
Intrapartum Epidural Use and Pharmacologic Interactions with Antiretroviral Drugs

Ritonavir inhibition of cytochrome P450 (CYP) 3A4 decreases the elimination of fentanyl by 67%, raising concerns about possible increased risk of respiratory depression, particularly with patient-controlled analgesia during labor, in women receiving ritonavir-containing regimens. However, a recent pharmacokinetic simulation study suggests that even with maximal clinical dosing regimens of epidural fentanyl over 24 hours, ritonavir-induced CYP3A4 inhibition is unlikely to produce plasma fentanyl concentrations associated with a decrease in minute ventilation. This suggests that epidural anesthesia can be used safely regardless of ARV regimen.

Postpartum Hemorrhage, Antiretroviral Drugs, and Methergine Use

Oral or parenteral methergine or other ergot alkaloids are often used as first-line treatment for postpartum hemorrhage resulting from uterine atony. However, methergine should not be coadministered with drugs that are potent CYP3A4 enzyme inhibitors, including protease inhibitors (PIs). Concomitant use of ergotamines and PIs has been associated with exaggerated vasoconstrictive responses. When uterine atony results in excessive postpartum bleeding in women receiving PIs, methergine should be used only if alternative treatments such as prostaglandin F2-alpha, misoprostol, or oxytocin are unavailable. If no alternative medications are available and the need for pharmacologic treatment outweighs the risks, methergine should be used in as low a dose and for as short a period as possible. In contrast, additional uterotonic agents may be needed when other ARV drugs that are CYP3A4 inducers (e.g., nevirapine, efavirenz, etravirine) are used because of the potential for decreased methergine levels and inadequate treatment effect.

References


Postpartum Care  

Postpartum Follow-Up of HIV-Infected Women

The postpartum period provides an opportunity to review and optimize women’s health care. Comprehensive medical care and supportive services are particularly important for HIV-infected women and their families, who often face multiple medical and social challenges. Components of comprehensive care include the following services as needed:

- Primary, gynecologic/obstetric, and HIV specialty care for the HIV-infected woman;
- Pediatric care for her infant;
- Family planning services;
- Mental health services;
- Substance abuse treatment;
- Support services;
- Coordination of care through case management for a woman, her child(ren), and other family members; and
- Prevention of secondary transmission for serodiscordant partners, including counseling on the use of condoms, combination antiretroviral therapy (cART) to maintain virologic suppression in the infected partner (i.e., Treatment as Prevention [TasP]), and potential use of pre-exposure prophylaxis (PrEP) by the uninfected partner.

Support services should be tailored to the individual woman’s needs and can include case management; child care; respite care; assistance with basic life needs, such as housing, food, and transportation; peer counseling; and legal and advocacy services. Ideally, this care should begin before pregnancy and continue throughout pregnancy and the postpartum period.

Immediate linkage to care, comprehensive medical assessment, counseling, and follow-up are required for women who test positive on rapid HIV antibody assay during labor or at delivery. To minimize the delay in

Panel's Recommendations

- Decisions regarding continuing combination antiretroviral therapy (cART) after delivery should be made in consultation with the woman and her HIV provider, ideally before delivery (AIII). cART is currently recommended for all HIV-infected individuals to reduce the risk of disease progression and to prevent HIV sexual transmission (AI). Decisions should take into account current recommendations for initiation of cART in adults, HIV RNA levels, adherence issues, whether a woman has an HIV-uninfected sexual partner, and patient preferences.

- Because the immediate postpartum period poses unique challenges to antiretroviral adherence, arrangements for new or continued supportive services should be made before hospital discharge for women continuing cART (AII).

- Contraceptive counseling should be a critical aspect of postpartum care (AII).

- Women with a positive rapid HIV antibody test during labor require immediate linkage to HIV care and comprehensive follow-up, including confirmation of HIV infection. If infection is confirmed, a full health assessment is warranted, including evaluation for associated medical conditions, counseling related to newly diagnosed HIV infection, and assessment of need for cART and opportunistic infection prophylaxis (AII).

- Breastfeeding is not recommended for HIV-infected women in the United States (AII).

Rating of Recommendations:  A = Strong; B = Moderate; C = Optional

Rating of Evidence:  I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion
definitive diagnosis, the fourth-generation combined antibody-antigen test should be employed if available (or confirmatory HIV antibody testing should be performed as soon as possible after an initial positive rapid test). The updated Centers for Disease Control and Prevention algorithm for HIV testing may allow for results of the antigen/antibody combination immunoassay and then the HIV-1/HIV-2 antibody differentiation assay to be available prior to a woman’s discharge after delivery. Women who test positive on rapid HIV antibody assay should not breastfeed unless a confirmatory HIV test is negative. Women with a new HIV diagnosis should receive the same thorough evaluation as other newly identified infected patients, including recommendation of cART and prophylaxis for opportunistic infections, as indicated. Other children and partner(s) should be referred for HIV testing. Counseling on prevention of secondary transmission to the uninfected partner should include condoms, cART for the infected partner to maintain viral suppression, and potential use of PrEP by the uninfected partner.

During the postpartum period, maternal medical services must be coordinated between obstetric care providers and HIV specialists. Decisions to continue cART after delivery should be made in consultation with a woman and her HIV provider, ideally prior to delivery. It is especially critical to ensure continuity of cART between the antepartum and postpartum periods.

cART is currently recommended for all HIV-infected individuals to reduce the risk of disease progression and to prevent HIV sexual transmission. The START and TEMPRANO trials were randomized clinical trials that demonstrated that early cART can reduce the risk of disease progression even in individuals with CD4 T lymphocyte cell count >500 cells/mm³, and the HPTN 052 randomized clinical trial demonstrated that early cART can reduce risk of sexual transmission to a discordant partner by 96%. It is important to counsel a woman that no single method (including treatment) is 100% protective against HIV transmission, so safer sexual practices should be continued.

Studies have demonstrated significant decreases in cART adherence postpartum. During the postpartum period, women may have difficulty with medical appointment follow-up, which can affect cART adherence. Systematic monitoring of retention in HIV care is recommended for all HIV-infected individuals, but special attention is warranted during the postpartum period. A number of studies have suggested that postpartum depression may be common among HIV-infected women. Women should be counseled that postpartum physical and psychological changes and the stresses and demands of caring for a new baby may make adherence more difficult and that additional support may be needed during this period.

Health care providers should be vigilant in screening for signs of depression, intimate partner violence, and illicit drug or alcohol use that may require intervention to avoid problems with cART adherence. Interventions to improve adherence to medical care and cART can include medication management services, referral to psychological services, community outreach, one-on-one adherence support, group education and support, peer support, reminder devices, and home visits by HIV case managers. Poor adherence has been shown to be associated with virologic failure, development of resistance, and decreased long-term effectiveness of cART. Simplification of a cART regimen (e.g., a change to once-daily medications) can be considered. For women who are unable to adhere to their regimen postpartum, it may be preferable to temporarily interrupt cART while they work with their health care provider on strategies to improve adherence. Efforts to maintain adequate adherence during the postpartum period may ensure effectiveness of therapy (see the section on Adherence in the Adult and Adolescent Antiretroviral Guidelines). For women continuing cART who had received increased protease inhibitor doses during pregnancy, available data suggest that standard doses can be used again, beginning immediately after delivery.

It is important that comprehensive family planning and preconception care be integrated into routine prenatal and health visits. Lack of breastfeeding is associated with earlier return of fertility; ovulation returns as early as 6 weeks postpartum, and earlier in some women—even before resumption of menses—putting them at risk of pregnancy shortly after delivery. Interpregnancy intervals of less than 18 months have been associated with increased risk of poor perinatal and maternal outcomes in HIV-uninfected women. Because of the stresses and demands of a new baby, women may be more receptive to use of effective contraception,
yet simultaneously at higher risk of nonadherence to contraceptive use and, thus, unintended pregnancy. This is an important concern in women who are on an efavirenz-containing regimen because of the potential risk of teratogenicity in the first 5 to 6 weeks of pregnancy (the neural tube closes at 36–39 days after the last menstrual period). A dual-protection strategy (e.g., use of condoms plus a second highly effective contraceptive) is ideal for HIV-infected women because it provides simultaneous protection against unintended pregnancy, transmission of HIV to a partner, and acquisition or transmission of sexually transmitted disease. Longer-term reversible contraceptive methods, such as injectables, implants, and intrauterine devices (IUDs) should be included as options.

The postpartum period is a critical time for addressing safer sex practices in order to reduce sexual transmission of HIV to HIV-uninfected partners and contraception to avoid unwanted pregnancies. Ideally these issues will be addressed during the prenatal period. There are drug-drug interactions between a number of antiretroviral (ARV) drugs and hormonal contraceptives as discussed in Preconception Counseling and Care for HIV-Infected Women of Childbearing Age and Table 3. A systematic review conducted for the World Health Organization has summarized the research on hormonal contraception, IUD use, and risk of HIV infection and recommends the use of all contraceptive methods in women with HIV. Findings from a systematic review of hormonal contraceptive methods and risk of HIV transmission to uninfected partners concluded that oral contraceptives and medroxyprogesterone do not increase risk of HIV transmission in women who are on cART though data are limited and have methodological issues. Permanent sterilization is appropriate only for women who are certain they do not desire future childbearing.

Avoidance of breastfeeding has been and continues to be a standard, strong recommendation for HIV-infected women in the United States, because maternal cART dramatically reduces but does not eliminate breastmilk transmission. Further, safe infant feeding alternatives are readily available in the United States. In addition there are concerns about other potential risks, including toxicity for the neonate or increased risk of development of ARV drug resistance, should transmission occur, due to variable passage of drugs into breastmilk. However, clinicians should be aware that women may face social, familial, and personal pressures to consider breastfeeding despite this recommendation. It is important to address possible barriers to formula feeding beginning during the antenatal period.

Similarly, there are risks of HIV transmission via premastication (prechewing) of infant food.

References


and Interventions to Reduce Perinatal HIV Transmission in the United States
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health


General Considerations for Choice of Infant Prophylaxis

All HIV-exposed infants should receive postpartum antiretroviral (ARV) drugs to reduce perinatal transmission of HIV. In all situations, infant prophylaxis should be initiated as soon as possible after delivery. The 6-week neonatal zidovudine prophylaxis regimen is generally recommended for all HIV-exposed infants. However, a 4-week neonatal zidovudine prophylaxis regimen for full-term infants can be considered if the mother has received standard combination antiretroviral therapy (cART) during pregnancy with consistent viral suppression and there are no concerns related to maternal adherence.

For infants born to mothers who received antepartum/intrapartum ARV drugs but have had suboptimal viral suppression (>1000 copies/mL) near delivery, should receive prophylaxis with zidovudine given for 6 weeks combined with three doses of nevirapine in the first week of life (i.e., at birth, 48 hours later, and 96 hours after the second dose), begun as soon after birth as possible.

Some experts recommend triple-antiretroviral prophylaxis for infants at higher risk of acquisition. A decision to administer triple-antiretroviral prophylaxis should be made only in consultation with a pediatric HIV specialist, preferably before delivery, and should be accompanied by parental counseling on the potential risks (e.g., neonatal toxicity), and benefits of this approach.

For infants born to mothers with unknown HIV status, expedited HIV testing of mothers and/or infants is recommended as soon as possible, either during labor or after birth, with immediate initiation of infant antiretroviral prophylaxis if the initial expedited test is positive. If supplemental testing is negative, antiretroviral prophylaxis can be discontinued.

The National Perinatal HIV Hotline (1-888-448-8765) provides free clinical consultation on all aspects of perinatal HIV, including infant care.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion
• Who received only intrapartum ARV drugs;
• Who received neither antepartum nor intrapartum ARV drugs;
• With unknown HIV status; and
• With known ARV drug-resistant virus.

In each of these situations, there is a spectrum of transmission risk that depends on a number of maternal and infant factors, including maternal viral load, mode of delivery, and gestational age at delivery. The risks and benefits of infant exposure to ARV drugs in addition to zidovudine will differ depending on where the mother/child falls in the risk spectrum. Thus, a generic recommendation cannot be made regarding use of combination drug regimens for infant prophylaxis. Each situation needs to be considered individually, balancing potential benefits (in terms of preventing perinatal transmission of HIV) with risks (in terms of toxicity to the infant). In addition, appropriate drug formulations and dosing regimens for neonates are incompletely defined and data are minimal on the safety of combination drugs in the neonate (see Short-Term Antiretroviral Drug Safety and Choice for Neonatal Prophylaxis and the Pediatric Antiretroviral Guidelines).

Data from the NICHD-HPTN 040/PACTG 1043 study have provided guidance for management of infants born to women who received no ARV prophylaxis during pregnancy. In that study, 1,746 formula-fed infants born to HIV-infected women who did not receive any ARV drugs during pregnancy were randomized to 1 of 3 infant prophylaxis regimens: the standard 6-week zidovudine regimen; 6 weeks of zidovudine plus three doses of nevirapine given during the first week of life (first dose at birth–48 hours, second dose 48 hours after first dose, and third dose 96 hours after second dose); and 6 weeks of zidovudine plus 2 weeks of lamivudine/nelfinavir. The risk of intrapartum transmission was significantly lower in the two- and three-drug arms (2.2% and 2.5%, respectively, vs. 4.9% for 6 weeks of zidovudine alone; \( P = .046 \) for each experimental arm vs. zidovudine alone). Although transmission rates with the two combination regimens were similar, neutropenia was significantly more common with the three-drug regimen than with the two-drug or zidovudine-alone regimen (27.5% vs. 15%, \( P < .0001 \)). In other studies, significantly higher rates of neutropenia and anemia have been reported with co-administration of zidovudine and lamivudine to infants. Thus, based on comparable efficacy and reduced toxicity, the Panel recommends 6 weeks of zidovudine plus three doses of nevirapine for infants whose mothers have not received antepartum ARV drugs (Table 8).

Despite the paucity of available data, the use of combination ARV prophylaxis for infants in high-risk situations is increasing. Surveillance of obstetric and pediatric HIV infection in the United Kingdom and Ireland through the National Study of HIV in Pregnancy and Childhood noted that between 2001 and 2004, 9% of HIV-exposed infants received triple-drug prophylaxis compared with 13% between 2005 and 2008. Similarly, in an Internet-based poll of 134 U.S.-based perinatal HIV service providers, 62% reported using combination postnatal prophylaxis in high-risk situations in the past year. Zidovudine, lamivudine, and nevirapine was the combination regimen used most often. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) has pooled data from 5,285 mother-infant pairs included in 8 European cohorts between 1996 and 2010 and evaluated the use of combination prophylaxis. Among the 1,105 infants receiving combination prophylaxis, 13.5% received zidovudine plus lamivudine, 22.7% received zidovudine plus single-dose nevirapine, 55.8% received zidovudine plus single-dose nevirapine plus lamivudine, and 4.4% received a regimen including a protease inhibitor (PI). In these observational cohorts, there was no difference in infant infection rates between one drug and combination prophylactic regimens. The authors concluded that the lack of difference may be related to residual confounding or the fact that combination prophylaxis may only be effective in a subset of infants. Canadian investigators have reported outcomes in 136 infants considered at high risk of acquisition who received treatment-level doses of triple ARV prophylaxis within 72 hours of birth. Of the infants born into scenarios associated with higher risk of HIV transmission; 12 were found to be HIV-infected; no major toxicities were identified.

A case of a “functional cure” of HIV in an infant was reported in 2013. The infant was born by vaginal delivery at 35 weeks’ gestation to a woman who received no prenatal care and was diagnosed as HIV-infected by expedited testing during labor; delivery occurred before maternal intrapartum ARV prophylaxis.
could be given. At age 30 hours, the infant initiated a regimen of zidovudine, lamivudine, and nevirapine (the latter drug administered at a higher therapeutic dose rather than standard prophylactic dosing). The infant was found to have a positive HIV DNA polymerase chain reaction (PCR) in a sample obtained at age 30 hours and an HIV RNA level of 19,812 copies/mL on an HIV RNA PCR assay performed at age 31 hours. Based on these tests, the infant was continued on treatment for HIV infection, thought to be acquired in utero. Nevirapine was replaced by lopinavir/ritonavir at day 7 of life (Note: This decision preceded warnings from the Food and Drug Administration [FDA] against use of lopinavir/ritonavir in infants younger than age 14 days). At age 18 months, the mother discontinued therapy; levels of plasma RNA, proviral DNA, and HIV antibodies remained undetectable in the child for over 2 years on no therapy. Unfortunately, virologic rebound was identified shortly before the child turned 4 years of age. Of interest, another case of virologic rebound following 4 years of suppression in an infant treated since birth has subsequently been reported.

There are two key safety issues related to the choice of ARV drugs in these infants. First, although the use of nevirapine to prevent perinatal transmission has been found to be safe in neonates and low-birthweight infants (see Antiretroviral Drug Dosing for Premature Infants), these prophylaxis-dose regimens target trough drug levels of 100 ng/mL, with peak levels averaging 1000 to 1500 ng/mL. However, there have been no studies in neonates under age 2 weeks or preterm infants to determine the appropriate dosing or safety of nevirapine administered at therapeutic doses, designed to maintain trough drug concentrations above 3000 ng/mL and peak levels below 10,000 ng/mL for treatment of HIV-infected individuals. Second, lopinavir/ritonavir, as used in the first infant described, is not recommended for neonates younger than age 14 days because of the potential for significant toxicity (see Short-Term Antiretroviral Drug Safety and Choice for Neonatal Prophylaxis). Therefore, the risks of this approach in terms of infant toxicity (particularly in preterm infants) and efficacy require further study before a general recommendation can be made.

In these and all other scenarios, decisions about use of combination ARV prophylaxis in infants should be made in consultation with a pediatric HIV specialist before delivery, if possible, and should be accompanied by a discussion with the mothers about potential risks and benefits of this approach.

The National Perinatal HIV Hotline

The National Perinatal HIV Hotline (888-448-8765) is a federally funded service providing free clinical consultation for difficult cases to providers caring for HIV-infected pregnant women and their infants, and can provide referral to local or regional pediatric HIV specialists.

Recommendations for Infant Antiretroviral Prophylaxis in Specific Clinical Situations

Infants Born to Mothers Who Received Antepartum/Intrapartum Antiretroviral Drugs with Effective Viral Suppression

The risk of HIV acquisition is small in infants born to women who received standard ARV prophylaxis regimens during pregnancy and labor and had undetectable viral loads at delivery or by scheduled cesarean section to mothers with low viral loads at delivery. The optimal minimum duration of neonatal zidovudine prophylaxis has not been established in clinical trials. In the United States, the standard 6-week infant zidovudine regimen has been recommended, based on data from PACTG studies 076 and 316 (both performed during an era when a greater proportion of women did not receive antenatal cART). In the United Kingdom and many other European countries, a 4-week neonatal zidovudine prophylaxis regimen is now recommended for infants born to mothers who have received cART regimens and have viral suppression, with no apparent increase in the overall HIV perinatal transmission rate. In addition, a 4-week zidovudine regimen has been reported to allow earlier recovery from anemia in otherwise healthy infants compared with the 6-week zidovudine regimen. Therefore, a 4-week neonatal zidovudine prophylaxis regimen can be considered in full-term infants when a mother has received standard cART during pregnancy with consistent viral suppression and there are no concerns related to maternal adherence.

In infants born to women with effective viral suppression, combining zidovudine with additional ARV drugs to reduce transmission risk is not recommended because the risk of transmission is low and any potential benefit...
would be very limited. Any potential benefits must be balanced by the known toxicities of ARV drugs in infants.

**Infants Born to Mothers Who Have Received Antepartum/Intrapartum Antiretroviral Drugs but Have Suboptimal Viral Suppression Near Delivery**

All infants born to women who have received antepartum/intrapartum ARVs but with suboptimal viral suppression near delivery should receive zidovudine for 6 weeks. No specific data address whether a more intensive combination infant prophylaxis regimen (two or three drugs) provides additional protection against transmission when maternal antepartum/intrapartum prophylaxis is received but viral replication near delivery is significant. Extrapolation of findings from the previously discussed NICHD-HPTN 040/PACTG 1043 study\(^5\) suggests that combination infant prophylaxis should be considered, depending on assessment of risk based on maternal viral load and mode of delivery. That decision should be made in consultation with a pediatric HIV specialist before delivery and accompanied by maternal counseling on the potential risks and benefits of this approach. Although there are no clinical trials to identify the optimal combination infant prophylaxis regimen, it is clear that combination regimens are being used in this and other scenarios with a higher risk of perinatal transmission in the United States, Europe, and Canada.\(^7\)-\(^10\)

Many data support the observation that the risk of perinatal transmission is related to maternal antepartum viral load in women on no ARV drugs as well as women receiving these drugs.\(^14\)-\(^16\) Scheduled cesarean delivery is recommended for prevention of perinatal transmission in women who have received antepartum ARV drugs but who have detectable viremia (HIV RNA >1000 copies/mL) near the time of delivery (see Intrapartum Care and Transmission and Mode of Delivery). In PACTG 316, transmission occurred in 0% of 17 infants when maternal HIV RNA levels at delivery were >10,000 copies/mL and delivery was by scheduled cesarean delivery.\(^2\) However, not all women with detectable viremia near delivery will undergo cesarean delivery. The risk of acquisition of HIV will be higher in infants born to mothers with higher viral loads near delivery, particularly if delivery is vaginal. The gradient of transmission risk is based on HIV RNA levels. In the Women and Infants Transmission Study (WITS), the risk of transmission of HIV was \(\leq 1.8\%\) in women who received cART and had HIV RNA levels <30,000 copies/mL at delivery; it increased to 4.8% in women with HIV RNA levels \(\geq 30,000\) copies/mL.\(^16\)

**Infants Born to Mothers Who Received Only Intrapartum Antiretroviral Drugs**

All infants whose mothers have received only intrapartum ARV drugs should receive the 2-drug regimen of 6 weeks of zidovudine plus 3 doses of nevirapine in the first week of life (first dose at birth to 48 hours, second dose 48 hours after first dose, and third dose 96 hours after second dose), based on the results of the NICHD-HPTN 040/PACTG 1043 study. Infant prophylaxis should be initiated as soon after delivery as possible. Infant prophylaxis is a critical component of prevention when no maternal antepartum ARV drugs have been received. The PETRA study demonstrated that intrapartum prophylaxis alone, without infant prophylaxis, is ineffective in reducing perinatal transmission.\(^17\) A study in Thailand indicated that longer infant prophylaxis with zidovudine (6 weeks versus 3 days) is required for optimal efficacy when maternal antenatal exposure to zidovudine is <4 weeks.\(^18\) In the NICHD-HPTN 040/PACTG 1043 trial, 41% of women received zidovudine during labor. Administration of intrapartum zidovudine did not affect transmission rates.\(^5\)

**Infants Born to Mothers Who Did Not Receive Antepartum or Intrapartum Antiretroviral Drugs**

The 2-drug regimen of 6 weeks of zidovudine plus three doses of nevirapine in the first week of life (first dose at birth to 48 hours, second dose 48 hours after first dose, and third dose 96 hours after second dose) is recommended for infants born to mothers who did not receive antepartum or intrapartum ARV drugs based on the results of the NICHD-HPTN 040/PACTG 1043 study, which demonstrated increased efficacy of combination regimens in reducing intrapartum transmission compared with use of zidovudine alone in infants.\(^5\) Prophylaxis should be initiated as soon after delivery as possible.

The interval during which infant prophylaxis can be initiated and still be of benefit is undefined. In the New York State study, when prophylaxis was delayed beyond 48 hours after birth, no efficacy could be demonstrated.\(^19\) Data from animal studies indicate that the longer the delay in institution of prophylaxis, the less
likely that infection will be prevented. In most studies of animals, ARV prophylaxis initiated 24 to 36 hours after exposure usually has been ineffective in preventing infection, although a delay in administration has been associated with decreased viremia. In the NICHD-HPTN 040/PACTG 1043 study, infant regimens were initiated within 48 hours of life and usually within 12 hours of life. Initiation of infant prophylaxis after age 2 days is not likely to be efficacious in preventing transmission and, by age 14 days, infection already would be established in most infants. Initiating prophylaxis as soon after delivery as possible increases its potential efficacy and minimizes potential harm, such as development of resistant virus, if infection has occurred.

**Infants Born to Mothers with Unknown HIV Infection Status**

Expedited HIV testing of mothers is recommended during labor for women with unknown HIV status and for mothers and/or infants as soon as possible after birth if expedited HIV testing was not performed during labor. Expedited test results should be available within 60 minutes. Commercially available antigen/antibody tests are preferred to those that test only for antibody. Oral fluid-based tests are not recommended for infant testing; blood or serum testing has notably better sensitivity in infants than does oral fluid testing. If expedited testing is positive, infant ARV prophylaxis should be initiated immediately, without waiting for the results of supplemental tests (see scenario: Infants Born to Mothers Who Did Not Receive Antepartum or Intrapartum Antiretroviral Drugs). Expedited HIV testing should be available on a 24-hour basis at all facilities with a maternity service and/or neonatal intensive care, special care or newborn nursery.

A positive initial test result in mothers or infants should be presumed to indicate maternal HIV infection until standard supplemental testing clarifies maternal status. A positive HIV antibody test in an infant indicates maternal but not necessarily infant HIV infection; diagnosis of HIV infection in infants younger than age 18 months requires virologic testing using a viral nucleic amplification test (NAT; includes DNA and RNA PCR and related assays). Initial positive HIV antibody tests in the mother can be confirmed using a recommended HIV-1/2 diagnostic testing algorithm. Supplemental tests should be performed on mothers (or their infants) as soon as possible after the initial positive test. If the test results on a mother (or infant) are negative, ARV prophylaxis can be discontinued. If the supplemental test results in the mother are positive or if the mother is unavailable or declines testing, an HIV NAT should be obtained urgently from the newborn to determine the infant’s HIV infection status. If the HIV NAT is positive, ARV prophylaxis should be promptly discontinued and the infant should receive treatment for HIV infection with standard cART according to the Pediatric Antiretroviral Guidelines. Clinicians should be aware of their state laws, as there is variability in the testing allowed without parental consent.

Breastfeeding should be stopped until HIV infection is confirmed or ruled out in a woman who is suspected of being HIV-infected based on an initial positive antibody test result. Pumping and temporarily discarding or freezing breast milk can be recommended. If HIV infection is ruled out, breastfeeding can resume. If HIV infection is confirmed, breastfeeding should be discontinued permanently.

**Infants Born to Mothers with Antiretroviral Drug-Resistant Virus**

The optimal prophylactic regimen for newborns delivered by women with ARV drug-resistant virus is unknown. ARV prophylaxis for infants born to mothers with known or suspected drug resistance should be determined in consultation with a pediatric HIV specialist before delivery or through consultation with the National Perinatal HIV Hotline (888-448-8765).

Data from WITS suggest that in women who have mixed zidovudine-resistant and zidovudine-sensitive viral populations, the virus sensitive to rather than resistant to the drugs may be preferentially transmitted. Thus, the 6-week infant zidovudine prophylaxis (along with maternal intravenous [IV] intrapartum zidovudine prophylaxis) continues to be recommended, even when maternal zidovudine-resistant virus with thymidine-associated mutations is identified.

Some studies have suggested that ARV drug-resistant virus may have decreased replicative capacity (reduced viral fitness) and transmissibility. However, perinatal transmission of multidrug-resistant virus has been reported both in the United States and in international settings.
The optimal prophylactic regimen for newborns of women with ARV resistance is unknown. Therefore, ARV prophylaxis for an infant born to a woman with known or suspected drug resistance should be determined in consultation with a pediatric HIV specialist, preferably before delivery. However, there is no evidence that neonatal prophylaxis regimens customized based on presence of maternal drug resistance are more effective than standard neonatal prophylaxis regimens.

### Short-Term Antiretroviral Drug Safety and Choice for Neonatal Prophylaxis

Infant prophylaxis with zidovudine has been associated with only minimal toxicity, consisting primarily of transient hematologic toxicity (mainly anemia), which generally resolves by age 12 weeks (see Initial Postnatal Management). Data are limited on the toxicity to infants of exposure to multiple ARV drugs.

The latest information on neonatal dosing for ARV drugs can be found in the Pediatric Antiretroviral Guidelines. Other than zidovudine, lamivudine is the nucleoside reverse transcriptase inhibitor (NRTI) with the most experience in use for neonatal prophylaxis. In early studies, neonatal exposure to combination zidovudine/lamivudine was generally limited to 117,34,35 or 2 weeks. Six weeks of infant zidovudine/lamivudine exposure also has been reported; these studies suggest that hematologic toxicity may be increased over that seen with zidovudine alone, although the infants also had in utero exposure to maternal combination therapy.

In a French study, more severe anemia and neutropenia were observed in infants exposed to 6 weeks of zidovudine/lamivudine for prophylaxis plus maternal antepartum zidovudine/lamivudine than in a historical cohort exposed only to maternal and infant zidovudine. Anemia was reported in 15% and neutropenia in 18% of infants exposed to zidovudine/lamivudine, with 2% of infants requiring blood transfusion and 4% requiring treatment discontinuation for toxicity. Similarly, in a Brazilian study of maternal antepartum and 6-week infant zidovudine/lamivudine prophylaxis, neonatal hematologic toxicity was common, with anemia seen in 69% and neutropenia in 13% of infants.6

Tenofovir disoproxil fumarate (tenofovir) with and without emtricitabine has been investigated in several small studies to define the safety and pharmacokinetics (PKs) of the agents in newborns. However, at this time, tenofovir and emtricitabine are not generally recommended for use in infant prophylaxis by the Panel because data on appropriate dosing are limited and the safety of these agents in the neonate is not well defined.

Experience with other NRTI drugs for neonatal prophylaxis is more limited.40,41 Hematologic and mitochondrial toxicity may be more common with exposure to multiple versus single NRTI drugs.6,42-45

Nevirapine is the only non-nucleoside reverse transcriptase inhibitor drug with a pediatric drug formulation and neonatal prophylactic (but not therapeutic) dosing information (see the Adult and Adolescent Antiretroviral Guidelines). In rare cases, chronic multiple-dose nevirapine therapy has been associated with severe and potentially life-threatening rash and hepatic toxicity. These toxicities have not been observed in infants receiving prophylactic dosing with single-dose nevirapine, the two-drug zidovudine regimen plus three doses of nevirapine in the first week of life in NICHD-HPTN 040/PACTG 1043), or in breastfeeding infants receiving nevirapine prophylaxis daily for 6 weeks to 6 months to prevent transmission of HIV via breast milk.5,47-50 Resistance to nevirapine can occur, however, with exposure to nevirapine in infants who become infected despite prophylaxis.51,52 ARV drug-resistance testing is recommended for all HIV-infected infants before initiation of cART (see the Adult and Adolescent Antiretroviral Guidelines).

Of the PIs, pediatric drug formulations are available for lopinavir/ritonavir, ritonavir, darunavir, tipranavir, and fosamprenavir, but their use in neonates in the first weeks of life is not recommended due to lack of dosing and safety information. In addition, lopinavir/ritonavir oral solution contains 42.4% alcohol and 15.3% propylene glycol, and enzymes that metabolize these compounds are immature in neonates, particularly preterm infants. No PK data are available for any PIs in the first 2 weeks of life. PK data are available for treatment of HIV-infected infants aged 2 to 6 weeks with lopinavir/ritonavir. Although the lopinavir area under the curve (AUC) was significantly lower with dosing 300 mg lopinavir/75 mg ritonavir/m² body surface area twice daily than observed for infants >6 weeks of age, treatment was well tolerated and 80% of 10 infants had viral control at 6 months.53 Studies are ongoing but data are not yet available for infants aged <2 weeks. However, in four
premature infants (2 sets of twins) started on lopinavir/ritonavir from birth, heart block developed that resolved after drug discontinuation.\textsuperscript{54,55} In studies of adults, both ritonavir and lopinavir/ritonavir cause dose-dependent prolongation of the PR interval, and cases of significant heart block, including complete heart block, have been reported. Elevation of 17-hydroxyprogesterone and dehydroepiandrosterone-sulfate has also been associated with administration of lopinavir/ritonavir compared with zidovudine in the neonatal period. Levels of 17-hydroxyprogesterone were greater in infants who were also exposed to lopinavir/ritonavir \textit{in utero} compared with those exposed only in the neonatal period. Term infants were asymptomatic but three premature newborns experienced life-threatening symptoms compatible with adrenal insufficiency, including hyponatremia and hyperkalemia with, in one case, cardionic shock.\textsuperscript{56} Based on these and other post-marketing reports of cardiac toxicity (including complete atrioventricular block, bradycardia, and cardiomyopathy), lactic acidosis, acute renal failure, adrenal dysfunction, central nervous system depression, respiratory complications leading to death, and metabolic toxicity,\textsuperscript{57} predominantly in preterm neonates, the FDA now recommends that lopinavir/ritonavir oral solution not be administered to neonates before a postmenstrual age (first day of the mother’s last menstrual period to birth plus the time elapsed after birth) of 42 weeks and a postnatal age of at least 14 days.

Raltegravir is the only integrase inhibitor with an available pediatric drug formulation. However, there are no PK and safety data on its use during the first weeks of life and it is not FDA-approved for use in infants aged <4 weeks or weight <3 kg. Raltegravir readily crosses the placenta; its elimination was highly variable and extremely prolonged in some infants following maternal dosing. Raltegravir competes with bilirubin for albumin binding sites, which could increase unbound (free) unconjugated bilirubin levels in the neonate.\textsuperscript{58} An \textit{in vitro} study has demonstrated that the effect of raltegravir on neonatal bilirubin binding is unlikely to be clinically significant unless raltegravir concentrations 50- to 100-fold higher than typical peak concentrations with usual dosing are reached.\textsuperscript{59} Use of raltegravir in neonates is not recommended until adequate PK and safety data are available.

\textbf{Neonatal Antiretroviral Drug Dosing}

\textbf{Table 8. Recommended Neonatal Dosing for Prevention of Perinatal Transmission of HIV}

<table>
<thead>
<tr>
<th>All HIV-Exposed Infants</th>
<th>Initiated as soon after delivery as possible</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosing</strong></td>
<td></td>
</tr>
<tr>
<td>ZDV</td>
<td></td>
</tr>
<tr>
<td>≥35 weeks’ gestation at birth: 4 mg/kg/dose PO twice daily, started as soon after birth as possible and preferably within 6–12 hours of delivery (or, if unable to tolerate oral agents, 3 mg/kg/dose IV, beginning within 6–12 hours of delivery, then every 12 hours)</td>
<td>Birth through 4-6 weeks\textsuperscript{a}</td>
</tr>
<tr>
<td>ZDV</td>
<td></td>
</tr>
<tr>
<td>≥30 to &lt;35 weeks’ gestation at birth: 2 mg/kg/dose PO (or 1.5 mg/kg/dose IV), started as soon after birth as possible, preferably within 6–12 hours of delivery, then every 12 hours, advanced to 3 mg/kg/dose PO (or 2.3 mg/kg/dose IV) every 12 hours at age 15 days</td>
<td>Birth through 6 weeks</td>
</tr>
<tr>
<td>ZDV</td>
<td></td>
</tr>
<tr>
<td>&lt;30 weeks’ gestation at birth: 2 mg/kg body weight/dose PO (or 1.5 mg/kg/dose IV) started as soon after birth as possible, preferably within 6–12 hours of delivery, then every 12 hours, advanced to 3 mg/kg/dose PO (or 2.3 mg/kg/dose IV) every 12 hours after age 4 weeks</td>
<td>Birth through 6 weeks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional Antiretroviral Prophylaxis Agents for HIV-Exposed Infants of Women who Received No Antepartum Antiretroviral Prophylaxis</th>
<th>Initiated as soon after delivery as possible</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVP In addition to ZDV as shown above</td>
<td>Birth weight 1.5–2 kg: 8 mg/dose PO</td>
</tr>
<tr>
<td></td>
<td>Birth weight &gt;2 kg: 12 mg/dose PO</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{a} A 6-week course of neonatal zidovudine is generally recommended. A 4-week neonatal zidovudine prophylaxis regimen may be considered when the mother has received standard ART during pregnancy with consistent viral suppression and there are no concerns related to maternal adherence.

**Key to Abbreviations:** ART = antiretroviral; IV = intravenously; NVP = nevirapine; PO = orally; ZDV = zidovudine
The recommended dose of zidovudine for post-exposure prophylaxis in full-term neonates is 4 mg/kg body weight orally (PO) twice daily, beginning as soon after birth as possible and preferably within 6 to 12 hours of delivery (see Table 8). Some PK studies suggest that the standard neonatal zidovudine dosing regimen might be excessive and associated with bone marrow and metabolic toxicity, but no alternative dosing regimens have been studied. If an infant is unable to tolerate oral medications, the zidovudine prophylaxis regimen can be administered IV. The zidovudine dosing requirements differ for premature infants and term infants (see Table 8 and Antiretroviral Drug Dosing for Premature Infants).

PKs and safety of the single-dose nevirapine regimen to mother and infant and chronic prophylactic nevirapine administration to infants to prevent HIV transmission during breastfeeding have been studied. The three-dose extended nevirapine regimen that was used in NICHD-HPTN 040/PACTG1043 and is recommended for HIV-exposed infants whose mothers did not receive ARV drugs during the antepartum period has also been studied. Nevirapine concentrations were measured in 14 newborns participating in a PK substudy during the second week of life and in single samples from 30 more newborns on Days 10 to 14. The median nevirapine elimination half-life was 30.2 hours (range: 17.8–50.3 hours) and the concentration remained greater than the target of 100 ng/mL in all infants through Day 10 of life.

Antiretroviral Drug Dosing for Premature Infants

Dosing recommendations for premature infants are available for only zidovudine (prophylaxis and therapy) and nevirapine (prophylaxis only) (see Table 8). Zidovudine is primarily cleared through hepatic glucuronidation to an inactive metabolite; this metabolic pathway is immature in neonates, leading to prolonged zidovudine half-life and decreased clearance compared with older infants. Clearance is further decreased in premature infants because their hepatic metabolic function is less mature than in term infants. The recommended zidovudine dosage for preterm infants is shown in Table 8.

Nevirapine PKs have been described in low-birthweight neonates receiving a single postnatal prophylaxis dose of the drug. In a study of 81 infants <37 weeks’ gestation, of which 29.6% were small for gestational age, half-lives were very long—median 59 hours in infants whose mothers received single-dose nevirapine and 69 hours in infants whose mothers did not receive single-dose nevirapine. AUC of nevirapine was higher and clearance lower (P < .0001) in small-for-gestational-age infants.

Use of ARV drugs other than zidovudine and nevirapine cannot be recommended at this time in premature infants because data on dosing and safety are lacking. Immature renal and hepatic metabolism can increase the risk of overdosing and toxicity. However, in situations where there is a high risk of infant HIV infection, consultation with a pediatric HIV specialist is recommended to determine if the benefits of combination ARV prophylaxis with drugs in addition to or other than zidovudine and nevirapine outweigh the potential risks.

Breastfeeding Infants of Mothers Diagnosed with HIV Infection Postpartum

Breastfeeding should be stopped until infection is confirmed or ruled out in women who are breastfeeding and suspected to have become HIV infected. Pumping and temporarily discarding or freezing breast milk can be recommended to mothers who are suspected of being HIV infected but whose infection is not yet confirmed and who want to continue to breastfeed. If HIV infection is ruled out, breastfeeding can resume. Breastfeeding is not recommended for women with documented HIV infection in the United States, including those receiving cART (see Infant Feeding Practices and Risk of HIV Transmission).

The risk of acquisition of HIV associated with breastfeeding depends on multiple infant and maternal factors, including maternal viral load and CD4 T lymphocyte (CD4) cell count. Infants of women who develop acute HIV infection while breastfeeding are at greater risk of becoming infected than are those whose mothers have chronic HIV infection because acute HIV infection is accompanied by a rapid increase in viral load and a corresponding decrease in CD4 cell count.

Other than discontinuing breastfeeding, optimal strategies for managing infants born to HIV-infected mothers who breastfed their infants prior to HIV diagnosis have yet to be defined. Some experts would consider the...
use of post-exposure prophylaxis in infants for 4 to 6 weeks after cessation of breastfeeding. Post-exposure prophylaxis, however, is less likely to be effective in this circumstance compared with other non-occupational exposures because the exposure to breast milk is likely to have occurred over a prolonged period rather than in a single exposure.\textsuperscript{79}

Several studies of infants breastfed by women with chronic HIV infection have shown that daily infant nevirapine, \textit{lamivudine}, or nevirapine plus zidovudine can reduce the risk of postnatal infection during breastfeeding.\textsuperscript{47-49,80} The NICHD-HPTN 040/PACTG 1043 study demonstrated that combination ARV prophylaxis was more effective than zidovudine prophylaxis alone for preventing intrapartum transmission in mothers who have not received antepartum ARV drugs.\textsuperscript{5} However, whether the combination regimens in this trial are effective for preventing transmission after cessation of breastfeeding in mothers with acute HIV infection is unknown.

Because of the high risk of postnatal transmission from a breastfeeding woman with acute HIV infection, an alternative approach favored by some experts would be to offer a cART regimen that would be effective for treatment of HIV, should an infant become infected. If this route is chosen, current recommendations for treatment should guide selection of an appropriate cART regimen (see the Pediatric Antiretroviral Guidelines). Regardless of whether post-exposure prophylaxis or “pre-emptive therapy” is chosen, the optimal duration of the intervention is unknown. A 28-day course may be reasonable based on current recommendations for non-occupational HIV exposure.\textsuperscript{79} As in other situations, decisions regarding administration of a prophylactic or preemptive treatment regimen should be accompanied by consultation with a pediatric HIV specialist and maternal counseling on the potential risks and benefits of this approach.

Infants should be tested for HIV infection at baseline and 4 to 6 weeks, 3 months, and 6 months after recognition of maternal infection to determine HIV status. In infants younger than age 18 months, HIV NAT should be used for diagnosis. HIV DNA PCR testing may be preferable for infants who are receiving combination ARV prophylaxis or preemptive treatment, because HIV RNA assays may be less sensitive in the presence of combination ARV drugs, which might lower infant plasma viral RNA to undetectable levels. However, HIV DNA PCR assays available in the United States may not detect non-subtype B or group O HIV as well as do many HIV RNA assays. Therefore, if non-subtype B or group O HIV infection is considered possible in an infant, both HIV DNA and RNA assays should be obtained from the infant. HIV antibody assays can be used in infants older than age 18 months.

If an infant is already receiving post-exposure ARV prophylaxis and is found to be HIV-infected, prophylaxis should be discontinued and treatment for HIV infection initiated with standard cART according to the Pediatric Antiretroviral Guidelines. Resistance testing should be performed and the cART regimen modified if needed (see the Pediatric Antiretroviral Guidelines).

References


**Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States**

---


Panel’s Recommendations

- A complete blood count and differential should be performed on newborns as a baseline evaluation (BIII).
- If hematologic abnormalities are identified in infants receiving prophylaxis, decisions on whether to continue infant antiretroviral prophylaxis need to be individualized. Consultation with an expert in pediatric HIV infection is advised if early discontinuation of prophylaxis is considered (CIII).
- Decisions about the timing of subsequent monitoring of hematologic parameters in infants depend on baseline hematologic values, gestational age at birth, clinical condition of the infants, the zidovudine dose being administered, receipt of other antiretroviral drugs and concomitant medications, and maternal antepartum therapy (CIII).
- Hemoglobin and neutrophil counts should be remeasured 4 weeks after initiation of prophylaxis for infants who receive combination zidovudine/lamivudine-containing antiretroviral prophylaxis regimens (AI).
- Routine measurement of serum lactate is not recommended. However, measurement can be considered if an infant develops severe clinical symptoms of unknown etiology (particularly neurologic symptoms) (CII).
- Virologic tests are required to diagnose HIV infection in infants aged <18 months and should be performed at 14 to 21 days of life and at ages 1 to 2 months and 4 to 6 months (All).
- To prevent *Pneumocystis jirovecii* pneumonia (PCP), all infants born to HIV-infected women should begin PCP prophylaxis at ages 4 to 6 weeks, after completing their antiretroviral prophylaxis regimen, unless there is adequate test information to presumptively exclude HIV infection (see the Pediatric Opportunistic Infections Guidelines) (All).
- Health care providers should routinely inquire about premastication, instruct HIV-infected caregivers to avoid this practice, and advise on safer feeding options (All).

**Hematologic Toxicity**

A complete blood count and differential should be performed on HIV-exposed newborns before initiation of infant antiretroviral (ARV) drug prophylaxis. Decisions about the timing of hematologic monitoring of infants after birth depend on a number of factors, including baseline hematologic values, gestational age at birth, clinical condition of the infants, which ARV drugs are being administered, receipt of concomitant medications, and maternal antepartum ARV drug regimen. Anemia is the primary complication seen in neonates given the standard 6-week postnatal zidovudine regimen. In PACTG 076, infants in the zidovudine group had lower hemoglobin levels at birth than those in the placebo group, with the maximal difference (1 g/dL) occurring at age 3 weeks. The lowest mean value for hemoglobin levels (10 g/dL) occurred at age 6 weeks in the zidovudine group. By age 12 weeks, hemoglobin values in both groups were similar. No significant differences in other laboratory parameters were observed between groups.

Some experts remeasure hematologic values in healthy infants receiving zidovudine prophylaxis only if symptoms are present. Hematologic safety data are limited on administration of 4 mg/kg of zidovudine twice daily in infants. When administering this dosing regimen, some experts remeasure hemoglobin and neutrophil counts routinely after 4 weeks of zidovudine prophylaxis and/or when diagnostic HIV polymerase chain reaction (PCR) tests are obtained.

In utero exposure to maternal combination ARV drug regimens may be associated with more anemia and/or neutropenia compared with that seen in infants exposed to zidovudine alone. In PACTG 316, where 77% of mothers received antenatal combination therapy, significant Grade 3 or higher anemia was noted in 13% and neutropenia in 12% of infants, respectively. Some experts recommend more intensive monitoring of hematologic and serum chemistry and liver function assays at birth and when diagnostic HIV PCR tests are
obtained in infants exposed to combination ARV drug regimens in utero or during the neonatal period.

In addition, data are limited on infants receiving zidovudine in combination with other ARVs for prophylaxis. However, higher rates of hematologic toxicity have been observed in infants receiving zidovudine/lamivudine combination prophylaxis compared with those receiving zidovudine alone or zidovudine plus nevirapine. Hemoglobin levels and neutrophil counts, therefore, should be remeasured 4 weeks after initiation of prophylaxis and/or at the time that diagnostic HIV PCR testing is done in infants who receive combination zidovudine/lamivudine-containing ARV prophylaxis regimens.

If hematologic abnormalities are found, decisions on whether to continue infant ARV prophylaxis need to be individualized. Considerations include the extent of the abnormality, whether related symptoms are present, duration of infant prophylaxis, and risk of HIV infection (as assessed by the mother’s history of ARV prophylaxis, viral load near delivery, and mode of delivery). In the United States, the standard 6-week infant zidovudine regimen has been recommended based on data from PACTG studies 076 and 316 (both performed during an era when women received zidovudine monotherapy antenatally). In the United Kingdom and other European countries, a 4-week neonatal chemoprophylaxis regimen is now recommended for infants born to mothers who have received combination antiretroviral therapy (cART) regimens and have viral suppression, with no apparent increase in the overall HIV perinatal transmission rate. Additionally, a 4-week zidovudine regimen has been reported to result in earlier recovery from anemia in otherwise healthy infants compared with the 6-week zidovudine regimen. Therefore, a 4-week zidovudine neonatal chemoprophylaxis regimen can be considered when a mother has received standard cART during pregnancy with consistent viral suppression and there are no concerns related to maternal adherence.

**Hyperlactatemia**

Hyperlactatemia has been reported in infants with in utero exposure to ARVs, but it appears to be transient and, in most cases, asymptomatic. Routine measurement of serum lactate is not recommended in asymptomatic neonates to assess for potential mitochondrial toxicity because the clinical relevance is unknown and the predictive value for toxicity appears poor. Serum lactate measurement should be considered, however, for infants who develop severe clinical symptoms of unknown etiology, particularly neurologic symptoms. In infants with symptoms, if the levels are significantly abnormal (>5 mmol/L), ARV prophylaxis should be discontinued and an expert in pediatric HIV infection should be consulted regarding potential alternate prophylaxis.

**Prophylaxis against Pneumocystis jirovecii Pneumonia**

To prevent Pneumocystis jirovecii pneumonia, all infants born to HIV-infected women should begin trimethoprim-sulfamethoxazole prophylaxis at age 4 to 6 weeks, after completion of the infant ARV prophylaxis regimen, unless there is adequate virologic test information to presumptively exclude HIV infection (see the Pediatric Opportunistic Infections Guidelines).

**HIV Testing of the Infant**

HIV infection in infants should be diagnosed using HIV nucleic acid amplification virologic assays, which include DNA and RNA PCR and related assays. Maternal HIV antibody crosses the placenta and will be detectable in all HIV-exposed newborns; therefore, standard antibody tests should not be used for HIV diagnosis in newborns. HIV virologic testing should be performed at 14 to 21 days of life and at ages 1 to 2 months and 4 to 6 months. Some experts also perform a virologic test at birth, especially in women who have not had good virologic control during pregnancy or if adequate follow-up of the infant cannot be assured. A positive HIV virologic test should be confirmed as soon as possible with a second HIV virologic test on a different specimen. Two positive HIV tests constitute a diagnosis of HIV infection. There is no evidence of a delay in HIV diagnosis with HIV DNA PCR assays in infants who have received the zidovudine regimen. However, the effect of maternal or infant exposure to combination ARV drug regimens on the sensitivity of infant virologic diagnostic testing—particularly using HIV RNA assays—is
unknown. Therefore, some experts prefer to use HIV DNA PCR assays for diagnosing infection in neonates who receive combination ARV drug regimens. Any newly diagnosed infant should undergo viral resistance testing by genotype and/or phenotype to assess for susceptibility to cART.

HIV can be **presumptively** excluded with 2 or more negative tests: one at age 14 days or older and the other at age 1 month or older. **Definitive** exclusion of HIV in non-breastfed infants can be based on two or more negative virologic tests, with one test performed at age 1 month or older and the other test at age 4 months or older. Many experts confirm HIV-negative status with an HIV antibody test at age 12 to 18 months. Persistence of HIV antibodies can occasionally occur at or beyond age 18 months. Alternative algorithms exist for presumptive and definitive HIV exclusion. This testing algorithm applies mainly to exposure to HIV subtype B, which is the predominant viral subtype found in the United States. Non-subtype B viruses predominate in some other parts of the world. Non-subtype B infection may not be detected by many commercially available nucleic acid tests, particularly HIV DNA PCR. Many of the newer HIV RNA assays have improved detection of non-subtype B HIV, but there are still variants that are either poorly detected or undetectable. If non-subtype B HIV infection is suspected based on maternal origins, then newer HIV RNA assays that have improved ability to detect non-subtype B HIV should be used as part of the initial diagnostic algorithm. For a detailed discussion of pediatric HIV diagnosis, see [Pediatric Antiretroviral Guidelines](https://aidsinfo.nih.gov/guidelines).

**Postnatal Management**

Following birth, HIV-exposed infants should have a detailed physical examination, and a thorough maternal history should be obtained. HIV-infected mothers may be coinfected with other pathogens that can be transmitted from mother to child, such as cytomegalovirus, herpes simplex virus, hepatitis B, hepatitis C, syphilis, toxoplasmosis, or tuberculosis. Infants born to mothers with such coinfections should undergo appropriate evaluation, as indicated by maternal CD4 T lymphocyte count and evidence of disease activity, to rule out transmission of additional infectious agents. The routine primary immunization schedule should be followed for HIV-exposed infants born to HIV-infected mothers. Modifications in the schedule for live virus vaccines may be required for infants with known HIV infection (see the [Pediatric Opportunistic Infections Guidelines](https://aidsinfo.nih.gov/guidelines)).

No evidence is available to enable the Panel to assess whether any changes in routine bathing practices, or timing of circumcision, are indicated for HIV-exposed newborns.

**Infant Feeding Practices and Risk of HIV Transmission**

In the United States, where safe infant feeding alternatives are available and free for women in need, HIV-infected women should not breastfeed their infants. Maternal receipt of cART is likely to reduce free virus in the breast milk, but the presence of cell-associated virus (intracellular HIV DNA) remains unaffected and, therefore, may continue to pose a transmission risk.

Late HIV transmission events in infancy have been reported in HIV-infected children suspected of acquiring HIV infection as a result of consuming premasticated food given to them by their caregivers. Phylogenetic comparisons of virus from cases and suspected sources and supporting clinical history and investigations identified the practice of feeding premasticated foods to infants as a potential risk factor for HIV transmission. Health care providers should routinely inquire about premastication, instruct HIV-infected caregivers against this feeding practice, and advise on safer feeding options.

**References**

3. El Beitune P, Duarte G. Antiretroviral agents during pregnancy: consequences on hematologic parameters in HIV-


Long-Term Follow-Up of Antiretroviral Drug-Exposed Infants

Panel's Recommendation

- Children with in utero/neonatal exposure to antiretroviral drugs who develop significant organ system abnormalities of unknown etiology, particularly of the nervous system or heart, should be evaluated for potential mitochondrial dysfunction (CIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Data remain insufficient to address the effect that exposure to zidovudine or other antiretroviral (ARV) agents in utero might have on long-term risk of neoplasia or organ system toxicities in children; however, the balance of evidence over 2 decades is reassuring. Potential toxicities require further, long-term investigation especially as individual antenatal ARV and ARV combinations continue to evolve. Initial data from follow-up of PACTG 076 infants through age 6 years did not indicate any differences in immunologic, neurologic, and growth parameters between infants who were exposed to the zidovudine regimen and those who received placebo, and no malignancies were noted. However, concerns remain that exposure to ARVs may have long-term effects on mitochondrial and immunologic function. Ongoing studies within the Pediatric HIV/AIDS Cohort Study (PHACS) and other HIV-exposed uninfected cohorts may help to identify the long-term risks of ARVs in exposed infants.

Potential Mitochondrial Toxicity

Nucleoside reverse transcriptase inhibitor (NRTI) drugs induce some degree of mitochondrial dysfunction reflecting varying affinity for mitochondrial gamma DNA polymerase. This affinity can interfere with mitochondrial replication, resulting in mitochondrial DNA (mt DNA) depletion and dysfunction. Aberrant histological morphology of mitochondria, mt DNA mutations, alterations in mt DNA levels in cord blood mononuclear cells, and even aneuploidy in cord blood cells have all been described in both non-human primates and neonates exposed in utero to NRTIs. Reported increased and decreased alterations in mt DNA levels add further complexity to interpretation of their clinical significance; in addition, the data may be confounded by stage of maternal HIV infection and differences in laboratory assays and cell lines used.

One study has reported that respiratory chain mitochondrial function is subtly perturbed, at least transiently, with an increased incidence of abnormal newborn metabolic screen results for products of intermediary metabolism (elevated amino acids and acylcarnitines) in HIV-exposed (but uninfected) infants compared with HIV-unexposed infants. The degrees to which these theoretical concerns and even documented mitochondrial abnormalities are clinically relevant are not yet known but are significantly outweighed by the robust, proven efficacy of maternal and infant ARV prophylaxis to prevent perinatal HIV transmission.

Evidence of clinically apparent effects of mitochondrial toxicity is also conflicting. A low rate of hyperlactatemia (3.4%) is documented among HIV-exposed, uninfected infants born to US women receiving ARV therapy. However, earlier studies from the French Perinatal Study Group cohort noted a significantly increased incidence of clinical effects possibly reflecting mitochondrial dysfunction including seizures, cognitive and motor delays, abnormal neuroimaging, hyperlactatemia, cardiac dysfunction, and two deaths, with abnormal mitochondrial histology noted among some HIV-uninfected infants born to HIV-infected women (who received or did not receive ARV drugs during pregnancy: 12/2,644 vs. 0/1,748, respectively, P = 0.002). Further clinical studies from the United States and Europe have not duplicated these French reports. In a report from a long-term follow-up study in the United States (PACTG 219/219C), 20 children with possible symptoms of mitochondrial dysfunction were identified among a cohort of 1,037 HIV-exposed uninfected infants. Definitive diagnosis was not possible because none of the children had biopsies.
for mitochondrial function; however, 3 of the 20 children had no exposure to ARV drugs. In the 17 remaining children, there was an association between symptoms and first exposure to zidovudine/lamivudine limited to the third trimester, but overall exposure to NRTIs was not associated with symptoms. Some small alterations in mt DNA and oxidative phosphorylation enzyme activities were documented in stored specimens from these children, but the clinical significance of these observations remains unknown.25,26

Given the above data, mitochondrial dysfunction should be considered in uninfected children with perinatal exposure to ARV drugs who present with severe clinical findings of unknown etiology, particularly neurologic findings. It is important that the long-term medical record of an uninfected child includes information about ARV exposure, should unusual symptoms develop later in life, or if adverse late effects of HIV or ARV exposure in uninfected children are identified in the future.8,27,28

Potential Immunologic Dysfunction

The potential impact of HIV exposure on the immune system of an uninfected infant is unclear. One study reported lower CD4 T lymphocyte (CD4) cell counts in HIV-exposed uninfected infants born to mothers whose viral load at the time of delivery was >1,000 copies/mL compared to HIV-exposed uninfected infants whose mothers had a viral load <50 copies/mL at the time of delivery.29 The French Perinatal Cohort Group have reported an increased risk of serious bacterial infections with encapsulated organisms in HIV-exposed infants born to mothers with low CD4 number near the time of delivery.30 Other data suggest that exposure to HIV in utero may be associated with alterations in CD4 and CD8 cell-mediated immune responses in infants to vaccines and non-specific antigens in infants.31 Further study is needed regarding the reproducibility of these data, whether findings are transient or prolonged, and whether they are primarily associated with advanced maternal HIV disease.

Conclusion

Ongoing evaluations of the early and late effects of in utero exposure to ARV drugs include the Pediatric HIV/AIDS Cohort Study Surveillance Monitoring of Antiretroviral Toxicity Study, natural history studies, and HIV/AIDS surveillance conducted by state health departments and the Centers for Disease Control and Prevention. Because many of the available follow-up data to date relate to in utero exposure to antenatal zidovudine or other NRTIs alone, and most HIV-infected pregnant women currently receive combination ARV drug regimens, it is critical that studies to evaluate potential adverse effects of in utero drug exposure continue to be supported. HIV surveillance databases from states that require HIV reporting provide an opportunity to collect population-based information concerning in utero exposure to ARVs. To the extent permitted by federal law and regulations, data from these confidential registries can be compared with information from birth defect and cancer registries to identify potential adverse outcomes.

References


5. Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA. Impact of nucleoside reverse transcriptase...


23. Brogley SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of


Appendix A: Review of Clinical Trials of Antiretroviral Interventions to Prevent Perinatal HIV Transmission

August 6, 2015; last reviewed August 6, 2015

One of the major achievements in HIV research was the demonstration by the Pediatric AIDS Clinical Trials Group (PACTG) 076 clinical trial that administration of zidovudine to pregnant women and their infants could reduce the risk of perinatal transmission by nearly 70%.1 Following the results of PACTG 076, researchers began to explore the development of shorter, less expensive prophylactic regimens more applicable to resource-constrained settings. In addition, a number of studies have examined optimal regimens to reduce postnatal transmission during breastfeeding. This Appendix provides a table summarizing results of major studies of antiretroviral (ARV) interventions to prevent perinatal transmission (see Supplemental Table 1) and a brief discussion of lessons learned. In many cases, the direct comparison of results from trials of these regimens is not possible because the studies involved diverse patient populations residing in different geographic locations, infected with diverse viral subtypes, and with different infant feeding practices. However, some generalizations are relevant to understanding the use of ARV drugs for prevention of perinatal transmission in both resource-limited and resource-rich countries.

**Combination antenatal prophylaxis taken over a longer duration is more effective than a short-course single-drug regimen in reducing perinatal transmission.**

The use of ARV drugs to prevent transmission is highly effective, even in HIV-infected women with advanced disease.2,3 Efficacy has been demonstrated for a number of short-course ARV regimens, including those with zidovudine alone, zidovudine plus lamivudine, single-dose nevirapine, and single-dose nevirapine combined with either short-course zidovudine or zidovudine/lamivudine.4-13 In general, combination regimens are more effective than single-drug regimens in reducing perinatal transmission. In addition, for prevention of perinatal transmission, administration of ARV drugs during the antepartum, intrapartum, and postpartum periods is superior to administration of ARV drugs during only the antepartum and intrapartum periods or the intrapartum and postpartum periods.5,14,15

Almost all trials in resource-limited countries have included oral intrapartum prophylaxis, with varying durations of maternal antenatal and/or infant (and sometimes maternal) postpartum prophylaxis. Perinatal transmission is reduced by regimens with antenatal components starting as late as 36 weeks’ gestation, even when lacking an infant prophylaxis component.10-12 However, longer-duration antenatal zidovudine prophylaxis, beginning at 28 weeks’ gestation, is more effective than shorter-duration zidovudine prophylaxis, beginning at 35 weeks’ gestation.13 The European National Study of HIV in Pregnancy and Childhood demonstrated that each additional week of an antenatal, triple-drug regimen corresponded to a 10% reduction in risk of transmission.16 More prolonged infant post-exposure prophylaxis does not appear to substitute for longer-duration maternal ARV prophylaxis.13

The PROMISE study is the first randomized clinical trial to demonstrate the superiority of combination antiretroviral therapy over zidovudine-based prophylaxis for prevention of in utero transmission in women with CD4 T lymphocyte (CD4) cell counts >350 cells/mm3.17 Pregnant women were randomized to one of three study arms:

- Zidovudine plus single-dose nevirapine at delivery plus postpartum tenofovir disoproxil fumarate/emtricitabine tail
- Zidovudine plus lamivudine plus ritonavir-boosted lopinavir
- Tenofovir plus emtricitabine plus ritonavir-boosted lopinavir

The rate of perinatal transmission through 14 days of life was significantly lower among women receiving triple ARV prophylaxis (0.6%, 9 infections among 1,710 infants) compared with those in the zidovudine arm (1.8%, 25 infections among 1,326 infants).
Regimens that do not include maternal ARV prophylaxis during pregnancy have been evaluated because some women may lack antenatal care and present for prenatal care for the first time when they go into labor. Regimens that include only intrapartum and postpartum drug administration also have been shown to be effective in reducing perinatal transmission.\(^4\)\(^6\) However, without continued infant post-exposure prophylaxis, intrapartum pre-exposure prophylaxis alone with nucleoside reverse transcriptase inhibitor drugs (zidovudine/lamivudine) is not effective in reducing transmission.\(^5\) The SAINT trial demonstrated that intrapartum/postpartum zidovudine/lamivudine and single-dose intrapartum/newborn nevirapine are similar in efficacy and safety.\(^6\)

**Combination infant ARV prophylaxis is recommended in the United States for infants whose mothers have not received antenatal ARV drugs.**

In some situations, it may be impossible to administer maternal antepartum and intrapartum therapy, and only infant prophylaxis may be an option. In the absence of maternal therapy, the standard infant prophylaxis regimen of 6 weeks of zidovudine was effective in reducing HIV transmission compared with no prophylaxis, based on epidemiological data in resource-rich countries.\(^18\) A trial in Malawi in breastfeeding infants demonstrated that adding 1 week of zidovudine therapy to infant single-dose nevirapine reduced risk of transmission by 36% compared with infant single-dose nevirapine alone.\(^7\)

To define the optimal infant prophylaxis regimen in the absence of maternal antepartum ARV drug administration in a formula-fed population of infants such as in the United States, the NICHD-HPTN 040/P1043 (NCT00099359) clinical trial compared 3 infant ARV regimens in formula-fed infants born to mothers who did not receive ARV drugs during the current pregnancy: standard 6 weeks of zidovudine alone versus 6 weeks of zidovudine plus 3 doses of nevirapine given in the first week of life (first dose birth to 48 hours, second dose 48 hours after first dose, third dose 96 hours after second dose) versus 6 weeks of zidovudine plus lamivudine and nelfinavir given from birth through age 2 weeks.\(^19\) The study demonstrated that both the dual- and triple-combination regimens reduced the risk of intrapartum transmission by approximately 50% compared with infant prophylaxis with zidovudine alone, although there was more hematologic toxicity with the triple regimen (see Supplemental Table 1). Based on these data, combination ARV prophylaxis is now recommended in the United States for infants whose mothers have not received antenatal ARV drugs, with the dual regimen of zidovudine plus three doses of nevirapine in the first week of life being preferred because of lower rates of toxicity (see Infant Antiretroviral Prophylaxis).

**Adding single-dose intrapartum nevirapine is not recommended for women in the United States who are receiving standard recommended antenatal ARV prophylaxis.**

PACTG 316, a clinical trial conducted in the United States, Europe, Brazil, and the Bahamas, demonstrated that for non-breastfeeding women in resource-rich countries, the addition of single-dose nevirapine did not offer significant benefit in the setting of combination ARV prophylaxis throughout pregnancy and very low viral load at the time of delivery.\(^20\) Thus, adding single-dose intrapartum nevirapine is not recommended for women in the United States who are receiving standard recommended antenatal ARV prophylaxis (see Intrapartum Antiretroviral Therapy/Prophylaxis).

**Breastfeeding by HIV-infected women is not recommended in the United States.**

Breastfeeding by HIV-infected women (including those receiving ARV drugs) is not recommended in the United States, where replacement feeding is affordable, feasible, acceptable, sustainable, and safe and the risk of infant mortality due to diarrheal and respiratory infections is low.\(^21\) Clinical trials have demonstrated that both infant prophylaxis (primarily using daily infant nevirapine) during breastfeeding and maternal triple-drug prophylaxis during breastfeeding decrease postnatal infection (see Supplemental Table 1).\(^22\)\(^29\) Hypothetically, maternal triple-drug prophylaxis may be less effective than infant prophylaxis if the maternal regimen is first started postpartum or late in pregnancy because it takes several weeks to months before full viral suppression in breast milk is achieved.\(^26\)\(^30\) Importantly, although significantly lowering the risk of postnatal infection, neither infant nor maternal postpartum ARV prophylaxis completely eliminates the risk...
of HIV transmission through breast milk. Therefore, breastfeeding is not recommended for HIV-infected women in the United States (including those receiving combination ARV drug regimens). Finally, both infant nevirapine prophylaxis and maternal triple-drug prophylaxis during breastfeeding may be associated with the development of ARV drug resistance in infants who become infected despite prophylaxis; multi-class drug resistance has been described in breastfeeding infants infected despite maternal triple-drug prophylaxis.

**Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission** (page 1 of 7)

<table>
<thead>
<tr>
<th>Study; Location(s); Mode of Infant Feeding</th>
<th>Antiretroviral Drugs</th>
<th>Antepartum and Intrapartum</th>
<th>Postpartum</th>
<th>Perinatal Transmission Rate and Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediatric AIDS Clinical Trials Group (PACTG) 076; United States, France; Formula feeding</td>
<td>ZDV vs. placebo</td>
<td>Long (from 14 weeks) IV IP</td>
<td>Long (6 weeks); infant only</td>
<td>Perinatal transmission at 18 months was 8.3% in ZDV arm vs. 25.5% in placebo arm (68% efficacy).</td>
</tr>
<tr>
<td>CDC short-course ZDV trial; Thailand; Formula feeding</td>
<td>ZDV vs. placebo</td>
<td>Short (from 36 weeks) Oral IP</td>
<td>None</td>
<td>Perinatal transmission at 6 months was 9.4% in ZDV arm vs. 18.9% in placebo arm (50% efficacy).</td>
</tr>
<tr>
<td>DITRAME (ANRS 049a) trial; Ivory Coast, Burkina Faso; Breastfeeding</td>
<td>ZDV vs. placebo</td>
<td>Short (from 36 weeks) Oral IP</td>
<td>Short (1 week); mother only</td>
<td>Perinatal transmission was 18.0% in ZDV arm vs. 27.5% in placebo arm at 6 months (38% efficacy) and 21.5% vs. 30.6%, respectively, at 15 months (30% efficacy). Perinatal transmission was 22.5% in ZDV arm vs. 30.2% in placebo arm in pooled analysis at 24 months (26% efficacy).</td>
</tr>
<tr>
<td>CDC short-course ZDV trial; Ivory Coast; Breastfeeding</td>
<td>ZDV vs. placebo</td>
<td>Short (from 36 weeks) Oral IP</td>
<td>None</td>
<td>Perinatal transmission was 16.5% in ZDV arm vs. 26.1% in placebo arm at 3 months (37% efficacy). Perinatal transmission was 22.5% in ZDV arm vs. 30.2% in placebo arm in pooled analysis at 24 months (26% efficacy).</td>
</tr>
<tr>
<td>PETRA trial; South Africa, Tanzania, Uganda; Breastfeeding and formula feeding</td>
<td>AP/IP/PP ZDV plus 3TC vs. IP/PP ZDV plus 3TC vs. IP-only ZDV plus 3TC vs. Placebo</td>
<td>Short (from 36 weeks) Oral IP</td>
<td>Short (1 week); mother and infant</td>
<td>Perinatal transmission was 5.7% at 6 weeks for AP/IP/PP ZDV plus 3TC, 8.9% for IP/PP ZDV plus 3TC, 14.2% for IP-only ZDV plus 3TC, and 15.3% for placebo (efficacy compared with placebo: 63%, 42%, and 0%, respectively). Perinatal transmission was 14.9% at 18 months for AP/IP/PP ZDV plus 3TC, 18.1% for IP/PP ZDV plus 3TC, 20.0% for IP-only ZDV plus 3TC, and 22.2% for placebo (efficacy compared with placebo: 34%, 18%, and 0%, respectively).</td>
</tr>
<tr>
<td>HIVNET 012 trial; Uganda; Breastfeeding</td>
<td>SD NVP vs. ZDV</td>
<td>No AP ARV Oral IP: • SD NVP vs. oral ZDV</td>
<td>SD NVP within 72 hours of birth, infant only vs. ZDV (1 week); infant only</td>
<td>Perinatal transmission was 11.8% in NVP arm vs. 20.0% in ZDV arm at 6–8 weeks (42% efficacy) and 15.7% in NVP arm vs. 25.8% in ZDV arm at 18 months (41% efficacy).</td>
</tr>
</tbody>
</table>

**Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States**

F-3

Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission (page 2 of 7)

<table>
<thead>
<tr>
<th>Study; Location(s); Mode of Infant Feeding</th>
<th>Antiretroviral Drugs</th>
<th>Antepartum and Intrapartum</th>
<th>Postpartum</th>
<th>Perinatal Transmission Rate and Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAINT trial; South Africa; Breastfeeding and formula feeding</td>
<td>SD NVP vs. ZDV plus 3TC</td>
<td>No AP ARV Oral IP: • SD NVP vs. ZDV plus 3TC</td>
<td>SD NVP within 48 hours of birth, mother and infant vs. ZDV plus 3TC (1 week); mother and infant</td>
<td>Perinatal transmission was 12.3% in SD NVP arm vs. 9.3% in ZDV plus 3TC arm at 8 weeks (difference not statistically significant, ( P = 0.11 )).</td>
</tr>
<tr>
<td>Perinatal HIV Prevention Trial (PHPT-1); Thailand; Formula feeding</td>
<td>Four ZDV regimens with different durations of AP and infant PP administration; no placebo</td>
<td>Long (from 28 weeks), short (from 36 weeks) Oral IP</td>
<td>Long (6 weeks), short (3 days); infant only</td>
<td>Short-short arm was stopped at interim analysis (10.5%). Perinatal transmission was 6.5% in long-long arm vs. 4.7% in long-short arm and 8.6% in short-long arm at 6 months (no statistical difference). In utero transmission was significantly higher with short vs. long maternal therapy regimens (5.1% vs. 1.6%).</td>
</tr>
<tr>
<td>PACTG 316 trial; Bahamas, Belgium, Brazil, France, Germany, Italy, Spain, Sweden, Switzerland, United Kingdom, United States; Formula feeding</td>
<td>SD NVP vs. placebo among women already receiving ZDV alone (23%) or ZDV plus other ARV drugs (77% combination therapy)</td>
<td>Non-study ARV regimen Oral IP: • Placebo vs. SD NVP plus IV ZDV</td>
<td>Placebo vs. SD NVP within 72 hours of birth plus non-study ARV drugs (ZDV); infant only</td>
<td>77% of women received dual- or triple-combination ARV regimens during pregnancy. Trial stopped early because of very low perinatal transmission in both arms: 1.4% in SD NVP arm vs. 1.6% in placebo arm (53% of perinatal transmission was in utero).</td>
</tr>
<tr>
<td>Perinatal HIV Prevention Trial (PHPT-2); Thailand; Formula feeding</td>
<td>ZDV alone vs. ZDV plus maternal and infant SD NVP vs. ZDV plus maternal SD NVP</td>
<td>ZDV from 28 weeks Oral IP: • ZDV alone, or • ZDV plus SD NVP</td>
<td>ZDV for 1 week with or without SD NVP; infant only</td>
<td>ZDV-alone arm was stopped because of higher perinatal transmission than the NVP-NVP arm (6.3% vs. 1.1%, respectively). In arms in which the mother received SD NVP, the perinatal transmission rate did not differ significantly between the infant receiving or not receiving SD NVP (2.0% vs. 2.8%, respectively).</td>
</tr>
<tr>
<td>DITRAME Plus (ANRS 1201.0) trial; Ivory Coast; Breastfeeding and formula feeding</td>
<td>Open label, ZDV plus SD NVP</td>
<td>ZDV from 36 weeks Oral IP: • ZDV plus SD NVP</td>
<td>SD NVP plus ZDV for 1 week; infant only</td>
<td>Perinatal transmission was 6.5% (95% CI, 3.9%–9.1%) at 6 weeks; perinatal transmission for historical control group receiving short ZDV (98% breastfed) was 12.8%.</td>
</tr>
<tr>
<td>DITRAME Plus (ANRS 1201.1) trial; Ivory Coast; Breastfeeding and formula feeding</td>
<td>Open label, ZDV plus 3TC plus SD NVP</td>
<td>ZDV plus 3TC from 32 weeks (stopped at 3 days PP) Oral IP: • ZDV plus 3TC plus SD NVP</td>
<td>SD NVP plus ZDV for 1 week; infant only</td>
<td>Perinatal transmission was 4.7% (95% CI, 2.4%–7.0%) at 6 weeks; perinatal transmission for historical control group receiving short ZDV (98% breastfed) was 12.8%.</td>
</tr>
<tr>
<td>NVAZ trial; Malawi; Breastfeeding</td>
<td>Neonatal SD NVP vs. SD NVP plus ZDV</td>
<td>No AP or IP ARV (latecomers)</td>
<td>SD NVP with or without ZDV for 1 week; infant only</td>
<td>Perinatal transmission was 15.3% in SD NVP plus ZDV arm and 20.9% in SD NVP-only arm at 6–8 weeks. Perinatal transmission rates at 6–8 weeks among infants who were HIV uninfected at birth were 7.7% and 12.1%, respectively (36% efficacy).</td>
</tr>
</tbody>
</table>
**Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission** (page 3 of 7)

<table>
<thead>
<tr>
<th>Study; Location(s); Mode of Infant Feeding</th>
<th>Antiretroviral Drugs</th>
<th>Antepartum and Intrapartum</th>
<th>Postpartum</th>
<th>Perinatal Transmission Rate and Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Postnatal NVP plus ZDV trial; Malawi;</strong>&lt;sup&gt;8&lt;/sup&gt; Breastfeeding</td>
<td>Neonatal SD NVP vs. SD NVP plus ZDV</td>
<td>No AP ARV</td>
<td>SD NVP with or without ZDV for 1 week; infant only</td>
<td>Perinatal transmission was 16.3% in NVP plus ZDV arm and 14.1% in SD NVP-only arm at 6–8 weeks (difference not statistically significant). Perinatal transmission rates at 6–8 weeks among infants who were HIV uninfected at birth were 6.5% and 16.9%, respectively.</td>
</tr>
<tr>
<td><strong>Post-Exposure Infant Prophylaxis; South Africa;</strong>&lt;sup&gt;9&lt;/sup&gt; Breastfeeding and formula feeding</td>
<td>Neonatal SD NVP vs. ZDV for 6 weeks</td>
<td>No AP or IP ARV</td>
<td>SD NVP vs. ZDV for 6 weeks</td>
<td>For formula-fed infants only, perinatal transmission was 14.3% in SD NVP arm vs. 14.1% in ZDV arm at 6 weeks (not significant, ( P = 0.30 )). For breastfed infants only, perinatal transmission was 12.2% in SD NVP arm and 19.6% in ZDV arm (&lt;span class=&quot;math( P = 0.03 )).</td>
</tr>
<tr>
<td><strong>Mashi; Botswana;</strong>&lt;sup&gt;38,39&lt;/sup&gt; Breastfeeding and formula feeding</td>
<td>Initial: • Short-course ZDV with/without maternal and infant SD NVP and with/without breastfeeding Revised: • Short-course ZDV plus infant SD NVP with/without maternal SD NVP and with/without breastfeeding; women with CD4 cell counts &lt;200 cells/mm&lt;sup&gt;3&lt;/sup&gt; receive combination therapy.</td>
<td>First Randomization: • ZDV from 34 weeks Oral IP: • ZDV plus either SD NVP or placebo Second Randomization: • Breastfeeding plus ZDV (infant) 6 months plus SD NVP; infant only vs. • Formula feeding plus ZDV (infant) 4 weeks plus SD NVP; infant only</td>
<td>Initial Design: • In formula-feeding arm, perinatal transmission at 1 month was 2.4% in maternal and infant SD NVP arm and 8.3% in placebo arm (( P = 0.05 )). • In breastfeeding plus infant ZDV arm, perinatal transmission at 1 month was 8.4% in SD NVP arm and 4.1% in placebo arm (difference not statistically significant). Revised Design: • Perinatal transmission at 1 month was 4.3% in maternal plus infant SD NVP arm and 3.7% in maternal placebo plus infant SD NVP arm (no significant difference; no interaction with mode of infant feeding). Perinatal transmission at 7 months was 9.1% in breastfeeding plus ZDV arm and 5.6% in formula-feeding arm; mortality at 7 months was 4.9% in breastfeeding plus ZDV arm vs. 9.3% in formula-feeding arm; HIV-free survival at 18 months was 15.6% in the breastfeeding plus ZDV arm vs. 14.2% in the formula-feeding arm.</td>
<td></td>
</tr>
<tr>
<td><strong>SWEN; Uganda, Ethiopia, India;</strong>&lt;sup&gt;23&lt;/sup&gt; Breastfeeding</td>
<td>SD NVP vs. NVP for 6 weeks</td>
<td>No AP ARV</td>
<td>Infant SD NVP vs. NVP for 6 weeks</td>
<td>Postnatal Infection in Infants Uninfected at Birth: • Perinatal transmission at 6 weeks was 5.3% in SD NVP arm vs. 2.5% in extended NVP arm (risk ratio 0.54, ( P = 0.009 )). • Perinatal transmission at 6 months was 9.0% in SD NVP arm vs. 6.9% in extended NVP arm (risk ratio 0.80, ( P = 0.16 )). HIV-free survival was significantly lower in extended NVP arm at both 6 weeks and 6 months of age.</td>
</tr>
</tbody>
</table>
Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission (page 4 of 7)

<table>
<thead>
<tr>
<th>Study; Location(s); Mode of Infant Feeding</th>
<th>Antiretroviral Drugs</th>
<th>Antepartum and Intrapartum</th>
<th>Postpartum</th>
<th>Perinatal Transmission Rate and Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEPI-Malawi Trial; Malawi; Breastfeeding</td>
<td>SD NVP plus ZDV for 1 week (control) vs. Two extended infant regimens (NVP or NVP/ZDV) for 14 weeks</td>
<td>No AP ARV Oral IP: • SD NVP (if mother presents in time)</td>
<td>Infant SD NVP plus ZDV for 1 week (control) vs. Control plus NVP for 14 weeks vs. Control plus NVP/ZDV for 14 weeks</td>
<td>Postnatal infection in Infants Uninfected at Birth: • Perinatal transmission at age 6 weeks was 5.1% in control vs. 1.7% in extended NVP (67% efficacy) and 1.6% in extended NVP/ZDV arms (69% efficacy). • Perinatal transmission at age 9 months was 10.6% in control vs. 5.2% in extended NVP (51% efficacy) and 6.4% in extended NVP/ZDV arms (40% efficacy). No significant difference in perinatal transmission between the extended prophylaxis arms; however, more hematologic toxicity with NVP/ZDV.</td>
</tr>
<tr>
<td>MITRA; Tanzania; Breastfeeding</td>
<td>Infant 3TC for 6 months (observational)</td>
<td>ZDV/3TC from 36 weeks through labor</td>
<td>Maternal ZDV/3TC for 1 week, infant 3TC for 6 months</td>
<td>Perinatal transmission at age 6 months was 4.9% (postnatal perinatal transmission between ages 6 weeks and 6 months was 1.2%).</td>
</tr>
<tr>
<td>Kisumu Breastfeeding Study (KiBS); Kenya; Breastfeeding</td>
<td>Maternal triple-drug prophylaxis (observational)</td>
<td>ZDV/3TC/NVP (NFV if CD4 count &gt;250 cells/mm³) from 34 weeks through labor</td>
<td>Maternal ZDV/3TC/NVP (NFV if CD4 count &gt;250 cells/mm³) for 6 months, infant SD NVP</td>
<td>Perinatal transmission at age 6 months was 5.0% (postnatal perinatal transmission between ages 7 days and 6 months was 2.6%).</td>
</tr>
<tr>
<td>MITRA-PLUS; Tanzania; Breastfeeding</td>
<td>Maternal triple-drug prophylaxis (observational)</td>
<td>ZDV/3TC/NVP (NFV if CD4 count &gt;200 cells/mm³) from 34 weeks through labor</td>
<td>Maternal ZDV/3TC/NVP (NFV if CD4 count &gt;200 cells/mm³) for 6 months, infant ZDV/3TC for 1 week</td>
<td>Perinatal transmission at age 6 months was 5.0% (postnatal perinatal transmission between ages 6 weeks and 6 months was 0.9%), not significantly different from 6-month infant prophylaxis in MITRA.</td>
</tr>
<tr>
<td>Kesho Bora; Multi-African; Breastfeeding primarily</td>
<td>Antepartum ZDV/SD NVP with no postnatal prophylaxis vs. Maternal triple-drug prophylaxis in women with CD4 counts of 200–500 cells/mm³</td>
<td>Arm 1: • ZDV/3TC/LPV/r From 28 weeks through labor</td>
<td>Arm 1: • Maternal ZDV/3TC/LPV/r for 6 months, infant SD NVP plus ZDV for 1 week Arm 2: • Maternal ZDV/3TC/LPV/r for 6 months, infant SD NVP plus ZDV for 1 week (no further postnatal prophylaxis)</td>
<td>Perinatal transmission at birth was 1.8% with maternal triple-drug prophylaxis (Arm 1) and 2.5% with ZDV/SD NVP (Arm 2), not significantly different. In women with CD4 counts 350–500 cells/mm³, perinatal transmission at birth was 1.7% in both arms. Perinatal transmission at age 12 months was 5.4% with maternal triple-drug prophylaxis (Arm 1) and 9.5% with ZDV/SD NVP (with no further postnatal prophylaxis after 1 week) (Arm 2) (P = 0.029).</td>
</tr>
</tbody>
</table>
**Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission** (page 5 of 7)

<table>
<thead>
<tr>
<th>Study; Location(s); Mode of Infant Feeding</th>
<th>Antiretroviral Drugs</th>
<th>Antepartum and Intrapartum</th>
<th>Postpartum</th>
<th>Perinatal Transmission Rate and Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mma Bana; Botswana; Breastfeeding</td>
<td>Maternal triple-drug prophylaxis (compares 2 regimens) in women with CD4 cell counts &gt;200 cells/mm³</td>
<td>Arm 1: • ZDV/3TC/ABC Arm 2: • ZDV/3TC/LPV/r From 26 weeks through labor</td>
<td>Arm 1: • Maternal ZDV/3TC/ABC for 6 months, infant SD NVP plus ZDV for 4 weeks Arm 2: • Maternal ZDV/3TC/LPV/r for 6 months, infant SD NVP plus ZDV for 4 weeks</td>
<td>Perinatal transmission at age 6 months overall was 1.3%: 2.1% in ZDV/3TC/ABC Arm 1 and 0.4% in ZDV/3TC/LPV/r Arm 2 (P = 0.53).</td>
</tr>
<tr>
<td>BAN; Malawi; Breastfeeding</td>
<td>Postpartum maternal triple-drug prophylaxis vs. infant NVP in women with CD4 cell counts ≥250 cells/mm³</td>
<td>No AP drugs IP Regimens Arm 1 (Control): • ZDV/3TC plus SD NVP Arm 2: • ZDV/3TC plus SD NVP Arm 3: • ZDV/3TC plus SD NVP</td>
<td>Arm 1 (Control): • Maternal ZDV/3TC for 1 week, infant SD NVP plus ZDV/3TC for 1 week Arm 2: • Control as above, then maternal ZDV/3TC/LPV/r for 6 months Arm 3: • Control as above, then infant NVP for 6 months</td>
<td>Postnatal Infection in Infants Uninfected at Age 2 Weeks: • Perinatal transmission at age 28 weeks was 5.7% in control Arm 1, 2.9% in maternal triple-drug prophylaxis Arm 2 (P = 0.009 vs. control), and 1.7% in infant NVP Arm 3 (P &lt;0.001 vs. control). • Perinatal transmission at age 48 weeks was 7.0% in control Arm 1, 4.0% in maternal triple-drug prophylaxis Arm 2 (P = 0.0273 vs. control), and 4% in infant NVP Arm 3 (P = 0.0027 vs. control). No significant difference between maternal triple-drug prophylaxis (Arm 2) and infant NVP (Arm 3) (P = 0.12 at 28 weeks and P = 0.426 at 48 weeks).</td>
</tr>
<tr>
<td>HPTN 046; South Africa, Tanzania, Uganda, Zimbabwe; Breastfeeding</td>
<td>Postpartum prophylaxis of breast milk transmission of HIV with 6 weeks vs. 6 months of infant NVP</td>
<td>AP drugs allowed if required for maternal health</td>
<td>All infants received daily NVP from birth through age 6 weeks. Arm 1: • Daily infant NVP from age 6 weeks through age 6 months Arm 2: • Daily infant placebo from age 6 weeks through age 6 months</td>
<td>In infants uninfected at age 6 weeks, the 6-month infant HIV infection rate was 1.1% (0.3% to 1.8%) in the extended NVP Arm 1 and 2.4% (1.3% to 3.6%) in the placebo Arm 2 (P = 0.048). 18-month postnatal infection rates were 2.2% (1.1% to 3.3%) in the extended NVP Arm 1 and 3.1% (1.9% to 4.4%) in the placebo Arm 2 (P = 0.28). HIV infection and mortality rates did not differ between arms at any age through 18 months. At infant randomization at age 6 weeks, 29% of mothers in each arm were receiving a triple-drug ARV regimen for the treatment of HIV. For mothers receiving triple-drug ARV regimens at the time of randomization, in infants uninfected at age 6 weeks, the 6-month infant HIV infection rate was 0.2% and not statistically different between the extended NVP Arm 1 (0.5%) and placebo Arm 2 (0%). For mothers with CD4 counts &gt;350 cells/mm³ who were not receiving triple-drug ARV regimens, in infants uninfected at age 6 weeks, the 6-month infant HIV infection rate was 0.7% (0% to 1.5%) in the extended NVP Arm 1 and 2.8% (1.3% to 4.4%) in the placebo Arm 2 (P = 0.014).</td>
</tr>
</tbody>
</table>
Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission (page 6 of 7)

<table>
<thead>
<tr>
<th>Study; Location(s); Mode of Infant Feeding</th>
<th>Antiretroviral Drugs</th>
<th>Antepartum and Intrapartum</th>
<th>Postpartum</th>
<th>Perinatal Transmission Rate and Efficacy</th>
</tr>
</thead>
</table>
| NICHD-HPTN 040/PACTG 1043 trial; Brazil, Argentina, South Africa, United States; Formula feeding | Infant prophylaxis with 6 weeks ZDV vs. 6 weeks infant ZDV plus three doses of NVP in first week of life vs. 6 weeks infant ZDV plus 2 weeks of 3TC/NFV | No AP drugs if mother presented early enough, IV ZDV during labor through delivery | Arm 1 (Control): • Infant ZDV for 6 weeks  
• Control as above plus NVP with first dose within 48 hours of birth, second dose 48 hours later, and third dose 96 hours after the second dose  
Arm 2: • Control as above plus 3TC and NFV from birth through age 2 weeks  
Arm 3: • Control as above, plus 3TC and NFV from birth through age 2 weeks | IP HIV transmission among infants with negative HIV test at birth: 4.8% (3.2% to 7.1%) with ZDV (Arm 1) vs. 2.2% (1.2% to 3.9%) with ZDV plus NVP (Arm 2) ($P = 0.046$ compared with Arm 1) vs. 2.4% (1.4% to 4.3%) with ZDV plus 3TC/NFV (Arm 3) ($P = 0.046$ compared with Arm 1).  
Overall HIV transmission rates, including in utero infection: 11.0% (8.7% to 14.0%) with ZDV (Arm 1) vs. 7.1% (5.2% to 9.6%) with ZDV plus NVP (Arm 2) ($P = 0.035$ compared with Arm 1) vs. 7.4% (5.4% to 9.9%) with ZDV plus 3TC/NFV (Arm 3) ($P = 0.035$ compared with Arm 1).  
Grade 3 or 4 neutropenia more frequent in ZDV/3TC/NFV Arm 3, 70 infants, compared with ZDV-alone Arm 1, 33 infants, or ZDV/NVP Arm 2, 32 infants ($P <0.001$). |

| ANRS 12174 trial; Burkina Faso, South Africa, Uganda, Zambia; Breastfeeding | Compared two infant ARV prophylaxis regimens during breastfeeding; infants testing PCR-negative at birth, born to mothers with CD4 counts >350 cells/mm$^3$ | As per standard of care | Arm 1: • Daily infant LPV/r from 1 week through 50 weeks of age  
Arm 2: • Daily infant 3TC from 1 week through 50 weeks of age | Postnatal Infection in Infants Uninfected at Birth:  
• Postnatal transmission at age 50 weeks was 1.4% (0.70–2.76) in Arm 1 and 1.5% (0.80–2.91) in Arm 2 ($P = 0.83$).  
• HIV-free survival was 96.5% (84.6–97.7) in Arm 1 and 96.3% (94.4–97.5) in Arm 2 ($P = 0.85$). |

| PROMOTE; Uganda; Breastfeeding | Compared two triple-ARV regimens; no CD4 restriction | Arm 1: • AZT/3TC/LPV/r  
Arm 2: • AZT/3TC/EFV  
• ARVs started at 12–28 weeks’ gestation and continued through labor | Randomized regimen continued postpartum through 1 year of breastfeeding | HIV-free survival was 92.9% in the LPV/r arm vs 97.2% in the EFV arm ($P = 0.10$).  
Only 2 of 374 liveborn infants acquired infection, both in the LPV/r arm. |
Supplemental Table 1. Results of Major Studies on Antiretroviral Prophylaxis to Prevent Perinatal HIV Transmission (page 7 of 7)

<table>
<thead>
<tr>
<th>Study Location(s); Mode of Infant Feeding</th>
<th>Antiretroviral Drugs</th>
<th>Antepartum and Intrapartum</th>
<th>Postpartum</th>
<th>Perinatal Transmission Rate and Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROMISE; India, Malawi, South Africa, Tanzania, Uganda, Zambia, Zimbabwe; breastfeeding and formula feeding (antepartum component)</td>
<td>Compared two ARV regimens during pregnancy among women &gt;14 weeks gestation and CD4 counts ≥350 cells/mm³</td>
<td>Arm 1: • ZDV during pregnancy plus SD NVP plus TDF plus FTC at delivery Arm 2: • ZDV plus 3TC plus LPV/r Arm 3: • TDF plus FTC plus LPV/r</td>
<td>Arm 1: • TDF/FTC tail continued for 6–14 days postpartum Arms 2 and 3: • Triple-drug regimen continued for 6–14 days postpartum Infants received once-daily NVP for 6 weeks.</td>
<td>Infant HIV Infection Rates by Age 14 Days Arm 1: • 1.8% (25/1386) Arm 2: • 0.5% (7/1385) Arm 3: • 0.6% (2/325) Combined triple-ARV arms vs. Arm 1 difference in perinatal transmission risk: -1.28% (95% CI, -2.11% to -0.44%)</td>
</tr>
</tbody>
</table>

Key to Abbreviations: 3TC = lamivudine; ABC = abacavir; AP = antepartum; ARV = antiretroviral; CD4 = CD4 T lymphocyte; CDC = Centers for Disease Control and Prevention; CI = confidence interval; EFV = efavirenz; FTC = emtricitabine; IP = intrapartum; IV = intravenous; LPV/r = ritonavir-boosted lopinavir; NFV = nelfinavir; NVP = nevirapine; PCR = polymerase chain reaction; PP = postpartum; SD = single-dose; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

References


### Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NNRTIs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir (ABC)</td>
<td>Ziagen</td>
<td>Tablet:</td>
<td>Standard Adult Doses:</td>
<td>High placental transfer to fetus. b</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 300 mg</td>
<td>ABC (Ziagen):</td>
<td>No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Solution:</td>
<td>• 300 mg twice daily or 600 mg once daily, without regard to food</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 20 mg/mL</td>
<td>Epzicom:</td>
<td>Hypersensitivity reactions occur in approximately 5% to 8% of non-pregnant individuals; a much smaller percentage are fatal and are usually associated with re-challenge. Rate in pregnancy is unknown. Testing for HLA-B*5701 identifies patients at risk of reactions and should be done and documented as negative before starting ABC. Patients should be educated regarding symptoms of hypersensitivity reaction.</td>
</tr>
<tr>
<td>(3TC/ABC)</td>
<td>Epzicom</td>
<td>Tablet:</td>
<td>Epzicom:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ABC 600 mg plus 3TC 300-mg tablet</td>
<td>• 1 tablet once daily without regard to food</td>
<td></td>
</tr>
<tr>
<td>(ZDV/3TC/ABC)</td>
<td>Trizivir</td>
<td>Tablet:</td>
<td>Trizivir:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ABC 300 mg plus 3TC 150 mg plus ZDV 300-mg tablet</td>
<td>• 1 tablet twice daily without regard to food</td>
<td></td>
</tr>
<tr>
<td>(DTG/ABC/3TC)</td>
<td>Triumeq</td>
<td>Tablet:</td>
<td>Triumeq:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DTG 50 mg plus ABC 600 mg plus 3TC 300-mg tablet</td>
<td>• 1 tablet daily without regard to food</td>
<td></td>
</tr>
<tr>
<td><strong>Didanosine</strong></td>
<td>ddI (Videx)</td>
<td>Buffered Tablets (Non-EC):</td>
<td>Standard Adult Doses</td>
<td>Low-moderate placental transfer to fetus. b</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No longer available</td>
<td>Body Weight ≥60 kg:</td>
<td>In the APR, an increased rate of birth defects with ddI compared to general population was noted after both first-trimester (20/423, 4.7%; 95% CI, 2.9% to 7.2%) and later exposure (20/461, 4.3%; 95% CI 2.7% to 6.6%). No specific pattern of defects was noted and clinical relevance is uncertain.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Solution:</td>
<td>• 400 mg once daily</td>
<td>ddI should not be used with d4T. Lactic acidosis, sometimes fatal, has been reported in pregnant women receiving ddI and d4T together.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 10 mg/mL oral solution</td>
<td>With TDF:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Videx EC (EC Beadlets) Capsules:</td>
<td>• 250 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 125 mg</td>
<td>Body Weight &lt;60kg:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 200 mg</td>
<td>• 250 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 250 mg</td>
<td>With TDF:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 400 mg</td>
<td>• 200 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Generic Delayed-Release Capsules:</td>
<td>With TDF:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 200 mg</td>
<td>• 200 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 250 mg</td>
<td>take 1/2 hour before or 2 hours after a meal.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 400 mg</td>
<td>take 1/2 hour before or 2 hours after a meal.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Note:</td>
<td>Preferred dosing with oral solution is twice daily (total daily dose divided into 2 doses); take 1/2 hour before or 2 hours after a meal.</td>
<td></td>
</tr>
</tbody>
</table>

**Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States**

April 29, 2016
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy\(^a\) (page 2 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Emtricitabine (FTC) Emtriva</strong></td>
<td>Capsules: 200 mg</td>
<td>PK in Pregnancy: • PK not significantly altered in pregnancy. Dosing in Pregnancy: • No change in dose indicated.</td>
<td>High placental transfer to fetus.(^b)</td>
<td>June 7, 2016</td>
</tr>
<tr>
<td><strong>(FTC/TDF) Truvada</strong></td>
<td>Oral Solution: 10 mg/mL</td>
<td>Standard Adult Dose(s) Emtriva (FTC) Capsule: • 200 mg once daily without regard to food</td>
<td>No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects). If HBV-coinfected, it is possible that a HBV flare may occur if the drug is stopped; see HIV/Hepatitis B Virus Coinfection.</td>
<td></td>
</tr>
<tr>
<td><strong>(FTC/TDF/EFV) Atripla</strong></td>
<td>Truvada: • FTC 200 mg plus TDF 300 mg tablet Atripla: • FTC 200 mg plus TDF 300 mg plus EFV 600 mg tablet</td>
<td>Atripla: • 1 tablet once daily at or before bedtime. Take on an empty stomach to reduce side effects.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(FTC/TDF/RPV) Complera</strong></td>
<td>Complera: • FTC 200 mg plus TDF 300 mg plus RPV 25 mg tablet</td>
<td>Complera: • 1 tablet once daily with food</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(FTC/TDF/EVG/COBI) Stribild</strong></td>
<td>Stribild: • FTC 200 mg plus TDF 300 mg plus EVG 150 mg plus COBI 150 mg tablet</td>
<td>Stribild: • 1 tablet once daily with food</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(FTC/TAF/RPV) Odefsey</strong></td>
<td>Odefsey: • FTC 200 mg plus TAF 25 mg plus RPV 25 mg tablet</td>
<td>Odefsey: • 1 tablet once daily with food</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(FTC/TAF/EVG/COBI) Genvoya</strong></td>
<td>Genvoya: • FTC 200 mg plus TAF 10 mg plus EVG 150 mg plus COBI 150 mg tablet</td>
<td>Genvoya: • 1 tablet once daily with food</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lamivudine</strong></td>
<td>3TC (Epivir) Tablets: • 150 mg • 300 mg Oral Solution: • 10 mg/mL <strong>Combivir</strong>: • 3TC 150 mg plus ZDV 300 mg tablet <strong>Epzicom</strong>: • 3TC 300 mg plus ABC 600 mg tablet <strong>Trizivir</strong>: • 3TC 150 mg plus ZDV 300 mg plus ABC 300 mg tablet <strong>Triumeq</strong>: • 3TC 300 mg plus ABC 600 mg plus DTG 50-mg tablet</td>
<td><strong>Standard Adult Dose(s)</strong> 3TC (Lamivudine): • 150 mg twice daily or 300 mg once daily, without regard to food <strong>Combivir</strong>: • 1 tablet twice daily without regard to food <strong>Epzicom</strong>: • 1 tablet once daily without regard to food <strong>Trizivir</strong>: • 1 tablet twice daily without regard to food <strong>Triumeq</strong>: • 1 tablet once daily without regard to food</td>
<td>High placental transfer to fetus.(^b) No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects). If HBV-coinfected, it is possible that an HBV flare may occur if the drug is stopped; see <a href="#">HIV/Hepatitis B Virus Coinfection</a>.</td>
<td>June 7, 2016</td>
</tr>
<tr>
<td><strong>Stavudine</strong></td>
<td>d4T (Zerit) Capsules: • 15 mg • 20 mg • 30 mg • 40 mg Oral Solution: • 1 mg/mL following reconstitution</td>
<td><strong>Standard Adult Dose(s)(^d)</strong> Body Weight ≥60 kg: • 40 mg twice daily without regard to meals Body Weight &lt;60 kg: • 30 mg twice daily without regard to meals <strong>PK in Pregnancy</strong>: • PK not significantly altered in pregnancy. <strong>Dosing in Pregnancy</strong>: • No change in dose indicated.</td>
<td>High placental transfer.(^b) No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects). d4T should not be used with ddI or ZDV. Lactic acidosis, sometimes fatal, has been reported in pregnant women receiving ddI and d4T together.</td>
<td>June 7, 2016</td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir Disoproxil Fumarate (TDF) Viread</td>
<td>TDF (Viread)</td>
<td>Standard Adult Dose</td>
<td>High placental transfer to fetus.(^b)</td>
<td>June 7, 2016</td>
</tr>
<tr>
<td>(TDF/FTC) Truvada</td>
<td>Tablet: • 300 mg</td>
<td>TDF (Viread) Tablet: • 300 mg once daily without regard to food</td>
<td>No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects).</td>
<td></td>
</tr>
<tr>
<td>(TDF/FTC/EFV) Atripla</td>
<td>Powder: • 40 mg/1 g oral powder</td>
<td>Powder: • 8 mg/kg (up to maximum 300 mg), take with food</td>
<td>Studies in monkeys (at doses approximately 2-fold higher than that for human therapeutic use) show decreased fetal growth and reduction in fetal bone porosity within 2 months of starting maternal therapy. Human studies demonstrate no effect on intrauterine growth, but data are conflicting about potential effects on growth outcomes later in infancy.</td>
<td></td>
</tr>
<tr>
<td>(TDF/FTC/RPV) Complera</td>
<td>Truvada: • TDF 300 mg plus FTC 200 mg tablet</td>
<td>Truvada: • 1 tablet once daily without regard to food</td>
<td>If HBV-coinfected, it is possible that an HBV flare may occur if TDF is stopped; see HIV/Hepatitis B Virus Coinfection.</td>
<td></td>
</tr>
<tr>
<td>(TDF/FTC/EVG/COBI) Stribild</td>
<td>Atripla: • TDF 300 mg plus FTC 200 mg plus EFV(^c) 600 mg tablet</td>
<td>Atripla: • 1 tablet once daily at or before bedtime. Take on an empty stomach to reduce side effects.</td>
<td>Renal function should be monitored because of potential for renal toxicity.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Complera: • TDF 300 mg plus FTC 200 mg plus RPV 25 mg tablet</td>
<td>Complera: • 1 tablet once daily with food</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stribild: • TDF 300 mg plus FTC 200 mg plus EVG 150 mg plus COBI 150 mg tablet</td>
<td>Stribild: • 1 tablet once daily with food</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PK in Pregnancy: • AUC lower in third trimester than postpartum but trough levels adequate</td>
<td>Dosing in Pregnancy: • No change in dose indicated.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy\textsuperscript{a} (page 5 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine (AZT, ZDV) Retrovir</td>
<td>ZDV (Retrovir) Capsule: • 100 mg Tablet: • 300 mg Oral Solution: • 10 mg/mL Intravenous Solution: • 10 mg/mL Combivir: • ZDV 300 mg plus 3TC 150 mg tablet Trizivir: • ZDV 300 mg plus 3TC 150 mg plus ABC 300 mg tablet</td>
<td>Standard Adult Dose(s) ZDV (Retrovir): • 300 mg BID or 200 mg TID, without regard to food Active Labor: • 2 mg/kg IV loading dose, followed by 1 mg/kg/hour continuous infusion from beginning of active labor until delivery Combivir: • Tablet twice daily, without regard to food Trizivir: • Tablet twice daily, without regard to food PK in Pregnancy: • PK not significantly altered in pregnancy. Dosing in Pregnancy: • No change in dose indicated.</td>
<td>High placental transfer to fetus\textsuperscript{b} No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects).</td>
<td>August 6, 2015</td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancya (page 6 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NNRTI Drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NNRTIs are recommended for use in combination regimens with 2 NRTI drugs. Hypersensitivity reactions, including hepatic toxicity and rash, more common in women; unclear if increased in pregnancy.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efavirenz (EFV) Sustiva (EFV/TDF/FTC) Atripla</td>
<td>EFV (Sustiva) Capsules: • 50 mg • 200 mg Tablet: • 600 mg Atripla: • EFV 600 mg plus TDF 300 mg plus FTC 200 mg tablet</td>
<td>Standard Adult Dose EFV (Sustiva): • 600 mg once daily at or before bedtime, on empty stomach to reduce side effects Atripla: • 1 tablet once daily at or before bedtime, on empty stomach to reduce side effects PK in Pregnancy: • AUC decreased during third trimester, compared with postpartum, but nearly all third-trimester participants exceeded target exposure. Dosing in Pregnancy: • No change in dose indicated.</td>
<td>Moderate placental transfer to fetus.b Potential fetal safety concern: cynomolgus monkeys receiving EFV during the first trimester at a dose resulting in plasma levels comparable to systemic human therapeutic exposure had 3 of 20 infants with significant CNS or other malformations. In humans, there is no increase in overall birth defects with first-trimester EFV exposure. However, in humans with first-trimester exposure, there have been 6 retrospective case reports and 1 prospective case report of CNS defects and 1 prospective case report of anophthalmia with facial clefts. The relative risk with first-trimester exposure is unclear. Non-pregnant women of childbearing potential should undergo pregnancy testing before EFV initiation and counseling about potential risk to the fetus and desirability of avoiding pregnancy while on EFV-containing regimens. Alternate ARV regimens that do not include EFV should be strongly considered in women who are planning to become pregnant or who are sexually active and not using effective contraception. Because the risk of neural tube defects is restricted to the first 5–6 weeks of</td>
<td>August 6, 2015</td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etravirine (ETR) Intelence</td>
<td>Tablets:</td>
<td>Standard Adult Dose(s):</td>
<td>Variable placental transfer, usually in the moderate to high categories, ranging from 0.19–4.25 (data from 18 mother-infant pairs). Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
<td>April 29, 2016</td>
</tr>
<tr>
<td></td>
<td>• 25 mg</td>
<td>• 200 mg twice daily with food</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 100 mg</td>
<td>• PK data in pregnancy (n = 26) suggest 1.2–1.6 fold increased etravirine exposure during pregnancy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 200 mg</td>
<td>• No change in dose indicated.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For patients unable to swallow tablets whole, the tablets may be dispersed in a glass of water.

pregnancy and pregnancy is rarely recognized before 4–6 weeks of pregnancy, and unnecessary ARV drug changes during pregnancy may be associated with loss of viral control and increased risk of perinatal transmission, EFV may be continued in pregnant women receiving an EFV-based regimen who present for antenatal care in the first trimester (see HIV-Infected Pregnant Women Who are Currently Receiving Antiretroviral Treatment).
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy\(^a\) (page 8 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nevirapine (NVP)</td>
<td>NVP (Viramune) Tablets: • 200 mg Oral Suspension: • 50 mg/5 mL Viramune XR Tablets: • 100 mg • 400 mg</td>
<td>Standard Adult Dose: • 200 mg once daily Viramune immediate release for 14 days (lead-in period); thereafter, 200 mg twice daily or 400 mg (Viramune XR tablet) once daily, without regard to food. • Repeat lead-in period if therapy is discontinued for &gt;7 days. • In patients who develop mild-to-moderate rash without constitutional symptoms during lead-in, continue lead-in dosing until rash resolves, but ≤28 days total. PK in Pregnancy: • PK not significantly altered in pregnancy. Dosing in Pregnancy: • No change in dose indicated.</td>
<td>High placental transfer to fetus.(^b) No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects and 2-fold increase in risk of birth defects in more common classes, cardiovascular and genitourinary). Increased risk of symptomatic, often rash-associated, and potentially fatal liver toxicity among women with CD4 counts ≥250/mm(^3) when first initiating therapy; pregnancy does not appear to increase risk. NVP should be initiated in pregnant women with CD4 cell counts ≥250 cells/mm(^3) only if benefit clearly outweighs risk because of potential increased risk of life-threatening hepatotoxicity in women with high CD4 cell counts. Elevated transaminase levels at baseline may increase the risk of NVP toxicity. Women who become pregnant while taking NVP-containing regimens and are tolerating them well can continue therapy, regardless of CD4 cell count.</td>
<td>June 7, 2016</td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancya  (page 9 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rilpivirine (RPV) Endurant</td>
<td>RPV (Endurant) Tablets: • 25 mg Complera: • RPV 25 mg plus TDF 300 mg plus FTC 200 mg tablet</td>
<td>Standard Adult Dose RPV (Endurant): • 25 mg once daily with food Complera: • 1 tablet once daily with food PK in Pregnancy: • RPV PK highly variable during pregnancy. RPV AUC and trough concentration reduced 20% to 30% in pregnancy compared with postpartum, but most pregnant women exceeded target exposure. Dosing in Pregnancy: • Routine dosing adjustment in all women is not recommended for RPV during pregnancy. Individual patients should be closely monitored.</td>
<td>Moderate to high placental transfer to fetus.b No evidence of teratogenicity in rats or rabbits. Insufficient data to assess for teratogenicity in humans.</td>
<td>June 7, 2016</td>
</tr>
</tbody>
</table>
### Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protease Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Must be combined with low-dose RTV boosting in pregnancy

<table>
<thead>
<tr>
<th><strong>Atazanavir (ATV)</strong> Reyataz</th>
<th>Atazanavir (Reyataz)</th>
<th>Standard Adult Dose</th>
<th>Low placental transfer to fetus. (^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capsules:</strong></td>
<td></td>
<td>Atazanavir (Reyataz)</td>
<td>No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects).</td>
</tr>
<tr>
<td>• 100 mg</td>
<td></td>
<td>ARV-Naive Patients</td>
<td>Must be given as low-dose RTV-boosted regimen in pregnancy.</td>
</tr>
<tr>
<td>• 150 mg</td>
<td></td>
<td>Without RTV Boosting:</td>
<td>Effect of in utero ATV exposure on infant indirect bilirubin levels is unclear. Non-pathologic elevations of neonatal hyperbilirubinemia have been observed in some but not all clinical trials to date.</td>
</tr>
<tr>
<td>• 200 mg</td>
<td></td>
<td>• ATV 400 mg once daily with food; ATV without RTV boosting is not recommended when used with TDF, (H_2)-receptor antagonists, or PPIs, or during pregnancy.</td>
<td>Oral powder (but not capsules) contains phenylalanine, which can be harmful to patients with phenylketonuria.</td>
</tr>
<tr>
<td>• 300 mg</td>
<td></td>
<td>With RTV Boosting:</td>
<td></td>
</tr>
<tr>
<td>Oral Powder:</td>
<td></td>
<td>• ATV 300 mg plus RTV 100 mg once daily with food</td>
<td></td>
</tr>
<tr>
<td>• 50 mg packet</td>
<td></td>
<td>When combined with EFV in ARV-naive patients: ATV 400 mg plus RTV 100 mg once daily with food</td>
<td></td>
</tr>
</tbody>
</table>

**Atazanavir/ Cobicistat (ATV/COBI)** Evotaz

| **Evotaz:**                  | Atazanavir/ Cobicistat (ATV/COBI) Evotaz | ARV-Experienced Patients: |                                                          |
|-----------------------------|-----------------------------------------|• ATV 300 mg plus RTV 100 mg once daily with food |                                                          |
|                            | • ATV 300 mg plus RTV 100 mg once daily with food | • Do not use with PPIs or EFV. |                                                          |
|                            | • If combined with an \(H\_2\)-receptor antagonist: ATV 300 mg plus RTV 100 mg once daily with food | • If combined with an \(H\_2\)-receptor antagonist and TDF: ATV 400 mg plus RTV 100 mg once daily with food |                                                          |
|                            | • If combined with an \(H\_2\)-receptor antagonist and TDF: ATV 400 mg plus RTV 100 mg once daily with food | Powder Formulation: |                                                          |
|                            |                                          | • Oral powder is taken once daily with food at the same recommended adult dosage as the capsules along with ritonavir. |                                                          |

**Evotaz:**

| One tablet once daily with food. | PK in Pregnancy Atazanavir (Reyataz): |                                                          |

\(^b\) June 7, 2016

**Protease Inhibitors**

PIs are recommended for use in combination regimens with 2 NRTI drugs. Hyperglycemia, new onset or exacerbation of diabetes mellitus, and diabetic ketoacidosis reported with PI use; unclear if pregnancy increases risk. Conflicting data regarding preterm delivery in women receiving PIs (see [Combination Antiretroviral Drug Regimens and Pregnancy Outcomes](http://aidsinfo.nih.gov/guidelines)).
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancya  (page 10 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>• ATV concentrations reduced during pregnancy; further reduced when given concomitantly with TDF or H2-receptor antagonist. Evotaz: • No PK studies in human pregnancy.</td>
<td>Atazanavir (Reyataz): • Use of unboosted ATV is not recommended during pregnancy. • Use of ATV not recommended for treatment-experienced pregnant women taking TDF and an H2-receptor antagonist. • Use of an increased dose (400 mg ATV plus 100 mg RTV once daily with food) during the second and third trimesters results in plasma concentrations equivalent to those in non-pregnant adults on standard dosing. Although some experts recommend increased ATV dosing in all women during the second and third trimesters, the package insert recommends increased ATV dosing only for ARV-experienced pregnant women in the second and third trimesters also receiving either TDF or an H2-receptor antagonist. Evotaz: • Insufficient data to make dosing recommendation.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darunavir (DRV) Prezista</td>
<td></td>
<td>Standard Adult Dose</td>
<td>Low placental transfer to fetus.(^b)</td>
<td>August 6, 2015</td>
</tr>
<tr>
<td>Note: Must be combined with low-dose ritonavir (RTV) or cobicistat (COBI) boosting</td>
<td></td>
<td>ARV-Naive Patients:</td>
<td>No evidence of teratogenicity in mice, rats, or rabbits. No evidence of human teratogenicity.</td>
<td></td>
</tr>
<tr>
<td>Darunavir/ Cobicistat (DRV/COBI) Prezcobix</td>
<td></td>
<td>ARV-Experienced Patients:</td>
<td>Must be given as low-dose, RTV-boosted regimen.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tablets:</td>
<td>If No DRV Resistance Mutations:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 75 mg</td>
<td>• DRV 800 mg plus RTV 100 mg once daily with food</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 150 mg</td>
<td>• DRV 800 mg plus COBI 150 mg once daily with food</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 600 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 800 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Suspension:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 100 mg/mL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tablet (Co-Formulated):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• DRV 800 mg plus COBI 150 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dosing in Pregnancy:
- Once-daily dosing with DRV/RTV is not recommended during pregnancy. Twice-daily DRV/RTV dosing recommended for all pregnant women. Increased twice-daily DRV dose (DRV 800 mg plus RTV 100 mg with food) during pregnancy is being investigated.
- No pregnancy PK/safety data for DRV/COBI co-formulation, so not recommended for use in pregnancy.
### Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
</table>
| Fosamprenavir (FPV) Lexiva (a prodrug of amprenavir) | Tablets: • 700 mg Oral Suspension: • 50 mg/mL | **Standard Adult Dose**  
ARV-Naive Patients:  
• FPV 1400 mg twice daily without food, or  
• FPV 1400 mg plus RTV 100 or 200 mg once daily without food, or  
• FPV 700 mg plus RTV 100 mg twice daily without food  
PI-Experienced Patients (Once-Daily Dosing Not Recommended):  
• FPV 700 mg plus RTV 100 mg twice daily without food  
Co-Administered with EFV:  
• FPV 700 mg plus RTV 100 mg twice daily without food; or  
• FPV 1400 mg plus RTV 300 mg once daily without food  
**PK in Pregnancy:**  
• With RTV boosting, AUC is reduced during the third trimester. However, exposure is greater during the third trimester with boosting than in non-pregnant adults without boosting, and trough concentrations achieved during the third trimester were adequate for patients without PI resistance mutations.  
**Dosing in Pregnancy:**  
• Use of unboosted FPV or once-daily FPV with RTV boosting is **not recommended** during pregnancy. No change is indicated in standard boosted twice-daily dose (FPV 700 mg plus RTV 100 mg twice daily without food). | Low placental transfer to fetus. b  
Insufficient data to assess for teratogenicity in humans. Increased fetal loss in rabbits but no increase in defects in rats and rabbits. Must be given as low-dose RTV-boosted regimen in pregnancy. | June 7, 2016 |
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indinavir (IDV) Crixivan</td>
<td></td>
<td>Capsules:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 400 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Must be combined with low-dose RTV boosting in pregnancy

**Indinavir**: Must be combined with low-dose RTV boosting in pregnancy.

**Indinavir**: Use of unboosted IDV is **not recommended** during pregnancy.

**PK in Pregnancy**:
- IDV exposure markedly reduced when administered without RTV boosting during pregnancy.
- IDV exposure low with IDV 400 mg/RTV 100 mg dosing during pregnancy; no PK data available on alternative boosted dosing regimens in pregnancy.

**Dosing in Pregnancy**:
- Use of unboosted IDV is **not recommended** during pregnancy.

**Use in Pregnancy**:
- Minimal placental transfer to fetus.
- No evidence of human teratogenicity in cases reported to the APR (can rule out 2-fold increase in overall birth defects).
- Must be given as low-dose, RTV-boosted regimen in pregnancy.
- Theoretical concern regarding increased indirect bilirubin levels, which may exacerbate physiologic hyperbilirubinemia in neonates. Minimal placental passage mitigates this concern.

**Last Reviewed**: June 7, 2016
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy<sup>a</sup> (page 14 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
</table>
| Lopinavir/ Ritonavir (LPV/r) | Kaletra    | Tablets (Co-Formulated):  
• LPV 200 mg plus RTV 50 mg  
• LPV 100 mg plus RTV 25 mg  
Oral Solution:  
• LPV 400 mg plus RTV 100 mg/5 mL | Standard Adult Dose:  
• LPV 400 mg plus RTV 100 mg twice daily, or  
• LPV 800 mg plus RTV 100 mg once daily  
Tablets:  
• Take without regard to food.  
Oral Solution:  
• Take with food.  
With EFV or NVP (PI-Naive or PI-Experienced Patients):  
• LPV 500 mg plus RTV 125 mg tablets twice daily without regard to meals (use a combination of two LPV 200 mg plus RTV 50 mg tablets and one LPV 100 mg plus RTV 25 mg tablet), or  
• LPV 533 mg plus RTV 133 mg oral solution (6.5 mL) twice daily with food  
PK in Pregnancy:  
• With twice-daily dosing, LPV exposure is reduced in pregnant women receiving standard adult doses; increasing the dose by 50% results in exposure equivalent to that seen in non-pregnant adults receiving standard doses.  
• No PK data are available for once-daily dosing in pregnancy.  
Dosing in Pregnancy:  
• Once daily dosing is not recommended during pregnancy.  
• Some experts recommend that an increased dose (i.e., LPV 600 mg plus RTV 150 mg twice daily without regard to meals) should be used in the second and third trimesters, especially in PI-experienced pregnant women and women who start treatment during pregnancy with a baseline viral load >50 copies/mL.  
• If standard dosing is used, monitor virologic response and LPV drug levels, if available. | Low placental transfer to fetus.<sup>b</sup>  
No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects).  
Oral solution contains 42% alcohol and 15% propylene glycol and is not recommended for use in pregnancy.  
Once-daily LPV/r dosing is not recommended during pregnancy. | August 6, 2015 |
### Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelfinavir (NFV) Viracept</td>
<td></td>
<td>Tablets:</td>
<td>Standard Adult Dose:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 250 mg</td>
<td>• 1250 mg twice daily or 750 mg three times daily with food</td>
<td>Minimal to low placental transfer to fetus.&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 625 mg</td>
<td>PK in Pregnancy:</td>
<td>No evidence of human teratogenicity; can rule out 1.5-fold increase in overall birth defects and 2-fold increase in risk of birth defects in more common classes, cardiovascular, and genitourinary.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Tablets can be dissolved in small amount of water.)</td>
<td>• Lower NFV exposure in third trimester than postpartum in women receiving NFV 1250 mg twice daily; however, generally adequate drug levels are achieved during pregnancy, although levels are variable in late pregnancy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Powder for Oral Suspension:</td>
<td>Dosing in Pregnancy:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 50 mg/g</td>
<td>• Three-times-daily dosing with 750 mg with food not recommended during pregnancy. No change in standard dose (1250 mg twice daily with food) indicated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>June 7, 2016</td>
</tr>
<tr>
<td>Saquinavir (SQV) Invirase</td>
<td></td>
<td>Tablet:</td>
<td>Standard Adult Dose:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 500 mg</td>
<td>• SQV 1000 mg plus RTV 100 mg twice a day with food or within 2 hours after a meal</td>
<td>Low placental transfer to fetus.&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Note: Must be combined with low-dose RTV for PK boosting</td>
<td>Capsule:</td>
<td>• 200 mg</td>
<td>PK in Pregnancy:</td>
<td>Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Based on limited data, SQV exposure may be reduced in pregnancy but not sufficient to warrant a dose change.</td>
<td>Must be boosted with low-dose RTV.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dosing in Pregnancy:</td>
<td>Baseline ECG recommended before starting because PR and/or QT interval prolongations have been observed. Contraindicated in patients with preexisting cardiac conduction system disease.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• No change in dose indicated.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

<sup>b</sup> Minimal to low placental transfer to fetus.
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy\(^\text{a}\) (page 16 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tipranavir (TPV) Aptivus</strong></td>
<td>Capsules: • 250 mg Oral Solution: • 100 mg/mL</td>
<td><strong>Standard Adult Dose:</strong> • TPV 500 mg plus RTV 200 mg twice daily <strong>With RTV Tablets:</strong> • Take with food. <strong>With RTV Capsules or Solution:</strong> • Take without regard to food; however, administering with food may help make the dose more tolerable. <strong>PK in Pregnancy:</strong> • Limited PK data in human pregnancy. <strong>Dosing in Pregnancy:</strong> • Insufficient data to make dosing recommendation.</td>
<td>Moderate placental transfer to fetus reported in one patient.(^\text{b}) Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits. Must be given as low-dose RTV-boosted regimen.</td>
<td>June 7, 2016</td>
</tr>
</tbody>
</table>

**Entry Inhibitors**

| Enfuvirtide (T20) Fuzeon | Injectable: • Supplied as lyophilized powder. Each vial contains 108 mg of T20; reconstitute with 1.1 mL of sterile water for injection for SQ delivery of approximately 90 mg/1 mL. | **T20 is indicated for advanced HIV disease and must be used in combination with other ARVs to which the patient’s virus is susceptible by resistance testing.** **Standard Adult Dose:** • 90 mg (1 mL) twice daily without regard to meals **PK in Pregnancy:** • No PK data in human pregnancy. **Dosing in Pregnancy:** • Insufficient data to make dosing recommendation. | Minimal to low placental transfer to fetus.\(^\text{b}\) No data on human teratogenicity. | August 6, 2015 |
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Maraviroc (MVC) Selzentry</strong></td>
<td>Tablets:</td>
<td>Standard Adult Dose:</td>
<td></td>
<td>August 6, 2015</td>
</tr>
<tr>
<td></td>
<td>• 150 mg</td>
<td>• 300 mg twice daily with or without food</td>
<td>No evidence of teratogenicity in rats or rabbits.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 300 mg</td>
<td>• Maraviroc must be used in combination with other ARVs in HIV-1-infected adults with only CCR5-tropic virus.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Dose Adjustments:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increase to 600 mg BID when used with potent CYP3A inducers: EFV, ETR, and rifampin.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Decrease to 150 mg BID when used with CYP3A inhibitors: all PIs except tipranavir/ritonavir, itraconazole.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>PK in Pregnancy:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No PK studies in human pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Dosing in Pregnancy:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Insufficient data to make dosing recommendation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Integrase Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(DTG/ABC/3TC) Triumeq</strong></td>
<td>• 50 mg</td>
<td>ARV-Naive or ARV-Experienced but Integrase Inhibitor-Naive Patients DTG (Tivicay):</td>
<td>Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in mice, rats, or rabbits.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Triumeq:</td>
<td>• 1 tablet once daily, without regard to food.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• DTG 50 mg plus ABC 600 mg plus 300-mg 3TC tablet</td>
<td>DTG/ABC/3TC (Triumeq):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1 tablet once daily, without regard to food.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ARV-Naive or ARV-Experienced (but Integrase Inhibitor-Naive) if Given with EFV, FPV/r, TPV/r, or Rifampin; or Integrase Inhibitor-Experienced DTG (Tivicay):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1 tablet twice daily, without regard to food.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>PK in Pregnancy:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Limited PK data in human pregnancy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Dosing in Pregnancy:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Insufficient data to make dosing recommendation.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy\(^a\) (page 18 of 20)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
</table>
| Elvitegravir (EVG)          | Vitekta    | Tablet (Vitekta): | • 85 mg  
• 150 mg | Standard Adult Dose (Vitekta):  
• EVG (as Vitekta) must be used in combination with an HIV PI co-administered with RTV and another ARV drug.  
Recommended Elvitegravir Dosage Taken Once Daily with Food (All Drugs Administered Orally) | No data on placental transfer of EVG/COBI are available.  
Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits. | August 6, 2015 |
| Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/ TDF) | Stribild | Tablet (Stribild):  
• EVG 150 mg plus COBI 150 mg plus FTC 200 mg plus TDF 300 mg | Dosage of Elvitegravir  
85 mg once daily  
150 mg once daily | Dosage of Concomitant PI  
Atazanavir 300 mg once daily  
Lopinavir 400 mg twice daily | Dosage of Concomitant RTV  
100 mg once daily  
100 mg twice daily | |
| Dosage of Elvitegravir  
85 mg once daily  
150 mg once daily | Dosage of Concomitant PI  
Atazanavir 300 mg once daily  
Lopinavir 400 mg twice daily | Dosage of Concomitant RTV  
100 mg once daily  
100 mg twice daily | |
| Dosage of Elvitegravir  
85 mg once daily  
150 mg once daily | Dosage of Concomitant PI  
Atazanavir 300 mg once daily  
Lopinavir 400 mg twice daily | Dosage of Concomitant RTV  
100 mg once daily  
100 mg twice daily | |
| Dosage of Elvitegravir  
85 mg once daily  
150 mg once daily | Dosage of Concomitant PI  
Atazanavir 300 mg once daily  
Lopinavir 400 mg twice daily | Dosage of Concomitant RTV  
100 mg once daily  
100 mg twice daily | |
| Dosage of Elvitegravir  
85 mg once daily  
150 mg once daily | Dosage of Concomitant PI  
Atazanavir 300 mg once daily  
Lopinavir 400 mg twice daily | Dosage of Concomitant RTV  
100 mg once daily  
100 mg twice daily | |
| Dosage of Elvitegravir  
85 mg once daily  
150 mg once daily | Dosage of Concomitant PI  
Atazanavir 300 mg once daily  
Lopinavir 400 mg twice daily | Dosage of Concomitant RTV  
100 mg once daily  
100 mg twice daily | |
### Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name ( Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raltegravir</td>
<td>Isentress</td>
<td>Film-Coated Tablets: • 400 mg</td>
<td>Standard Adult Dose: • 400 mg twice daily without regard to food</td>
<td>High placental transfer to fetus. Insufficient data to assess for teratogenicity in humans. Increased skeletal variants in rats, no increase in defects in rabbits. Case report of markedly elevated liver transaminases with use in late pregnancy. Severe, potentially life-threatening and fatal skin and hypersensitivity reactions have been reported in non-pregnant adults. Chewable tablets contain phenylalanine.</td>
<td>August 6, 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chewable Tablets: • 25 mg • 100 mg</td>
<td>With Rifampin: • 800 mg twice daily without regard to food</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PK in Pregnancy: • Decreased levels in third trimester not of sufficient magnitude to warrant change in dosing.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dosing in Pregnancy: • No change in dose indicated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacoenhancers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cobicistat</td>
<td>Tybost</td>
<td>Tablet (Tybost): • 150mg</td>
<td>Standard Adult Dose Tybost: • As an alternative PK booster with atazanavir or darunavir: One tablet (150 mg) once daily with food. Stribild, Evotaz, Prezcobix: • One tablet once daily with food. PK in Pregnancy: • No PK studies in human pregnancy. Dosing in Pregnancy: • Insufficient data to make dosing recommendation.</td>
<td>No data on placental transfer of COBI are available. Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
<td>August 6, 2015</td>
</tr>
<tr>
<td>Elvitegravir/Cobicistat</td>
<td></td>
<td>Tablet (Stribild): • EVG 150 mg plus COBI 150 mg plus TDF 300 mg plus FTC 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenofovir Disoproxil Fumarate/Emtricitabine</td>
<td>Stribild</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir/Cobicistat</td>
<td>Evotaz</td>
<td>Tablet (Evotaz): • ATV 300 mg plus COBI 150 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir/Cobicistat</td>
<td>Prezcobix</td>
<td>Tablet (Prezcobix): • DRV 800 mg plus COBI 150 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablet (Tybost): • 150mg</td>
<td>Standard Adult Dose Tybost: • As an alternative PK booster with atazanavir or darunavir: One tablet (150 mg) once daily with food. Stribild, Evotaz, Prezcobix: • One tablet once daily with food. PK in Pregnancy: • No PK studies in human pregnancy. Dosing in Pregnancy: • Insufficient data to make dosing recommendation.</td>
<td>No data on placental transfer of COBI are available. Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
<td>August 6, 2015</td>
</tr>
</tbody>
</table>
Table 7. Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
<th>Last Reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ritonavir (RTV) Norvir</td>
<td>Capsules: • 100 mg Tablets: • 100 mg Oral Solution: • 80 mg/mL</td>
<td>Standard Adult Dose as PK Booster for Other PIs: • 100–400 mg per day in 1–2 divided doses (refer to other PIs for specific dosing recommendations.) Tablet: • Take with food. Capsule or Oral Solution: • To improve tolerability, recommended to take with food if possible. PK in Pregnancy: • Lower levels during pregnancy compared with postpartum. Dosing in Pregnancy: No dosage adjustment necessary when used as booster.</td>
<td>Low placental transfer to fetus. No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects). Should only be used as low dose booster for other PIs. Oral solution contains 43% alcohol and therefore may not be optimal for use in pregnancy.</td>
<td>June 7, 2016</td>
</tr>
</tbody>
</table>

a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).
b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

High: >0.6
Moderate: 0.3–0.6
Low: <0.3
c See Teratogenicity for discussion of EFV and risks in pregnancy.

4 WHO recommends maximum dose of 30 mg twice daily regardless of weight.

Key to Abbreviations: 3TC = lamivudine; ABC = abacavir; APR = Antiretroviral Pregnancy Registry; ARV = antiretroviral; ATV = atazanavir; AUC = area under the curve; AZT = zidovudine; BID = twice daily; CD4 = CD4 T lymphocyte; CI = confidence interval; CNS = central nervous system; COBI = cobicistat; d4T = stavudine; ddl = didanosine; DTG = dolutegravir; DRV = darunavir; EC = enteric coated; ECG = electrocardiogram; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; FDA = Food and Drug Administration; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HBV = hepatitis B virus; IDV = indinavir; IV = intravenous; LPV = lopinavir; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NFV = nevirapine; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PK = pharmacokinetic; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SQ = subcutaneous; SQV = saquinavir; TDF = tenofovir disoproxil fumarate; TID = three times a day; TPV = tipranavir; TPV/r = tipranavir/ritonavir; T20 = enfuvirtide; WHO = World Health Organization; ZDV = zidovudine
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors

Data are available from clinical trials in human pregnancy for the nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine, abacavir, lamivudine, didanosine, emtricitabine, and stavudine and the nucleotide NRTI tenofovir disoproxil fumarate (TDF). The nucleoside analogue drugs require three intracellular phosphorylation steps to form the triphosphate nucleoside, which is the active drug moiety. TDF, an acyclic nucleotide analogue drug, contains a monophosphate component attached to the adenine base and, hence, requires only two phosphorylation steps to form the active moiety.

For information regarding the nucleoside analogue drug class and potential mitochondrial toxicity in pregnancy and to the infant, see the Recommendations for Use of Antiretroviral Drugs During Pregnancy and Long-Term Follow-Up of Antiretroviral Drug-Exposed Infants section.

Abacavir (Ziagen, ABC)

(Last updated April 29, 2016; last reviewed April 29, 2016)

The available human and animal data suggest that abacavir does not increase the risk of major birth defects overall compared with the background rate.¹

Animal Studies

Carcinogenicity

Abacavir is mutagenic and clastogenic in some in vitro and in vivo assays. In long-term carcinogenicity studies in mice and rats, malignant tumors of the preputial gland of males and the clitoral gland of females were observed in both species, and malignant hepatic tumors and nonmalignant hepatic and thyroid tumors were observed in female rats. The tumors were seen in rodents at doses that were 6 to 32 times that of human therapeutic exposure.¹

Reproduction/Fertility

No effect of abacavir on reproduction or fertility in male and female rodents has been seen at doses of up to 500 mg/kg/day (about 8 times that of human therapeutic exposure based on body surface area).¹

Teratogenicity/Developmental Toxicity

Abacavir is associated with developmental toxicity (decreased fetal body weight and reduced crown-rump length) and increased incidence of fetal anasarca and skeletal malformations in rats treated with abacavir during organogenesis at doses of 1000 mg/kg (about 35 times that of human therapeutic exposure based on area under the curve [AUC]). Toxicity to the developing embryo and fetus (i.e., increased resorptions and decreased fetal body weight) occurred with administration of 500 mg/kg/day of abacavir to pregnant rodents. The offspring of female rats were treated with 500 mg/kg of abacavir, beginning at embryo implantation and ending at weaning. In these animals, an increased incidence of stillbirth and lower body weight was seen throughout life. However, in the rabbit, no evidence of drug-related developmental toxicity was observed and no increase in fetal malformations was observed at doses up to 700 mg/kg (about 8.5 times that of human therapeutic exposure).¹

Placental and Breast Milk Passage

Abacavir crosses the placenta and is excreted into the breast milk of lactating rats.¹ ²
Human Studies in Pregnancy

Pharmacokinetics

A Phase I study of abacavir in pregnant women indicates that the AUC drug concentration during pregnancy was similar to that at 6 to 12 weeks postpartum and in non-pregnant individuals. A population pharmacokinetics (PK) study (266 samples from 150 pregnant women) found no effect of any co-variate (including age, body weight, pregnancy or gestational age) on abacavir PK. Thus, no dose adjustment for abacavir is needed during pregnancy.

Placental and Breast Milk Passage

Placental transfer of abacavir is high, with cord blood to maternal plasma concentration ratios at delivery of approximately 1.0. In the Mma Bana study, at 1 month postpartum, the median breast milk-to-plasma ratio for abacavir was 0.85 in the 15 women tested, and the drug was detected in the plasma of 1 of 9 breastfeeding infants whose mothers were receiving abacavir.

Teratogenicity

In the Antiretroviral Pregnancy Registry, sufficient numbers of first-trimester exposures to abacavir in humans have been monitored to be able to detect at least a 2-fold increase in risk of overall birth defects. No such increase in birth defects has been observed with abacavir. Among cases of first-trimester abacavir exposure reported to the Antiretroviral Pregnancy Registry, the prevalence of birth defects was 2.9% (29 of 993 births; 95% CI, 2.0% to 4.2%) compared with 2.7% in the U.S. population, based on Centers for Disease Control and Prevention surveillance. There was no association of birth defects with first-trimester exposure to abacavir in the SMARTT study (aOR 0.94 [0.53–1.65]), in the French Perinatal Study (aOR 1.01, [0.73–1.41]), or in a series of 897 births to HIV-infected women in Spain between 2000 to 2009 (aOR 0.99, [0.34–2.87]).

Safety

Serious hypersensitivity reactions have been associated with abacavir therapy in non-pregnant adults, but these reactions have rarely been fatal; symptoms include fever, skin rash, fatigue, and gastrointestinal symptoms such as nausea, vomiting, diarrhea, or abdominal pain. Abacavir should not be restarted following a hypersensitivity reaction because more severe symptoms will occur within hours and may include life-threatening hypotension and death. Patients who test positive for HLA-B*5701 are at highest risk; HLA screening should be done before initiation of abacavir. Two meta-analyses have confirmed the association of this genotype and the hypersensitivity reaction.

Excerpt from Table 7a

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abacavir (ABC)</td>
<td>Ziagen</td>
<td>ABC (Ziagen):</td>
<td>Standard Adult Doses:</td>
<td>High placental transfer to fetus. b</td>
</tr>
<tr>
<td>(3TC/ABC) Epzicom</td>
<td></td>
<td>Tablet:</td>
<td>ABC (Ziagen):</td>
<td>No evidence of human teratogenicity</td>
</tr>
<tr>
<td>(ZDV/3TC/ABC) Trizivir</td>
<td></td>
<td>• 300 mg</td>
<td>• 300 mg twice daily or 600 mg once daily, without regard to food</td>
<td>(can rule out 2-fold increase in overall birth defects).</td>
</tr>
<tr>
<td>(DTG/ABC/3TC) Triumeq</td>
<td></td>
<td>Solution:</td>
<td>Epzicom:</td>
<td>Hypersensitivity reactions occur in approximately 5% to 8% of non-pregnant individuals; a much smaller percentage are fatal and are usually associated with re-challenge. Rate in pregnancy is unknown. Testing for HLA-B*5701 identifies patients at risk of reactions and should be done and documented as negative before starting ABC. Patients should be educated regarding symptoms of hypersensitivity reaction.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 20 mg/mL</td>
<td>• 1 tablet once daily without regard to food</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ABC 600 mg plus 3TC 300-mg tablet Trizivir:</td>
<td>• 1 tablet twice daily without regard to food</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trizivir:</td>
<td>Trizivir:</td>
<td>PK not significantly altered in pregnancy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ABC 300 mg plus 3TC 150 mg plus ZDV 300-mg tablet Triumeq:</td>
<td>• PK not significantly altered in pregnancy.</td>
<td>Dosing in Pregnancy:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Triumeq:</td>
<td>Triumeq:</td>
<td>• No change in dose indicated.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DTG 50 mg plus ABC 600 mg plus 3TC 300-mg tablet</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Appendix B, Table 7).

b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

High: >0.6 Moderate: 0.3–0.6 Low: <0.3

Key to Abbreviations: 3TC = lamivudine; ABC = abacavir; DTG = dolutegravir; PK = pharmacokinetic; ZDV = zidovudine

Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

---

References


**Didanosine (Videx, ddI)**

(Last updated April 29, 2016; last reviewed April 29, 2016)

Didanosine is classified as Food and Drug Administration (FDA) Pregnancy Category B.¹

**Animal Studies**

*Carcinogenicity Studies*

Didanosine is both mutagenic and clastogenic in several *in vitro* and *in vivo* assays. Long-term animal carcinogenicity screening studies of 0.7 to 1.7 times human exposure in mice and 3 times human exposure in rats have been negative.²

*Reproduction/Fertility*

At approximately 12 times the estimated human exposure, didanosine was slightly toxic to female rats and their pups during mid and late lactation. These rats showed reduced food intake and body weight gains; however, the physical and functional development of the offspring was not impaired and there were no major changes in the F2 generation.

*Teratogenicity/Developmental Toxicity*

No evidence of teratogenicity or toxicity was observed with administration of didanosine at 12 and 14 times human exposure, respectively, in pregnant rats and rabbits.

*Placental and Breast Milk Passage*

A study in rats showed that didanosine and/or its metabolites are transferred to the fetus through the placenta.

**Human Studies in Pregnancy**

*Pharmacokinetics*

A Phase I study (PACTG 249) of didanosine was conducted in 14 HIV-infected pregnant women enrolled at gestational age 26 to 36 weeks and treated through 6 weeks postpartum.² The drug was well tolerated during pregnancy by the women and the fetuses. Pharmacokinetic (PK) parameters after oral administration were not significantly affected by pregnancy, and dose modification from the usual adult dosage is not needed.

*Placental and Breast Milk Passage*

Placental transfer of didanosine was low-moderate in a Phase I/II safety and PK study.² This was confirmed in a study of 100 HIV-infected pregnant women who were receiving nucleoside reverse transcriptase inhibitors (NRTIs) (generally as part of a two- or three-drug combination antiretroviral [ARV] regimen). At the time of delivery, cord-to-maternal-blood ratio for didanosine (n = 10) was 0.38 (range 0.0–2.0) and in 15 of 24 (62%) samples, cord blood concentrations for didanosine were below the limits of detection.³ It is not known if didanosine is excreted in human breast milk.

*Teratogenicity*

The French Perinatal Cohort reported an association of head and neck birth defects with first-trimester exposure to didanosine (0.5%, AOR = 3.4 (95% Confidence Interval [CI] 1.1–10.4), \( P = 0.04 \)).⁴ The PHACS/SMARTT cohort found no association between any NRTIs and birth defects.⁵ Among 897 births to HIV-infected women in a Spanish cohort, there was no significant difference in the rate of birth defects between first-trimester compared to the second- and third-trimester exposure (OR 0.61, 95% CI, 0.16, 2.27).⁶ Among cases of first-trimester didanosine exposure reported to the Antiretroviral Pregnancy Registry, prevalence of birth defects was 4.7% (20 of 423 births; 95% CI, 2.9% to 7.2%) compared with 2.7% in the U.S. population, based on Centers for Disease Control and Prevention surveillance.⁷ All defects were reviewed in detail by the Registry, and no pattern of defects was discovered. The rate and types of defects will continue to be closely monitored.

*Safety*

Lactic acidosis, fatal in some cases, has been described in pregnant women receiving the combination of...
didanosine and stavudine along with other ARV agents, the FDA and Bristol-Myers Squibb have issued a warning to health care professionals that pregnant women may be at increased risk of fatal lactic acidosis when prescribed didanosine and stavudine in combination.

Excerpt from Table 7

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Didanosine (ddI)</td>
<td>Videx</td>
<td>Buffered Tablets (Non-EC):</td>
<td>Standard Adult Doses</td>
<td>Low-moderate placental transfer to fetus.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No longer available</td>
<td>Body Weight ≥60 kg:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Solution:</td>
<td>• 400 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 10 mg/mL oral solution</td>
<td><strong>With TDF:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Videx EC (EC Beadlets) Capsules:</td>
<td>• 250 mg once daily; take 1/2 hour before or 2 hours after a meal.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 125 mg</td>
<td>Body Weight &lt;60 kg:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 200 mg</td>
<td>• 250 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 250 mg</td>
<td><strong>With TDF:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 400 mg</td>
<td>• 200 mg once daily; take 1/2 hour before or 2 hours after a meal.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Generic Delayed-Release Capsules:</td>
<td><strong>Note:</strong> Preferred dosing with oral solution is twice daily (total daily dose divided into 2 doses); take 1/2 hour before or 2 hours after a meal.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 200 mg</td>
<td>PK in Pregnancy:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 250 mg</td>
<td>• PK not significantly altered in pregnancy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 400 mg</td>
<td>Dosing in Pregnancy:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• No change in dose indicated.</td>
<td></td>
</tr>
</tbody>
</table>

References


a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Appendix B, Table 7).

b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

High: >0.6
Moderate: 0.3–0.6
Low: <0.3

Key to Abbreviations: APR = Antiretroviral Pregnancy Registry; CI = confidence interval; ddI = didanosine; EC = enteric coated; PK = pharmacokinetic; TDF = tenofovir disoproxil fumarate


Emtricitabine (Emtriva, FTC)

(Last updated June 7, 2016; last reviewed June 7, 2016)

Emtricitabine is classified as Food and Drug Administration Pregnancy Category B.

Animal Studies

Carcinogenicity

Emtricitabine was neither mutagenic nor clastogenic in a series of in vitro and animal in vivo screening tests. In long-term carcinogenicity studies of oral emtricitabine, no drug-related increases in tumor incidence were found in mice at doses up to 26 times the human systemic exposure or in rats at doses up to 31 times the human systemic exposure at the therapeutic dose.\(^1\)

Reproduction/Fertility

No effect of emtricitabine on reproduction or fertility was observed with doses that produced systemic drug exposures (as measured by area under the curve [AUC]) approximately 60-fold higher in female and male mice and 140-fold higher in male rats than human exposure at the recommended therapeutic dose.\(^1\)

Teratogenicity/Developmental Toxicity

Incidence of fetal variations and malformations was not increased with emtricitabine dosing in mice that resulted in systemic drug exposure 60-fold higher than observed with human exposure at recommended doses or in rabbits with dosing resulting in drug exposure 120-fold higher than human exposure.\(^1\)

Placental and Breast Milk Passage

Emtricitabine has been shown to cross the placenta in mice and rabbits; the average fetal/maternal drug concentration was 0.4 in mice and 0.5 in rabbits.\(^2\)

Human Studies in Pregnancy

Pharmacokinetics

Emtricitabine pharmacokinetic (PK) parameters have been evaluated in 18 HIV-infected pregnant women receiving antiretroviral therapy including emtricitabine (200 mg once daily) at 30 to 36 weeks’ gestation and 6 to 12 weeks postpartum.\(^3\) Emtricitabine exposure was modestly lower during the third trimester (8.6 mcg*h/mL [5.2–15.9]) compared with the postpartum period (9.8 mcg*h/mL [7.4–30.3]). Two-thirds (12 of 18) of pregnant women versus 100% (14 of 14) of postpartum women met the AUC target (10th percentile in non-pregnant adults). Trough emtricitabine levels were also lower during pregnancy (minimum plasma concentration 52 ng/mL [14–180]) compared with the postpartum period (86 ng/mL [<10 to 306]). In the IMPAACT P1026s study, similar alterations were seen, but the 24-hour, post-dose levels were well above the inhibitory concentration 50% (IC\(_{50}\)) in all patients.\(^4\) Similar differences in PK parameters of emtricitabine among women during pregnancy or after delivery were found in the PACTG 394 study\(^2\) and in a European study.\(^6,7\) The increase in emtricitabine clearance in pregnancy correlated with the normal pregnancy-related increase in glomerular filtration rate.\(^7\) These changes are not believed to be large enough to warrant dosage adjustment during pregnancy.

Placental and Breast Milk Passage

Emtricitabine has been shown to have high placental transfer in pregnant women. In 18 women who received 200 mg emtricitabine once daily during pregnancy, mean cord blood concentration was 300 ± 268 ng/mL and the mean ratio of cord blood/maternal emtricitabine concentrations was 1.17 ± 0.6 (n = 9).\(^3\) In a study of 15 women who received emtricitabine during pregnancy, the mean cord-to-maternal-blood ratio was 1.2 (90% confidence interval [CI], 1.0–1.5).\(^4\) In 8 women who were given a single dose of 600 mg emtricitabine with 900 mg tenofovir disoproxil fumarate (TDF), the median cord blood emtricitabine concentration was 717 ng/mL (range 21–1,072), and the median cord blood/maternal ratio was 0.85 (range 0.46–1.07).\(^5\)

Emtricitabine is excreted into human milk. In a study in the Ivory Coast, 5 HIV-infected women who exclusively breastfed their newborn infants were given 400 mg emtricitabine, 600 mg TDF, and 200 mg
nevirapine at onset of labor, followed by 200 mg emtricitabine and 300 mg TDF once daily for 7 days postpartum. The median minimal and maximal concentrations of emtricitabine in breast milk were 177 and 679 ng/mL, respectively (interquartile ranges 105–254 and 658–743 ng/mL, respectively), well above the estimated emtricitabine IC$_{50}$ for HIV-1.$^8$

**Teratogenicity/Developmental Toxicity**

In a study of pregnancies occurring during an HIV pre-exposure prophylaxis (PrEP) trial in which HIV-uninfected participants were randomized to placebo, TDF, or TDF plus emtricitabine, there was no increase in congenital anomalies in the TDF-plus-emtricitabine arm.$^9$ There was no overall difference in the rate of pregnancy loss in the TDF-plus-emtricitabine or TDF-alone arms of this PrEP study. In a large French cohort, emtricitabine exposure in the first trimester was associated with lower risk of birth defects.$^{10}$ In the Antiretroviral Pregnancy Registry (APR), sufficient numbers of first-trimester exposures to emtricitabine in humans have been monitored to be able to detect at least a 1.5-fold increased risk of overall birth defects and a 2-fold increase in cardiovascular and genitourinary defects (the most common classes). No such increase in birth defects has been observed with emtricitabine. Among cases of first-trimester emtricitabine exposure reported to the APR, the prevalence of birth defects was $2.4\%$ (47 of 1,984 births; 95% CI, 1.7% to 3.1%), compared with a 2.7% total prevalence in the U.S. population, based on Centers for Disease Control and Prevention surveillance.$^{11}$

**Excerpt from Table 7**

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Emtricitabine</strong> (FTC)</td>
<td>Emtriva</td>
<td>Capsules: 200 mg</td>
<td>Standard Adult Dose(s) Emtriva (FTC) Capsule: 200 mg once daily without regard to food</td>
<td>High placental transfer to fetus.$^b$ No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects). If HBV-coinfected, it is possible that a HBV flare may occur if the drug is stopped; see HIV/Hepatitis B Virus Coinfection.</td>
</tr>
<tr>
<td>(FTC/TDF) Truvada</td>
<td>Truvada</td>
<td>Capsules: 200 mg, Oral Solution: 10 mg/mL</td>
<td>Truvada: 1 tablet once daily without regard to food</td>
<td></td>
</tr>
<tr>
<td>(FTC/TDF/EFV) Atripla</td>
<td>Atripla</td>
<td>Capsules: 200 mg, Oral Solution: 60 mg/mL</td>
<td>Atripla: 1 tablet once daily at or before bedtime. Take on an empty stomach to reduce side effects.</td>
<td></td>
</tr>
<tr>
<td>(FTC/TDF/RPV) Complera</td>
<td>Complera</td>
<td>Capsules: 200 mg, Oral Solution: 25 mg/ml</td>
<td>Complera: 1 tablet once daily with food</td>
<td></td>
</tr>
<tr>
<td>(FTC/TDF/EVG/COBI) Stribild</td>
<td>Stribild</td>
<td>Capsules: 200 mg, Oral Solution: 150 mg/ml</td>
<td>Stribild: 1 tablet once daily with food</td>
<td></td>
</tr>
<tr>
<td>(FTC/TAF/RPV) Odefsey</td>
<td>Odefsey</td>
<td>Capsules: 200 mg, Oral Solution: 25 mg/ml</td>
<td>Odefsey: 1 tablet once daily with food</td>
<td></td>
</tr>
<tr>
<td>(FTC/TAF/EVG/COBI) Genvoya</td>
<td>Genvoya</td>
<td>Capsules: 200 mg, Oral Solution: 150 mg/ml</td>
<td>Genvoya: 1 tablet once daily with food</td>
<td></td>
</tr>
</tbody>
</table>

$^a$Excerpt from Table 7 (page 1 of 2)
Excerpt from Table 7\textsuperscript{a} (page 2 of 2)

\textsuperscript{a} Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

\textsuperscript{b} Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

High: >0.6 Moderate: 0.3–0.6 Low: <0.3

\textsuperscript{c} See Teratogenicity for discussion of EFV and risks in pregnancy.

Key to Abbreviations: COBI = cobicistat; EFV = efavirenz; FTC = emtricitabine; HBV = hepatitis B virus; PK = pharmacokinetic; RPV = rilpivirine; TDF = tenofovir disoproxil fumarate

References


**Lamivudine (Epivir, 3TC)**

*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Available evidence does not suggest that lamivudine use by pregnant women is associated with an increased risk of adverse fetal or pregnancy outcomes.

**Animal Studies**

**Carcinogenicity**

Lamivudine has weak mutagenic activity in one *in vitro* assay but no evidence of *in vivo* genotoxicity in rats at 35 to 45 times human exposure. Long-term animal carcinogenicity screening studies at 10 and 58 times human exposure have been negative in mice and rats, respectively.\(^1\)

**Reproduction/Fertility**

Lamivudine administered to rats at doses up to 4000 mg/kg/day, producing plasma levels 47 to 70 times those in humans, revealed no evidence of impaired fertility and no effect on the offspring’s survival, growth, and development up to the time of weaning.\(^1\)

**Teratogenicity/Developmental Toxicity**

There is no evidence of lamivudine-induced teratogenicity at 35 times human plasma levels in rats and rabbits. Early embryo lethality was seen in rabbits at doses similar to human therapeutic exposure but not in rats at 35 times the human exposure level.\(^1\)

**Human Studies in Pregnancy**

**Pharmacokinetics**

Pregnancy does not significantly affect lamivudine pharmacokinetic parameters, as reported in two separate studies.\(^2,3\) This was confirmed in a larger analysis of 114 pregnant women, 123 women in labor, and 47 non-pregnant women, in which all received standard once- or twice-daily lamivudine doses.\(^4\) Pregnant women had a 22% higher apparent clearance than non-pregnant and postpartum women, but this increase did not lead to sub-therapeutic exposure. The level of lamivudine exposure in pregnant women, although lower than exposure in non-pregnant and parturient women, was relatively close to data reported previously for non-pregnant adults.\(^4\) Thus, no dose adjustment in pregnancy is necessary.

**Placental and Breast Milk Passage**

Lamivudine readily crosses the placenta in humans, achieving cord blood levels comparable to maternal concentrations.\(^3\) In a study of 123 mother/infant pairs, the placental transfer expressed as fetal-to-maternal area under the curve (AUC) ratio was 0.86, and the lamivudine amniotic fluid accumulation, expressed as the amniotic fluid-to-fetal AUC ratio, was 2.9.\(^4\) Other studies have also noted accumulation of lamivudine in amniotic fluid due to urinary excretion of lamivudine by the fetus into amniotic fluid.\(^2\)

Lamivudine is excreted into human breast milk. In a study in Kenya of 67 HIV-infected nursing mothers receiving a combination regimen of zidovudine, lamivudine, and nevirapine, the median breast milk lamivudine concentration was 1214 ng/mL and the median ratio of lamivudine concentration in breast milk to that in plasma was 2.56.\(^2\) In infants who were exposed to lamivudine only via breast milk, median plasma lamivudine concentration was 23 ng/mL (IC\(_{50}\) of lamivudine against wild-type HIV = 0.6–21 ng/mL).

**Teratogenicity/Developmental Toxicity**

In a large French cohort, lamivudine exposure in the first trimester was associated with an increased risk of overall birth defects (adjusted odds ratio = 1.37; 95% confidence interval [CI], 1.06–1.73) but there was no organ system or specific birth defect that predominated.\(^6\) However, in the Antiretroviral Pregnancy Registry (APR), sufficient numbers of first-trimester exposures to lamivudine in humans have been monitored to detect at least a 1.5-fold increase in risk of overall birth defects and a 2-fold increase in cardiovascular and...
genitourinary defects (the most common classes). No such increase in birth defects has been observed with lamivudine. Among cases of first-trimester lamivudine exposure reported to the APR, the prevalence of birth defects was 3.1% (143 of 4,566 births; 95% CI, 2.6% to 3.7%) compared with a 2.7% total prevalence in the U.S. population, based on Centers for Disease Control and Prevention surveillance.\(^7\)

**Other Pregnancy Outcomes**

An analysis of APR data demonstrated lower risk of spontaneous abortions, induced abortions, and preterm births for lamivudine-containing regimens compared with non-lamivudine antiretroviral regimens.\(^8\)

### Excerpt from Table 7\(^a\)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamivudine (3TC) Epivir</td>
<td>3TC (Epivir)</td>
<td>Standard Adult Dose(s)</td>
<td>High placental transfer to fetus.(^b)</td>
</tr>
<tr>
<td>(3TC/ZDV) Combivir</td>
<td>Tablets: 150 mg 300 mg</td>
<td>3TC (Lamivudine): 150 mg twice daily or 300 mg once daily, without regard to food</td>
<td>No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects).</td>
</tr>
<tr>
<td>(3TC/ABC) Epzicom</td>
<td>Oral Solution: 10 mg/mL</td>
<td>Combivir: 1 tablet twice daily without regard to food</td>
<td>If HBV-coinfected, it is possible that an HBV flare may occur if the drug is stopped; see HIV/Hepatitis B Virus Coinfection.</td>
</tr>
<tr>
<td>(3TC/ZDV/ABC) Trizivir</td>
<td>Combivir: 3TC 150 mg plus ZDV 300 mg tablet</td>
<td>Epzicom: 1 tablet once daily without regard to food</td>
<td></td>
</tr>
<tr>
<td>(3TC/ABC/DTG) Triumeq</td>
<td>Epzicom: 3TC 300 mg plus ABC 600 mg tablet</td>
<td>Trizivir: 1 tablet twice daily without regard to food</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trizivir: 3TC 150 mg plus ZDV 300 mg plus ABC 300 mg tablet</td>
<td>Triumeq: 1 tablet once daily without regard to food</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Triumeq: 3TC 300 mg plus ABC 600 mg plus DTG 50-mg tablet</td>
<td>PK in Pregnancy: PK not significantly altered in pregnancy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dosing in Pregnancy: No change in dose indicated.</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

\(^b\) Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- **High:** >0.6
- **Moderate:** 0.3–0.6
- **Low:** <0.3

**Key to Abbreviations:** 3TC = lamivudine; ABC = abacavir; DTG = dolutegravir; HBV = hepatitis B virus; PK = pharmacokinetic; ZDV = zidovudine

### References


Stavudine (Zerit, d4T)

(Last updated June 7, 2016; last reviewed June 7, 2016)

Stavudine is classified as Food and Drug Administration (FDA) Pregnancy Category C.

Animal Studies

Carcinogenicity
Stavudine is clastogenic in in vitro and in vivo assays but not mutagenic in in vitro assays. In 2-year carcinogenicity studies in mice and rats, stavudine was non-carcinogenic in doses producing exposures 39 (mice) and 168 (rats) times human exposure at the recommended therapeutic dose. At higher levels of exposure (250 [mice] and 732 [rats] times human exposure at therapeutic doses), benign and malignant liver tumors occurred in mice and rats and urinary bladder tumors occurred in male rats.1

Reproduction/Fertility
Stavudine has not been shown to have an effect on reproduction or fertility in rodents. No evidence of impaired fertility was seen in rats with exposures (based on C_max) up to 216 times that observed following a clinical dosage of 1 mg/kg/day.1 A dose-related cytotoxic effect has been observed on preimplantation mouse embryos, with inhibition of blastocyst formation at a concentration of 100 µM and of post-blastocyst development at 10 µM.2

Teratogenicity/Developmental Toxicity
No evidence of teratogenicity was noted in rats or rabbits with exposures (based on C_max) up to 399 and 183 times, respectively, that seen at a clinical dosage of 1 mg/kg/day. In rat fetuses, the incidence of a common skeletal variation—unossified or incomplete ossification of sternebra—was increased at 399 times human exposure, although no effect was observed at 216 times human exposure. A slight post-implantation loss was noted at 216 times human exposure, with no effect noted at approximately 135 times human exposure. An increase in early rat neonatal mortality (birth to day 4) occurred at 399 times human exposure, although survival of neonates was unaffected at approximately 135 times the human exposure.1

Placental and Breast Milk Passage
A study in rats showed that stavudine is transferred to the fetus through the placenta. The concentration in fetal tissue was approximately one-half the concentration in maternal plasma.1

In primates (pig-tailed macaques), fetal/maternal plasma concentrations were approximately 0.80.3 Stavudine is excreted into the breast milk of lactating rats.1

Human Studies in Pregnancy

Pharmacokinetics
In a Phase I/II safety and pharmacokinetic (PK) study of combination stavudine and lamivudine in pregnant HIV-infected women and their infants (PACTG 332), both drugs were well tolerated, with stavudine PK parameters similar to those in non-pregnant adults.4

Placental and Breast Milk Passage
Stavudine crosses the human placenta, resulting in a cord/maternal blood concentration of 1.0–1.3.3 Stavudine also crosses into human breast milk, resulting in breast milk/maternal plasma concentrations of 1.0 to 1.76. Concentrations in nursing infants were negligible.6,7

Teratogenicity/Developmental Toxicity
No association was found between first-trimester exposure to stavudine and birth defects in a large French
cohort study that had 70% power to detect an increased adjusted odds ratio of 1.5.\(^8\) In the Antiretroviral Pregnancy Registry (APR), sufficient numbers of first-trimester exposures to stavudine in humans have been monitored to be able to detect at least a two-fold increased risk of overall birth defects. No such increase in birth defects has been observed with stavudine. Among cases of first-trimester stavudine exposure reported to the APR, the prevalence of birth defects was 2.6% (21 of 810 births; 95% CI, 1.6% to 3.9%) compared with a total prevalence in the U.S. population of 2.7%, based on Centers for Disease Control and Prevention surveillance.\(^9\)

**Other Safety Data**

Lactic acidosis, in some cases fatal, has been described in pregnant women receiving the combination of didanosine and stavudine along with other antiretroviral agents.\(^{10-12}\) The FDA and Bristol-Myers Squibb have issued a warning to health care professionals that pregnant women may be at increased risk of fatal lactic acidosis when prescribed didanosine and stavudine in combination (see Recommendations for Use of Antiretroviral Drugs During Pregnancy and Long-Term Follow-Up of Antiretroviral Drug-Exposed Infants). These drugs should not be prescribed together for pregnant women.

**Excerpt from Table 7\(^a\)**

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stavudine (d4T) Zerit</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsules:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 15 mg</td>
<td></td>
<td>Standard Adult Dose(s)(^a)</td>
<td></td>
</tr>
<tr>
<td>• 20 mg</td>
<td></td>
<td>Body Weight ≥60 kg:</td>
<td></td>
</tr>
<tr>
<td>• 30 mg</td>
<td></td>
<td>• 40 mg twice daily without regard to meals</td>
<td></td>
</tr>
<tr>
<td>• 40 mg</td>
<td></td>
<td>Body Weight &lt;60 kg:</td>
<td></td>
</tr>
<tr>
<td>Oral Solution:</td>
<td></td>
<td>• 30 mg twice daily without regard to meals</td>
<td></td>
</tr>
<tr>
<td>• 1 mg/mL following reconstitution</td>
<td></td>
<td>PK in Pregnancy:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• PK not significantly altered in pregnancy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dosing in Pregnancy:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No change in dose indicated</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

\(^b\) Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- **High:** >0.6
- **Moderate:** 0.3–0.6
- **Low:** <0.3

\(^c\) See Teratogenicity for discussion of EFV and risks in pregnancy.

\(^d\) WHO recommends maximum dose of 30 mg twice daily regardless of weight.

**Key to Abbreviations:** d4T = stavudine; ddi = didanosine; PK = pharmacokinetic; WHO = World Health Organization; ZDV = zidovudine

**References**


**Tenofovir Disoproxil Fumarate (Viread, TDF)**

*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Tenofovir disoproxil fumarate (TDF), an orally bioavailable form of tenofovir, is classified as Food and Drug Administration Pregnancy Category B.¹

**Animal Studies**

*Carcinogenicity*

Tenofovir is mutagenic in one of two *in vitro* assays and has no evidence of clastogenic activity. Long-term oral carcinogenicity studies of tenofovir in mice and rats were carried out at 16 times (mice) and 5 times (rats) human exposure. In female mice, liver adenomas were increased at exposures 16 times that observed in humans at therapeutic doses. In rats, the study was negative for carcinogenic findings at exposures up to 5 times that observed in humans at the therapeutic dose.²

*Reproduction/Fertility*

Reproduction studies have been performed in rats and rabbits at doses up to 14 and 19 times the human dose, respectively, based on body surface area comparisons and revealed no evidence of impaired fertility or harm to the fetus associated with tenofovir. There were also no effects on fertility, mating performance, or early embryonic development when tenofovir was administered to male rats (600 mg/kg/day; equivalent to 10 times the human dose based on body surface area) for 28 days before mating and to female rats for 15 days before mating through Day 7 of gestation. There was, however, an alteration of the estrous cycle in female rats administered 600 mg/kg/day.³

*Teratogenicity/Developmental Toxicity*

Chronic exposure of fetal monkeys to tenofovir at high doses (exposure equivalent to 25 times the area under the curve (AUC) achieved with therapeutic dosing in humans) resulted in lower fetal circulating insulin-like growth factor (IGF)-1, higher IGF binding protein-3 levels, and lower body weights. A slight reduction in fetal bone porosity was also observed. Effects on these parameters were observed within 2 months of maternal treatment.³

*Placental and Breast Milk Passage*

Intravenous administration of tenofovir to pregnant cynomolgus monkeys resulted in a fetal/maternal concentration of 17%, demonstrating that tenofovir crosses the placenta.²

**Human Studies in Pregnancy**

*Pharmacokinetics*

In a retrospective population pharmacokinetic study of 46 pregnant women and 156 non-pregnant women receiving combination regimens including tenofovir, pregnant women had a 39% higher apparent clearance of tenofovir compared with non-pregnant women, which decreased slightly but significantly with increasing age.³ In a P1026s study of 37 pregnant women receiving TDF-based combination therapy at 30 to 36 weeks’ gestation and 6 to 12 weeks postpartum, the percentage of women with tenofovir AUC exceeding the target of 9.9 µg*hour/mL (the 10th percentile in non-pregnant adults) was lower in the third trimester (73%, 27 of 37 women) than postpartum (84%, 27 of 32 women); trough levels and AUCs were 17% to 20% lower during the third trimester compared to postpartum. The median weight of the women below the target exposure (97.9 kg) was significantly higher than the median weight of the women who met the target exposure (74.2 kg).³ In another study of 34 women receiving TDF plus emtricitabine in the third trimester and postpartum, tenofovir AUC, peak, and trough were all about 25% lower in pregnant women compared to postpartum women, but these decreased exposures were not associated with virologic failure.⁵ Standard dosing during pregnancy continues to be recommended.
Placental and Breast Milk Passage

In studies of pregnant women on chronic TDF, the cord-to-maternal-blood ratio of tenofovir ranged from 0.60 to 1.03, indicating high placental transfer.\cite{4,7} In studies of pregnant women receiving single-dose TDF (with and without emtricitabine) in labor, the drugs were well tolerated and the median tenofovir cord-to-maternal-blood ratio at delivery ranged from 0.55 to 0.73.\cite{8,9} Intracellular tenofovir concentrations were detected in the peripheral blood mononuclear cells from cord blood in all infants after a single maternal dose of 600 mg TDF with 400 mg emtricitabine, but intracellular tenofovir-diphosphate was detectable in only 2 (5.5%) of 36 infants.\cite{10}

Sixteen breast milk samples were obtained from 5 women who received 600 mg TDF at the start of labor followed by 300 mg daily for 7 days. Tenofovir levels in breast milk ranged from 5.8 to 16.3 ng/mL, resulting in nursing infants ingesting an estimated daily amount of tenofovir that corresponds to 0.03% of the proposed oral dose of TDF for neonates.\cite{11} Because the form of tenofovir in breastmilk is expected to have lower bioavailability than TDF, these exposures are likely overestimates. No studies have measured tenofovir blood levels in infants breastfed by women taking TDF.

Reproduction/Fertility

A retrospective analysis of 7,275 women (1,199 receiving TDF-based antiretroviral therapy) demonstrated a slight reduction in pregnancy rates, but the findings were limited by the observational nature of the data and additional studies are needed for confirmation.\cite{12}

Teratogenicity/Developmental Toxicity

In a study of 431 pregnancies occurring during an HIV pre-exposure prophylaxis trial in which HIV-uninfected women were randomized to placebo, TDF, or TDF plus emtricitabine, there was no difference in risk of congenital anomalies between the TDF-containing and placebo arms.\cite{13} No association was seen between maternal TDF and offspring birth defects in three large U.S. cohorts: PACT 219/219C (n = 2,202 with 214 first-trimester TDF exposures), P1025 (n = 1,112 with 138 first-trimester TDF exposures),\cite{14,15} and Pediatric HIV AIDS Cohort Study (n = 2,580 with 431 first-trimester TDF exposures).\cite{16} In the French Perinatal Cohort, no association was found between birth defects and TDF with a power of 70% for an odds ratio of 1.5 (n = 13,124 with 823 first-trimester TDF exposures).\cite{17} Finally, in the Antiretroviral Pregnancy Registry (APR), sufficient numbers of first-trimester exposures to TDF in humans have been monitored to be able to detect at least a 1.5-fold increased risk of overall birth defects and a 2-fold increase in risk of birth defects in the cardiovascular and genitourinary systems. No increase in birth defects has been observed with TDF. Among cases of first-trimester TDF exposure reported to the APR, the prevalence of birth defects was 2.3% (60 of 2,608 births; 95% confidence interval [CI], 1.8% to 3.0%), compared with a 2.7% total prevalence in the U.S. population, based on Centers for Disease Control and Prevention surveillance.\cite{18}

Other Safety Data

In a United Kingdom cohort of 71 pregnant women receiving TDF, retrospective analysis of serum creatinine and estimated glomerular filtration rate (eGFR) measured throughout pregnancy and 6 weeks after delivery revealed no decline in renal function during pregnancy and normal renal function (>90 mL/min) 6 weeks postpartum (one woman’s postpartum eGFR was 60 mL/min).\cite{19}

Among 382 pregnancies occurring in 302 women in Uganda and Zimbabwe participating in the DART trial—approximately two-thirds of whom received TDF through more than 90% of their pregnancies—there were no differences noted in mortality, birth defects, or growth.\cite{20} In the Pediatric HIV/AIDS Cohort Study from the United States, 449 (21%) of the 2,029 HIV-exposed but uninfected infants had in utero exposure to TDF, and there was no difference at birth between those exposed to combination drug regimens with or without TDF in low birthweight, small-for-gestational-age, and newborn length-for-age and head circumference-for-age z-scores (LAZ and HCAZ, respectively). However, at age 1 year, infants exposed to combination regimens with TDF had a slight but significantly lower adjusted mean LAZ and HCAZ than those without TDF exposure (LAZ: -0.17 vs. -0.03, \(P = 0.04\); HCAZ: 0.17 vs. 0.42, \(P = 0.02\), but no difference in weight-for-age z-score (WAZ). There were no significant differences between those with and
without TDF exposure at age 1 year when defining low LAZ or HCAZ as \( \leq 1.5 \) z-score. Thus, these slightly lower mean LAZ and HCAZ scores are of uncertain significance.\(^{21}\) In a different U.S. study (P1025), maternal TDF use was similarly not associated with differences in body size parameters at birth; however, among the 1,496 infants followed for 6 months, TDF exposure after the first trimester, relative to no exposure, was associated with being underweight (WAZ <5%) at age 6 months (OR [95% CI]: 2.06 [1.01, 3.95], \( P = 0.04 \)).\(^{22}\)

In a cross-sectional study of 68 HIV-exposed uninfected children enrolled at ages 1 to 6 years who had \textit{in utero} exposure to combination regimens with (\( N = 33 \)) or without (\( N = 35 \)) TDF, evaluation of quantitative bone ultrasound and parameters of bone metabolism gave similar measures between groups.\(^{23}\) In contrast, a study evaluating whole body dual-energy X-ray absorptiometry scans within 4 weeks of birth among 74 infants exposed to more than 8 weeks of TDF \textit{in utero} and 69 infants with no TDF exposures, the adjusted mean whole body bone mineral content (BMC) was significantly lower in the TDF group by 6.3 g (\( P = 0.004 \)) as was the whole-body-less-head BMC (-2.6 g, \( P = 0.056 \)). The duration and clinical significance of these findings require further longitudinal evaluation.\(^{24}\)

Excerpt from Table 7\(^a\)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir Disoproxil Fumarate (TDF)</td>
<td>TDF (Viread) Tablet: • 300 mg Powder: • 40 mg/1 g oral powder</td>
<td>Standard Adult Dose TDF (Viread) Tablet: • 300 mg once daily without regard to food Powder: • 8 mg/kg (up to maximum 300 mg), take with food Truvada: • 1 tablet once daily without regard to food Atripla: • 1 tablet once daily at or before bedtime. Take on an empty stomach to reduce side effects. Complera: • 1 tablet once daily with food Stribild: • 1 tablet once daily with food PK in Pregnancy: • AUC lower in third trimester than postpartum but trough levels adequate Dosing in Pregnancy: • No change in dose indicated.</td>
<td>High placental transfer to fetus.(^b) No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects). Studies in monkeys (at doses approximately 2-fold higher than that for human therapeutic use) show decreased fetal growth and reduction in fetal bone porosity within 2 months of starting maternal therapy. Human studies demonstrate no effect on intrauterine growth, but data are conflicting about potential effects on growth outcomes later in infancy. If HBV-coinfected, it is possible that an HBV flare may occur if TDF is stopped; see \textit{HIV/Hepatitis B Virus Coinfection}. Renal function should be monitored because of potential for renal toxicity.</td>
</tr>
</tbody>
</table>

\( ^a \) Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see \textit{Adult Guidelines, Appendix B, Table 7}).

\( ^b \) Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

<table>
<thead>
<tr>
<th>Category</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>&gt;0.6</td>
</tr>
<tr>
<td>Moderate</td>
<td>0.3–0.6</td>
</tr>
<tr>
<td>Low</td>
<td>&lt;0.3</td>
</tr>
</tbody>
</table>

\( ^c \) See \textit{Teratogenicity} for discussion of EFV and risks in pregnancy.

\textbf{Key to Abbreviations}: AUC = area under the curve; COBI = cobicistat; EFV = efavirenz; FTC = emtricitabine; HBV = hepatitis B virus; PK = pharmacokinetic; RPV = rilpivirine; TDF = tenofovir disoproxil fumarate
References


Zidovudine (Retrovir, AZT, ZDV)  
(Last updated August 6, 2015; last reviewed August 6, 2015)

Zidovudine is classified as Food and Drug Administration Pregnancy Category C.

Animal Studies

Carcinogenicity

Zidovudine was shown to be mutagenic in two in vitro assays and clastogenic in one in vitro and two in vivo assays, but not cytogenic in a single-dose in vivo rat study. Long-term carcinogenicity studies have been performed with zidovudine in mice and rats. In mice, seven late-appearing (>19 months) vaginal neoplasms (5 non-metastasizing squamous cell carcinomas, 1 squamous cell papilloma, and 1 squamous polyp) occurred in animals given the highest dose. One late-appearing squamous cell papilloma occurred in the vagina of an animal given an intermediate dose. No vaginal tumors were found at the lowest dose. In rats, two late-appearing (>20 months), non-metastasizing vaginal squamous cell carcinomas occurred in animals given the highest dose. No vaginal tumors occurred at the low or middle dose in rats. No other drug-related tumors were observed in either sex in either species. At doses that produced tumors in mice and rats, the estimated drug exposure (as measured by area under the curve [AUC]) was approximately three times (mice) and 24 times (rats) the estimated human exposure at the recommended therapeutic dose of 100 mg every 4 hours. How predictive the results of rodent carcinogenicity studies may be for humans is unknown.

Two transplacental carcinogenicity studies were conducted in mice. In one study, zidovudine was administered at doses of 20 mg/kg/day or 40 mg/kg/day from gestational Day 10 through parturition and lactation, with postnatal dosing continuing in offspring for 24 months. The drug doses administered in this study produced zidovudine exposures approximately three times the estimated human exposure at recommended doses. After 24 months, an increase in incidence of vaginal tumors was noted with no increase in tumors in the liver or lung or any other organ in either gender. These findings are consistent with results of the standard oral carcinogenicity study in mice, as described earlier. In a second study, zidovudine was administered at maximum tolerated doses of 12.5 mg/day or 25 mg/day (~1,000 mg/kg non-pregnant body weight or ~450 mg/kg of term body weight) to pregnant mice from Days 12 to 18 of gestation. There was an increase in the number of tumors in the lung, liver, and female reproductive tracts in the offspring of mice receiving the higher dose of zidovudine.

Reproduction/Fertility

When administered to male and female rats at doses up to seven times the usual adult dose based on body surface area, zidovudine had no effect on fertility, as judged by rates of conception. Zidovudine has been shown to have no effect on reproduction or fertility in rodents. A dose-related cytotoxic effect on preimplantation mouse embryos can occur, with inhibition of blastocyst and post-blastocyst development at zidovudine concentrations similar to levels achieved with human therapeutic doses.

Teratogenicity/Developmental Toxicity

Oral teratology studies in the rat and in the rabbit at doses up to 500 mg/kg/day revealed no evidence of teratogenicity with zidovudine. Zidovudine treatment resulted in embryo/fetal toxicity, as evidenced by an increase in the incidence of fetal resorptions in rats given 150 or 450 mg/kg/day and rabbits given 500 mg/kg/day. The doses used in the teratology studies resulted in peak zidovudine plasma concentrations (after one-half of the daily dose) in rats 66 to 226 times and in rabbits 12 to 87 times mean steady-state peak human plasma concentrations (after one-sixth of the daily dose) achieved with the recommended daily dose (100 mg every 4 hours). In an in vitro experiment with fertilized mouse oocytes, zidovudine exposure resulted in a dose-dependent reduction in blastocyst formation. In an additional teratology study in rats, a dose of 3,000 mg/kg/day (very near the oral median lethal dose in rats of 3,683 mg/kg) caused marked maternal toxicity and an increase in incidence of fetal malformations. This dose resulted in peak zidovudine plasma concentrations 350 times peak human plasma concentrations (estimated AUC in rats at this dose level
was 300 times the daily AUC in humans given 600 mg/day). No evidence of teratogenicity was seen in this experiment at doses of 600 mg/kg/day or less.

Increased fetal resorption occurred in pregnant rats and rabbits treated with zidovudine doses that produced drug plasma concentrations 66 to 226 times (rats) and 12 to 87 times (rabbits) the mean steady-state peak human plasma concentration following a single 100-mg dose of zidovudine. No other developmental anomalies were reported. In another developmental toxicity study, pregnant rats received zidovudine up to near-lethal doses that produced peak plasma concentrations 350 times peak human plasma concentrations (300 times the daily AUC in humans given 600 mg/day zidovudine). This dose was associated with marked maternal toxicity and an increased incidence of fetal malformations. However, there were no signs of teratogenicity at doses up to one-fifth the lethal dose.

**Human Studies in Pregnancy**

**Pharmacokinetics**

Zidovudine pharmacokinetics are not significantly altered by pregnancy, and standard adult doses are recommended.\(^5,6\)

**Placental and Breast Milk Passage**

Zidovudine rapidly crosses the human placenta, achieving cord-to-maternal-blood ratios of about 0.80. The ratio of zidovudine in amniotic fluid to that in maternal plasma is 1.5.\(^7\) Zidovudine is excreted into human breast milk with breast milk-to-maternal-plasma zidovudine concentration ratios ranging from 0.44 to 1.35. No zidovudine was detectable in the plasma of the nursing infants, who received zidovudine only via breast milk.\(^8-10\)

**Teratogenicity/Developmental Toxicity**

In PACTG 076, the incidence of minor and major congenital abnormalities was similar between zidovudine and placebo groups, and no specific patterns of defects were seen.\(^5,11\) Similarly, no increase in birth defects was detected among infants enrolled in the large observational cohorts PACTG 219/219C and P1025.\(^12,13\) A previous report from the Women and Infants Transmission Study described a 10-fold increased risk of hypospadias, but this finding was not confirmed in a more detailed analysis.\(^14,15\) The French Perinatal Cohort reported that first-trimester zidovudine exposure was associated with congenital heart defects (2.3%, or 74/3,267; adjusted odds ratio = 2.2 [95% confidence interval (CI), 1.3–3.7]).\(^16\) In the PHACS/SMARTT cohort, there was no association between first-trimester exposure and congenital anomalies.\(^17\) In the Antiretroviral Pregnancy Registry, sufficient numbers of first-trimester exposures to zidovudine have been monitored to be able to detect at least a 1.5-fold increased risk of overall birth defects and a 2-fold increased incidence of defects in the more common classes, including the genitourinary system. No such increase in birth defects has been observed with zidovudine. With first-trimester zidovudine exposure, the prevalence of birth defects was 3.2% (129 of 4,034 births; 95% CI, 2.7%–3.8%), compared with a total prevalence in the U.S. population of 2.7%, based on Centers for Disease Control and Prevention surveillance.\(^18\)

Cancer has been observed no more frequently among zidovudine-exposed infants than among other HIV-exposed or HIV-unexposed infants in a long-term follow-up study for the original PACTG 076 study,\(^19\) in prospective cohort studies,\(^20\) and in matches between HIV surveillance and cancer registries.\(^21,22\)

**Other Safety Data**

In the placebo-controlled perinatal trial PACTG 076, no difference in disease progression was seen between women who received zidovudine and those who received a placebo, based on follow-up through 4 years postpartum.\(^23\)

No differences in immunologic, neurologic, or growth parameters were seen between PACTG 076 infants with in utero zidovudine exposure and those who received a placebo, based on nearly 6 years of follow-up.\(^18,19\)

Mitochondrial dysfunction in mothers and infants exposed to nucleoside reverse transcriptase inhibitors (NRTIs) during pregnancy has been described in some case reports, case series, prospective cohorts, and...
surveillance systems, but not in others. The result of the dysfunction, although fatal in a few cases, is more often asymptomatic and self-limited (e.g., leukopenia, anemia). At present, while a recognized possibility, the risk of NRTI-associated mitochondrial dysfunction in these mother-infant pairs does not outweigh the clear benefit of these drugs in preventing perinatal HIV transmission.

**Excerpt from Table 7**

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine (AZT, ZDV)</td>
<td>Retrovir</td>
<td>ZDV (Retrovir)</td>
<td>Standard Adult Dose(s)</td>
<td>High placental transfer to fetus. No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capsule: 100 mg</td>
<td>ZDV (Retrovir): 300 mg BID or 200 mg TID, without regard to food</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tablet: 300 mg</td>
<td>Active Labor: 2 mg/kg IV loading dose, followed by 1 mg/kg/hour continuous infusion from beginning of active labor until delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Solution: 10 mg/mL</td>
<td>Combivir: Tablet twice daily, without regard to food</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intraavenous Solution: 10 mg/mL</td>
<td>Trizivir: Tablet twice daily, without regard to food</td>
<td></td>
</tr>
<tr>
<td>(ZDV/3TC)</td>
<td>Combivir</td>
<td>ZDV 300 mg plus 3TC 150 mg tablet</td>
<td>PK in Pregnancy: PK not significantly altered in pregnancy.</td>
<td></td>
</tr>
<tr>
<td>(ZDV/3TC/ABC)</td>
<td>Trizivir</td>
<td>ZDV 300 mg plus 3TC 150 mg plus ABC 300 mg tablet</td>
<td>Dosing in Pregnancy: No change in dose indicated.</td>
<td></td>
</tr>
</tbody>
</table>

*a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

*b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- High: >0.6
- Moderate: 0.3–0.6
- Low: <0.3

Key to Abbreviations: 3TC = lamivudine; ABC = abacavir; AZT = zidovudine; IV = intravenous; PK = pharmacokinetic; TID = three times a day; ZDV = zidovudine

**References**


Non-Nucleoside Reverse Transcriptase Inhibitors

Glossary of Terms for Supplement

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinogenic</td>
<td>Producing or tending to produce cancer</td>
</tr>
<tr>
<td></td>
<td>• Some agents, such as certain chemicals or forms of radiation, are both mutagenic and clastogenic.</td>
</tr>
<tr>
<td></td>
<td>• Genetic mutations and/or chromosomal damage can contribute to cancer formation.</td>
</tr>
<tr>
<td>Clastogenic</td>
<td>Causing disruption of or breakages in chromosomes</td>
</tr>
<tr>
<td>Genotoxic</td>
<td>Damaging to genetic material such as DNA and chromosomes</td>
</tr>
<tr>
<td>Mutagenic</td>
<td>Inducing or capable of inducing genetic mutation</td>
</tr>
<tr>
<td>Teratogenic</td>
<td>Interfering with fetal development and resulting in birth defects</td>
</tr>
</tbody>
</table>

Five non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) are currently approved: delavirdine, efavirenz, etravirine, nevirapine and rilpivirine. Delavirdine is no longer available in the United States.

For information about potential interactions between NNRTIs and methergine, see the Postpartum Hemorrhage, Antiretroviral Drugs, and Methergine Use section.

**Efavirenz (Sustiva, EFV)**

*(Last updated August 6, 2015; last reviewed August 6, 2015)*

Regarding embryo-fetal toxicity, the Food and Drug Administration (FDA) advises women to avoid becoming pregnant while taking efavirenz and health care providers to avoid administration in the first trimester of pregnancy as fetal harm may occur.¹

**Animal Studies**

**Carcinogenicity**

Efavirenz was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. A study evaluating genotoxicity of efavirenz in mice noted DNA damage in brain cells after daily dosing for 36 days; no damage was seen in liver, heart, or peripheral blood cells.² Long-term animal carcinogenicity studies with efavirenz have been completed in mice and rats. At systemic drug exposures approximately 1.7-fold higher than in humans receiving standard therapeutic doses, no increase in tumor incidence above background was observed in male mice, but in female mice, an increase above background was seen in hepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas. No increase in tumor incidence above background was observed in male and female rats with systemic drug exposures lower than that in humans receiving therapeutic doses.

**Reproduction/Fertility**

No effect of efavirenz on reproduction or fertility in rodents has been seen.

**Teratogenicity/Developmental Toxicity**

An increase in fetal resorption was observed in rats at efavirenz doses that produced peak plasma concentrations and area under the curve (AUC) values in female rats equivalent to or lower than those achieved in humans at the recommended human dose (600 mg once daily). Efavirenz produced no reproductive toxicities when given to pregnant rabbits at doses that produced peak plasma concentrations similar to and AUC values approximately half of those achieved in humans administered efavirenz (600 mg once daily). Central nervous system (CNS) malformations and cleft palate were observed in 3 of 20 infants born to pregnant cynomolgus monkeys receiving efavirenz from gestational days 20 to 150 at a dose of 60 mg/kg/day (resulting in plasma concentrations 1.3 times that of systemic human therapeutic exposure, with fetal umbilical venous drug concentrations approximately 0.7 times the maternal values).³ The malformations

---

¹ Some agents, such as certain chemicals or forms of radiation, are both mutagenic and clastogenic. Genetic mutations and/or chromosomal damage can contribute to cancer formation.

² EFV was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. A study evaluating genotoxicity of efavirenz in mice noted DNA damage in brain cells after daily dosing for 36 days; no damage was seen in liver, heart, or peripheral blood cells.

³ EFV produced no reproductive toxicities when given to pregnant rabbits at doses that produced peak plasma concentrations similar to and AUC values approximately half of those achieved in humans administered efavirenz (600 mg once daily). Central nervous system (CNS) malformations and cleft palate were observed in 3 of 20 infants born to pregnant cynomolgus monkeys receiving efavirenz from gestational days 20 to 150 at a dose of 60 mg/kg/day (resulting in plasma concentrations 1.3 times that of systemic human therapeutic exposure, with fetal umbilical venous drug concentrations approximately 0.7 times the maternal values).
included anencephaly and unilateral anophthalmia in one fetus, microphthalmia in another fetus, and cleft palate in a third fetus.

Placental and Breast Milk Passage
Efavirenz readily crosses the placenta in rats, rabbits, and primates, producing cord blood concentrations similar to concentrations in maternal plasma. Maternal and fetal blood concentrations in pregnant rabbits and cynomolgus monkeys are equivalent, while fetal concentrations in rats exceeded maternal concentrations.

Human Studies in Pregnancy
Pharmacokinetics/Pharmacogenomics

In an intensive sampling pharmacokinetic (PK) study of 25 pregnant women receiving efavirenz during the third trimester as part of clinical care, efavirenz clearance was slightly increased and trough levels were decreased compared with levels measured postpartum. These differences are not of sufficient magnitude to warrant dose adjustment during pregnancy. A recent review of this study plus four others that measured single efavirenz concentrations in pregnant women found that efavirenz concentrations were not significantly affected by pregnancy and that high rates of HIV RNA suppression at delivery were achieved with efavirenz regimens.

In a pharmacogenomics study, non-pregnant individuals with the CYP2B6 516 TT genotype had more than 3-fold increases in both short-term and long-term efavirenz exposure, as measured by plasma and hair drug levels, suggesting there could be significant variation in drug levels with CYP2B6 polymorphisms. The frequency of this allele varies between different ethnic populations, ranging from 3.4% in white, 6.7% in Hispanic and 20% in African Americans.

PK interactions between efavirenz and some hormonal contraceptives have been reported, with the potential for failure of the progesterone component, potentially affecting efficacy of emergency contraception, combined oral contraceptive pills, progestin-only pills, and progestin implants. A retrospective chart review study suggests that efavirenz may decrease the efficacy of levonorgestrel implants (e.g., Jadelle). Pregnancy occurred among 15 (12.4%) of 115 women on efavirenz using Jadelle, compared to no pregnancies among 208 women on nevirapine-based regimens and no pregnancies among 13 women on lopinavir/ritonavir-based regimens (P < 0.001) (see Preconception Counseling and Care). Barrier contraception should always be used in combination with hormonal contraceptives. A study evaluating the interaction between efavirenz and depot medroxyprogesterone acetate (DMPA) in 17 women found no change in the PK profile of either efavirenz or DMPA with concomitant use. DMPA levels remained above the level needed for inhibition of ovulation throughout the dosing interval. In addition intrauterine devices (IUDs), both copper-containing and levonorgestrel-containing, would be expected to maintain efficacy.

Placental and Breast Milk Passage

In a study of 25 mother-infant pairs, median efavirenz cord blood/maternal blood concentration was 0.49 (range 0.37–0.74). In a study of 13 women in Rwanda, efavirenz was given during the last trimester of pregnancy and for 6 months after delivery. Efavirenz concentrations were measured in maternal plasma, breast milk, and infant plasma. Efavirenz concentration was significantly higher in maternal plasma than skim breast milk (mean breast milk to mean maternal plasma concentration ratio 0.54) and higher in skim breast milk than in infant plasma (mean skim breast milk to mean newborn plasma concentration ratio 4.08). Mean infant plasma efavirenz concentrations were 860 ng/mL and the mean infant plasma efavirenz concentration was 13.1% of maternal plasma concentrations. All infants had detectable plasma concentrations of efavirenz, and 8 of 13 newborns had plasma efavirenz concentrations below the minimum therapeutic concentration of 1,000 ng/mL recommended for treatment of HIV-infected adults. In a study of 51 women in Nigeria receiving efavirenz 600 mg daily, the median (range) milk/maternal plasma ratio was 0.82 (0.51–1.1) and the median (range) infant efavirenz concentration was 178 (88–340) ng/mL. In a study of plasma and hair drug concentration in 56 mother-infant pairs receiving efavirenz-based therapy during...
pregnancy and breastfeeding, infant plasma levels at delivery and hair levels at age 12 weeks suggested moderate in utero transfer during pregnancy and breastfeeding, with approximately one-third of transfer occurring postpartum (40% cumulative with 15% during breastfeeding). All mothers and infants had detectable efavirenz plasma levels at 0, 8, and 12 weeks and mean infant-to-maternal-hair concentration at 12 weeks postpartum was 0.40 for efavirenz. No data currently are available about the safety and PK of efavirenz in neonates.

**Teratogenicity Data**

In pregnancies with prospectively reported exposure to efavirenz-based regimens in the Antiretroviral Pregnancy Registry through January 2015, birth defects were observed in 20 of 852 live births with first-trimester exposure (2.3%, 95% confidence interval [CI], 1.4% to 3.6%). Although these data provide sufficient numbers of first-trimester exposures to rule out a 2-fold or greater increase in the risk of overall birth defects, the low incidence of neural tube defects in the general population means that a larger number of exposures are still needed to be able to definitively rule out an increased risk of this specific defect. Prospective reports to the Antiretroviral Pregnancy Registry of defects after first-trimester efavirenz exposure have documented one neural tube defect case (sacral aplasia, myelomeningocele, and hydrocephalus with fetal alcohol syndrome) and one case of bilateral facial clefts, anophthalmia, and amniotic band. Among retrospective cases, there are six reports of CNS defects, including three cases of meningo(myel)encephalocele in infants born to mothers receiving efavirenz during the first trimester. Retrospective reports can be biased toward reporting of more unusual and severe cases and are less likely to be representative of the general population experience.

In an updated meta-analysis of 23 studies (including the Antiretroviral Pregnancy Registry data) reporting on birth outcomes among women exposed to efavirenz during the first trimester, there were 44 infants with birth defects among 2,026 live births to women receiving first-trimester efavirenz (rate of overall birth defects 1.63%, 95% CI, 0.78% to 2.48%). The rate of overall birth defects was similar among women exposed to efavirenz-containing regimens and non-efavirenz-containing regimens during the first trimester (pooled relative risk [RR] 0.78, 95% CI, 0.56–1.08). Across all births, one neural tube defect (myelomeningocele) was observed, giving a point prevalence of 0.05% (95% CI, <0.01 to 0.28), within the range reported in the general population. However, the number of reported first-trimester efavirenz exposures still remains insufficient to rule out a significant increase in low-incidence birth defects (incidence of neural tube defects in the general U.S. population is 0.02% to 0.2%).

A recent French study of 13,124 live births between 1994 and 2010 included an analysis of 372 infants born after first-trimester efavirenz exposure. In the primary analysis using the European Surveillance of Congenital Anomalies (EUROCAT) classification system, no increase in birth defects after first trimester efavirenz exposure was detected compared to those without efavirenz exposure in pregnancy (adjusted odds ratio 1.16, 95% CI, 0.73–1.85). In a secondary analysis using the modified Metropolitan Atlanta Congenital Defect Program classification used by the Antiretroviral Pregnancy Registry, an association was found between first-trimester efavirenz exposure and neurologic defects. However, none of the four defects (i.e., ventricular dilatation with anomalies of the white substance, partial agenesis of the corpus callosum, subependymal cyst, and pachygyria) were neural tube defects, and none of the defects had common embryology. First-trimester efavirenz exposure was not associated with an increased risk of defects in a Pediatric HIV/AIDS Cohort Study analysis that included 2,580 live births, 94 after first-trimester efavirenz exposure or an analysis of a national cohort in Italy that included 1,257 pregnancies, 80 after first-trimester efavirenz exposure.

Although two small studies (Pediatric AIDS Clinical Trials Group [PACTG] protocol 219/219C and PACTG protocol P1025) reported a higher rate of birth defects among infants with first-trimester exposure to efavirenz compared with those without exposure, the number of exposures was small (35 exposures in PACTG 219/219C and 42 in P1025) and there is overlap in defect cases between the 2 studies. Thus, additional data are needed on first-trimester efavirenz exposures to more conclusively determine if risk of neural tube defects is elevated.
The FDA advises women to avoid becoming pregnant while taking efavirenz and health care providers to avoid administration in the first trimester of pregnancy as fetal harm may occur. Although the limited data on first-trimester efavirenz exposure cannot rule out a 2- or 3-fold increased incidence of a rare outcome, such as neural tube defects, the available data from the meta-analysis on more than 2,000 births suggest that there is not a large increase (e.g., a 10-fold increase to a rate of 1%) in the risk of neural tube defects with first-trimester exposure. Pregnancy should be avoided in women receiving efavirenz, and treatment with efavirenz should be avoided during the first 8 weeks of pregnancy (the primary period of fetal organogenesis) whenever possible because of the potential for teratogenicity. Women of childbearing potential should undergo pregnancy testing before initiation of efavirenz and should be counseled about the potential risk to the fetus and desirability of avoiding pregnancy. Alternate antiretroviral (ARV) regimens that do not include efavirenz should be strongly considered in women who are planning to become pregnant (or who are sexually active and not using effective contraception) if such alternative regimens are acceptable to provider and patient and will not compromise the woman’s health. However, given that the risk of neural tube defects is restricted to the first 5 to 6 weeks of pregnancy (the neural tube closes at 36 to 39 days after last menstrual period), pregnancy is rarely recognized before 4 to 6 weeks of pregnancy, and ARV drug changes in pregnancy may be associated with loss of viral control and thus increase risk of transmission to the infant, efavirenz can be continued in pregnant women receiving efavirenz-based antiretroviral therapy who present for antenatal care in the first trimester. In such situations, additional fetal monitoring (e.g., second-trimester ultrasound) should be considered to evaluate fetal anatomy.
### Excerpt from Table 7a

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efavirenz (EFV) Sustiva</strong></td>
<td>EFV (Sustiva)</td>
<td><strong>Standard Adult Dose</strong>&lt;br&gt;• 600 mg once daily at or before bedtime, on empty stomach to reduce side effects</td>
<td>Moderate placental transfer to fetus.(^b)&lt;br&gt;Potential fetal safety concern: cynomolgus monkeys receiving EFV during the first trimester at a dose resulting in plasma levels comparable to systemic human therapeutic exposure had 3 of 20 infants with significant CNS or other malformations. In humans, there is no increase in overall birth defects with first-trimester EFV exposure. However, in humans with first-trimester exposure, there have been 6 retrospective case reports and 1 prospective case report of CNS defects and 1 prospective case report of anophthalmia with facial clefts. The relative risk with first-trimester exposure is unclear. In humans, there is no increase in overall birth defects with first-trimester EFV exposure. However, in humans with first-trimester exposure, there have been 6 retrospective case reports and 1 prospective case report of CNS defects and 1 prospective case report of anophthalmia with facial clefts. The relative risk with first-trimester exposure is unclear.</td>
</tr>
<tr>
<td>(EFV/TDF/FTC) Atripla</td>
<td>EFV 600 mg plus TDF 300 mg plus FTC 200 mg tablet</td>
<td><strong>Atripla</strong>: &lt;br&gt;• 1 tablet once daily at or before bedtime, on empty stomach to reduce side effects</td>
<td>Alternate ARV regimens that do not include EFV should be strongly considered in women who are planning to become pregnant or who are sexually active and not using effective contraception.</td>
</tr>
<tr>
<td></td>
<td>Atripla:</td>
<td><strong>PK in Pregnancy</strong>: &lt;br&gt;• AUC decreased during third trimester, compared with postpartum, but nearly all third-trimester participants exceeded target exposure.</td>
<td>Because the risk of neural tube defects is restricted to the first 5–6 weeks of pregnancy and pregnancy is rarely recognized before 4–6 weeks of pregnancy, and unnecessary ARV drug changes during pregnancy may be associated with loss of viral control and increased risk of perinatal transmission, EFV may be continued in pregnant women receiving an EFV-based regimen who present for antenatal care in the first trimester (see <a href="http://aidsinfo.nih.gov/guidelines">HIV-Infected Pregnant Women Who are Currently Receiving Antiretroviral Treatment</a>).</td>
</tr>
</tbody>
</table>

---

\(^a\) Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see [Adult Guidelines, Appendix B, Table 7](http://aidsinfo.nih.gov/guidelines)).

\(^b\) Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- **High**: >0.6
- **Moderate**: 0.3–0.6
- **Low**: <0.3

**Key to Abbreviations:** ARV = antiretroviral; CNS = central nervous system; EFV = efavirenz; FTC = emtricitabine; PK = pharmacokinetic; TDF = tenofovir disoproxil fumarate
References


Etravirine (Intelicence, ETR)
(Last updated April 29, 2016; last reviewed April 29, 2016)

Etravirine is classified as Food and Drug Administration Pregnancy Category B.

Animal Studies
Carcinogenicity
Etravirine was neither mutagenic nor clastogenic in a series of in vitro and animal in vivo screening tests.\(^1\)

Etravirine was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to approximately 104 weeks. Daily doses of 50, 200, and 400 mg/kg were administered to mice and doses of 70, 200, and 600 mg/kg were administered to rats in the initial period of approximately 41 to 52 weeks. The high and middle doses were subsequently adjusted because of tolerability and reduced by 50% in mice and by 50% to 66% in rats to allow for completion of the studies. In the mouse study, statistically significant increases in the incidences of hepatocellular carcinoma and of hepatocellular adenomas or carcinomas combined were observed in treated females. In the rat study, no statistically significant increases in tumor findings were observed in either sex. The relevance to humans of these liver tumor findings in mice is unknown. Because of tolerability of the formulation in these rodent studies, maximum systemic drug exposures achieved at the doses tested were lower than those in humans at the clinical dose (400 mg/day), with animal versus human area under the curve (AUC) ratios being 0.6-fold (mice) and 0.2- to 0.7-fold (rats).\(^1\)

Reproduction/Fertility
No effect on fertility and early embryonic development was observed when etravirine was tested in rats at maternal doses up to 500 mg/kg/day, resulting in systemic drug exposure equivalent to the recommended human dose (400 mg/day).\(^1\)

Teratogenicity/Developmental Toxicity
Animal reproduction studies in rats and rabbits at systemic exposures equivalent to those at the recommended human dose of 400 mg/day revealed no evidence of fetal toxicity or altered development. Developmental toxicity studies were performed in rabbits (at oral doses up to 375 mg/kg/day) and rats (at oral doses up to 1000 mg/kg/day). In both species, no treatment-related embryo-fetal effects (including malformations) were observed. In addition, no treatment effects were observed in a separate prenatal and postnatal study performed in rats at oral doses up to 500 mg/kg/day. The systemic exposures achieved in these animal studies were equivalent to those at the recommended human dose (400 mg/day).\(^1\)

Human Studies in Pregnancy
Pharmacokinetics
Etravirine pharmacokinetics (PK) in pregnant women have been reported in two studies. Ramgopal et al. found that AUC, C\(_{\text{min}}\) and C\(_{\text{max}}\) were increased approximately 1.4 fold in the second trimester (n = 13) and 1.2 to 1.4 fold in the third trimester (n = 10) compared with the same women postpartum (n = 10).\(^2\) Similarly, Best and colleagues found increases by 1.3 to 1.6 fold in AUC, Cmin, and Cmax during the third trimester (n = 13) compared with the same women postpartum (n = 9).\(^3\) Etravirine was well tolerated in both of these studies. Case report data are available describing etravirine use in a total of seven pregnant women.\(^4\) No adverse effects associated with etravirine use were reported. One report described etravirine PK in four pregnant women whose etravirine PK parameters were similar to those in non-pregnant adults.\(^5\)

Placental and Breast Milk Passage
The median (range) ratio of etravirine concentrations in cord blood to maternal plasma at delivery in 6 mother-infant pairs was 0.76 (0.19–4.25).\(^3\) The median (range) cord blood-to-maternal concentrations in 10 mother-infant pairs in another study was 0.32 (0.19–0.63).\(^2\) Etravirine concentrations in cord blood and maternal plasma at delivery were 112 ng/mL and 339 ng/mL, respectively (cord/maternal ratio of 33%), in one
mother-infant pair.\textsuperscript{5} In a second mother-infant pair, cord blood and maternal plasma at delivery were 218 ng/mL and 421 ng/mL (cord/maternal ratio of 51%).\textsuperscript{5} Placental passage of etravirine was described in a report of the use of etravirine, ritonavir-boosted darunavir, and enfuvirtide in a woman who gave birth to twins, with cord blood etravirine levels of 414 ng/mL in Twin 1 and 345 ng/mL in Twin 2 (no maternal delivery etravirine concentration reported).\textsuperscript{4}

In 8 women who began etravirine on postpartum day 1, plasma and breast milk concentrations were measured on postpartum days 5 and 14.\textsuperscript{7} Plasma PK were not different between days 5 and 14 and were similar to published PK parameters of etravirine in non-pregnant adults. Breast milk AUC\textsubscript{0–12} was higher in mature milk (Day 14) than in colostrum/transitional milk (Day 5); 12,954 ± 10,200 versus 4,372 ± 3,016 ng-h/mL (\(P = 0.046\)). Median etravirine concentrations in plasma and breast milk on Day 5 were 300 ng/mL and 241 ng/mL (within subject breast milk/plasma ratio of 109%). Median plasma and breast milk concentrations on day 14 were 197 ng/mL and 798 ng/mL (within-subject breast milk/plasma ratio of 327%). The maximum concentration in breast milk was significantly higher than in plasma (1,245 ± 1,159 vs. 531 ± 336 ng/mL, \(P = 0.04\)). Two women had detectable HIV RNA in breast milk on Day 14 despite suppressed plasma viral load. Etravirine concentrations in plasma and breast milk were similar in these two women compared to women with undetectable HIV RNA in breast milk. Etravirine penetrates well and may accumulate in breast milk.

**Teratogenicity/Developmental Toxicity**

In eight reported cases of etravirine use in pregnancy, no maternal, fetal, or neonatal toxicity was noted.\textsuperscript{4,6} One infant was born with a small accessory auricle on the right ear with no other malformations, but no birth defects were noted in the other children.\textsuperscript{4} Fewer than 200 first-trimester pregnancy exposures have been reported to the Antiretroviral Pregnancy Registry; therefore, no conclusions can be made about risk of birth defects.\textsuperscript{8}

**Excerpt from Table 7\textsuperscript{a}**

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etravirine (ETR) Intellence</td>
<td>Tablets: • 25 mg • 100 mg • 200 mg</td>
<td>Standard Adult Dose(s): • 200 mg twice daily with food PK in Pregnancy: • PK data in pregnancy (n = 26) suggest 1.2–1.6 fold increased etravirine exposure during pregnancy. Dosing in Pregnancy: • No change in dose indicated.</td>
<td>Variable placental transfer, usually in the moderate to high categories, ranging from 0.19–4.25 (data from 18 mother-infant pairs).\textsuperscript{b} Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Appendix B, Table 7).

\textsuperscript{b} Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- High: >0.6
- Moderate: 0.3–0.6
- Low: <0.3

**Key to Abbreviations:** ETR= etravirine; PK = pharmacokinetic

**References**


**Nevirapine (Viramune, NVP)**

*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Nevirapine is classified as Food and Drug Administration Pregnancy Category B.

**Animal Studies**

*Carcinogenicity*

Nevirapine showed no evidence of mutagenic or clastogenic activity in a battery of *in vitro* and *in vivo* studies. Hepatocellular adenomas and carcinomas were increased at all doses in male mice and rats and at higher doses in female mice and rats. Systemic exposure at all doses studied was lower than systemic exposure in humans receiving therapeutic nevirapine doses. Given the lack of genotoxic activity of nevirapine, the relevance to humans of hepatocellular neoplasms in nevirapine-treated mice and rats is unknown.

**Reproduction/Fertility**

Evidence of impaired fertility was seen in female rats at nevirapine doses providing systemic exposure comparable to human therapeutic exposure.

**Teratogenicity/Developmental Toxicity**

Teratogenic effects of nevirapine have not been observed in reproductive studies with rats and rabbits at systemic exposures approximately equivalent to or 50% greater than the recommended human dose (based on area under the curve [AUC]). In rats, however, a significant decrease in fetal weight occurred at doses producing systemic concentrations approximately 50% higher than human therapeutic exposure.

**Human Studies in Pregnancy**

**Pharmacokinetics**

The pharmacokinetics (PKs) of nevirapine have been evaluated in pregnant women receiving nevirapine as part of antiretroviral therapy (ART) during pregnancy. A study that determined nevirapine PKs in 26 women during pregnancy (7 second trimester, 19 third trimester) and again in the same women 4 to 12 weeks after delivery found that pregnancy did not alter nevirapine PK parameters. In contrast, nevirapine clearance was 20% greater, AUC was 28% lower, and maximum plasma concentration was 30% lower in 16 pregnant women compared with 13 non-pregnant women, based on nevirapine PK data from a therapeutic drug monitoring program that included 12-hour sampling; they also reported high variability in plasma nevirapine concentrations. A Dutch study reported a nonsignificant trend toward lower nevirapine exposure during pregnancy, with steady-state nevirapine concentrations of 5.2 mcg/mL in 45 pregnant women compared to 5.8 mcg/mL in 152 non-pregnant women (*P* = 0.08). No dose adjustment during pregnancy is currently recommended for nevirapine.

**Placental and Breast Milk Passage**

Nevirapine demonstrates rapid and effective placental transfer, achieving near equivalent concentrations in maternal and cord blood (cord-to-maternal-blood ratio ranging from 0.60 to 1.02). Nevirapine has also been shown to be excreted into human breast milk. In a study of 57 Malawian women receiving postpartum nevirapine-based therapy, breast-milk-to-maternal-serum concentration ratio was approximately 0.6; detectable nevirapine concentrations were found in the breastfeeding infants (inter-quartile range 0.54–1.06 mcg/mL). In data from 15 breastfeeding women receiving nevirapine-based therapy in Botswana, median maternal plasma concentration at 1 month postpartum was 6.71 mcg/mL and median maternal breast milk concentration was 1.83 mcg/mL, for a median maternal breast-milk-to-plasma ratio of 0.27. Infant exposure was measured at 1 month in 9 infants; all infants had biologically significant detectable nevirapine concentrations in their blood, with a median level of 0.37 mcg/mL (range, 0.24–1.2 mcg/mL), representing approximately 6% of median maternal value. Similar data were reported in a study of 67 mothers receiving nevirapine-based therapy in Kenya; the median concentration of nevirapine in breast milk was 4.55 mcg/mL, with median concentrations at 2, 6, and 14 weeks postpartum in breastfeeding infants of 0.99 mcg/mL, 1.03 mcg/mL, and 0.73 mcg/mL, respectively.
Teratogenicity/Developmental Toxicity

In the Antiretroviral Pregnancy Registry (APR), sufficient numbers of first-trimester exposures to nevirapine in humans have been monitored to be able to detect at least a 1.5-fold increase in risk of overall birth defects and a 2-fold increase in risk of birth defects in more commonly seen classes of birth defects in the cardiovascular and genitourinary systems. No such increase in birth defects has been observed with nevirapine. Among cases of first-trimester nevirapine exposure reported to the APR, the prevalence of birth defects was 2.9% (32 of 1,105 births; 95% CI, 2.0% to 4.1%) compared with a total prevalence of 2.7% in the U.S. population, based on monitoring by Centers for Disease Control and Prevention surveillance. Similarly, the French Perinatal Cohort recently reported no association between nevirapine and birth defects with 71% power to detect a 1.5-fold increase.11

Safety

Severe, life-threatening, and (in some cases) fatal hepatotoxicity—including fulminating and cholestatic hepatitis, hepatic necrosis, and hepatic failure and severe, life-threatening hypersensitivity skin reactions, including Stevens-Johnson syndrome (SJS)—has been reported in HIV-infected patients receiving nevirapine in combination with other drugs for treatment of HIV disease and in a small number of individuals receiving nevirapine as part of ART for post-exposure prophylaxis of nosocomial or sexual exposure to HIV. In general, in controlled clinical trials, clinical hepatic events, regardless of severity, occurred in 4.0% (range 0% to 11.0%) of patients who received nevirapine; however, the risk of nevirapine-associated liver failure or hepatic mortality has been lower, in the range of 0.04% to 0.40%. The greatest risk of severe rash or hepatic events occurs during the first 6 to 18 weeks of therapy, although the risk of toxicity continues past this period and monitoring should continue at frequent intervals.

Incidence of severe nevirapine-associated skin rash has been reported to be 5.5 to 7.3 times more common in women than men and has been reported in pregnant women. Other studies have found that hepatic adverse events (AEs) with systemic symptoms (often rash) were 3.2-fold more common in women than men. Several studies suggest that the degree of risk of hepatic toxicity varies with CD4 T lymphocyte (CD4) cell count. In a summary analysis of data from 17 clinical trials of nevirapine therapy, women with CD4 cell counts ≥250 cells/mm³ were 9.8 times more likely than women with lower CD4 cell counts to experience symptomatic, often rash-associated, nevirapine-related hepatotoxicity. Higher CD4 cell counts have also been associated with increased risk of severe nevirapine-associated skin rash. Rates of hepatotoxicity and rash similar to those in US studies have been seen in international cohorts of non-pregnant women, although not all have reported an association with CD4 cell counts ≥250 cells/mm³. In a study of 359 non-pregnant women randomized to nevirapine-based therapy in sub-Saharan Africa, higher nevirapine exposure was associated with development of severe skin toxicity, and baseline CD4 cell counts ≥250 cells/mm³ were associated with nevirapine-related liver toxicity and drug discontinuation. Some researchers have suggested that genetic variation in drug metabolism polymorphisms (e.g., CYP2B6 variants), TRAF proteins, and immune human leukocyte antigen loci may be associated with higher risk of nevirapine-associated AEs and that the relationship between genetic variants and AEs may vary by race.

Although deaths as a result of hepatic failure have been reported in HIV-infected pregnant women receiving nevirapine as part of an ART regimen, it is uncertain whether pregnancy increases the risk of hepatotoxicity in women receiving nevirapine or other antiretroviral drugs. In a systematic review of 20 studies including 3,582 pregnant women from 14 countries, the pooled proportion of women experiencing a severe hepatotoxic event was 3.6% (95% CI, 2.4% to 4.8%) and severe rash was 3.3% (95% CI, 2.1% to 4.5%); overall 6.2% of women stopped nevirapine due to an AE (95% CI, 4.0% to 8.4%). These results were comparable to published frequencies in the general adult population and frequencies comparable to non-pregnant women within the same cohorts. These data suggest that the frequency of AEs associated with nevirapine during pregnancy is not higher than reported for nevirapine in the general population, consistent with data from two multicenter prospective cohorts in which pregnancy was not associated with an increased risk of nevirapine-associated hepatic toxicity. In contrast, a recent analysis of data collected in the United Kingdom and Ireland from 2000 to 2011 evaluated 3,426 women, one quarter of whom were pregnant, and found that pregnant women taking efavirenz, maraviroc, or nevirapine were at increased risk of liver enzyme elevation.
In the systematic review, there was a nonsignificant trend toward an increased likelihood of cutaneous events (OR 1.1, 95% CI, 0.8–1.6) and severe cutaneous adverse events in pregnant women with CD4 cell counts ≥250 cell/mm³ (OR 1.4, 95% CI, 0.8–2.4). A separate systematic review of 14 studies did report a significant association of increased toxicity risk with initiation of nevirapine-based therapy during pregnancy in women with CD4 cell counts ≥250 cells/mm³. A small case-control study (6 cases, 30 controls) in South Africa recently reported that pregnancy increased the chance of developing SJS (OR 14.28, P = 0.006, 95% CI, 1.54–131.82). Nevirapine (as a component of a combination regimen) should be initiated in pregnant women with CD4 cell counts ≥250 cells/mm³ only if the benefit clearly outweighs the risk. Women with CD4 cell counts <250 cells/mm³ can receive nevirapine-based regimens, and women who become pregnant while taking nevirapine and who are tolerating their regimens well can continue therapy, regardless of CD4 cell count.

Because pregnancy itself can mimic some of the early symptoms of hepatotoxicity (i.e., pregnancy-related nausea and vomiting), health care providers caring for women receiving nevirapine during pregnancy should be aware of this potential complication. Frequent and careful monitoring of clinical symptoms and hepatic transaminases (i.e., alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) is necessary, particularly during the first 18 weeks of therapy. Some clinicians measure serum transaminases at baseline, every 2 weeks for the first month, and then monthly for the first 18 weeks; in patients with preexisting liver disease, monitoring should be performed more frequently when initiating therapy and monthly thereafter. Transaminase levels should be checked in all women who develop a rash while receiving nevirapine. Patients who develop suggestive clinical symptoms accompanied by elevation in serum transaminase levels (ALT and/or AST) or have asymptomatic but severe transaminase elevations should stop nevirapine and not receive the drug in the future.

**Excerpt from Table 7**

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nevirapine (NVP)</td>
<td>NVP (Viramune)</td>
<td>Standard Adult Dose: 200 mg once daily Viramune immediate release for 14 days (lead-in period); thereafter, 200 mg twice daily or 400 mg (Viramune XR tablet) once daily, without regard to food.</td>
<td>High placental transfer to fetus. No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects and 2-fold increase in risk of birth defects in more common classes, cardiovascular and genitourinary). Increased risk of symptomatic, often rash-associated, and potentially fatal liver toxicity among women with CD4 counts ≥250/mm³ when first initiating therapy; pregnancy does not appear to increase risk. Nevirapine should be initiated in pregnant women with CD4 cell counts ≥250 cells/mm³ only if benefit clearly outweighs risk because of potential increased risk of life-threatening hepatotoxicity in women with high CD4 cell counts. Elevated transaminase levels at baseline may increase the risk of NVP toxicity. Women who become pregnant while taking NVP-containing regimens and are tolerating them well can continue therapy, regardless of CD4 cell count.</td>
</tr>
<tr>
<td>Viramune</td>
<td>Tablets: 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viramune XR (Extended Release)</td>
<td>Oral Suspension: 50 mg/5 mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note: Generic available for all formulations</td>
<td>Viramune XR Tablets: 100 mg, 400 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| PK in Pregnancy:  | PK not significantly altered in pregnancy. Dosing in Pregnancy: No change in dose indicated. |

---

a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- High: >0.6
- Moderate: 0.3–0.6
- Low: <0.3

Key to Abbreviations: CD4 = CD4 T lymphocyte; NVP = nevirapine; PK = pharmacokinetic.
References


**Rilpivirine (Edurant, RPV)**

*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Rilpivirine is classified as Food and Drug Administration Pregnancy Category B.

**Animal Studies**

*Carcinogenicity*

Rilpivirine was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. Rilpivirine was not carcinogenic in rats when administered at doses 3 times higher than exposure in humans at the recommended dose of 25 mg once daily. Hepatocellular neoplasms were observed in both male and female mice at doses 21 times that of human therapeutic exposure; the observed hepatocellular findings in mice may be rodent-specific.

**Reproduction/Fertility**

No effect on fertility was observed when rilpivirine was tested in rats at maternal doses up to 400 mg/kg/day, resulting in systemic drug exposure equivalent to 40 times the recommended human dose.

**Teratogenicity/Developmental Toxicity**

No evidence of embryonic or fetal toxicity or an effect on reproductive function was observed in rat and rabbit dams treated with rilpivirine during pregnancy and lactation at doses 15 and 70 times higher, respectively, than exposure in humans at the recommended dose of 25 mg once daily.

**Placental and Breast Milk Passage**

Studies in lactating rats and their offspring indicate that rilpivirine is present in rat milk.

**Human Studies in Pregnancy**

*Pharmacokinetics*

A case report describing rilpivirine pharmacokinetic (PK) evaluations at 32 weeks’ gestation and again postpartum in 2 HIV-infected pregnant women showed that rilpivirine area under the curve [AUC] was decreased by 30% to 43% during pregnancy, while postpartum AUC was similar to that seen in non-pregnant adults. A similar finding was reported in a study presenting PK and safety data from 32 HIV-infected pregnant women receiving rilpivirine. Median rilpivirine AUC and trough concentrations were reduced by about 20% to 30% in the second and third trimesters, compared with postpartum. Median trough rilpivirine concentrations were significantly lower at 14 visits where the women had detectable HIV-1 RNA (30 ng/mL) compared to 62 visits with undetectable HIV-1 RNA (63 ng/mL). Ninety percent of women had trough concentrations above the protein-adjusted EC$_{90}$ for rilpivirine. PK exposure was highly variable in this study.

**Placental and Breast Milk Passage**

In the case report described above, cord blood and maternal plasma rilpivirine concentrations obtained from one mother-infant pair were 0.016 and 0.021 mg/L, for a cord blood/maternal concentration ratio of 0.74. The PK and safety study described above included rilpivirine delivery concentration data from 9 mother-infant pairs, with median (range) cord blood rilpivirine plasma concentration of 53.8 ng/mL (<10.0 to 219.7 ng/mL), maternal delivery plasma rilpivirine concentration of 103.3 ng/mL (<10.0 to 273.4 ng/mL) and cord blood/maternal plasma ratio of 0.55 (0.38 to 0.83). An *ex vivo* human cotyledon perfusion model also showed that rilpivirine crosses the placenta with fetal transfer rates ranging from 17% to 37%. No data exist on whether rilpivirine is excreted in breast milk in humans.

**Teratogenicity/Developmental Toxicity**

The number of first-trimester exposures to rilpivirine that have been monitored to date in the Antiretroviral Pregnancy Registry is insufficient to allow conclusions to be drawn regarding risk of birth defects.
Excerpt from Table 7a

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rilpivirine (RPV) Edurant</td>
<td>Complera</td>
<td>RPV (Edurant) Tablets: • 25 mg Complera: • RPV 25 mg plus TDF 300 mg plus FTC 200 mg tablet</td>
<td>Standard Adult Dose RPV (Edurant): • 25 mg once daily with food Complera: • 1 tablet once daily with food PK in Pregnancy: • RPV PK highly variable during pregnancy, RPV AUC and trough concentration reduced 20% to 30% in pregnancy compared with postpartum, but most pregnant women exceeded target exposure. Dosing in Pregnancy: • Routine dosing adjustment in all women is not recommended for RPV during pregnancy. Individual patients should be closely monitored.</td>
<td>Moderate to high placental transfer to fetus.b No evidence of teratogenicity in rats or rabbits. Insufficient data to assess for teratogenicity in humans.</td>
</tr>
</tbody>
</table>

a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- **High:** >0.6
- **Moderate:** 0.3–0.6
- **Low:** <0.3

Key to Abbreviations: AUC = area under the curve; FTC = emtricitabine; PK = pharmacokinetic; RPV = rilpivirine; TDF = tenofovir disoproxil fumarate

References


Protease Inhibitors

<table>
<thead>
<tr>
<th>Glossary of Terms for Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carcinogenic</strong>: Producing or tending to produce cancer</td>
</tr>
<tr>
<td>- Some agents, such as certain chemicals or forms of radiation, are both mutagenic and clastogenic.</td>
</tr>
<tr>
<td>- Genetic mutations and/or chromosomal damage can contribute to cancer formation.</td>
</tr>
<tr>
<td><strong>Clastogenic</strong>: Causing disruption of or breakages in chromosomes</td>
</tr>
<tr>
<td><strong>Genotoxic</strong>: Damaging to genetic material such as DNA and chromosomes</td>
</tr>
<tr>
<td><strong>Mutagenic</strong>: Inducing or capable of inducing genetic mutation</td>
</tr>
<tr>
<td><strong>Teratogenic</strong>: Interfering with fetal development and resulting in birth defects</td>
</tr>
</tbody>
</table>

For information regarding the PI class of drugs and potential metabolic complications during pregnancy and pregnancy outcome, see [Combination Antiretroviral Drug Regimens and Pregnancy Outcome](https://aidsinfo.nih.gov/guidelines).

**Atazanavir (Reyataz, ATV)**

*(Last updated June 7, 2016; last reviewed June 7, 2016)*

According to the Food and Drug Administration, atazanavir has been evaluated in a limited number of women during pregnancy, and available human and animal data suggest that atazanavir does not increase the risk of major birth defects overall compared to the background rate.¹

**Animal Carcinogenicity Studies**

In *in vitro* and *in vivo* assays, atazanavir shows evidence of clastogenicity but not mutagenicity. Two-year carcinogenicity studies in mice and rats were conducted with atazanavir. In female mice, the incidence of benign hepatocellular adenomas was increased at systemic exposures 2.8- to 2.9-fold higher than those in humans at the recommended therapeutic dose (300 mg atazanavir boosted with 100 mg ritonavir once daily). There was no increase in the incidence of tumors in male mice at any dose. In rats, no significant positive trends in the incidence of neoplasms occurred at systemic exposures up to 1.1-fold (males) or 3.9-fold (females) higher than those in humans at the recommended therapeutic dose.¹

**Reproduction/Fertility**

No effect of atazanavir on reproduction or fertility in male and female rodents was seen at area under the curve (AUC) levels that were 0.9-fold in males and 2.3-fold in females compared with the exposures achieved in humans at the recommended therapeutic dose.¹

**Teratogenicity/Developmental Toxicity**

In animal reproduction studies, there was no evidence of teratogenicity in offspring born to animals at systemic drug exposure levels (AUC) 0.7 (in rabbits) to 1.2 (in rats) times those observed at the human clinical dose (300 mg atazanavir boosted with 100 mg ritonavir once daily). In developmental toxicity studies in rats, maternal dosing that produced systemic drug exposure 1.3 times the human exposure resulted in maternal toxicity and also resulted in weight loss or suppression of weight gain in the offspring. However, offspring were unaffected at lower maternal doses that produced systemic drug exposure equivalent to that observed in humans at the recommended therapeutic dose.¹ A more recent study demonstrated an association of maternal PI use (including atazanavir) with lower progesterone levels which correlated with lower birthweight in mice, but this potential mechanism requires further study.²,³

**Placental and Breast Milk Passage**

Atazanavir is excreted in the milk of lactating rats and was associated with neonatal growth retardation that reversed after weaning.¹
Human Studies in Pregnancy

Pharmacokinetics

Several studies have investigated the pharmacokinetics (PKs) and virologic outcomes of atazanavir/ritonavir in pregnancy. Overall, most pregnant women achieved undetectable HIV RNA at the time of delivery. In a retrospective study reporting trough atazanavir concentrations at a median of 30 weeks’ gestation (14 in the third trimester) in 19 pregnant women receiving atazanavir 300 mg and ritonavir 100 mg once daily, all but two women had a trough atazanavir concentration >100 ng/mL. In studies that have evaluated full PK profiles of atazanavir when administered daily as 300 mg with 100 mg ritonavir during pregnancy, atazanavir AUC was lower during pregnancy than in historic data from HIV-infected non-pregnant adults. In one of the studies there was no difference between atazanavir AUC during pregnancy and postpartum, but AUC at both times was lower than that in non-pregnant HIV-infected historic controls. In the other studies, atazanavir AUC was lower during pregnancy than it was in the same patients postpartum and in non-pregnant control populations.

Atazanavir/ritonavir combined with tenofovir disoproxil fumarate (TDF) and emtricitabine provides a complete once-a-day antiretroviral therapy regimen for pregnant women; however, the atazanavir AUC in pregnant women in the third trimester receiving concomitant TDF compared with women who were not receiving concomitant TDF was 30% lower, an effect similar to that seen in non-pregnant adults. The increase in atazanavir AUC postpartum relative to that in the third trimester was similar for women taking concomitant TDF and for those not taking concomitant TDF. In one of the studies, atazanavir AUC was lower during pregnancy than it was in the same patients postpartum and in non-pregnant control populations.

In studies investigating an increased dose of atazanavir of 400 mg with 100 mg ritonavir once daily during pregnancy, pregnant women receiving the increased dose without TDF had an atazanavir AUC equivalent to that seen in historic non-pregnant HIV-infected controls receiving standard-dose atazanavir without TDF. Pregnant women receiving the increased atazanavir dose with TDF had an AUC equivalent to that seen in non-pregnant HIV-infected patients receiving standard-dose atazanavir with TDF. Although some experts recommend increased atazanavir dosing in all women during the second and third trimesters, the package insert recommends increased atazanavir dosing only for antiretroviral-experienced pregnant women in the second and third trimesters also receiving either TDF or an H2-receptor antagonist. TDM of atazanavir in pregnancy may also be useful. For additional details about dosing with interacting concomitant medications, please see Drug Interactions in the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.

Placental and Breast Milk Passage

In studies of women receiving atazanavir/ritonavir-based combination therapy during pregnancy, cord blood atazanavir concentration averaged 13% to 21% of maternal serum levels at delivery.

In a study of three women, the median ratio of breast milk atazanavir concentration to that in plasma was 13%.

Teratogenicity/Developmental Toxicity

In a multicenter U.S. cohort of HIV-exposed but uninfected children, first-trimester atazanavir exposure was associated with increased odds of congenital anomalies of skin (aOR = 5.24, P = 0.02) and musculoskeletal system (aOR = 2.55, P = 0.007). On the other hand, there was no association between first-trimester atazanavir exposure and birth defects in a French cohort, though this study had <50% power to detect an adjusted odds ratio of 1.5. The Antiretroviral Pregnancy Registry has monitored sufficient numbers of first-trimester exposures to atazanavir in humans to be able to detect at least a 1.5-fold increase in risk of overall birth defects and no such increase in birth defects has been observed with atazanavir. The prevalence of birth
defects with first-trimester atazanavir exposure was 2.2% (24 of 1,093 births; 95% confidence interval [CI], 1.4% to 3.2%) compared with a 2.7% total prevalence in the U.S. population, based on Centers for Disease Control and Prevention surveillance.18

Maternal PI use (including atazanavir) was associated with lower progesterone levels, but the clinical significance of this finding requires further study.2

Other Safety Data

Elevation in indirect (unconjugated) bilirubin attributable to atazanavir-related inhibition of hepatic uridine diphosphate glucuronosyltransferase (UGT) enzyme occurs frequently during treatment with atazanavir, including during pregnancy.19 The effects on the fetus of elevated maternal indirect bilirubin throughout pregnancy are unknown. Dangerous or pathologic postnatal elevations in bilirubin have not been reported in infants born to mothers who received atazanavir during pregnancy.1,5,7,8,10,20-22 Although some studies have suggested that neonatal bilirubin elevations requiring phototherapy occur more frequently after prenatal atazanavir exposure, decisions to use phototherapy to treat infants with hyperbilirubinemia frequently are subjective and guidelines for phototherapy of infants vary between countries, making it difficult to compare the severity of hyperbilirubinemia between patients within a study and in different studies.20,21 Elevated neonatal bilirubin in atazanavir-exposed neonates is not associated with UGT-1 genotypes associated with decreased UGT function.22

In an evaluation of neurodevelopmental in 374 HIV-exposed but uninfected—infants aged 9 to 15 months, the adjusted mean score on the language domain of the Bayley-III test was significantly lower for infants with perinatal exposure to atazanavir compared to those with exposure to other drugs.23 In a study of language assessments among 792 HIV-exposed—but uninfected—children (aged 1 and 2 years) atazanavir-exposed children had an increased risk of late language emergence at age 12 months (adjusted odds ratio 1.83, 95% CI, 1.10–3.04) compared with atazanavir-unexposed children but the association was not significant at 24 months.24

Hypoglycemia (glucose <40 mg/dL) that could not be attributed to maternal glucose intolerance, difficult delivery, or sepsis has been reported in three of 38 atazanavir-exposed infants with glucose samples collected in the first day of life. All three hypoglycemic infants’ glucose samples were adequately collected and processed in a timely fashion.1 This finding of infant hypoglycemia is similar to a prior report in which two (both nelfinavir) of 14 infants exposed to PIs (nelfinavir, saquinavir, and indinavir) developed hypoglycemia in the first day of life.25
### Generic Name (Abbreviation) Trade Name

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atazanavir (ATV) Reyataz</strong>&lt;br&gt;Note: Must be combined with low-dose RTV boosting in pregnancy</td>
<td><strong>Atazanavir (Reyataz)</strong>&lt;br&gt;<strong>Capsules:</strong>&lt;br&gt;• 150 mg&lt;br&gt;• 200 mg&lt;br&gt;• 300 mg&lt;br&gt;<strong>Oral Powder:</strong>&lt;br&gt;• 50 mg packet</td>
<td><strong>Standard Adult Dose</strong>&lt;br&gt;&lt;br&gt;<strong>Atazanavir [Reyataz]</strong>&lt;br&gt;&lt;br&gt;<strong>ARV-Naive Patients</strong>&lt;br&gt;&lt;br&gt;<strong>Without RTV Boosting:</strong>&lt;br&gt;• ATV 400 mg once daily with food; ATV without RTV boosting &lt;b&gt;is not recommended&lt;/b&gt; when used with TDF, H₂-receptor antagonists, or PPIs, or during pregnancy.&lt;br&gt;&lt;br&gt;<strong>With RTV Boosting:</strong>&lt;br&gt;• ATV 300 mg plus RTV 100 mg once daily with food&lt;br&gt;• When combined with EFV in ARV-naive patients: ATV 400 mg plus RTV 100 mg once daily with food&lt;br&gt;&lt;br&gt;<strong>ARV-Experienced Patients:</strong>&lt;br&gt;• ATV 300 mg plus RTV 100 mg once daily with food&lt;br&gt;• Do not use with PPIs or EFV.&lt;br&gt;• If combined with an H₂-receptor antagonist: ATV 300 mg plus RTV 100 mg once daily with food&lt;br&gt;• If combined with an H₂-receptor antagonist and TDF: ATV 400 mg plus RTV 100 mg once daily with food&lt;br&gt;<strong>Powder Formulation:</strong>&lt;br&gt;• Oral powder is taken once daily with food at the same recommended adult dosage as the capsules along with ritonavir.</td>
</tr>
<tr>
<td><strong>Atazanavir/Cobicistat (ATV/COBI) Evotaz</strong></td>
<td><strong>Evotaz:</strong>&lt;br&gt;• ATV 300 mg plus COBI 150 mg tablet&lt;br&gt;<strong>PK in Pregnancy</strong>&lt;br&gt;&lt;br&gt;<strong>Atazanavir (Reyataz):</strong>&lt;br&gt;• ATV concentrations reduced during pregnancy; further reduced when given concomitantly with TDF or H₂-receptor antagonist.&lt;br&gt;&lt;br&gt;<strong>Evotaz:</strong>&lt;br&gt;• No PK studies in human pregnancy.&lt;br&gt;&lt;br&gt;<strong>Dosing in Pregnancy</strong>&lt;br&gt;&lt;br&gt;<strong>Atazanavir [Reyataz]:</strong>&lt;br&gt;• Use of unboosted ATV &lt;b&gt;is not recommended&lt;/b&gt; during pregnancy.&lt;br&gt;• Use of ATV not recommended for treatment-experienced pregnant women taking TDF &lt;b&gt;and&lt;/b&gt; an H₂-receptor antagonist.&lt;br&gt;• Use of an increased dose (400 mg ATV plus 100 mg RTV once daily with food) during the second and third trimesters results in plasma concentrations equivalent to those in non-pregnant adults on standard dosing. Although some experts recommend increased ATV dosing in all women during the second and third trimesters, the package insert recommends increased ATV dosing only for ARV-experienced pregnant women in the second and third trimesters also receiving either TDF or an H₂-receptor antagonist.&lt;br&gt;&lt;br&gt;<strong>Evotaz:</strong>&lt;br&gt;• Insufficient data to make dosing recommendation.</td>
<td></td>
</tr>
</tbody>
</table>

---

**Excerpt from Table 7**

| Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio: |
| High: >0.6 | Moderate: 0.3–0.6 | Low: <0.3 |

**Key to Abbreviations:** ARV = antiretroviral; ATV = atazanavir; COBI = cobicistat; EFV = efavirenz; PK = pharmacokinetic; PPI = proton pump inhibitors; RTV = ritonavir; TDF = tenofovir disoproxil fumarate

**Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States**

---

References


Darunavir (Prezista, DRV)
(Last reviewed August 6, 2015; last updated August 6, 2015)

Darunavir is classified as Food and Drug Administration Pregnancy Category C.

Animal Studies
Carcinogenicity
Darunavir was neither mutagenic nor clastogenic in a series of in vitro and animal in vivo screening tests. A dose-related increase in the incidence of hepatocellular adenomas and carcinomas was observed in both male and female mice and rats as well as an increase in thyroid follicular cell adenomas in male rats. The observed hepatocellular findings in rodents are considered to be of limited relevance to humans. Repeated administration of darunavir to rats caused hepatic microsomal enzyme induction and increased thyroid hormone elimination, which predispose rats, but not humans, to thyroid neoplasms. At the highest tested doses, the systemic exposures to darunavir (based on area under the curve) were between 0.4- and 0.7-fold (mice) and 0.7- and 1-fold (rats) those observed in humans at the recommended therapeutic doses (600/100 mg twice daily or 800/100 mg/day).

Reproduction/Fertility
No effects on fertility and early embryonic development were seen with darunavir in rats.

Teratogenicity/Developmental Toxicity
No embryotoxicity or teratogenicity was seen in mice, rats, or rabbits. Because of limited bioavailability of darunavir in animals and dosing limitation, the plasma exposures were approximately 50% (mice and rats) and 5% (rabbits) of those obtained in humans. In the rat prenatal and postnatal development study, a reduction in pup weight gain was observed with darunavir alone or with ritonavir exposure via breast milk during lactation. In juvenile rats, single doses of darunavir (20 mg/kg–160 mg/kg at age 5–11 days) or multiple doses of darunavir (40 mg/kg–1000 mg/kg at age 12 days) caused mortality. The deaths were associated with convulsions in some of the animals. Within this age range, exposures in plasma, liver, and brain were dose- and age-dependent and were considerably greater than those observed in adult rats. These findings were attributed to the ontogeny of the cytochrome P450 liver enzymes involved in the metabolism of darunavir and the immaturity of the blood-brain barrier. Sexual development, fertility, or mating performance of offspring was not affected by maternal treatment.

Placental and Breast Milk Passage
No animal studies of placental passage of darunavir have been reported. Passage of darunavir into breast milk has been noted in rats.

Human Studies in Pregnancy
Pharmacokinetics
Three intensive pharmacokinetic (PK) studies of darunavir/ritonavir administered as 600 mg/100 mg twice a day or 800 mg/100 mg once a day during pregnancy have been completed.1-3 These studies demonstrate 17% to 33% reductions in darunavir plasma concentrations during the third trimester compared with postpartum.1-3 Two of these studies measured darunavir protein binding during pregnancy with conflicting results. One study found no change in darunavir protein binding during the third trimester while the other found a decrease.1-4 Because of low trough levels with once-daily dosing, twice-daily dosing of darunavir is recommended during pregnancy, especially for antiretroviral-experienced patients. A study of use of an increased twice-daily darunavir dose during pregnancy is underway. The PK and safety of darunavir/cobicistat during pregnancy have not been studied.
**Placental and Breast Milk Passage**

In an *ex vivo* human cotyledon perfusion model, the mean fetal transfer rate was 15%. In 4 studies reporting data from between eight and 14 subjects each, the median ratio of darunavir concentration in cord blood to that in maternal delivery plasma ranged from 13% to 24%. No data are available describing breast milk passage of darunavir in humans.

**Teratogenicity Data**

Among cases of first-trimester darunavir exposure reported to the Antiretroviral Pregnancy Registry, prevalence of birth defects was 2.3% (6 of 258 births; 95% CI, 0.9% to 5.0%) compared with 2.7% in the U.S. population, based on Centers for Disease Control and Prevention surveillance.

**Other Safety Issues**

No safety issues have been observed in case reports and small PK studies of darunavir in pregnancy.

---

### Excerpt from Table 7

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darunavir (DRV) Prezista</td>
<td>Tablets: • 75 mg • 150 mg • 600 mg • 800 mg Oral Suspension: • 100 mg/mL Table (Co-Formulated): • DRV 800 mg plus COBI 150 mg</td>
<td>Standard Adult Dose ARV-Naive Patients: • DRV 800 mg plus RTV 100 mg once daily with food • DRV 800 mg plus COBI 150 mg once daily with food ARV-Experienced Patients: If No DRV Resistance Mutations: • DRV 800 mg plus RTV 100 mg once daily with food • DRV 800 mg plus COBI 150 mg once daily with food If Any DRV Resistance Mutations: • DRV 600 mg plus RTV 100 mg twice daily with food</td>
<td>Low placental transfer to fetus. No evidence of teratogenicity in mice, rats, or rabbits. Must be given as low-dose, RTV-boosted regimen.</td>
</tr>
<tr>
<td>Darunavir/ Cobicistat (DRV/COBI) Prezcobix</td>
<td>Tablets: • 75 mg • 150 mg • 600 mg • 800 mg Oral Suspension: • 100 mg/mL Table (Co-Formulated): • DRV 800 mg plus COBI 150 mg</td>
<td>PK in Pregnancy: • Decreased exposure in pregnancy with use of DRV/RTV. Dosing in Pregnancy: • Once-daily dosing with DRV/RTV is not recommended during pregnancy. Twice-daily DRV/RTV dosing recommended for all pregnant women. Increased twice-daily DRV dose (DRV 800 mg plus RTV 100 mg with food) during pregnancy is being investigated. • No pregnancy PK/safety data for DRV/COBI co-formulation, so not recommended for use in pregnancy.</td>
<td></td>
</tr>
</tbody>
</table>

* Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

**Key to Abbreviations:**
- **ARV** = antiretroviral
- **COBI** = cobicistat
- **DRV** = darunavir
- **PK** = pharmacokinetic
- **RTV** = ritonavir

**References**


**Fosamprenavir (Lexiva, FPV)**

*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Fosamprenavir is classified as Food and Drug Administration Pregnancy Category C.

**Animal Studies**

*Carcinogenicity*

Fosamprenavir and amprenavir were neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. Carcinogenicity studies of fosamprenavir showed an increase in the incidence of hepatocellular adenomas and hepatocellular carcinomas at all doses tested in male mice and at the highest dose tested in female mice. In rats, the incidence of hepatocellular adenomas and thyroid follicular cell adenomas in males (all doses tested) and in females (two highest doses tested) was also increased. Repeat dose studies in rats produced effects consistent with enzyme activation, which predisposes rats, but not humans, to thyroid neoplasms. In rats only, there was an increase in interstitial cell hyperplasia at higher doses and an increase in uterine endometrial adenocarcinoma at the highest dose tested. The incidence of endometrial findings was slightly increased over concurrent controls but was within background range for female rats. Thus, the relevance of the uterine endometrial adenocarcinomas is uncertain. Exposures in the carcinogenicity studies were 0.3- to 0.7 (mice) and 0.7- to 1.4 (rats) times those in humans given 1400 mg twice daily of fosamprenavir alone and were 0.2- to 0.3 (mice) and 0.3- to 0.7 (rats) times those in humans given 1400 mg once daily of fosamprenavir plus 200 mg ritonavir once daily or 0.1- to 0.3 (mice) and 0.3- to 0.6 (rats) times those in humans given 700 mg fosamprenavir plus 100 mg ritonavir twice daily.

*Reproduction/Fertility*

No impairment of fertility or mating was seen in rats at doses providing 3 to 4 times the human exposure to fosamprenavir alone or exposure similar to that with fosamprenavir and ritonavir dosing in humans. No effect was seen on the development or maturation of sperm in rats at these doses.

*Teratogenicity/Developmental Toxicity*

Fosamprenavir was studied in rabbits at 0.8 times and in rats at twice the exposure in humans to fosamprenavir alone and at 0.3 (rabbits) and 0.7 (rats) times the exposure in humans to the combination of fosamprenavir and ritonavir. In rabbits administered fosamprenavir (alone or in combination), the incidence of abortion was increased. In contrast, administration of amprenavir at a lower dose in rabbits was associated with abortions and an increased incidence of minor skeletal variations from deficient ossification of the femur, humerus, and trochlea. Fosamprenavir administered to pregnant rats (at twice human exposure) was associated with a reduction in pup survival and body weights in rats. F1 female rats had an increased time to successful mating, an increased length of gestation, a reduced number of uterine implantation sites per litter, and reduced gestational body weights, compared to controls.

*Placental and Breast Milk Passage*

Amprenavir is excreted in the milk of lactating rats.

**Human Studies in Pregnancy**

*Pharmacokinetics*

Data on fosamprenavir in pregnant women are limited. Fosamprenavir pharmacokinetic (PK) data have been reported in 26 women during pregnancy and postpartum. Following standard dosing with fosamprenavir 700 mg and ritonavir 100 mg, fosamprenavir area under the curve and 12-hour trough concentration were somewhat lower during pregnancy and higher postpartum, compared to historical data. Fosamprenavir exposure during pregnancy appeared to be adequate for patients without protease inhibitor resistance mutations. For the postpartum period, potential PK interactions with hormonal contraceptives should be taken into account (see Table 3 in Preconception Counseling and Care).
Placental and Breast Milk Passage

In a small study of women receiving fosamprenavir during pregnancy, the median (range) amprenavir concentration in cord blood was 0.27 (0.09–0.60) µg/mL, and the median (range) ratio of amprenavir concentration in cord blood to that in maternal plasma at the time of delivery was 0.24 (0.06–0.93). A second small study in pregnancy yielded a similar mean ratio (95% confidence interval) of amprenavir concentration in cord blood to that in maternal plasma at the time of delivery of 0.27 (0.24, 0.30). Whether amprenavir is excreted in human breast milk is unknown.

Teratogenicity/Developmental Toxicity

Two birth defects out of 108 live births with first-trimester exposure and two birth defects out of 36 live births with second- or third-trimester exposure have been reported to the Antiretroviral Pregnancy Registry. These numbers are insufficient to allow conclusions to be drawn regarding the risk of birth defects.

Excerpt from Table 7

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Fosamprenavir</em> (FPV)</td>
<td>Tablets:</td>
<td><strong>Standard Adult Dose</strong></td>
<td>Low placental transfer to fetus. b</td>
</tr>
<tr>
<td><em>Lexiva</em> (a prodrug of amprenavir)</td>
<td>700 mg</td>
<td><strong>ARV-Naive Patients:</strong></td>
<td>Insufficient data to assess for teratogenicity in humans. Increased fetal loss in rabbits but no increase in defects in rats and rabbits. Must be given as low-dose RTV-boosted regimen in pregnancy.</td>
</tr>
<tr>
<td>Oral Suspension:</td>
<td>50 mg/mL</td>
<td><strong>FPV 1400 mg twice daily without food, or</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI-Experienced Patients (Once-Daily Dosing Not Recommended):</strong></td>
<td></td>
<td><strong>FPV 1400 mg plus RTV 100 or 200 mg once daily without food, or</strong></td>
<td></td>
</tr>
<tr>
<td>PK in Pregnancy:</td>
<td></td>
<td><strong>FPV 700 mg plus RTV 100 mg twice daily without food</strong></td>
<td></td>
</tr>
<tr>
<td>• With RTV boosting, AUC is reduced during the third trimester. However, exposure is greater during the third trimester with boosting than in non-pregnant adults without boosting, and trough concentrations achieved during the third trimester were adequate for patients without PI resistance mutations.</td>
<td></td>
<td><strong>FPV 700 mg plus RTV 100 mg twice daily without food; or</strong></td>
<td></td>
</tr>
<tr>
<td>Dosing in Pregnancy:</td>
<td></td>
<td><strong>FPV 1400 mg plus RTV 300 mg once daily without food</strong></td>
<td></td>
</tr>
<tr>
<td>• Use of unboosted FPV or once-daily FPV with RTV boosting is not recommended during pregnancy. No change is indicated in standard boosted twice-daily dose (FPV 700 mg plus RTV 100 mg twice daily without food).</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).
b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio: High: >0.6 Moderate: 0.3–0.6 Low: <0.3

Key to Abbreviations: ARV = antiretroviral; AUC = area under the curve; EFV = efavirenz; FPV = fosamprenavir; PI = protease inhibitor; PK = pharmacokinetic; RTV= ritonavir

References


**Indinavir (Crixivan, IDV)**
*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Indinavir is classified as Food and Drug Administration Pregnancy Category C.

**Animal Studies**

*Carcinogenicity*

Indinavir is neither mutagenic nor clastogenic in both *in vitro* and *in vivo* assays. No increased incidence of any tumor types occurred in long-term studies in mice. At the highest dose studied in rats (640 mg/kg/day or 1.3-fold higher than systemic exposure at human therapeutic doses), thyroid adenomas were seen in male rats.*

**Reproduction/Fertility**

No effect of indinavir has been seen on reproductive performance, fertility, or embryo survival in rats.*

**Teratogenicity/Developmental Toxicity**

There has been no evidence of teratogenicity or treatment-related effects on embryonic/fetal survival or fetal weights of indinavir in rats, rabbits, or dogs at exposures comparable to, or slightly greater than, therapeutic human exposure. In rats, developmental toxicity manifested by an increase in supernumerary and cervical ribs was observed at doses comparable to those administered to humans. No treatment-related external or visceral changes were observed in rats. No treatment-related external, visceral, or skeletal changes were seen in rabbits (fetal exposure limited, approximately 3% of maternal levels) or dogs (fetal exposure approximately 50% of maternal levels). Indinavir was administered to Rhesus monkeys during the third trimester (at doses up to 160 mg/kg twice daily) and to neonatal Rhesus monkeys (at doses up to 160 mg/kg twice daily). When administered to neonates, indinavir caused an exacerbation of the transient physiologic hyperbilirubinemia seen in this species after birth; serum bilirubin values were approximately 4-fold greater than controls at 160 mg/kg twice daily. A similar exacerbation did not occur in neonates after *in utero* exposure to indinavir during the third trimester. In Rhesus monkeys, fetal plasma drug levels were approximately 1% to 2% of maternal plasma drug levels approximately 1 hour after maternal dosing at 40, 80, or 160 mg/kg twice daily.*

**Placental and Breast Milk Passage**

Significant placental passage of indinavir occurs in rats and dogs, but only limited placental transfer occurs in rabbits. Indinavir is excreted in the milk of lactating rats at concentrations slightly greater than maternal levels.*

**Human Studies in Pregnancy**

*Pharmacokinetics*

The optimal dosing regimen for use of indinavir in pregnant patients has not been established. Two studies of the pharmacokinetics (PKs) of unboosted indinavir (800 mg 3 times/day) during pregnancy demonstrated significantly lower indinavir plasma concentrations during pregnancy than postpartum.* Use of unboosted indinavir is not recommended in HIV-infected pregnant patients because of the substantially lower antepartum exposures observed in these studies and the limited experience in this patient population.

Several reports have investigated use of indinavir/ritonavir during pregnancy. In an intensive PK study of 26 Thai pregnant women receiving 400 mg indinavir/100 mg ritonavir twice a day, indinavir plasma concentrations were significantly lower during pregnancy than postpartum. The median trough indinavir concentration was 0.13 µg/mL; 24% of subjects had trough concentrations below 0.10 µg/mL, the target trough concentration used in therapeutic drug monitoring programs; and 81% had RNA viral loads <50 copies/mL at delivery.* In a study of pregnant French women receiving 400 mg indinavir/100 mg ritonavir twice a day, the median indinavir trough concentration was 0.16 µg/mL, 18% of subjects had trough concentrations below 0.12 µg/mL, and 93% had HIV RNA level <200 copies/mL at delivery.* In a small study of two patients who received indinavir 800 mg and ritonavir 200 mg twice daily, third-trimester indinavir area under the curve exceeded that for historical non-pregnant controls.* The available data are insufficient to allow for definitive...
Placental and Breast Milk Passage

In studies of pregnant women receiving unboosted indinavir and their infants, transplacental passage of indinavir was minimal. In a study of Thai pregnant women receiving indinavir/ritonavir, median cord blood indinavir concentration was 0.12 µg/mL, median maternal plasma delivery concentration was 0.96 µg/mL, and the median ratio between indinavir concentrations in cord blood and maternal plasma at delivery was 0.12. In one woman taking indinavir 600 mg and ritonavir 200 mg twice daily, indinavir concentrations in breast milk were 90% to 540% of plasma concentrations over the first 5 days after delivery.

Teratogenicity/Developmental Toxicity

Although the French Perinatal Cohort reported an association of head and neck birth defects with first trimester exposure to indinavir (3 defects in 350 first-trimester exposures, 0.9%), the Antiretroviral Pregnancy Registry (APR) has not observed an increase in birth defects with indinavir. Among cases of first-trimester indinavir exposure reported to the APR, defects have been seen in 2.4% (7/289; 95% CI, 1.0% to 4.9%) compared to total prevalence of birth defects in the U.S. population based on Centers for Disease Control and Prevention surveillance of 2.7%.

Excerpt from Table 7

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indinavir (IDV) Crixivan</strong></td>
<td>Capsules: • 200 mg • 400 mg</td>
<td><strong>Standard Adult Dose Without RTV Boosting:</strong> • IDV 800 mg every 8 hours, taken 1 hour before or 2 hours after meals; may take with skim milk or low-fat meal. <strong>With RTV Boosting:</strong> • IDV 800 mg plus RTV 100 mg twice daily without regard to meals <strong>PK in Pregnancy:</strong> • IDV exposure markedly reduced when administered without RTV boosting during pregnancy. IDV exposure low with IDV 400 mg/RTV 100 mg dosing during pregnancy; no PK data available on alternative boosted dosing regimens in pregnancy. <strong>Dosing in Pregnancy:</strong> • Use of unboosted IDV is not recommended during pregnancy.</td>
<td><strong>Minimal placental transfer to fetus.</strong> <strong>No evidence of human teratogenicity in cases reported to the APR (can rule out 2-fold increase in overall birth defects).</strong> <strong>Must be given as low-dose, RTV-boosted regimen in pregnancy.</strong> <strong>Theoretical concern regarding increased indirect bilirubin levels, which may exacerbate physiologic hyperbilirubinemia in neonates. Minimal placental passage mitigates this concern.</strong></td>
</tr>
</tbody>
</table>

References


**Lopinavir/Ritonavir (Kaletra, LPV/r)**

*(Last updated August 6, 2015; last reviewed August 6, 2015)*

Lopinavir/ritonavir (LPV/r) is classified as Food and Drug Administration Pregnancy Category C.

### Animal Studies

#### Carcinogenicity

Neither lopinavir nor ritonavir was found to be mutagenic or clastogenic in a battery of *in vitro* and *in vivo* assays. The LPV/r combination was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to 104 weeks. Results showed an increased incidence of benign hepatocellular adenomas and increased combined incidence of hepatocellular adenomas plus carcinoma in male and female mice and male rats at doses that produced approximately 1.6 to 2.2 times (mice) and 0.5 times (rats) the human exposure at the recommended therapeutic dose of 400 mg/100 mg (based on area under the curve $[AUC]_{0–24hr}$ measurement). Administration of LPV/r did not cause a statistically significant increase in incidence of any other benign or malignant neoplasm in mice or rats.

#### Reproduction/Fertility

Lopinavir in combination with ritonavir at a 2:1 ratio produced no effects on fertility in male and female rats with exposures approximately 0.7-fold for lopinavir and 1.8-fold for ritonavir of the exposures in humans at the recommended therapeutic dose.

#### Teratogenicity/Developmental Toxicity

No evidence exists of teratogenicity with administration of LPV/r to pregnant rats or rabbits. In rats treated with a maternally toxic dosage (100 mg lopinavir/50 mg ritonavir/kg/day), embryonic and fetal developmental toxicities (e.g., early resorption, decreased fetal viability, decreased fetal body weight, increased incidence of skeletal variations, and skeletal ossification delays) were observed. Drug exposure in the pregnant rats was 0.7-fold for lopinavir and 1.8-fold for ritonavir of the exposures in humans at the recommended therapeutic dose. In a perinatal and postnatal study in rats, a decrease in survival of pups between birth and postnatal Day 21 occurred with exposure to 40 mg lopinavir/20 mg ritonavir/kg/day or greater. In rabbits, no embryonic or fetal developmental toxicities were observed with a maternally toxic dosage, where drug exposure was 0.6-fold for lopinavir and 1-fold for ritonavir of the exposures in humans at the recommended therapeutic dose.

In a study of pregnant rats receiving chronic administration of zidovudine, lopinavir, and ritonavir, maternal body weight gain was significantly reduced, but no adverse fetal parameters were observed. In pregnant mice, ritonavir, lopinavir and atazanavir were associated with significantly lower progesterone levels, and the lower progesterone levels directly correlated with lower fetal weight.

### Placental and Breast Milk Passage

No information is available on placental transfer of lopinavir in animals. Studies in rats show secretion of lopinavir in breast milk.

### Human Studies in Pregnancy

#### Pharmacokinetics

The original capsule formulation of LPV/r has been replaced by a tablet formulation that is heat-stable, has improved bioavailability characteristics, and does not have to be administered with food. Pharmacokinetic (PK) studies of standard adult LPV/r doses (400 mg/100 mg twice a day) using either the capsule or tablet formulations in pregnant women have demonstrated a reduction in lopinavir plasma concentrations during pregnancy of around 30% compared with that in non-pregnant adults. Further reductions in lopinavir exposure by 33% were demonstrated in food-insecure, malnourished pregnant women in Uganda compared to well-nourished, historical pregnant controls. The authors attributed this reduction to decreased bioavailability. Increasing dose of LPV/r during pregnancy to 600 mg/150 mg (tablets) results in lopinavir plasma concentrations equivalent to those seen in non-pregnant adults receiving standard doses.


of clinical experience suggest that most, but not all, pregnant women receiving standard LPV/r tablet dosing during pregnancy will have trough lopinavir concentrations that exceed 1.0 mcg/mL, the usual trough concentration target used in therapeutic drug monitoring programs for antiretroviral-naive subjects, but not the higher trough concentrations recommended for protease inhibitor (PI)-experienced subjects.\textsuperscript{4,7} A population PK study of LPV/r in 154 pregnant women demonstrated that body weight influences lopinavir clearance and volume, with larger women (>100 kg) or women who missed a dose at higher risk for subtherapeutic trough concentrations when taking the standard dose during pregnancy.\textsuperscript{12} In one study of 29 women, lopinavir plasma protein binding was reduced during pregnancy, but the resulting increase in free (unbound) drug was insufficient to make up for the reduction in total plasma lopinavir concentration associated with pregnancy.\textsuperscript{13} In a study of 12 women, total lopinavir exposure was significantly decreased throughout pregnancy, but unbound AUC and C12 did not differ throughout pregnancy, even with an increased dose of 500/125 mg.\textsuperscript{14} Bonafe, et al. randomized 32 pregnant women to standard dose and 31 pregnant women to the 600/150 mg dose of LPV/r at gestational ages between 14 and 33 weeks. No differences in adverse events were seen between groups. In women with baseline viral loads $>50$ copies/mL, 45% in the standard dose group had plasma viral loads $>50$ copies/mL during the last 4 weeks of pregnancy, compared to 10.5% in the increased dose group ($P = 0.01$). In women with baseline viral loads $<50$ copies/mL, no difference was seen between groups in viral load measurements in the last 4 weeks of pregnancy.\textsuperscript{15}

These studies have led some experts to support use of an increased dose of LPV/r in HIV-infected pregnant women during the second and third trimesters, especially in PI-experienced pregnant women and women who start treatment during pregnancy with a baseline viral load $>50$ copies/mL. If standard doses of LPV/r are used during pregnancy, virologic response and lopinavir drug concentrations, if available, should be monitored. An alternative strategy to increasing LPV/r dosing during pregnancy by using 3 adult 200/50 mg tablets to provide a dose of 600/150 mg is to add a pediatric LPV/r tablet (100/25 mg) to the standard dose of 2 adult 200/50 mg tablets to provide a dose of 500/125 mg.\textsuperscript{14} Once-daily dosing of LPV/r is not recommended in pregnancy because no data exist to address whether drug levels are adequate with such administration.

\textit{Placental and Breast Milk Passage}

Lopinavir crosses the human placenta; in the P1026s PK study, the average ratio of lopinavir concentration in cord blood to maternal plasma at delivery was 0.20 $\pm$ 0.13. In contrast, in a study of plasma and hair drug concentration in 51 mother-infant pairs in Uganda receiving LPV/r during pregnancy and breastfeeding, infant plasma levels at delivery and hair levels at age 12 weeks suggested significant in utero transfer: 41% of infants had detectable plasma lopinavir concentrations at birth and mean infant-to-maternal-hair concentrations at 12 weeks postpartum were 0.87 for lopinavir.\textsuperscript{16} However, transfer during breastfeeding was not observed, and no infant had detectable plasma lopinavir levels at 12 weeks. Lopinavir concentrations in human breast milk are very low to undetectable and lopinavir concentrations in breastfeeding infants whose mothers received lopinavir are not clinically significant.\textsuperscript{16-20}

\textit{Teratogenicity/Developmental Toxicity}

The French Perinatal Cohort found no association between birth defects and lopinavir or ritonavir with 85% power to detect a 1.5-fold increase.\textsuperscript{21} The Pediatric HIV/AIDS Cohort Study found no association between lopinavir and congenital anomalies.\textsuperscript{22} In the Antiretroviral Pregnancy Registry, sufficient numbers of first-trimester exposures to LPV/r have been monitored for detection of at least a 2-fold increase in risk of overall birth defects. No such increase in birth defects has been observed with LPV/r. Among cases of first-trimester exposure to LPV/r reported to the Antiretroviral Pregnancy Registry, the prevalence of birth defects was 2.2% (26 of 1174; 95% CI, 1.4% to 3.2%) compared with a total prevalence of 2.7% in the U.S. population, based on Centers for Disease Control and Prevention surveillance.\textsuperscript{23}

\textit{Safety}

LPV/r oral solution contains 42.4% (volume/volume) alcohol and 15.3% (weight/volume) propylene glycol. Reduced hepatic metabolic and kidney excretory function in newborns can lead to accumulation of lopinavir.
as well as alcohol and propylene glycol, resulting in adverse events such as serious cardiac, renal, metabolic, or respiratory problems. Preterm babies may be at increased risk because their metabolism and elimination of lopinavir, propylene glycol, and alcohol are further reduced. Post-marketing surveillance has identified 10 neonates (i.e., babies aged <4 weeks), nine of whom were born prematurely, who received LPV/r and experienced life-threatening events. In a separate report comparing 50 HIV-exposed newborns treated with LPV/r after birth to 108 HIV-exposed neonates treated with zidovudine alone, elevated concentrations of 17-hydroxyprogesterone and dehydroepiandrosterone-sulfate, consistent with impairment of 21α-hydroxylase activity, were seen only in the lopinavir-exposed infants. All term infants were asymptomatic but three of eight preterm infants had life-threatening symptoms, including hyponatremia, hyperkalemia, and cardiogenic shock, consistent with adrenal insufficiency. LPV/r oral solution should not be administered to neonates before a postmenstrual age (first day of the mother’s last menstrual period to birth, plus the time elapsed after birth) of 42 weeks and a postnatal age of at least 14 days has been attained.

Excerpt from Table 7a

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lopinavir/ Ritonavir (LPV/r) Kaletra</td>
<td>Tablets (Co-Formulated):  • LPV 200 mg plus RTV 50 mg  • LPV 100 mg plus RTV 25 mg  Oral Solution:  • LPV 400 mg plus RTV 100 mg/5 mL</td>
<td>Standard Adult Dose:  • LPV 400 mg plus RTV 100 mg twice daily, or  • LPV 800 mg plus RTV 100 mg once daily  Tablets:  • Take without regard to food.  Oral Solution:  • Take with food.  With EFV or NVP (PI-Naive or PI-Experienced Patients):  • LPV 500 mg plus RTV 125 mg tablets twice daily without regard to meals (use a combination of two LPV 200 mg plus RTV 50 mg tablets and one LPV 100 mg plus RTV 25 mg tablet), or  • LPV 533 mg plus RTV 133 mg oral solution (6.5 mL) twice daily with food  PK in Pregnancy:  • With twice-daily dosing, LPV exposure is reduced in pregnant women receiving standard adult doses; increasing the dose by 50% results in exposure equivalent to that seen in non-pregnant adults receiving standard doses.  • No PK data are available for once-daily dosing in pregnancy.  Dosing in Pregnancy:  • Once daily dosing is not recommended during pregnancy.  • Some experts recommend that an increased dose (i.e., LPV 600 mg plus RTV 150 mg twice daily without regard to meals) should be used in the second and third trimesters, especially in PI-experienced pregnant women and women who start treatment during pregnancy with a baseline viral load &gt;50 copies/mL.  • If standard dosing is used, monitor virologic response and LPV drug levels, if available.</td>
<td>Low placental transfer to fetus.  b  No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects).  Oral solution contains 42% alcohol and 15% propylene glycol and is not recommended for use in pregnancy.  Once-daily LPV/r dosing is not recommended during pregnancy.</td>
</tr>
</tbody>
</table>

a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B Table 7).

b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

<table>
<thead>
<tr>
<th>High</th>
<th>Moderate</th>
<th>Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;0.6</td>
<td>0.3–0.6</td>
<td>&lt;0.3</td>
</tr>
</tbody>
</table>

Key to Abbreviations: EFV = efavirenz; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NVP = nevirapine; PI = protease inhibitor; PK = pharmacokinetic; RTV = ritonavir

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

References


Nelfinavir (Viracept, NFV)

(Prev. Class. B; last updated June 7, 2016; last reviewed June 7, 2016)

Nelfinavir is classified as Food and Drug Administration Pregnancy Category B.

Animal Studies

Carcinogenicity

Nelfinavir was neither mutagenic nor clastogenic in a series of in vitro and animal in vivo screening tests. However, incidence of thyroid follicular cell adenomas and carcinomas was increased over baseline in male rats receiving nelfinavir dosages of 300 mg/kg/day or higher (equal to a systemic exposure similar to that in humans at therapeutic doses) and female rats receiving 1000 mg/kg/day (equal to a systemic exposure 3-fold higher than that in humans at therapeutic doses).\(^1\)

Reproduction/Fertility

No effect of nelfinavir has been seen on reproductive performance, fertility, or embryo survival in rats at exposures comparable to human therapeutic exposure.\(^1\) Additional studies in rats indicated that exposure to nelfinavir in females from mid-pregnancy through lactation had no effect on the survival, growth, and development of the offspring to weaning. Maternal exposure to nelfinavir also did not affect subsequent reproductive performance of the offspring.

Teratogenicity/Developmental Toxicity

No evidence of teratogenicity has been observed in pregnant rats at exposures comparable to human exposure and in rabbits with exposures significantly less than human exposure.\(^1\)

Human Studies in Pregnancy

Pharmacokinetics

A Phase I/II safety and pharmacokinetic (PK) study (PACTG 353) of nelfinavir in combination with zidovudine and lamivudine was conducted in pregnant HIV-infected women and their infants.\(^2\) In the first 9 pregnant HIV-infected women enrolled in the study, nelfinavir administered at a dose of 750 mg 3 times daily produced drug exposures that were variable and generally lower than those reported in non-pregnant adults with both twice- and three-times-daily dosing. Therefore, the study was modified to evaluate an increased dose of nelfinavir given twice daily (1250 mg twice daily), which resulted in adequate levels of the drug in pregnancy. However, in two other small studies of women given 1250 mg nelfinavir twice daily in the second and third trimesters, drug concentrations in both those trimesters were somewhat lower than in non-pregnant women.\(^3,4\)

In a PK study of combination therapy including the new nelfinavir 625-mg tablet formulation (given as 1250 mg twice daily) in 25 women at 30 to 36 weeks’ gestation (and 12 at 6–12 weeks postpartum), peak levels and area under the curve were lower in the third trimester than postpartum.\(^5\) Only 16% (4 of 25) of women during the third trimester and 8% (1/12) of women postpartum had trough values greater than the suggested minimum trough of 800 ng/mL; however, viral load was <400 copies/mL in 96% of women in the third trimester and 86% postpartum.

Placental and Breast Milk Passage

In a Phase I study in pregnant women and their infants (PACTG 353), transplacental passage of nelfinavir was minimal.\(^2\) In addition, in a study of cord blood samples from 38 women treated with nelfinavir during pregnancy, the cord blood nelfinavir concentration was less than the assay limit of detection in 24 (63%), and the cord blood concentration was low (median, 0.35 µg/mL) in the remaining 14 women.\(^6\) Among 20 mother-infant pairs in the Netherlands, the cord blood-to-maternal-plasma ratio for nelfinavir was 0.14 compared to 0.67 for nevirapine and 0.24 for lopinavir.\(^7\)
Nelfinavir also has low breast milk passage. In a PK study conducted in Kisumu, Kenya, concentrations of nelfinavir and its active metabolite, M8, were measured in maternal plasma and breast milk from 26 mothers receiving nelfinavir as part of antiretroviral therapy and from their 27 infants at birth, 2, 6, 14, and 24 weeks. Peak nelfinavir concentrations were recorded in maternal plasma and breast milk at Week 2. Median breast milk-to-plasma ratio was 0.12 for nelfinavir and 0.03 for its active metabolite (i.e., M8). Nelfinavir and M8 concentrations were below the limit of detection in 20/28 (71%) of infant plasma dried blood spots tested from nine infants over time points from delivery through Week 24. Overall transfer to breast milk was low and resulted in non-significant exposure to nelfinavir among breastfed infants through age 24 weeks.

Teratogenicity/Developmental Toxicity

In the Antiretroviral Pregnancy Registry (APR), sufficient numbers of first-trimester exposures to nelfinavir have been monitored to be able to detect at least a 1.5-fold increased risk of overall birth defects and a 2-fold increased risk of birth defects in the more common classes of birth defects—the cardiovascular and genitourinary systems. No such increase in birth defects has been observed with nelfinavir. Among cases of first-trimester nelfinavir exposure reported to the APR, prevalence of birth defects was 3.9% (47 of 1,215 births; 95% CI, 2.8% to 5.1%) compared with a 2.7% total prevalence in the U.S. population, based on Centers for Disease Control and Prevention surveillance.

Excerpt from Table 7a

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
</table>
| **Nelfinavir (NFV) Viracept**          | Tablets:  • 250 mg  • 625 mg  (Tablets can be dissolved in small amount of water.)  Powder for Oral Suspension:  • 50 mg/g | Standard Adult Dose:  • 1250 mg twice daily or 750 mg three times daily with food  PK in Pregnancy:  • Lower NFV exposure in third trimester than postpartum in women receiving NFV 1250 mg twice daily; however, generally adequate drug levels are achieved during pregnancy, although levels are variable in late pregnancy.  Dosing in Pregnancy:  • Three-times-daily dosing with 750 mg with food not recommended during pregnancy. No change in standard dose (1250 mg twice daily with food) indicated. | Minimal to low placental transfer to fetus.  
No evidence of human teratogenicity; can rule out 1.5-fold increase in overall birth defects and 2-fold increase in risk of birth defects in more common classes, cardiovascular, and genitourinary.  
Contains aspartame; should not be used in individuals with phenylketonuria. |

a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

High: >0.6  
Moderate: 0.3–0.6  
Low: <0.3  

Key to Abbreviations: NFV = nelfinavir; PK = pharmacokinetic

References


**Saquinavir (Invirase, SQV)**

*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Saquinavir is classified as Food and Drug Administration Pregnancy Category B.

**Animal Studies**

*Carcinogenicity*

Saquinavir was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. Carcinogenicity studies found no indication of carcinogenic activity in rats and mice administered saquinavir for approximately 2 years at plasma exposures approximately 29% (rat) and 65% (mouse) of those obtained in humans at the recommended clinical dose boosted with ritonavir.

*Reproduction/Fertility*

No effect of saquinavir has been seen on reproductive performance, fertility, or embryo survival in rats. Because of limited bioavailability of saquinavir in animals, the maximal plasma exposures achieved in rats were approximately 26% of those obtained in humans at the recommended clinical dose boosted with ritonavir.

*Teratogenicity/Developmental Toxicity*

No evidence of embryotoxicity or teratogenicity of saquinavir has been found in rabbits or rats. Because of limited bioavailability of saquinavir in animals and/or dosing limitations, the plasma exposures (area under the curve [AUC] values) in the respective species were approximately 29% (using rat) and 21% (using rabbit) of those obtained in humans at the recommended clinical dose boosted with ritonavir.

*Placental and Breast Milk Passage*

Placental transfer of saquinavir in the rat and rabbit was minimal. Saquinavir is excreted in the milk of lactating rats.

**Human Studies in Pregnancy**

*Pharmacokinetics*

Studies of saquinavir pharmacokinetics (PK) in pregnancy with the original hard-gel capsule formulation demonstrated reduced saquinavir exposures compared to postpartum and dosing recommendations for 800 to 1200 mg saquinavir with 100 mg ritonavir. The PK of saquinavir with the current 500-mg tablets boosted with ritonavir at a dose of 1000 mg saquinavir/100 mg ritonavir given twice daily has been studied in pregnant women in two studies. One study performed intensive sampling on HIV-infected pregnant women at 20 weeks’ gestation (n = 16), 33 weeks’ gestation (n = 31), and 6 weeks postpartum (n = 9). PK parameters were comparable during pregnancy and postpartum. The second study performed intensive sampling in 14 pregnant women at 24 and 34 weeks’ gestation and 6 weeks postpartum. Saquinavir AUC was similar during the second trimester and postpartum. Although there was a 50% reduction in saquinavir AUC in the third trimester compared to postpartum, no subject experienced loss of virologic control and all but one maintained adequate third-trimester trough levels of saquinavir. In an observational study of saquinavir concentrations collected as part of clinical care between 11 and 13 hours after dosing with the tablet formulation (1000 mg saquinavir/100 mg ritonavir) in HIV-infected pregnant women during the third trimester (n = 20) and at delivery (n = 5), saquinavir plasma concentrations averaged around 1.15 mg/L and exceeded the usual trough drug concentration target for saquinavir of 0.1 mg/L in all but one subject.

One study of 42 pregnant women receiving a combination antiretroviral drug regimen that included ritonavir-boosted saquinavir reported abnormal transaminase levels in 13 women (31%) within 2 to 4 weeks of treatment initiation, although the abnormalities were mild (toxicity Grade 1–2 in most, Grade 3 in 1 woman). In a study of 62 pregnant women on a regimen that included ritonavir-boosted saquinavir, one severe adverse event occurred (maternal Grade 3 hepatotoxicity).
Placental and Breast Milk Passage

In a Phase I study in pregnant women and their infants (PACTG 386), transplacental passage of saquinavir was minimal.\(^1\) In addition, in a study of eight women treated with saquinavir during pregnancy, the cord blood concentration of saquinavir was less than the assay limit of detection in samples from all women.\(^2\) It is not known if saquinavir is excreted in human milk.

Teratogenicity/Developmental Toxicity

The 184 first-trimester saquinavir exposures monitored by the Antiretroviral Pregnancy Registry are too few to be able to accurately calculate the prevalence of birth defects in exposed cases.\(^3\)

Excerpt from Table 7\(^a\)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saquinavir (SQV)</td>
<td>Invirase</td>
<td>Tablet: • 500 mg</td>
<td>Standard Adult Dose: • SQV 1000 mg plus RTV 100 mg twice a day with food or within 2 hours after a meal</td>
<td>Low placental transfer to fetus.(^b)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capsule: • 200 mg</td>
<td>PK in Pregnancy: • Based on limited data, SQV exposure may be reduced in pregnancy but not sufficient to warrant a dose change.</td>
<td>Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dosing in Pregnancy: • No change in dose indicated.</td>
<td>Must be boosted with low-dose RTV.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Baseline ECG recommended before starting because PR and/or QT interval prolongations have been observed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Contraindicated in patients with preexisting cardiac conduction system disease.</td>
</tr>
</tbody>
</table>

\(^a\) Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

\(^b\) Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- High: >0.6
- Moderate: 0.3–0.6
- Low: <0.3

Key to Abbreviations: ECG = electrocardiogram; PK = pharmacokinetic; RTV = ritonavir; SQV = saquinavir

References


**Tipranavir (Aptivus, TPV)**

*(Last reviewed June 7, 2016; last updated June 7, 2016)*

Tipranavir is classified as Food and Drug Administration Pregnancy Category C.

**Animal Studies**

**Carcinogenicity**

Tipranavir was neither mutagenic nor clastogenic in a battery of five *in vitro* and animal *in vivo* screening tests. Long-term carcinogenicity studies in mice and rats have been conducted with tipranavir. Mice were administered 30, 150, or 300 mg/kg/day tipranavir, 150/40 mg/kg/day tipranavir/ritonavir (TPV/r) in combination, or 40 mg/kg/day ritonavir. Incidence of benign hepatocellular adenomas and combined adenomas/carcinomas was increased in females of all groups except females given the low dose of tipranavir. Such tumors also were increased in male mice at the high dose of tipranavir and in the TPV/r combination group. Incidence of hepatocellular carcinoma was increased in female mice given the high dose of tipranavir and in both sexes receiving TPV/r. The combination of tipranavir and ritonavir caused an exposure-related increase in this same tumor type in both sexes. The clinical relevance of the carcinogenic findings in mice is unknown. Systemic exposures in mice (based on area under the curve [AUC] or maximum plasma concentration) at all dose levels tested were below those in humans receiving the recommended dose level. Rats were administered 30, 100, or 300 mg/kg/day tipranavir, 100/26.7 mg/kg/day TPV/r in combination, or 10 mg/kg/day ritonavir. No drug-related findings were observed in male rats. At the highest dose of tipranavir, an increased incidence of benign follicular cell adenomas of the thyroid gland was observed in female rats. Based on AUC measurements, exposure to tipranavir at this dose level in rats is approximately equivalent to exposure in humans at the recommended therapeutic dose. This finding is probably not relevant to humans because thyroid follicular cell adenomas are considered a rodent-specific effect secondary to enzyme induction.  

**Reproduction/Fertility**

Tipranavir had no effect on fertility or early embryonic development in rats at exposure levels similar to human exposures at the recommended clinical dose (500/200 mg of TPV/r BID).*

**Teratogenicity/Developmental Toxicity**

No teratogenicity was detected in studies of pregnant rats and rabbits at exposure levels approximately 1.1-fold and 0.1-fold human exposure. Fetal toxicity (decreased ossification and body weights) was observed in rats exposed to 400 mg/kg/day or more of tipranavir (~0.8-fold human exposure). Fetal toxicity was not seen in rats and rabbits at levels of 0.2-fold and 0.1-fold human exposures. In rats, no adverse effects on development were seen at levels of 40 mg/kg/day (~0.2-fold human exposure), but at 400 mg/kg/day (~0.8-fold human exposure), growth inhibition in pups and maternal toxicity were seen.  

**Placental and Breast Milk Passage**

No animal studies of placental or breast milk passage of tipranavir have been reported.

**Human Studies in Pregnancy**

**Pharmacokinetics**

No studies of tipranavir have been completed in pregnant women or neonates.

**Placental and Breast Milk Passage**

It is unknown if passage of tipranavir through the placenta or breast milk occurs in humans. A single case report described relatively high levels of tipranavir in the third trimester and relatively high placental transfer (0.41), as measured by cord blood.*

**Teratogenicity/Developmental Toxicity**

The four first-trimester exposures to tipranavir that have been monitored to date in the Antiretroviral Pregnancy Registry are insufficient to allow conclusions to be drawn regarding risk of birth defects.*

*Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States*  

G-90

### Excerpt from Table 7a

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tipranavir (TPV)</td>
<td>Capsules: • 250 mg</td>
<td><strong>Standard Adult Dose:</strong> • TPV 500 mg plus RTV 200 mg twice daily</td>
<td>Moderate placental transfer to fetus reported in one patient. b</td>
</tr>
<tr>
<td></td>
<td>Oral Solution: • 100 mg/mL</td>
<td><strong>With RTV Tablets:</strong> • Take with food.</td>
<td>Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
</tr>
<tr>
<td>Note: Must be combined with RTV for PK boosting</td>
<td><strong>With RTV Capsules or Solution:</strong> • Take without regard to food; however, administering with food may help make the dose more tolerable.</td>
<td><strong>PK in Pregnancy:</strong> • Limited PK data in human pregnancy.</td>
<td>Must be given as low-dose RTV-boosted regimen.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Dosing in Pregnancy:</strong> • Insufficient data to make dosing recommendation.</td>
<td></td>
</tr>
</tbody>
</table>

a Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

<table>
<thead>
<tr>
<th>PK in Pregnancy</th>
<th>RTV = ritonavir; TPV = tipranavir</th>
</tr>
</thead>
<tbody>
<tr>
<td>High: &gt;0.6</td>
<td>Moderate: 0.3–0.6</td>
</tr>
<tr>
<td>Low: &lt;0.3</td>
<td></td>
</tr>
</tbody>
</table>

Key to Abbreviations: PK = pharmacokinetic; RTV = ritonavir; TPV = tipranavir

### References


Entry Inhibitors

Drugs in this class of antiretroviral (ARV) drugs inhibits viral binding or fusion of HIV to host target cells. Binding of the viral envelope glycoprotein (gp)120 to the CD4 receptor induces conformational changes that enable gp120 to interact with a chemokine receptor such as CCR5 or CXCR4 on the host cell; binding of gp120 to the co-receptor causes subsequent conformational changes in the viral transmembrane gp41, exposing the fusion peptide of gp41, which inserts into the cell membrane. A helical region of gp41, called HR1, then interacts with a similar helical region, HR2, on gp41, resulting in a zipping together of the two helices and mediating the fusion of cellular and viral membranes. Enfuvirtide, which requires subcutaneous (SQ) administration, is a synthetic 36-amino-acid peptide derived from a naturally occurring motif within the HR2 domain of viral gp41, and the drug binds to the HR1 region, preventing the HR1-HR2 interaction and correct folding of gp41 into its secondary structure, thereby inhibiting virus-cell fusion. Enfuvirtide was approved for use in combination with other ARV drugs to treat advanced HIV infection in adults and children aged 6 years or older. Maraviroc interferes with viral entry at the chemokine co-receptor level; it is a CCR5 co-receptor antagonist approved for combination therapy for HIV infection in adults infected with CCR5-tropic virus.

**Enfuvirtide (Fuzeon, T-20)**

*Last updated August 6, 2015; last reviewed August 6, 2015*

Enfuvirtide is classified as Food and Drug Administration Pregnancy Category B.

**Animal Studies**

*Carcinogenicity*

Enfuvirtide was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. Long-term animal carcinogenicity studies of enfuvirtide have not been conducted.

*Reproduction/Fertility*

Reproductive toxicity has been evaluated in rats and rabbits. Enfuvirtide produced no adverse effects on fertility of male or female rats at doses up to 30 mg/kg/day administered subcutaneously (1.6 times the maximum recommended adult human daily dose on a body surface area basis).

*Teratogenicity/Developmental Toxicity*

Studies in rats and rabbits have shown no evidence of teratogenicity or effect on reproductive function with enfuvirtide.¹

**Placental and Breast Milk Passage**

Studies in rats and rabbits revealed no evidence of harm to the fetus from enfuvirtide administered in doses up to 27 times and 3.2 times, respectively, the adult human daily dose (on a body surface area basis). Studies of radiolabeled enfuvirtide administered to lactating rats indicated radioactivity in the milk; however, it is not

---

1. Glossary of Terms for Supplement

<table>
<thead>
<tr>
<th>Carcinogenic: Producing or tending to produce cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Some agents, such as certain chemicals or forms of radiation, are both mutagenic and clastogenic.</td>
</tr>
<tr>
<td>• Genetic mutations and/or chromosomal damage can contribute to cancer formation.</td>
</tr>
</tbody>
</table>

| Clastogenic: Causing disruption of or breakages in chromosomes |

| Genotoxic: Damaging to genetic material such as DNA and chromosomes |

| Mutagenic: Inducing or capable of inducing genetic mutation |

| Teratogenic: Interfering with fetal development and resulting in birth defects |

---

**Enfuvirtide (Fuzeon, T-20)**

*Last updated August 6, 2015; last reviewed August 6, 2015*

Enfuvirtide is classified as Food and Drug Administration Pregnancy Category B.

**Animal Studies**

*Carcinogenicity*

Enfuvirtide was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. Long-term animal carcinogenicity studies of enfuvirtide have not been conducted.

*Reproduction/Fertility*

Reproductive toxicity has been evaluated in rats and rabbits. Enfuvirtide produced no adverse effects on fertility of male or female rats at doses up to 30 mg/kg/day administered subcutaneously (1.6 times the maximum recommended adult human daily dose on a body surface area basis).

*Teratogenicity/Developmental Toxicity*

Studies in rats and rabbits have shown no evidence of teratogenicity or effect on reproductive function with enfuvirtide.¹

**Placental and Breast Milk Passage**

Studies in rats and rabbits revealed no evidence of harm to the fetus from enfuvirtide administered in doses up to 27 times and 3.2 times, respectively, the adult human daily dose (on a body surface area basis). Studies of radiolabeled enfuvirtide administered to lactating rats indicated radioactivity in the milk; however, it is not
known if this reflected radiolabeled enfuvirtide or metabolites (amino acid and peptide fragments) of enfuvirtide.

Human Studies in Pregnancy

Pharmacokinetics

Data on the use of enfuvirtide in human pregnancy are limited to case reports of a small number of women treated with the drug.\(^2-8\)

Placental and Breast Milk Passage

*In vitro* and *in vivo* studies suggest that enfuvirtide does not readily cross the human placenta. Published reports of a total of eight peripartum patients and their neonates and data from an *ex vivo* human placental cotyledon perfusion model demonstrated minimal placental passage of enfuvirtide.\(^2,5,9-11\)

Teratogenicity/Developmental Toxicity

In the Antiretroviral Pregnancy Registry and in a national cohort of pregnant women with HIV infection in Italy, insufficient numbers of first-trimester exposures to enfuvirtide in humans have been monitored to be able to make a risk determination.\(^12,13\)

Excerpt from Table 7\(^a\)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enfuvirtide (T20) Fuzeon Injectable:</td>
<td>T20 is indicated for advanced HIV disease and must be used in combination with other ARVs to which the patient’s virus is susceptible by resistance testing. Standard Adult Dose: • 90 mg (1 mL) twice daily without regard to meals PK in Pregnancy: • No PK data in human pregnancy. Dosing in Pregnancy: • Insufficient data to make dosing recommendation.</td>
<td>Minimal to low placental transfer to fetus.(^b) No data on human teratogenicity.</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

\(^b\) Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- **High:** >0.6
- **Moderate:** 0.3–0.6
- **Low:** <0.3

**Key to Abbreviations:** ARV = antiretroviral; PK = pharmacokinetic; SQ = subcutaneous; T20 = enfuvirtide

References


*Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States*

G-93


Maraviroc (Selzentry, MVC)  
(Last updated August 6, 2015; last reviewed August 6, 2015)

Maraviroc is classified as Food and Drug Administration Pregnancy Category B.

Animal Studies

Carcinogenicity
Maraviroc was neither mutagenic nor clastogenic in a series of in vitro and animal in vivo screening tests. Long-term animal carcinogenicity studies of maraviroc showed no drug-related increases in tumor incidence.

Reproduction/Fertility
Reproductive toxicity has been evaluated in rats and rabbits. Maraviroc produced no adverse effects on fertility of male or female rats at doses with exposures (area under the curve [AUC]) up to 20-fold higher than in humans given the recommended 300-mg, twice-daily dose.

Teratogenicity/Developmental Toxicity
The incidence of fetal variations and malformations was not increased in embryo-fetal toxicity studies in rats at AUC approximately 20-fold higher (and in rabbits at approximately 5-fold higher) than human exposures at the recommended 300-mg, twice-daily dose (up to 1000 mg/kg/day in rats and 75 mg/kg/day in rabbits).

Placental and Breast Milk Passage
Minimal placental passage was demonstrated in a study of single-dose maraviroc in rhesus macaques that showed poor placental transfer and rapid clearance from infant monkeys’ blood. Studies in lactating rats indicate that maraviroc is extensively secreted into rat milk.

Human Studies in Pregnancy

Pharmacokinetics
Data on the use of maraviroc in human pregnancy are limited to a small pharmacokinetic study that found exposure to maraviroc was 21% lower during the third trimester than postpartum.

Placental and Breast Milk Passage
An ex vivo human placental cotyledon perfusion model demonstrated minimal placental passage of maraviroc. In a study in humans of six mother/infant pairs, the median ratio of cord blood-to-maternal-plasma drug concentrations was 0.33 (0.03–0.56). Whether maraviroc is secreted into human milk is unknown.

Teratogenicity/Developmental Toxicity
In the Antiretroviral Pregnancy Registry, insufficient numbers of first-trimester exposures to maraviroc in humans have been monitored to be able to make a risk determination.
### Generic Name (Abbreviation) Trade Name

<table>
<thead>
<tr>
<th>Maraviroc (MVC) Selzentry</th>
<th>Tablets:</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• 150 mg • 300 mg</td>
<td></td>
<td>Standard Adult Dose: • 300 mg twice daily with or without food • Maraviroc must be used in combination with other ARVs in HIV-1-infected adults with only CCR5-tropic virus.</td>
<td>No evidence of teratogenicity in rats or rabbits.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dose Adjustments: • Increase to 600 mg BID when used with potent CYP3A inducers: EFV, ETR, and rifampin. • Decrease to 150 mg BID when used with CYP3A inhibitors: all PIs except tipranavir/ritonavir, itraconazole.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PK in Pregnancy: • No PK studies in human pregnancy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dosing in Pregnancy: • Insufficient data to make dosing recommendation.</td>
<td></td>
</tr>
</tbody>
</table>

### References


---

*Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).*

**Key to Abbreviations:** ARV = antiretroviral; BID = twice daily; MVC = maraviroc; PI = protease inhibitor; PK = pharmacokinetic
Integrase Inhibitors

<table>
<thead>
<tr>
<th>Glossary of Terms for Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carcinogenic:</strong> Producing or tending to produce cancer</td>
</tr>
<tr>
<td>• Some agents, such as certain chemicals or forms of radiation, are both mutagenic and clastogenic.</td>
</tr>
<tr>
<td>• Genetic mutations and/or chromosomal damage can contribute to cancer formation.</td>
</tr>
<tr>
<td><strong>Clastogenic:</strong> Causing disruption of or breakages in chromosomes</td>
</tr>
<tr>
<td><strong>Genotoxic:</strong> Damaging to genetic material such as DNA and chromosomes</td>
</tr>
<tr>
<td><strong>Mutagenic:</strong> Inducing or capable of inducing genetic mutation</td>
</tr>
<tr>
<td><strong>Teratogenic:</strong> Interfering with fetal development and resulting in birth defects</td>
</tr>
</tbody>
</table>

This class of antiretroviral (ARV) drugs inhibits integrase, the viral enzyme that catalyzes the two-step process of insertion of HIV DNA into the genome of the human cell. Integrase catalyzes a preparatory step that excises two nucleotides from one strand at both ends of the HIV DNA and a final “strand transfer” step that inserts the viral DNA into the exposed regions of cellular DNA. The integrase inhibitor drug class targets this second step in the integration process. Integration is required for the stable maintenance of the viral genome as well as for efficient viral gene expression and replication. Integrase also affects reverse transcription and viral assembly. Host cells lack the integrase enzyme. Because HIV integrase represents a distinct therapeutic target, integrase inhibitors would be expected to maintain activity against HIV that is resistant to other classes of ARV drugs.

**Dolutegravir (Tivicay, DTG)**  
*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Dolutegravir is classified as Food and Drug Administration Pregnancy Category B.

**Animal Carcinogenicity Studies**

Dolutegravir was not genotoxic or mutagenic *in vitro*. No carcinogenicity was detected in 2-year long-term studies in mice at exposures up to 14-fold higher than that achieved with human systemic exposure at the recommended dose, or in rats at exposures up to 10-fold higher in males and 15-fold higher in females than human exposure at the recommended dose.

**Reproduction/Fertility**

Dolutegravir did not affect fertility in male and female rats and rabbits at exposures approximately 27-fold higher than human clinical exposure, based on area under the curve, at the recommended dose.

**Animal Teratogenicity/Developmental Toxicity**

Studies in rats and rabbits have shown no evidence of developmental toxicity, teratogenicity or effect on reproductive function with dolutegravir.

**Placental and Breast Milk Passage**

Studies in rats have demonstrated that dolutegravir crosses the placenta in animal studies and is excreted into breast milk in rats.

**Human Studies in Pregnancy**

**Pharmacokinetics**

Human reports of dolutegravir use in human pregnancy are limited to two published case reports of dolutegravir use in single pregnant women and one presentation of dolutegravir safety, pharmacokinetic, and efficacy data from 21 pregnant women.\(^1\text{-}^3\) In both case reports, dolutegravir was used safely and effectively in pregnancy.\(^1\text{-}^3\) In the series of 21 pregnant women, dolutegravir plasma concentrations were lower during...
pregnancy than postpartum but HIV-1 RNA in the third trimester was below 50 copies/mL in all 15 women for whom third-trimester data were available. Dolutegravir was well tolerated by these pregnant women.³

**Placental and Breast Milk Passage**

No human data on placental passage or breast milk excretion are available.

**Teratogenicity Data**

In the Antiretroviral Pregnancy Registry, insufficient numbers of first-trimester exposures to dolutegravir in humans have been monitored to be able to make a risk determination.⁴ In the series of pregnant women discussed above, congenital anomalies were reported in 4 infants: total anomalous pulmonary venous return, cystic fibrosis and polycystic right kidney, congenital chin tremor, and sacral dimple with filum terminale fibrolipoma.

Excerpt from Table 7

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
</table>
| Dolutegravir (DTG) Tivicay (ABC/DTG/3TC) Triumeq | Tablets: 50 mg | **Standard Adult Dose**
| | | **ARV-Naive or ARV-Experienced (but Integrase Inhibitor-Naive Patients)**
| | | **DTG (Tivicay):**
| | | • 1 tablet once daily, without regard to food.
| | | **ABC/DTG/3TC (Triumeq):**
| | | • 1 tablet once daily, without regard to food.
| | | **ARV-Naive or ARV-Experienced (but Integrase Inhibitor-Naive) if Given with EFV, FPV/r, TPV/r, or Rifampin; or Integrase Inhibitor-Experienced DTG (Tivicay):**
| | | • 1 tablet twice daily, without regard to food.
| | | **PK in Pregnancy:**
| | | • **Limited** PK data in human pregnancy.
| | | **Dosing in Pregnancy:**
| | | • Insufficient data to make dosing recommendation.
| | | **Unknown placental transfer to fetus.**
| | | **Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in mice, rats, or rabbits.**

[Table 7](#)

Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see **Adult Guidelines, Appendix B, Table 7**).

**Key to Abbreviations:** 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; DTG = dolutegravir; EFV = efavirenz; FPV/r = fosamprenavir/ritonavir; PK = pharmacokinetic; TPV/r = tipranavir/ritonavir

**References**


**Elvitegravir**

(***Last updated August 6, 2015; last reviewed August 6, 2015***)

Elvitegravir is classified as Food and Drug Administration Pregnancy Category B.

**Animal Studies**

*Carcinogenicity*

Elvitegravir was not genotoxic or mutagenic *in vitro*. No carcinogenicity was detected in long-term studies in mice at exposures up to 14-fold and rats at exposures up to 27-fold that achieved with human systemic exposure at the recommended dose.¹

*Reproduction/Fertility*

Elvitegravir did not affect fertility in male and female rats at approximately 16- and 30-fold higher exposures than in humans at standard dosing. Fertility was normal in offspring.¹

*Teratogenicity/Developmental Toxicity*

Studies in rats and rabbits have shown no evidence of teratogenicity or effect on reproductive function with elvitegravir.¹

**Placental and Breast Milk Passage**

No data on placental passage are available for elvitegravir. Studies in rats have demonstrated that elvitegravir is secreted in breast milk.

**Human Studies in Pregnancy**

*Pharmacokinetics*

No pharmacokinetic studies of elvitegravir in human pregnancy have been reported.

**Placental and Breast Milk Passage**

No data are available on placental or breast milk passage of elvitegravir in humans.

**Teratogenicity/Developmental Toxicity**

In the Antiretroviral Pregnancy Registry, insufficient numbers of first-trimester exposures to elvitegravir in humans have been monitored to be able to make a risk determination.²
### Excerpt from Table 7

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elvitegravir (EVG)</td>
<td>Tablet (Vitekta):</td>
<td>Standard Adult Dose (Vitekta):</td>
<td>No data on placental transfer of EVG/COBI are available. Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
</tr>
<tr>
<td>Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate (EVG/COBI/ FTC/TDF)</td>
<td>Tablet (Stribild):</td>
<td>Recommended Elvitegravir Dosage Taken Once Daily with Food (All Drugs Administered Orally)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dosage of Elvitegravir</td>
<td>Dosage of Concomitant PI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>85 mg once daily</td>
<td>Atazanavir 300 mg once daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lopinavir 400 mg twice daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>150 mg once daily</td>
<td>Darunavir 600 mg twice daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fosamprenavir 700 mg twice daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tipranavir 500 mg twice daily</td>
</tr>
</tbody>
</table>

Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

**Key to Abbreviations:** ARV = antiretroviral; COBI = cobicistat; EVG = elvitegravir; FTC = emtricitabine; PI = protease inhibitor; PK = pharmacokinetic; RTV = ritonavir; TDF = tenofovir disoproxil fumarate

**References**

**Raltegravir (Isentress, RAL)**

*(Last updated August 6, 2015; last reviewed August 6, 2015)*

Raltegravir is classified as Food and Drug Administration Pregnancy Category C.

**Animal Studies**

*Carcinogenicity*

Raltegravir was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. Long-term carcinogenicity studies of raltegravir in mice did not show any carcinogenic potential at systemic exposures 1.8-fold (females) or 1.2-fold (males) greater than human exposure at the recommended dose. Treatment-related squamous cell carcinoma of the nose/nasopharynx was observed in female rats dosed with 600 mg/kg/day raltegravir (exposure 3-fold higher than in humans at the recommended adult dose) for 104 weeks. These tumors were possibly the result of local irritation and inflammation due to local deposition and/or aspiration of drug in the mucosa of the nose/nasopharynx during dosing. No tumors of the nose/nasopharynx were observed in rats receiving doses resulting in systemic exposures that were 1.7-fold (males) to 1.4-fold (females) greater than the human exposure at the recommended dose.

*Reproduction/Fertility*

Raltegravir produced no adverse effects on fertility of male or female rats at doses up to 600 mg/kg/day (providing exposures 3-fold higher than the exposure at the recommended adult human dose).

*Teratogenicity/Developmental Toxicity*

Studies in rats and rabbits revealed no evidence of treatment-related effects on embryonic/fetal survival or fetal weights from raltegravir administered in doses producing systemic exposures approximately 3- to 4-fold higher than the exposure at the recommended adult human daily dose. In rabbits, no treatment-related external, visceral, or skeletal changes were observed. However, treatment-related increases in the incidence of supernumerary ribs were seen in rats given raltegravir at 600 mg/kg/day (providing exposures 3-fold higher than the exposure at the recommended human daily dose).

*Placental and Breast Milk Passage*

Placental transfer of raltegravir was demonstrated in both rats and rabbits. In rats given a maternal dose of 600 mg/kg/day, mean fetal blood concentrations were approximately 1.5- to 2.5-fold higher than in maternal plasma at 1 and 24 hours post-dose, respectively. However, in rabbits, the mean drug concentrations in fetal plasma were approximately 2% of the mean maternal plasma concentration at both 1 and 24 hours following a maternal dose of 1000 mg/kg/day.

Raltegravir is secreted in the milk of lactating rats, with mean drug concentrations in milk about 3-fold higher than in maternal plasma at a maternal dose of 600 mg/kg/day. No effects in rat offspring were attributable to raltegravir exposure through breast milk.

**Human Studies**

*Pharmacokinetics*

Raltegravir pharmacokinetics (PK) were evaluated in 42 women during pregnancy in the IMPAACT P1026s study. Raltegravir PKs in these women showed extensive variability as seen in non-pregnant individuals. Median raltegravir area under the curve was reduced by approximately 50% during pregnancy. No significant difference was seen between the third trimester and postpartum trough concentrations. Plasma HIV RNA levels were under 400 copies/mL in 92% of women at delivery. Given the high rates of virologic suppression and the lack of clear relationship between raltegravir concentration and virologic effect in non-pregnant adults, no change in dosing was recommended during pregnancy. In a study of 22 women with paired third-trimester and postpartum data from the PANNA Network, the geometric mean ratios of third trimester/postpartum values were AUC$_{0-12hr}$ 0.71 (0.53–0.96), C$_{max}$ 0.82 (0.55–1.253), and C$_{12hr}$ 0.64 (0.34–1.22). One patient was below the target C$_{12hr}$ in the third trimester and none were below the threshold...
postpartum. No change in dosing during pregnancy was recommended based on these data. In the P1097 study of washout pharmacokinetics in 21 neonates born to women receiving ongoing raltegravir in pregnancy, raltegravir elimination was highly variable and extremely prolonged in some infants (median $t_{1/2}$ 26.6 hours, range 9.3–184 hours). In a case report of an infant born at 30 weeks’ gestation after the mother had received three doses of raltegravir, the cord blood level of raltegravir was 145 ng/mL; the level at age 2 days was 106 ng/mL and at 1 month was 29 ng/mL, still above the IC95 of 15 ng/mL.

Teratogenicity/Developmental Toxicity

As of January 31, 2015, six cases with defects have been reported among 180 infants with first-trimester exposure to raltegravir included in the Antiretroviral Pregnancy Registry—too few first-trimester exposures to be able to accurately calculate the prevalence of birth defects in exposed cases.

Placental and Breast Milk Passage

In humans, raltegravir appears to readily cross the placenta. In the IMPAACT P1026s study, the ratio of cord blood-to-maternal-plasma was 1.5. In the P1097 study, the median cord blood/maternal delivery plasma raltegravir concentration ratio was 1.48 (range 0.32–4.33), and in the PANNA study it was 1.21. Other case reports have shown cord blood/maternal blood drug level ratios of 1.00 to 1.06. In a series of three cases with preterm deliveries at 29 to 33 weeks’ gestation (in 2 cases raltegravir was added to the maternal antiretroviral regimen shortly before anticipated preterm delivery), cord blood-to-maternal-plasma ratios ranged from 0.44 to 1.88.

Whether raltegravir is secreted in human breast milk is unknown.

Safety

In the P1026s Study and the PANNA study, raltegravir was well tolerated, with no treatment-related serious adverse events in pregnant women, and all infants were at least 36 weeks’ gestation at delivery. In the P1097 study, no infant adverse events were determined to be related to maternal raltegravir exposure; one (4.6%) infant received phototherapy for treatment of hyperbilirubinemia. In multiple case reports and case series of 4, 5, and 14 pregnant women treated with raltegravir in combination with 2 or 3 other antiretroviral drugs because of persistent viremia or late presentation, the drug was well tolerated and led to rapid reduction in HIV RNA levels. However, in one case of similar use, 10- to 23-fold increases in liver transaminases were reported after initiation of raltegravir with resolution when raltegravir was discontinued. Drug levels were not measured in any of those studies. One case has been reported of drug reaction with eosinophilia and systemic symptoms syndrome with extensive pulmonary involvement in a postpartum woman that resolved with discontinuation of raltegravir. Such reactions have been reported in non-pregnant adults receiving raltegravir and should be considered in the differential diagnosis of fever during pregnancy or postpartum period in women on raltegravir.

Because raltegravir is highly protein bound to albumin, there is concern about displacement of bilirubin from albumin in the neonate, potentially increasing the risk of neonatal hyperbilirubinemia. In an in vitro study of the effect of raltegravir on bilirubin-albumin binding, raltegravir had minimal effect on bilirubin-albumin binding at concentrations of 5 μM and 10 μM, caused a small but statistically significant increase in unbound bilirubin at 100 μM, and caused potentially harmful increases at 500 and 1000 μM. These data suggest that the effect of raltegravir on neonatal bilirubin binding is unlikely to be clinically significant at typical peak concentrations reached in adults with usual dosing (adult concentrations with standard raltegravir doses were geometric mean $C_{\text{max}}$ of 4.5 μM, median $C_{\text{max}}$ of 6.5 μM and maximum observed $C_{\text{max}}$ of 10.2 μM). Raltegravir should not be used in neonates until PK and toxicity studies have been completed.

Chewable tablets contain phenylalanine.
### References


---

**Excerpt from Table 7**

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Raltegravir (RAL) Isentress</strong></td>
<td>Film-Coated Tablets: • 400 mg</td>
<td><strong>Standard Adult Dose:</strong> • 400 mg twice daily without regard to food</td>
<td>High placental transfer to fetus.(^b) Insufficient data to assess for teratogenicity in humans. Increased skeletal variants in rats, no increase in defects in rabbits. Case report of markedly elevated liver transaminases with use in late pregnancy. Severe, potentially life-threatening and fatal skin and hypersensitivity reactions have been reported in non-pregnant adults.</td>
</tr>
<tr>
<td></td>
<td>Chewable Tablets: • 25 mg • 100 mg</td>
<td><strong>With Rifampin:</strong> • 800 mg twice daily without regard to food</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PK in Pregnancy: • Decreased levels in third trimester not of sufficient magnitude to warrant change in dosing.</td>
<td><strong>Dosing in Pregnancy:</strong> • No change in dose indicated.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High placental transfer to fetus.(^b) Insufficient data to assess for teratogenicity in humans. Increased skeletal variants in rats, no increase in defects in rabbits. Case report of markedly elevated liver transaminases with use in late pregnancy. Severe, potentially life-threatening and fatal skin and hypersensitivity reactions have been reported in non-pregnant adults.</td>
</tr>
</tbody>
</table>

\(^{a}\) Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

\(^{b}\) Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:

- **High:** >0.6
- **Moderate:** 0.3–0.6
- **Low:** <0.3

**Key to Abbreviations:** PK = pharmacokinetic; RAL = raltegravir


Cobicistat (Tybost, COBI)
(Last updated August 6, 2015, last reviewed August 6, 2015)

Cobicistat is classified as Food and Drug Administration Pregnancy Category B.

Animal Studies

Carcinogenicity
At cobicistat exposures 7 times and 16 times the human systemic exposure, no increases in tumor incidence were seen in male and female mice. In rats, an increased incidence of follicular cell adenomas and/or carcinomas in the thyroid gland was observed at doses up to twice the typical human exposure. The follicular cell findings are considered rat-specific, and not relevant to humans.\(^1\)

Reproduction/Fertility
No effect has been seen on fertility in male or female rats.\(^1\)

Teratogenicity/Developmental Toxicity
Rats and rabbits treated with cobicistat during pregnancy at 1.4 and 3.3 times higher than the recommended human exposure have shown no evidence of teratogenicity.\(^1\)

Placental and Breast Milk Passage
No information is available on placental passage of cobicistat. Studies in rats have shown that cobicistat is secreted in breast milk.\(^1\)

Human Studies in Pregnancy

Pharmacokinetics
No pharmacokinetic studies of cobicistat have been conducted in pregnant women.

Placental and Breast Milk Passage
No data are available on placental or breast milk passage of cobicistat in humans.

Teratogenicity/Developmental Toxicity
In the Antiretroviral Pregnancy Registry, insufficient numbers of first-trimester exposures to cobicistat in humans have been monitored to be able to make a risk determination. Cobicistat is not currently reported separately in the Antiretroviral Pregnancy Registry. All reports of elvitegravir include exposure to cobicistat.\(^2\)
Excerpt from Table 7a

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cobicistat (COBI) Tybost</td>
<td>Tablet (Tybost): • 150mg</td>
<td>Standard Adult Dose Tybost: • As an alternative PK booster with atazanavir or darunavir: One tablet (150 mg) once daily with food.</td>
<td>No data on placental transfer of COBI are available. Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.</td>
</tr>
<tr>
<td>Elvitegravir/Cobicistat/ Tenofovir Disoproxil Fumarate/Emtricitabine (EVG/COBI/ TDF/FTC) Stribild</td>
<td>Tablet (Stribild): • EVG 150 mg plus COBI 150 mg plus TDF 300 mg plus FTC 200 mg</td>
<td>PK in Pregnancy: • No PK studies in human pregnancy. Dosing in Pregnancy: • Insufficient data to make dosing recommendation.</td>
<td></td>
</tr>
<tr>
<td>Atazanavir/Cobicistat (ATV/COBI) Evotaz</td>
<td>Tablet (Evotaz): • ATV 300 mg plus COBI 150 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir/Cobicistat (DRV/COBI) Prezcobix</td>
<td>Tablet (Prezcobix): • DRV 800 mg plus COBI 150 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Individual antiretroviral drug dosages may need to be adjusted in renal or hepatic insufficiency (for details, see Adult Guidelines, Appendix B, Table 7).

Key to Abbreviations: ATV = atazanavir; COBI = cobicistat; DRV = darunavir; EVG = elvitegravir; FTC = emtricitabine; PK = pharmacokinetic; TDF = tenofovir disoproxil fumarate

References
**Ritonavir (Norvir, RTV)**

*(Last updated June 7, 2016; last reviewed June 7, 2016)*

Ritonavir is classified as Food and Drug Administration Pregnancy Category B.

**Animal Studies**

*Carcinogenicity*

Ritonavir was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. Carcinogenicity studies in mice and rats have been completed. In male mice, a dose-dependent increase in adenomas of the liver and combined adenomas and carcinomas of the liver was observed at levels of 50, 100, or 200 mg/kg/day; based on area under the curve, exposure in male mice at the highest dose was approximately 0.3-fold that in male humans at the recommended therapeutic dose. No carcinogenic effects were observed in female mice with exposures 0.6-fold that of female humans at the recommended therapeutic dose. No carcinogenic effects were observed in rats at exposures up to 6% of recommended therapeutic human exposure.

*Reproduction/Fertility*

No effect of ritonavir has been seen on reproductive performance or fertility in rats at drug exposures 40% (male) and 60% (female) of that achieved with human therapeutic dosing; higher doses were not feasible because of hepatic toxicity in the rodents.

*Teratogenicity/Developmental Toxicity*

No ritonavir-related teratogenicity has been observed in rats or rabbits. Developmental toxicity, including early resorptions, decreased body weight, ossification delays, and developmental variations such as wavy ribs and enlarged fontanelles, was observed in rats; however, these effects occurred only at maternally toxic dosages (exposure equivalent to 30% of human therapeutic exposure). In addition, a slight increase in cryptorchidism was also noted in rats at exposures equivalent to 22% of the human therapeutic dose. In rabbits, developmental toxicity (resorptions, decreased litter size, and decreased fetal weight) was observed only at maternally toxic doses (1.8 times human therapeutic exposure based on body surface area).

*Placental and Breast Milk Passage*

Transplacental passage of ritonavir has been observed in rats with fetal tissue-to-maternal-serum ratios >1.0 at 24 hours post-dose in mid- and late-gestation fetuses.

**Human Studies in Pregnancy**

*Pharmacokinetics*

A Phase I/II safety and pharmacokinetic study (PACTG 354) of ritonavir (500 or 600 mg twice daily) in combination with zidovudine and lamivudine in pregnant HIV-infected women showed lower levels of ritonavir during pregnancy than postpartum. Ritonavir concentrations are also reduced during pregnancy versus postpartum when the drug is used at a low dose (100 mg) to boost the concentrations of other protease inhibitors.

*Placental and Breast Milk Passage*

In a human placental perfusion model, the clearance index of ritonavir was very low, with little accumulation in the fetal compartment and no accumulation in placental tissue. In a Phase I study of pregnant women and their infants (PACTG 354), transplacental passage of ritonavir was minimal, with an average cord blood-to-maternal-delivery concentration ratio of 5.3%. In a study of cord blood samples from 6 women treated with ritonavir during pregnancy, the cord blood concentration was less than the assay limit of detection in 5 of the women and was only 0.38 micrograms/mL in the remaining woman. In contrast, in a study of plasma and hair drug concentration in 51 mother-infant pairs in Uganda receiving lopinavir/ritonavir-based therapy during pregnancy and breastfeeding, infant plasma levels at delivery and hair levels at age 12 weeks suggested in...
transfer of ritonavir: 2% of infants had detectable plasma ritonavir concentrations at birth while mean infant-to-maternal-hair concentration at 12 weeks postpartum was 0.47 for ritonavir. However, transfer during breastfeeding was not observed, with no infant having detectable ritonavir plasma levels at 12 weeks.

Teratogenicity/Developmental Toxicity

In the Antiretroviral Pregnancy Registry (APR), sufficient numbers of first-trimester exposures to ritonavir have been monitored to be able to detect at least a 1.5-fold increase in risk of overall birth defects. No such increase in birth defects has been observed with ritonavir. Among cases of first-trimester ritonavir exposure reported to the APR, the prevalence of birth defects was 2.3% (63 of 2,720 births; 95% CI, 1.8% to 3.0%) compared with a total prevalence of 2.7% in the U.S. population, based on Centers for Disease Control and Prevention surveillance.

Excerpt from Table 7

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ritonavir (RTV) Norvir</td>
<td>Capsules:  • 100 mg  Tablets:  • 100 mg  Oral Solution:  • 80 mg/mL</td>
<td>Standard Adult Dose as PK Booster for Other PIs:  • 100–400 mg per day in 1–2 divided doses (refer to other PIs for specific dosing recommendations.) Tablet:  • Take with food. Capsule or Oral Solution:  • To improve tolerability, recommended to take with food if possible. PK in Pregnancy:  • Lower levels during pregnancy compared with postpartum. Dosing in Pregnancy:  • No dosage adjustment necessary when used as booster.</td>
<td>Low placental transfer to fetus. No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects). Should only be used as low-dose booster for other PIs. Oral solution contains 43% alcohol and therefore may not be optimal for use in pregnancy.</td>
</tr>
</tbody>
</table>

References


The Antiretroviral Pregnancy Registry (APR) is an epidemiologic project to collect observational, non-experimental data on antiretroviral (ARV) drug exposure during pregnancy for the purpose of assessing the potential teratogenicity of these drugs. Registry data will be used to supplement animal toxicology studies and assist clinicians in weighing the potential risks and benefits of treatment for individual patients. The registry is a collaborative project of the pharmaceutical manufacturers with an advisory committee of obstetric and pediatric practitioners.

It is strongly recommended that health care providers who are treating HIV-infected pregnant women and their newborns report cases of prenatal exposure to ARV drugs (either alone or in combination) to the APR. The registry does not use patient names and birth outcome follow-up is obtained from the reporting physician by registry staff.

**Referrals should be directed to:**

Antiretroviral Pregnancy Registry
Research Park
1011 Ashes Drive
Wilmington, NC 28405
Telephone: 1–800–258–4263
Fax: 1–800–800–1052
[http://www.APRegistry.com](http://www.APRegistry.com)
## Appendix C: Acronyms

(Last updated August 6, 2015; last reviewed August 6, 2015)

<table>
<thead>
<tr>
<th>Acronym/Abbreviation</th>
<th>Full Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3TC</td>
<td>lamivudine</td>
</tr>
<tr>
<td>ABC</td>
<td>abacavir</td>
</tr>
<tr>
<td>ACOG</td>
<td>American College of Obstetricians and Gynecologists</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>anti-HBc</td>
<td>anti-hepatitis B core antibody</td>
</tr>
<tr>
<td>anti-HBS</td>
<td>hepatitis B surface antibody</td>
</tr>
<tr>
<td>AOR</td>
<td>adjusted odds ratio</td>
</tr>
<tr>
<td>AP</td>
<td>antepartum</td>
</tr>
<tr>
<td>APR</td>
<td>Antiretroviral Pregnancy Registry</td>
</tr>
<tr>
<td>ART</td>
<td>antiretroviral therapy</td>
</tr>
<tr>
<td>ARV</td>
<td>antiretroviral</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>ATV</td>
<td>atazanavir</td>
</tr>
<tr>
<td>ATV/r</td>
<td>atazanavir/ritonavir</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the curve</td>
</tr>
<tr>
<td>AZT</td>
<td>zidovudine</td>
</tr>
<tr>
<td>BID</td>
<td>twice daily</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>cART</td>
<td>combination antiretroviral therapy</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CD4</td>
<td>CD4 T lymphocyte</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum plasma concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;min&lt;/sub&gt;</td>
<td>minimum plasma concentration</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>COBI</td>
<td>cobicistat</td>
</tr>
<tr>
<td>CVS</td>
<td>chorionic villus sampling</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>cytochrome P450 3A4</td>
</tr>
<tr>
<td>d4T</td>
<td>stavudine</td>
</tr>
<tr>
<td>ddI</td>
<td>didanosine</td>
</tr>
<tr>
<td>DMPA</td>
<td>depot medroxyprogesterone acetate</td>
</tr>
<tr>
<td>DRV</td>
<td>darunavir</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>DRV/r</td>
<td>darunavir/ritonavir</td>
</tr>
<tr>
<td>DTG</td>
<td>dolutegravir</td>
</tr>
<tr>
<td>DSMB</td>
<td>Data and Safety Monitoring Board</td>
</tr>
<tr>
<td>EC</td>
<td>enteric coated</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>EFV</td>
<td>efavirenz</td>
</tr>
<tr>
<td>EMS</td>
<td>ethyl methane sulfonate</td>
</tr>
<tr>
<td>EPPICC</td>
<td>The European Pregnancy and Paediatric HIV Cohort Collaboration</td>
</tr>
<tr>
<td>ETR</td>
<td>etravirine</td>
</tr>
<tr>
<td>EVG</td>
<td>elvitegravir</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FDC</td>
<td>fixed drug combination</td>
</tr>
<tr>
<td>FPV</td>
<td>fosamprenavir</td>
</tr>
<tr>
<td>FPV/r</td>
<td>fosamprenavir/ritonavir</td>
</tr>
<tr>
<td>FTC</td>
<td>emtricitabine</td>
</tr>
<tr>
<td>gp</td>
<td>glycoprotein</td>
</tr>
<tr>
<td>HAV</td>
<td>hepatitis A virus</td>
</tr>
<tr>
<td>HBG</td>
<td>hepatitis B immune globulin</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>HELLP</td>
<td>hemolysis, elevated liver enzymes, and low platelets</td>
</tr>
<tr>
<td>HGC</td>
<td>hard gel capsule</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRSA</td>
<td>Health Resources and Services Administration</td>
</tr>
<tr>
<td>HSR</td>
<td>hypersensitivity reaction</td>
</tr>
<tr>
<td>IC50</td>
<td>inhibitory concentration 50%</td>
</tr>
<tr>
<td>IDV</td>
<td>indinavir</td>
</tr>
<tr>
<td>IDV/r</td>
<td>indinavir/ritonavir</td>
</tr>
<tr>
<td>IGF</td>
<td>insulin-like growth factor</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IP</td>
<td>intrapartum</td>
</tr>
<tr>
<td>IQR</td>
<td>interquartile range</td>
</tr>
<tr>
<td>IRIS</td>
<td>immune reconstitution inflammatory syndrome</td>
</tr>
<tr>
<td>IUD</td>
<td>intrauterine device</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous/intravenously</td>
</tr>
<tr>
<td>LPV</td>
<td>lopinavir</td>
</tr>
<tr>
<td>LPV/r</td>
<td>lopinavir/ritonavir</td>
</tr>
<tr>
<td>MAC</td>
<td><em>Mycobacterium avium</em> complex</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>MACDP</td>
<td>Metropolitan Atlanta Congenital Defects Program</td>
</tr>
<tr>
<td>MIRIAD</td>
<td>Mother-Infant Rapid Intervention at Delivery (study)</td>
</tr>
<tr>
<td>mtDNA</td>
<td>mitochondrial DNA</td>
</tr>
<tr>
<td>MVC</td>
<td>maraviroc</td>
</tr>
<tr>
<td>NFV</td>
<td>nelfinavir</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>NNRTI</td>
<td>non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NRTI</td>
<td>nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NtRTI</td>
<td>nucleotide analogue reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NVP</td>
<td>nevirapine</td>
</tr>
<tr>
<td>OC</td>
<td>oral contraceptive</td>
</tr>
<tr>
<td>OI</td>
<td>opportunistic infection</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>PACTG</td>
<td>Pediatric AIDS Clinical Trials Group</td>
</tr>
<tr>
<td>The Panel</td>
<td>The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission</td>
</tr>
<tr>
<td>PCP</td>
<td>Pneumocystis jirovecii pneumonia</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PI</td>
<td>protease inhibitor</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PO</td>
<td>orally</td>
</tr>
<tr>
<td>PP</td>
<td>postpartum</td>
</tr>
<tr>
<td>PPI</td>
<td>proton pump inhibitor</td>
</tr>
<tr>
<td>PrEP</td>
<td>pre-exposure prophylaxis</td>
</tr>
<tr>
<td>PTD</td>
<td>preterm delivery</td>
</tr>
<tr>
<td>RAL</td>
<td>raltegravir</td>
</tr>
<tr>
<td>RDS</td>
<td>respiratory distress syndrome</td>
</tr>
<tr>
<td>RPV</td>
<td>rilpivirine</td>
</tr>
<tr>
<td>RR</td>
<td>relative risk</td>
</tr>
<tr>
<td>RTV</td>
<td>ritonavir</td>
</tr>
<tr>
<td>sd</td>
<td>single dose</td>
</tr>
<tr>
<td>SQ</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>SQV</td>
<td>saquinavir</td>
</tr>
<tr>
<td>SQV/r</td>
<td>saquinavir/ritonavir</td>
</tr>
<tr>
<td>STD</td>
<td>sexually transmitted disease</td>
</tr>
<tr>
<td>T20</td>
<td>enfuvirtide</td>
</tr>
<tr>
<td>TDF</td>
<td>tenofovir disoproxil fumarate</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>TDM</td>
<td>therapeutic drug monitoring</td>
</tr>
<tr>
<td>TID</td>
<td>three times daily</td>
</tr>
<tr>
<td>TPV</td>
<td>tipranavir</td>
</tr>
<tr>
<td>TPV/r</td>
<td>tipranavir/ritonavir</td>
</tr>
<tr>
<td>UGT</td>
<td>uridine diphosphate glucuronosyltransferase</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WITS</td>
<td>Women and Infants Transmission Study</td>
</tr>
<tr>
<td>ZDV</td>
<td>zidovudine</td>
</tr>
</tbody>
</table>